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Genomic instability is fundamental to the development of human neoplasia. This
thesis has examined aspects of two forms of instability prominent in sporadic colorectal
cancer, microsatellitc instability (MSI) and chromosomal instability. Microsatellite instability
describes a phenotype in which mutation of microsatellite sequences is widespread, probably
due to defects of components of the mismatch repair pathway. Clonal chromosomal
abnormalities, frequently observed in sporadic colorectal cancer, probably arise because of
instability at the chromosomal level, and there is substantial, though not conclusive, evidence
that they may result from defects of the p53 protein.
Several lines of evidence suggest that chromosomal instability and defects of p53 may
represent a mechanism, or mechanisms, of tumorigenesis distinct from that driven by defects
of the mismatch repair system. In this project, a series of experiments were undertaken to
investigate the microsatellite instability phenotype, its possible cause, and the extent to which
it coexists and interacts with chromosomal instability and p53 abnormalities. MSI was
examined in a large population of sporadic human colorectal cancers and related to clinical
and pathological tumour features in order to define traits which may suggest a distinct
biological basis. Such instability was found to confer significant survival advantage, and to
be inversely related to abnormality of the p53 protein, supporting the notion that these defects
represent distinct tumorigenic pathways. In an attempt to discover the cause of microsatellite
instability, mutation analysis of a likely candidate gene, hMSH2, was undertaken in selected
cases. This analysis yielded few exonic gene mutations, supporting data from other studies
which suggest that hMSH2 is not an important cause of the MSI phenotype in sporadic
colorectal cancer. To further investigate the MSI phenotype, the behaviour of stable and
unstable microsatellites over a period of time was examined through use of a series of
xenografited human cancers. This demonstrated maintenance of the primary tumour
phenotype in all xenografts over several months' passage in vivo, adding weight to the
argument that microsatellite instability is persistent and is driven by an underlying retained
defect.
To define unique patterns of chromosomal anomalies associated with MSI and defects
of p53, xenograftcd human colorectal cancers were analysed by Comparative Genomic
Hy bridisation (CGH). Cancers without MSI displayed a striking pattern of chromosome
change in almost all cases, involving combinations of deletion of 8p and 18q and duplication
of 8q. 13q and 20q. suggesting that clonal selection for genes of importance in these regions is
important in such cancers. In contrast, cancers with MSI did not display this pattern, and
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were associated with a decreased number of chromosomal gains. These data support the
hypothesis that (at least) two major mechanisms of oncogene and tumour suppressor gene
disruption exist. The relationship between p53 abnormalities and chromosome changes was
less clear, though a trend towards high levels of chromosomal anomalies in tumours with
defective p53 was seen. This study was extended by similar analysis of tumours taken from
mice lacking p53 and/or the mismatch repair gene Msh2. Tumours lacking all p53 function
usually had high levels of chromosomal defects, whereas those lacking Msh2 had few. When
both functions were removed, the phenotype of few chromosomal changes and extensive
microsatellite instability predominated, suggesting defective mismatch repair to be the
dominant pathway of instability in clonal selection during tumorigenesis. The data presented
here provide insight into the nature, co-existence and interaction of different forms of genomic
instability in cancer, which may ultimately help our understanding of the heterogenous nature
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Chapter 1
Genomic Instability in Colorectal Cancer
1.1. Introduction
This thesis is about the mechanisms of genomic instability which underlie the
initiation and progression of sporadic colorectal cancer. These processes are fundamental to
neoplastic development, and many genetic defects which have long been recognised as crucial
events in colorectal tumorigenesis occur as a direct result of genomic instability. Still others
generate and sustain such instability. Thus, the genetic defects in colorectal cancer can be
better understood in the context of the dynamic processes underlying the degeneration of the
cancer genome. To introduce this, this chapter gives an overview of current knowledge of the
genetic events and environmental influences which play a role in sporadic colorectal tumour
development. The specific types of genomic instability pertinent to this study and the
mechanisms which may cause them, namely microsatellite instability, defects of the mismatch
repair pathw ay, anomalies of the p53 protein and chromosomal lesions, are discussed.
Studies of sporadic cancer have been aided by increasing knowledge of hereditary disease, and
genetic events in inherited cancer are considered in relation to sporadic cancer. Finally, the
aims and objectives of this project are presented, together with a brief summary of the chosen
methods.
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1.2. Clinical aspects and aetiology of colorectal cancer
1.2.1. Incidence and distribution of colorectal cancer
Cancer of the large bowel is the second most common cause of cancer death in
Westernised countries, accounting for 19000 deaths each year in the UK. Incidence varies
considerably worldwide, one of the highest rates being in Scotland, at 20.5/100 000 males in
1991 (Cancer Research Campaign Factsheet 18.1 & 18.2. 1993). Incidence is increasing in
low-risk populations, such as Mediterranean countries. Central and South America. Asia and
Eastern Europe, as lifestyles become increasingly Westernised (Weisburger. 1991). Risk of
developing colorectal cancer increases with age: the likelihood of developing cancer at age 30-
34 is small (2.9/100 000) compared with the risk at age 85 or older (53 1.6/100 000) (Levin &
Dozois. 1991).
1.2.2. The adenoma-carcinoma sequence
Adenocarcinoma accounts for more than 90% of colorectal cancers. Several lines of
evidence support the hypothesis that many carcinomas derive from a premalignant dvsplastic
lesion, the adenoma. Firstly, population distribution of adenomas reflects that of carcinomas,
and populations acquiring increased risk of colorectal cancer through moving to areas with
high cancer incidence also acquire an increased risk of developing adenomas (Weisburger.
1991). Approximately 70% of all cancers occur distallv within the bowel, within the sigmoid
colon, descending colon and rectum. The distribution of adenomas is similar, with an age of
onset approximately 5 years earlier (Muto. 1975), consistent with sequential progression.
Finally, histological examination shows that adenoma and carcinoma tissue are often
contiguous: foci of carcinoma can be found within adenomas, and islands of residual adenoma
can be found within carcinomas (Lane. 1976). Although the progression from adenoma to
carcinoma is thought to occur in the vast majority of Western colorectal cancers, it is possible
that 'de novo' cancers sometimes arise without preexisting adenoma. In particular, it has been
suggested that cancers with flat morphology very often arise de novo in the Japanese
population (Wada et al., 1996), though this is disputed (Owen et al.. 1996).
Hyperplastic polyps, unlike dysplastic adenomas, are believed to be uninvolved in the
development of colorectal cancer (Lane. 1976), and recent molecular evidence supports this
notion. Mutation of the adenomatous polyposis (APC) gene (discussed in 1.3 .1) is very
common in all dysplastic lesions, microscopic aberrant crypt foci (ACFs). adenomas and
carcinomas, but rare in hyperplastic polyps (Jen et al., 1994a). In contrast, all hyperplastic
ACFs can be shown to harbour mutations of the Ki-ras oncogene (discussed in 1.3.4). whilst
the incidence of Ki-ras mutations in all other tumours is much lower. This suggests that
hyperplastic ACFs are not the precursors of either dysplastic or non-dysplastic colonic
tumours, whereas dysplastic ACFs could well precede adenoma and carcinoma formation.
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1.2.3. Treatment and prognosis of colorectal cancer
Prognosis for this disease is relatively poor, with about one third of all patients
surviving to 5 years after diagnosis (Cancer Research Campaign factsheet 18.1, 1993). The
primary treatment remains surgical, often in conjunction with radiotherapy for control of local
recurrence of rectal cancer. Adjuvant chemotherapy is used for control of occult liver
metastases, but colorectal carcinoma is relatively refractory to chemotherapy and
administration of such treatment affords only a small increase in survival of about 10-15%
(International multicentre pooled analysis of colorectal cancer trials investigators, 1995).
Most regimens employ the anti-metabolite 5-fluorouracil (5-FU) in combination with a
secondary factor such as folinic acid or levamisole. Prophylactic administration of aspirin
and other non-steroidal anti-inflammatory drugs (NSAIDS). which have been demonstrated to
have a strong protective effect against colorectal cancer in mice and man (Labayle et al.,
1991; Boolbol et al., 1996), is currently under investigation.
Histopathological staging is still described according to Dukes' classification of 1932,
and Dukes' stage remains the main histopathological predictor of survival (Newland et al.,
1981; Wiggcrs et al., 1988; Laurcnt-Puig et al., 1992). In addition, several genetic factors,
discussed in the text below, have a significant influence on prognosis. Notably, relatively
poor 5-year survival is associated with alterations of the p53 gene and certain chromosomal
alterations and deletions, whilst several studies indicate improved survival in patients whose
cancers have a diploid karyotype and in patients whose tumours demonstrate microsatellitc
instability.
1.2.4. Dietary factors and sporadic colorectal cancer
Diet is a major actiological factor in colorectal cancer, and is important to consider in
this discussion because the nature of genetic and cellular damage initiated by dietary
components may determine subsequent genetic events. Several dietary factors have been
demonstrated to be associated with increased risk of colorectal tumours. Principally, an
increased risk of cancer is associated with a diet high in saturated fat and low in fibre, though
the type of fat and fibre consumed is important (see Weisburger. (1991) and Reddy, (1993)
for reviews; Little et al., 1993; Olscn et al., 1994). Intake of calcium and certain vitamins
may also reduce risk (Weisburgcr. 1991; Olsen et al., 1994). Alcohol, especially beer intake,
is associated with increased risk of rectal carcinoma (Weisburger, 1991; Cancer Research
Campaign Factsheet 18.1, 1993). Studies in mice suggest that, although both dietary fat and
caloric intake affect tumour growth, the effect of caloric intake may be more profound (Sarkar
eta/., 1995).
Little is understood about the mechanisms by which dietary components affect
cellular proliferation. Some dietary constituents and products of digestion are directly
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genotoxic. whilst others may influence cellular processes such as apoptosis which affect the
rate of tumour initiation or progression. One example of a dietary component thought to be
directly damaging to DNA is the heterocyclic amine 2-amino-l-methyl-6-phenylimidazo[4,5-
b|p\ ridine (PhiP). present in some cooked food. PhiP induces colon tumours in rats in which,
in common with human colonic cancers, the APC gene is often truncated (Kakiuchi et al.,
1995). However, the characteristic mutagenic 'fingerprint' of PhiP (Yadollahi-Farsani et al.,
1996) does not suggest its direct involvement in mutation of APC in a large number of human
cancers. In contrast, bile acid, which increases as a result of high fat intake, is cytotoxic,
producing a high cell turnover and associated risk. Furthermore, bacterial degradation of bile
salts may result in production of carcinogens in the bowel lumen, so carcinogen production
from this process could be increased either by alteration in the bacterial population by changes
in dietary fibre and carbohydrate or by increased bile acid production (Burkitt, 1971). One
study indicates that caloric restriction slows tumour growth in mice through increasing the
apoptotic rate through reduction of insulin-like growth factor I (Dunn et al., 1997).
The overall carcinogenic effects of diet are partially governed by individual genetic
profile, either in terms of abnormalities in genes predisposing to cancer, discussed below, or
more subtle polymorphisms in metabolic enzymes. For example, heterocyclic amines, which
can be present in the diet, are activated by a pathway involving N-acetyl transferase, and
individuals with rapid acetylation phenotype arc at increased risk of colorectal cancer (Ilett et
al., 1987). A polymorphism of CYP1A1. an enzyme of key importance in the metabolism of
polvcvclic aromatic hydrocarbons, is associated with increased colorectal cancer risk
(Sivaraman el al., 1994). Similarly, individuals with bowel cancer have a slightly higher than
usual incidence of the null genotype of the GSTM1 locus, the product of which normally
detoxifies polycyclic aromatic hydrocarbon metabolites (Zhong et al., 1993). Patients with
proximal bowel cancer have a significantly increased incidence of the GSTM1 null allele,
suggesting a difference in the importance of this enzyme between the left and the right colon.
Finally, the mode of action of the mom J locus (modifier of miri) illustrates the
complexity of interaction between diet and genetic complement which is just beginning to be
elucidated. This is discussed in 1.3.1.1.
1.2,5. Predisposition to colorectal cancer
Several diseases confer an increased risk of bowel cancer. Up to 25% of ulcerative
colitis patients eventually develop the disease (Cotran et al., 1994) and, similarly, Crohn's
disease confers a cancer risk 4 to 20 times that of the general population (Levin & Dozois,
1991). However, by far the most dramatic risk is conferred by the inherited cancer
predisposition syndromes Familial Adenomatous Polyposis (FAP) and Hereditary Non-
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Polyposis Colorectal Cancer (HNPCC). These syndromes are described in the following
discussion of colorectal cancer genetics.
1.3. The genetics of colorectal cancer
The proliferation of a population of cells is regulated by both tumour suppressor
genes, which inhibit cell growth or promote death, and by proto-oncogenes. which promote
growth or inhibit death. Loss-of-function mutations of tumour suppressor genes or activating
mutations of proto-oncogenes (to create oncogenes) creates deregulation of growth control,
leading to the rate of cell proliferation surpassing the rate of cell death and subsequent tumour
formation.
Whilst oncogenes are dominantly-acting elements, tumour suppressor genes are
recessive at the cellular level and often require inactivation of both alleles in order to exert an
effect on cellular growth. A model for tumour suppressor gene function was developed on the
basis of observations of retinoblastoma, a rare childhood tumour of the eye (Knudson, 1971).
According to this model, known as Knudson's 'two-hit' hypothesis, sporadic disease would
only arise if two copies of the same gene were inactivated through mutation. However,
children who inherited one mutated copy of a gene require only one somatic event in order for
a tumour to develop.
Tumorigencsis in colorectal cancer is a multistep process characterised primarily by
the loss of function of tumour suppressor genes and. less frequently, by the mutation and
amplification of proto-oncogenes. Several genetic aberrations, summarised in Table 1 at the
end of this chapter and Figure 1, and described in the following sections, appear frequently in
colorectal cancer and it is widely accepted that an accumulation of lesions in critical genes is
necessary for the progression to carcinoma (Fcaron & Yogelstein, 1990; Kinzler &
Vogclstein. 1996) [Figure 11. Recent thought emphasises the dynamic processes involved in
the acquisition of such genetic lesions, which may occur in a cascade following a single
critical event such as a failure to respond to DNA damage or to initiate DNA repair. The
critical target genes which acquire mutations in sporadic and hereditary colorectal cancer are
thought to be largely, though not entirely (Markowitz et al.. 1995; Konishi el al., 1996),
similar, though the tumorigenic mechanisms through which the mutations occur can differ.
The remainder of this chapter describes the roles of the molecular events known to be
critical in the process of colorectal carcinogenesis, with reference to their relationship to
mechanisms of tumorigenesis.
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1.3 .1. The APC gene in Familial Adenomatous Polyposis and sporadic colorectal
cancer
Elucidation of the genetic basis of Familial Adenomatous Polyposis (FAP) has been
fundamental to understanding the early events occurring in sporadic colorectal cancer. FAP is
an autosomal dominant familial cancer predisposition syndrome affecting around 1 in 7000
people. The disease is characterised by the development of hundreds of thousands of
colorectal adenomatous polyps at an early age, some of which inevitably progress to cancer
without surgical intervention. Many of these individuals are also prone to develop
extracolonic manifestations such as congenital hypertrophy of the retinal pigmentosum
endothelium (CHRPE). osteomata and desmoid tumours.
Individuals with FAP carry one mutated copy of the APC tumour suppressor gene
(Groden et al., 1991; Joslyn et al.. 1991; Kinzler etcil., 1991a; Nishisho et al.. 1991).
Tumours develop when normal function of the remaining allele is lost (often through large
deletion of a portion of the chromosome containing APC, or through point mutation) though
only a few of the many benign lesions which develop progress to carcinoma. Thus, APC
functions as a classical tumour suppressor gene according to Knudson's hypothesis (Knudson,
1971). Germ-line mutations of the gene in FAP patients are mainly confined to one half of the
large terminal exon 15 (Miyoshi et al.. 1992a). and the vast majority cause truncation of the
protein product. Foss of function of APC is thought to act as a 'gatekeeper' to tumorigenesis,
after which an accumulation of other gene mutations characterise a relatively slow progression
to metastatic disease (Kinzler & Vogelstein. 1996).
Evidence for the involvement of APC in sporadic colorectal cancer came initially
from loss of heterozygosity (FOH) studies which demonstrated that the region of chromosome
5q containing APC was frequently deleted in these tumours (Solomon et al.. 1987; Vogelstein
eta!., 1988; Ashton-Rickardt et al., 1989 & 1991). Mutation analysis demonstrated somatic
mutations in over 60% of tumours, even in very small sporadic adenomas (Miyoshi et al.,
1992b; Powell et al.. 1992) and dysplastic aberrant crypt foci (Jen et al., 1994a),
predominantly within a small 'mutation cluster region' of the largest exon of APC (Miyoshi et
al., 1992b). Mutation of APC is now believed to occur in almost all colorectal neoplasms
(Miyoshi et al.. 1992a; Nagase & Nakamura., 1993). suggesting that the growth-regulatory
feature of APC is important in preventing proliferation at the earliest stages of tumorigenesis.
The biochemical properties and biological functions of APC are not fully understood.
The gene encodes a 3()()kD c\toplasmic protein expressed in the upper portion of the colonic
crypt, suggesting it is functional in the mature colonocyte (Smith et al., 1993). Wild-type
APC forms homodimcrs. and mutant proteins are thought to be able to inactivate the wild-type
protein in a dominant negative manner by formation of hcterodimers with wild-type protein
7
(Su et al., 1993a) APC associates with p-catenin (Rubinfeld et al., 1993; Su et al., 1993b),
which is thought to transmit signals from the E-cadherin adhesion proteins to the cell's
interior, suggesting a role for APC in cell adhesion and possibly intercellular communication.
In cell lines, wild-type, but not mutant. APC associates with the entire microtubule skeleton
when present at elevated levels (Munemitsu et al., 1994; Smith et al., 1994) and there is
evidence that it may be important for inducing polymerisation of tubulin (Munemitsu et al.,
1994). However, a recent study demonstrates that endogenous APC is only found near the
ends of microtubules that protrude into actively migrating membrane structures of epithelial
cells, suggesting that APC might be involved in directed cell migration (Nathke et al., 1996).
APC has also been shown to bind EB1. although the significance of this is not clear since the
function of EB 1 is not yet known (Su et al., 1995). Expression of APC in colorectal cancer
cells lacking endogenous APC increases the number of cells undergoing apoptotis (Morin et
al., 1996). and it has been postulated that APC is responsible for control of tissue
compartmcntalism of proteins involved in proliferation, differentiation and apoptosis (Polyak
et al., 1996a). Finally, an increased tendency for apparently normal fibroblasts and
lymphocytes from FAP patients to become tetraploid in vitro might suggest a role for APC in
maintenance of chromosomal stability (Dclhanty et al., 1983).
1.3.1.1. Factors modifying the polyposis phenotype
Patients display remarkable differences in phenotype according to the location of the
mutation within the APC gene. Mutations occurring 3' to exon 9 are associated with CHRPE,
whereas those occurring 5' to this boundary are not (Olschwang et al., 1993). Similarly, those
occurring 5' to exon 157 are associated with an attenuated disease phenotype (later onset of
disease and fewer polyps) whilst those 3' to exon 168 display more aggressive disease
phenotypc (Spirio et al., 1993). and a small central portion of the coding region is associated
with profuse polyp formation (Nagase et al., 1992). The observed differences in phenotype
may partly be accounted for by the extent to which normal APC function is impaired by
binding of a mutant form. Wild-type APC forms homodimers. but mutant APC can also bind
wild-type APC. thus allow ing it the potential to reduce the activity of the normal protein and
act in a dominant negative fashion (Joslvn et al., 1993; Su et al., 1993a). Severely truncated
proteins may be unable to form dimcrs. whereas longer proteins may more effectively
sequester wild-type protein (Cunningham & Dunlop. 1994).
The polyposis phenotype can also be attenuated by several other environmental and
genetic factors, which may eventually prove beneficial to the clinical management of FAP,
and possibly of other APC-induced tumours. Min mice develop multiple bowel polyps in a
similar manner to FAP patients as a result of carrying a heterozygous mutation of the APC
gene (Moser et al.. 1990). and their phenotype is modulated by an unlinked locus known as
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moml (modifier of min) (Moser et al., 1992; Dietrich et ai. 1993). The moml locus provides
a good illustration of the complexity of interaction between multiple genetic loci and diet in
colorectal cancer. Moml locus has been shown to be genetically identical to the gene
encoding a metabolic enzyme, type II non-pancrcatic phospholipase A2 (Plci2s) (MacPhee et
al., 1995). Low polyp number is associated with a null mutation in one allele of the gene.
Pla2s probably modifies polyp number by altering the cellular microenvironmcnt within the
colonic crypts, hydrolysing phosphoglvcerides to free fatty acids and lysophospholipids. It is
one of the enzymes responsible for the production of arachidonic acid, which in turn is rate
limiting for the production of prostaglandins. A decrease in levels of specific prostaglandins
is thought to be associated with protection against tumours and also regression of polyps.
However, it has been suggested that the action of Pla2s is complex, involving several different
mechanisms, including lipid homeostasis and digestion of dietary fats, maintenance of normal
bacterial flora, and elimination of aberrant crypt cells (MacPhee et al., 1995).
Other genetic and epigenetic factors may also modify the polyposis phenotype.
Hy pomethy lation induced both chemically and by crossing with mice deficient for DNA
methyTransferase {Dnmt mice) results in drastically reduced polyp number in min mice (Laird
et al.. 1995). This is suggested to be due to altered gene expression, as discussed in 1.3.10. or
due to a decrease in the rate of spontaneous mutations occurring at methylated bases,
decreasing the chance of knocking out the second APC allele which drives adenoma
formation. Min mice lacking the matrix metalloproteinase (MMP) matrilysin. which is
expressed in a high percentage of early human colorectal tumours, also exhibit markedly
reduced polyp number and size (Wilson et al., 1997). In another model, mice carrying a
truncating mutation of APC have drastically reduced intestinal polyp number when Cox-2 is
not expressed (Oshima et al., 1996). Cox-2 encodes an isoform of cyclooxygenase (Cox), an
enzyme responsible for metabolism of arachidonic acid to prostaglandins. As noted above,
decreased levels of prostaglandins are associated w ith protection against tumour formation.
Cox-2 is expressed at high levels in many colorectal tumours (Sano et al., 1995), and a recent
study has demonstrated a direct link between inhibition of growth of cell lines derived from
colorectal cancer and selective inhibition of the Cox-2 pathway (Sheng et al., 1997).
Treatment of FAP patients w ith the NSAID sulindac. which causes regression of polyps, is
associated w ith a decrease in levels of Cox-2 within colonic tumours (Kargman et al., 1995).
1.3.2. The p53 gene
The product of the p53 gene is a key participant in the maintenance of genomic
stability, and loss of normal p53 activity contributes to a wide variety of human cancers
(Nigro et al., 1989; Hollstcin et al., 1991; Greenblatt et al., 1994). The p53 gene, located on
chromosome 17p 13 (Bcnchimol et al., 1985; Isobe et al., 1986. McBride et al., 1986),
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encodes a nuclear phosphoprotein which has the ability to bind DNA and regulate
transcription of genes involved in cell cycle arrest and induction of apoptosis. In normal cells,
p53 activity- increases in response to events that may lead to uncontrolled cell growth, such as
DNA damage,- (Gottlieb & Oren. 1996) and for this reason it has been termed the 'guardian
of the genome' (Lane. 1992). p53 plays a critical role in the maintainance of genomic stability
by a variety of mechanisms, including cell cycle arrest, induction of apoptosis and
involvement in DNA replication and repair pathways.
The functions of p53 are complex and wide-ranging and it is not within the scope of
this thesis to discuss them all in detail. An overview of its main functions, with more detailed
discussion of its role in genomic instability, is presented.
1.3.2.1. The role ofp53 in cell cycle arrest and apoptosis
Under gcnotoxic stress, such as gamma irradiation or certain chemotherapeutic drugs,
different cell lineages are able to undergo p53-dependent cell-cycle arrest at the Gl/S phase
boundary ('G1 arrest') that is mediated by the cyclin-dependent kinase inhibitor p21 (also
called WAF1 or CIP1) (Diller el al., 1990; Kastan et al., 1991; Mercer et al., 1991; Kuerbitz
etal.. 1992; Lane etal., 1992; Lin et al., 1992; El-Deiry etal., 1994; Lowe et al., 1993a; Di
Leonardo. 1994). This arrest is thought to be necessary in order to permit repair prior to
engagement of the replication complex and thus prevent the replication of mutated DNA liable
to compromise genomic stability. DNA strand breaks are sufficient to trigger elevation in p53
levels and G1 arrest (Nelson & Kastan. 1994; Huang et al.. 1996a). and Jayaraman & Prives
(1995) showed that p53 is stimulated to bind specific DNA targets by short oligonucleotides
which simulate the broken DNA structures resulting from DNA damage. p53-dependent G1
arrest can occur also in the absence of DNA damage, in response to nucleotide depletion
(Livingstone et al., 1992; Yin et al., 1992; Linkc et a/.. 1996). hypoxia and heat (Graeber et
al.. 1994). but the G1 arrest induced by the latter two factors occurs through a combination of
p53-depcndent and p53-independent mechanisms. A p53-depcndent G2 arrest occurs in the
presence of microtubule poisons (Cross et al., 1995; Dileonardo et al., 1997), and after
exposure to ionizing radiation, though the latter response appears to be partially p53-
independent (Guillouf et al.. 1995; Agarwal et al., 1995).
In some cell types, the induction of wild-type p53 in response to DNA damage results
in cell death by apoptosis rather than cell cycle arrest (Yonish-Rouach et al.. 1991; Shaw et
al.. 1992; Clarke et al., 1993; Lowe et al., 1993a). The mechanism of p53-mediated
apoptosis is not clear; p53 is known to initiate apoptosis through up-regulation of Bax and
repression of Bcl-2 (Mivashita et al.. 1994). though neither is absolutely required for p53-
dependent apoptosis (Knudson et al., 1995). p53 may also up-regulate the apoptosis
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promoters KILLER/Dr5 (Wu et al.. 1997) and Fas/APO-1 (Owen-Schaub et al., 1995),
though p53-depcndent activation of apoptosis can occur independently of Fas through
CPP32P (Fuchs et al., 1997).
It is not known what determines the outcome of p53 induction. It is suggested that
cells can tend toward an apoptotic response if the components of the pathway of p5 3-induced
G1 arrest are deregulated or abrogated (discussed in Gottlieb & Oren, 1996). Whilst cells
respond to p53 induction following insult in a cell type-specific manner, certain cells, such as
those derived from colorectal cancer, naturally undergo either growth arrest ('A-lines') or
apoptosis ('D-hnes') in response to the same stimulus (Fowe et al., 1994; Polyak et al.,
1996b). p21 -mediated growth arrest appears to protect A-lines from apoptosis. but fusion of
both types of colorectal cancer cells indicates that the apoptotic response is dominant,
suggesting the presence of a trans-acting factor which overcomes the protective effect of p21
(Polyak et al.. 1996b). Expression of oncogenes also influences the apoptotic response. For
example inappropriate induction of c-myc in quiescent fibroblasts, though capable of driving
cells into S phase despite the presence of high levels of p53, results in cell death by p53-
dependent apoptosis (Hcrmcking & Eick. 1994). In a similar manner, suppression of
transformation of ElA-cxprcssing cells is achieved by p53-dcpendent apoptosis (Lowe et al.,
1994). p53-induced apoptosis might be a common mechanism for removal of cells that,
through oncogene expression, have bypassed the Gl/S checkpoint, thus preventing tumour
formation. The tumour suppressor function of p53 may rely, at least in part, on its ability to
induce apoptosis. so that when loss of p53 means that p53-mediated cell death no longer
counterbalances proliferation, cell numbers increase (Donehower et al.. 1995). The
appearance of aberrant p53 protein is associated w ith resistance to certain chemotherapeutic
agents in a variety of different tumour types, including colorectal cancers (for review see Wu
&. El-Deiry. 1997). and this is thought to be due at least in part to resistance to apoptosis
conferred by loss of normal p53 function (Lowe et al., 1993b).
Very recent evidence suggests that p53 interacts with another potential tumour
suppressor gene product. p33INGI (Garkavtscv et a!., 1998). Although little is known about
this protein as yet. p33/,VG; is known to be a nuclear protein which physically associates with
p53 and modulates the ability of p53 to act as a transcriptional activator. Neither of the two
genes can cause growth inhibition when the other is suppressed, and transcription from the
p21 promoter depends on expression of p33,NGI. Thus, p33WG7 appears to be a key
component of the p53 signalling pathway important in negative regulation of cell proliferation.
The determination of its importance in other p53-dependent cellular processes will be of great
interest.
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1.3.2.2 p53 and control ofgenomic stability
Many lines of evidence suggest that abnormalities of p53 strongly predispose to
chromosomal abnormalities. Individuals with the rare inherited Li-Fraumeni syndrome carry
one germ-line mutated copy of p53. and are at increased risk of a wide range of tumours,
especially soft tissue sarcomas, brain tumours, osteosarcomas, breast carcinomas, leukaemias
and adrenocortical carcinomas (Li and Fraumcni, 1969). Normal fibroblasts from such
individuals accumulate in vitro genomic aberrations such as polyploidy and random
chromosome losses, followed by development of dicentric chromosomes, double minutes,
chromosome breaks and telomcric associations (Bischoff et al.. 1990) with concomitant loss of
the wild-type p53 allele (Yin et al., 1992). These cells also have the ability to undergo
amplification of the CAD gene (encoding the trifunctional enzyme carbamoyCP synthetase,
aspartate transcarbamylase. dilvydroorotase) in response to the uridine biosynthesis inhibitor
PALA [N-(phosphonacetyl)-L-aspartate] (Livingstone et al.. 1992; Yin et al., 1992).
Furthermore, such cells develop changes in morphology, anchorage-independent growth and
escape senescence, though they remain non-tumorigenic when explanted into nude mice
(Bischoff et al.. 1990). This instability phenotype appears to be cell type-specific; Epstein-
Barr virus (EBV)-immortalized lymphoblastoid cells from both normal and Li-Fraumeni
individuals maintain functional genomic stability during long term in vitro culture, a feature
which may contribute to selective tissue localisation of tumours in Li-Fraumeni patients (Lalle
etal.. 1995).
Studies of murine cells deficient for p53 show a similar pattern. Mice with two
defective p53 alleles are developmentally normal but succumb to tumours (predominantly
lymphomas) by the age of 9-10 months (Donehower et al., 1992; Harvey et al., 1993a; Purdic
et al., 1994) whilst heterozygotes acquire tumours at a later age (Harvey et al.. 1993a). In
culture, cells derived from such mice have very unstable karyotypes, with a strong tendency to
increase their ploidy levels during growth (Harvey et al., 1993b; Purdic et al., 1994) and an
ability to undergo gene amplification (Livingstone et al., 1992; Yin et al., 1992). These cells
frequently undergo lack of cell partition at anaphase or unequal segregation of chromosomes
due to abnormal amplification of ccntrosomes (Fukasawa et a/., 1996). The acquisition of
genomic change in these cells is halted by introduction of wild-type p53 (Agapova et al.,
1996). Mice with p53-dcficient mammary adenocarcinomas (Wnt-1 transgene/p53-null
crosses) also develop tumours which frequently display aneuploidy, amplification and deletion
(Donchower et al.. 1995). Normal murine fibroblasts, like human colon cancer cells, display
an increase in the frequency of chromosome breaks and emergence of hyperdiploid cells on
expression of exogenous mutant p53 (Agapova et al.. 1996). Deficiency of p53 docs not,
however, affect the rate of point mutation (Nishino et al.. 1995; Sands et al.. 1995). Finally,
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in colorectal cancer, a strong significant correlation is seen between p53 mutation and
aneuploidy, including allelic losses of chromosome regions 17p. 18q and 5q and
hypotetraploid DNA index (Bell et al., 1993; Meling et al., 1993; Hamelin et al., 1994).
Moreover, abnormal p53 function arises as an event preceding, and perhaps facilitating,
clonal divergence of carcinomas in sporadic bowel lesions (Carder el al., 1993 & 1995).
Gottlieb & Oren (1996) propose that p53 maintains genomic stability, firstly, through
its role in G1 arrest, preventing gross chromosomal abnormalities such as translocation,
deletion or amplification by inhibition of replication of cells in which DNA is damaged, and,
secondly, through a G2 'spindle-surveillance' checkpoint, which prevents the formation of
aneuploid and polyploid cells. As a result of loss of normal p53 function, loss of cell-cycle
control and accompanying genomic instability favours a rapid accumulation of mutations
necessary for tumour development. As a further control, p53 regulates induction of apoptosis,
which is important in the elimination of damaged cells.
1.3.2.3. Mutation of p53 in colorectal cancer
Loss of normal p53 function is the most common genetic lesion in sporadic colorectal
cancer, occurring in about 75% of cases (Baker et al., 1990; Cunningham et al., 1992;
Kaklamanis et al., 1993). frequently through mutation of the gene. Inactivation of p53 in
sporadic cancer often involves both alleles; allelic deletions occur in more than 75% of
carcinomas (Vogclstcin et al., 1988; Cunningham et al., 1992). accompanied by mutations of
the second allele in 86% of cases (Baker et al., 1990). p53 mutations arising in sporadic
colorectal carcinoma arc predominantly missense, and frequently result in the nuclear
accumulation of abnormal protein with increased half-life, possibly through altered
conformation, oligomerization or interactions with other proteins such as certain heat shock
proteins (Finlay et al., 1988; Sturzbccher el al., 1988; Kraiss et al., 1991). allowing detection
by immunocytochemical methods (Levine. 1991). In some cells containing both mutant and
wild-type p53. the mutant form appears to stabilize the otherwise rapidly-degraded wild-type
protein through the formation of oligomers, possibly by altering the conformation of the wild-
type protein and thus behaving in a dominant negative fashion (Eliyahu et al., 1988; Milner &
Medcalf. 1991). Mutant p53 can also, under some circumstances, exhibit gain of function
(Dittmer et al., 1993). The cellular environment is important in maintenance of normal p53
function, since this can be abrogated by indirect interaction with viral proteins such as SV40
largeT antigen. HPV E6 and adenovirus Elb. and by cellular factors such as the proto-
oncogenc Mdm2 (discussed in Blagosklonny, 1997). In some human sarcomas, overexpressed
Mdm-2 binds to and stabilises p53. resulting in functional inactivation (Oliner et al., 1992),
and may be involved in degradation of p53 (Haupt et al., 1997).
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Mutations of the p53 gene, deletions of chromosome 17p and nuclear stabilisation of
the p53 protein occur rarely in adenomas (Vogclstein et al., 1988; van den Berg et al., 1989;
Baker et al., 1990; Fcaron and Vogelstein. 1990; Rodrigues et al., 1990; Campo et al., 1991;
Shirasawa et al., 1991; Kikuchi-Yanoslhta et al.. 1992; Starzynska et al., 1992; Kaklamanis
et al., 1993; Ried et al., 1996). indicating that loss of p53 function is associated with the
transition from adenoma to carcinoma. p53 abnormality or loss occurs more frequently in
distal colorectal cancers (Scott et al., 1991; Bell et al., 1993; Laurent-Puig et al., 1992;
Meling et al., 1993; Hamelin et al., 1994), and there is some evidence that p53 abnormality is
an independent predictor of poor prognosis in colorectal cancer (Sun et al., 1992; Stargynza
et al., 1992; Hamelin et al., 1994). although others find that it is not (Bell et al., 1993).
Given the apparent importance of abrogation of G1 arrest through loss of p53
function in colorectal cancer, tumours containing normal p53 gene product might be expected
to harbour defects in other components of this pathway, such as p21. However, somatic
mutations of p21 have been searched for in a series of colorectal lesions but no mutations
have been found (Li et al., 1995). Disruption of p21 protein distribution has been shown to
occur in dysplastic ACFs (Polyak et al., 1996a). in which normal tissue compartmcntalism of
the protein, in the upper non-proliferating third of the crypt, is lost.
1.3.2.4. The role ofp53 in DNA replication and repair
Evidence that p53 is directly involved in nucleotide excision repair (NER) comes from
the observation that the DNA repair rate is reduced in cells from individuals with Li-Fraumeni
syndrome and in colon cancer cells with abrogated p53 function (Ford et al., 1995; Smith et
al., 1995; Wang et al.. 1995). p53 is probably involved in control of NER and DNA
replication by both transcriptional and non-transcriptional means. p53 interacts with several
cellular components thought to be involved in replication and repair, including the single
strand binding protein RPA. XPB. XPD and CSB (for review see Gottlieb & Oren, 1996). In
addition, it interacts with the DNA damage-induced GADD45 protein (Kastan et al., 1992),
and through this activity may indirectly regulate levels of proliferating cell nuclear antigen
(PCNA) required for DNA synthesis in both replication and repair. The regulation of p21 by
p53 may also influence levels of PCNA (Mercer et al., 1991), since p21 has been shown to
modulate PCNA activity (Li et al.. 1994). The inhibitory effect of p53 on the replication
machinery may contribute to its ability to block the cell cycle at G1.
There is some evidence that the pathways of detecting and responding to DNA
damage may be interconnected. A recent report demonstrates the ability of p53 to bind the
promoter region of hMSH2. thus implicating p53 in the regulation of hMSH2 and possibly
implying a role for it in mismatch repair (Scherer el al., 1996), and there is evidence that p53
plays a direct role in recognition of insertion/deletion mismatches (Lee et al., 1995). This has
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important implications for the study of p53 and mismatch repair defects in colorectal cancer,
since in general tumours with defects in p53 tend not to have deficiencies in the MMR
pathway (Ionov et al., 1993; Kim et al., 1994a; Cottu et al., 1997; Remvikos et al., 1997).
This is discussed further later in this thesis.
In summary, though p53 may maintain stability of the genome by a variety of
different methods which are not yet fully understood, abnormalities of p53 have been
unequivocally linked with chromosomal abnormalities in a number of different systems.
Furthermore, there is strong evidence that loss of normal p53 leads to aneuploidy in colorectal
cancer. It is on the basis of this evidence that the relationship between p53 abnormalities and
chromosomal anomalies were examined in this study.
1.3 .3, Genes located on chromosome 18q
Loss of chromosome 18q occurs in about 70% of colorectal cancers, and is thus
thought to be a very important step in tumour progression (Vogclstein et al., 1988). Loss of
this region characterises the progression from early to late adenoma, and appears to be almost
universal in colorectal metastases (Ookawa et al., 1993; Frank et al.. 1997). Chromosome
18q status has strong prognostic value in Dukes' stage B cancers, with loss predicting poor
survival (Jen et al., 1994b). At least three putative tumour suppressor genes are located in
this region.
A gene in the commonly deleted region of 18q, DCC (Deleted in Colorectal Cancer),
was identified and found to exhibit deletion, somatic mutation and absent or greatly reduced
expression in most colorectal cancers (Vogelstein et al., 1988; Fearon et al., 1990; Itoh et al.,
1993; Cho et al., 1994). DCC has been shown to be be involved in cell adhesion, and
expression of antisensc DCC transforms Rat-1 fibroblasts (Narayanan et al., 1992). In flies
and vertebrates. DCC and related proteins are expressed in gut epithelia, and are readily
detectable on the mucin-secreting goblet cells (Hedrick el al., 1994; Kolodziej el al., 1996).
Colorectal cancer cells lacking DCC appear to be deficient in mucin staining, possibly
because either the goblet cells do not contribute to these cancers or because DCC is required
for differentiation to mucin-producing cells, whereas mucinous carcinomas almost always
retain DCC (Hcdrick et al., 1994). The gene encodes a nctrin-1 receptor, and is probably
involved in mediating axon guidance (Keino-Masu el al., 1996). Its role in neuronal
morphogenesis suggests that, in the gut. DCC may help to maintain tissue integrity or cell
morphology, and loss may contribute to metastasis (Kolodziej, 1997).
A subset of colorectal cancers demonstrate deletion and mutation of a second gene
located within 1Mb of DCC. DPC4 (Takagi et al., 1996; Thiagalingam et al., 1996). DPC4
shows sequence homology to the drosophila gene Mad. which is thought to transduce signals
from transforming growth factor p (TGFP) family members. A third closely-linked Mad-
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related gene, JV18. is shown to be mutated in a proportion of colorectal cancers (Riggins et
al., 1996) and a fourth. MADR2 is also mutated in a subset of colorectal cancers (Eppert et
al.. 1996). Mutation of another component of the TGFp growth-control pathway, the second
subunit of the TGFp receptor (TGFpRII), is almost ubiquitous in a subset of colorectal
tumours with microsatellitc instability (Markowitz et al.. 1995) and it is suggested that
mutation of genes encoding components of the TGFp signal transduction pathway may be one
method by which colorectal cancers without microsatellite instability become insensitive to the
growth-inhibiting properties of TGFp.
Thymidylate synthase (TS), a target enzyme for several chemotherapeutic drugs
including 5-fluorouracil (5-FU). is also encoded by a gene on chromosome 18q. TS
expression is reduced in a large proportion of colorectal cancers (Lasserre et al., 1994), which
might be expected to exhibit reduced drug sensitivity. However, whether a correlation exists
between TS expression and response to 5-FU remains controversial (Johnston el al., 1995;
Findlay et al., 1997).
The Bcl-2 gene, also located on chromosome 18q. is discussed below.
1.3.4. The ras genes
Although loss of function of tumour suppressor genes occurs frequently in colorectal
cancer, activation of proto-oncogcnes is generally less prevalent. However, mutation of the
Kirstcn ras (Ki-ras) oncogene is often acquired during colorectal tumour development.
Approximately 50% of colorectal carcinomas and adenomas >lcm in diameter harbour Ki-ras
mutations, predominantly in codons 12 and 13 (Bos et al., 1987; Forrester et al., 1987;
Vogclstein et al., 1988).
The ras family of genes are cytoplasmic proto-oncogenes involved in signal
transduction (Barbacid et al., 1987) which, in conjunction with other oncogenes, are capable
of transforming cells in culture (Ruley et al., 1983; Newbold et al., 1983). Furthermore,
disruption of mutant Ki-ras in cell lines derived from colorectal cancer has been shown to
result in altered cell morphology, loss of anchorage-independent growth, slower growth, a
reduction in tumorigenic potential, and concomitant reduction in expression of the c-myc
oncogene, suggesting a key role for Ki-ras in maintenance of the cancer phenotypc in these
tumour lines (Shirasawa et al., 1993).
1.3.5, Bcl-2 and Bax
Abrogation of proteins directly involved in the control of apoptosis could clearly be of
importance in maintaining normal cell turnover and preventing tumour growth. Two such
proteins. Bcl-2 and Bax. have been examined in colorectal cancer. Bcl-2 which encodes a
mitochondrial membrane protein, the expression of which inhibits programmed cell death (for
review sec Reed. 1994). Detectable Bcl-2 transcript is completely lacking in over half of all
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sporadic colorectal cancers, and this is associated with poor prognosis (Ofner et al., 1995).
The role of Bcl-2 in carcinogenesis is not clear: lack of transcript might be expected to
facilitate apoptosis. and therefore cause a reduction in tumour growth. However, this
paradoxical inhibition of tumour growth may be explained by the location of Bcl-2 in a
commonly deleted region of chromosome 18q. where Bcl-2 is deleted as a 'passenger' along
with other genes of importance in tumour growth (Pietenpol et al., 1994). Expression of Bax,
which promotes the apoptotic process, is also lacking in a over 50% of colorectal cancers with
microsatellitc instability, due to mutations in a polynucleotide tract within the coding region of
the gene (Rampino et al.. 1997).
1.3 .6, The c-mvc ttene
Expression of the oncogene c-myc is frequently increased in sporadic colorectal
cancer (Gallick el al., 1985; Sikora et al.. 1987). sometimes due to amplification of the gene
(Kafatos et al.. 1985). The c-myc gene encodes a nuclear protein with DNA binding capacity
which is capable of inducing apoptosis at all points throughout the cell cycle (Evan et al.,
1992) and thought to be essential for cell proliferation (Hcikkila et al.. 1987). Elevated levels
of c-myc product arc not seen in tumours with distant metastases, or in the metastases
themselves, indicating its involvement at an earlier stage of development (Gallick et al.,
1985). It is not yet known whether expression of c-myc is directly related to tumour initiation
or progression.
1.3,7. Other putative tumour suppressor genes in colorectal cancer
Frequent loss of heterozygosity indicates that regions of the genome harbour as yet
unidentified tumour suppressor genes important in colorectal cancer. Partial deletion of
chromosome lp occurs in up to half of all colorectal cancers (Reichmann et al., 1984; Leister
eta/.. 1990; Muleris et al.. 1990; Couturier-Turpin et al., 1992; Bardicta/., 1993a & 1995;
Bomme et al.. 1994; di Vinci et al., 1996) and is associated with poor prognosis (Gerdes et
al.. 1995). Some studies find that it also occurs in a high proportion of adenomas, with
frequency of loss lowest in tumours with low levels of dy splasia and highest in early foci of
cancer (Bardi et al.. 1993a; Bommc et al.. 1994; DiVinci et al.. 1996); other studies find lp
loss to be a later event (Reichmann et al.. 1984: Leister et al., 1990; Longy el al., 1993).
Detailed deletion mapping suggests that at least three separate loci may be involved (Leister et
al.. 1990; Praml et al.. 1995a). though no tumour suppressor genes have yet been
unequivocally identified. Introduction of lp36 into colon cancer cells supresses
tumorigenicity (Tanaka et al., 1993). and this region contains a candidate tumour suppressor,
p73. which encodes a protein with homology to p53 that can activate p53 target genes and
interact w ith p53 (Kaghad et al., 1997). Screening of the remaining allele in neuroblastoma,
where this region of lp is also frequently deleted, does not demonstrate mutations, but this
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gene has yet to be examined in colorectal cancer. In mice, Pla2s (Type II non-pancreatic
phospholipasc A2). the gene thought to be the modifier of the mm phenotype. Mom-\, is
located on the region of the mouse genome syntonic to human lp35-36 (Praml et al., 1995b),
a region often involved in deletion in colorectal cancer (MacPhee et al., 1995). However,
since the mode of action of Pla2s appears to be non-cell-autonomous, with the product being
most active in the colonic lumen rather than within the cell, it is difficult to see how loss of
this gene in a cell would be selected for in neoplastic progression. Indeed, somatic mutations
of this locus in colorectal tumours in which one allele is deleted are extremely rare (Riggins et
al., 1995).
Loss of material on chromosome 8p also occurs in about half of all sporadic
colorectal carcinomas (Cunningham et al., 1993) and is associated with the change from
adenoma to carcinoma (Cunningham et al., 1994). There is strong evidence to suggest that
this region of the genome harbours at least two colorectal tumour suppressor genes
(Cunningham et al., 1993; Fujiwara et al., 1993; Yarcmko et al., 1994; Farrington et al.,
1996). though no such gene has yet been convincingly identified. A recently-identified
candidate gene is KILLER/DR5. a tumour necrosis factor (TNF)-receptor related protein
involved in p53-depcndent apoptosis. Partial gene screening of the remaining allele in
colorectal cancers has not yet identified mutations (Wu et al., 1997).
Loss of heterozygosity studies in w hich the tumour suppressor gene APC was
identified initially identified another gene, MCC (mutated in colorectal cancer), located within
lOOkb of APC, as being frequently lost in colorectal cancer (Solomon et al., 1987; Vogelstein
et al.. 1988; Ashton -Rickardt et al.. 1991; Miki et al., 1991). The gene product of MCC
shows sequence homology to a murine G protein receptor, important in signal transduction.
Mutations in the gene were detected in several sporadic cancers, leading to speculation that it
may play an important role in colorectal cancer development (Kinzler et al.. 1991b).
However, no further mutations have been reported and the role of MCC in colorectal
carcinogenesis appears to be very limited (Curtis et al.. 1994).
There may be a role for retinoblastoma (Rb) in colorectal cancer, but. at least in
earlier stage cancers, it does not appear to function as a tumour suppressor gene (Meling et
al., 1991). Rather, it undergoes low-level amplification in almost 30% of cancers, though this
tends to happen in aneuploid cancers and may therefore be coincidental to whole chromosome
13 gain. It may, however, play a role in suppression of metastasis (Ookawa et al.. 1993;
Young et al., 1993).
1.3 ,8. Genetic lesions and metastasis
Little is known about the genetic requirements for metastasis. Loss of heterozygosity
of the gene nm-23. located on chromosome 17q21, is associated with metastatic progression
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(Cohn el al., 1991; Lconc el al., 1991; Wang et al1993). although this is not found in all
studies (Haut el al., 1991). Loss of the p53 and DCC genes appear to be essential to
metastasis (Ookavva et al., 1993; Frank el al., 1997). In addition, loss of regions of 13q
(including the Rb locus) and 14q occur more frequently in later stage carcinomas and liver
metastases when compared to the corresponding primary tumours (Ookawa et al., 1993;
Young et al., 1993a). Motility-relatcd protein (MRP/CD9), a gene implicated in cancer cell
motility and metastasis, is down-regulated in metastatic lesions compared with primary
tumours (Cajot et al., 1997).
1.3 ,9. Killing of host immune cells through FasL
Intriguing new findings indicate novel mechanisms by which cancer cells survive and
proliferate. One of the w ays in which cancer cells do this may be through the disabling of
host immune response. In vitro experiments suggest that colon cancer cells may be involved
in the active killing of immune cells. Cell line SW620 (derived from a lymph node metastasis)
expresses functional Fas ligand (FasL). the triggering agent of Fas receptor (FasR)-mediated
apoptosis within the immune system and a key molecule in normal immune development.
SW620 is capable of killing Jurkat T cells in a Fas-mediated manner but. despite also
expressing FasR itself, is resistant to being killed in a Fas-mediated manner (O'Connell et al.,
1996).
1.3.10, DNA Methylation
Extensive hypomethylation is evident within the genomes of colonic neoplasms,
occurring even in very small benign adenomas (Goelz et al., 1985a). DNA is methylated by a
covalent modification of cytosinc residues by DNA methyl transferase, a modification which
affects gene expression (for refs sec Goelz el al., 1985a). Hypomethylation does not appear
to be a feature of hyperplastic epithelium, and is therefore thought to be an early event in
tumour development, preceding malignancy. In colorectal cancer, reduction in methylation
occurs selectively, with some genes consistently hypomethylated and others variable. Thus,
whilst hypomethylation would allow increased expression of proto-oncogencs. specific areas
of hypcrmethylation can occur and expression of tumour suppressors could be reduced in this
way (deBustros et al., 1988; Silverman et al., 1989). This may even be driven by
hypomethylation of genes such as DNA methyltransfcrase, although the mechanism of gene
selection is unclear (Laird et al., 1995).
Reduced methylation may contribute to genomic instability. Strand breaks are
associated with hypomethylation. probably because a reduction in methylation affects
chromatin structure, allowing increased access of changed regions to DNA damaging agents
such as nucleases (Lewis & Bird. 1991). In addition, it reduces binding sites for methyl-
specific proteins, making some regions more accessible to oxidant- and/or enzyme-induced
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strand breaks. Loss of chromosome condensation in this way may also lead to chromosome
non-disjunction (Schmid et al.. 1984). Thus, hypomcthylation may facilitate whole or partial
chromosome loss or gain and chromosomal rearrangement.
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Figure 1
Genetic changes associated with the development of colorectal cancer
This figure, based on a model proposed by Fearon and Vogelstein, (1996), shows the
temporal relationship between critical genetic events thought to be involved in development of
most colorectal cancers. APC mutations arc thought to initiate tumour formation in both
sporadic and inherited colorectal cancer, and are present in the germ-line of FAP patients.
Neoplasia progresses as a result of mutations in Ki-ras, one or more tumour suppressor genes
located 011 chromosome 18q. which include DCC, DPC4 and JV18, and p53. Mismatch
repair gene mutations, a feature of almost all HNPCC cancers and a proportion of sporadic
cancers, may speed up the tumorigenic process by increasing the rate of mutation in these or
other genes, but also predispose to mutations in other genes where 'target' repetetive sequences
are present, such as in the TGFp receptor subunit II (TGFpRII). Bax and hMSH6. The
genetic events associated with metastasis arc poorly understood, but may involve loss of
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1.3.11. Microsatellite instability and mismatch repair defects in colorectal cancer
Analysis of Hereditary Non-Polyposis Colorectal Cancer (HNPCC) has shown
underlying defects of the process of mismatch repair to be fundamental to development of
cancer in patients with this disease. This has laid the basis for a deeper understanding of
genetic instability in sporadic colorectal cancer.
The genetics of HNPCC and the mismatch repair pathway arc discussed briefly
below.
1.3.11.1. The genetic basis ofmicrosatellite instability in HNPCC
HNPCC is a dominantly-inherited disease characterised by predisposition to early-
onset colorectal cancer, often with familial clustering of endometrial and ovarian cancer and
sometimes stomach, small intestine, hepatobiliary, kidney and ureter cancer. It is thought to
account for up to 5% of all colorectal cancers, and could affect as many as one in 200
individuals (Leach el ai. 1993). HNPCC kindreds are defined by the Amsterdam Criteria,
which arc: (i) at least three relatives with histologically verified colorectal cancer, one of them
a first degree relative of the other two, (ii) at least two successive generations are affected, and
(iii) cancer onset is under 50 years of age in one of the affected persons (Vasen et al., 1994).
Cancers from up to 86% of HNPCC patients exhibit microsatellite instability (MSI),
a term which describes the acquisition of multiple new alleles at microsatellite sequences
throughout the genome (Aaltonen et al.. 1993; Ionov et a/.. 1993; Wu et al., 1994). Cells in
which this phenomenon is present lack efficient repair of small insertions/deletions and point
mutations which occur during replication, and have been designated replication error positive
(RER+) when instability is detectable at two or more loci (Aaltonen et al., 1993). Most
individuals w ith HNPCC carry germ-line mutations of components of the mismatch repair
pathway, principally hMSH2, which linkage analysis and mutation screening suggest accounts
for about 50% of all families (Pcltomaki et al., 1993; Liu et al., 1994; Nystrom-Lahti et
al.. 1994; Wijncn et al., 1995; Liu et al., 1996a). A further 40% of families harbour germ-line
mutations in the mismatch repair gene hMLHl. whilst hPMS 1. hPMS2. hMSH3 and hMSH6
are thought to account for the remaining 10% (Bronncr et al., 1994; Nicolaides et al.. 1994;
Papadopoulos et al., 1994; Tannergard etal., 1994; Liu et al., 1996a; Akiyama et al.. 1997;
Miyaki et al., 1997). Interestingly, families in which colorectal cancer is common but where
the criteria for HNPCC arc not met harbour very few mismatch repair gene mutations (Wijnen
etal., 1997).
The human mismatch repair process is still poorly understood, but more is known
about the homologous processes in bacterial and yeast systems. These are discussed below.
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1.3.11.2. Mismatch repair
Mismatch repair is critical for correction of mutations arising through errors of DNA
replication or some types of chemical damage. It has also been shown to play a role in the
processing of recombination intermediates (Rayssiguier et al., 1989; Baker et al., 1995; Selva
et al., 1995) and in control of a cell cycle checkpoint, triggering G2 cell cycle arrest (Hawn et
al.. 1995). Components of the mismatch repair system. MutS and MutL. have been
implicated in transcription-coupled nucleotide excision repair (Mellon et al., 1996). These
elements are also involved in recognition of neurodegenerative disease-associated trinucleotide
repeats (Pearson et al., 1997). though triplet repeats in the myotonic dystrophy and fragile X
locus are stable in mismatch repair-deficient cells (Kramer et al., 1996). Cells in which
effective mismatch repair is lacking possess a massively increased mutation rate referred to as
the 'mutator phenotype'.
MutHLS-type mismatch repair in E.coli and S.cerevisiae
Understanding the processes of mismatch repair in bacterial and yeast systems has
provided a basis on which to begin studying the repair process in man. The major mechanism
of mismatch repair in E.coli is the MutHLS pathway, summarised in Figure 2a. Mismatch
recognition. DNA binding, determination of strand-specificity and nicking of DNA involves
three key components. MutS. MutL and MutH. whilst excision and resynthesis involves a
number of other gene products. A similar mismatch repair system involving components
homologous to those of the bacterial MutHLS pathway has been characterised in S.cerevisiae
(Reviewed in Kolodner. 1996). This process is described in Figure 2b.
S.cerevisiae contains six proteins homologous to bacterial MutS. MSH1-6 (for MutS
Homologue). and employs three of these homologucs. MSH2. MSH3 and MSH6 directly in
the DNA binding component of its mismatch repair pathw ay. MSH2 recognises and repairs
both insertion/deletion and single base mispairs in conjunction with MSH6 and MSH3,
although the functions of MSH3 and MSH6 are partially redundant (Acharya et al., 1996;
Marsischky et al., 1996). The precise function of MSH4 and MSH5 is unclear, although
MSH4 mutants, whilst not deficient for mismatch repair, undergo non-disjunction of
homologous chromosomes at meiosis 1 (Ross-Macdonald et al., 1994). S.cerevisiae has at
least two homologues of MutL. MLH1 (MutL Homologue) and PMS1 (Post-Mciotic
Segregation) (Rccnan el al.. 1992 a&b). though no homologuc of MutH has yet been
identified. Mutations ofMSH2. MSH3. MSH6. PMS1 and MLHI and the endo/exonuclease
RTHl all cause widespread repetitive DNA tract destabilisation similar to that observed in
human cancer (Strand et al.. 1994 & 1995; Johnson et al., 1996a; Marsischky et a!.. 1996;
reviewed in Kolodner et al.. 1996). Furthermore, gene conversion events are common in
S.cerevisiae mutants lacking PMS1.MSH2 and MLHI. suggesting a role for these components
24
in regulation of recombination (reviewed in Kolodner. 1996). It is not known how daughter
strand recognition is accomplished in S. cerevisiae mismatch repair, since hcmimethylation is
not apparent.
Mismatch repair in man
In vitro studies of cells derived from human colorectal cancers with replication errors
demonstrate the presence of different complementation groups and the existence of trans¬
acting factors with the ability to correct defective repair (Umar et al., 1994; Boyer et ah,
1995). Current knowledge indicates that human cells undergo repair of base mismatches and
small insertion/deletion mutations by a process similar to that of S.cerevisiae (Figure 2c).
hMSH2. a 97kDa protein homologous to yeast MSH2 and bacterial MutS (Leach et al., 1993;
Fishel et a!.. 1993). is capable of independently binding mismatched nucleotides (Fishel et ah,
1994) and is thought to be an absolute requirement for mismatch repair; absence of hMSH2
results in an extreme mutator phenotype with numerous mutations in repeat units and
increased rate of point mutation (Bhattacharyya et al., 1994; Shibata et al., 1994; Boycr et
al., 1995). Generation of antibodies against hMSH2 has shown it to be an exclusively nuclear
protein highly expressed in the testis, thymus and proliferative cells of the gut, but also
expressed at lower levels in skin, heart, lung, skeletal muscle, smooth muscle, thyroid, liver
and the germinal centres of lymphoid follicles (Wilson et al., 1995; Leach et al., 1996).
hMSH2 acts in conjunction with I1MSH6 (also termed GTBP. or pi60) to form a heterodimer
termed hMutSa (Palombo et al., 1995; Papadopoulos et al., 1995). hMSH6 appears to be
preferentially involved in repair of base mismatches rather than frameshift mutations, since
homozygous mutation results in a rate of point mutation rate 350-450-fold higher than
mismatch repair-proficient cell lines [a rate comparable w ith that of other mismatch repair-
deficient lines] (Bhattachaiyya et al.,1994; Glaab et al.. 1997) and frequent reductions in
length of mononucleotide tracts (Drummond et al., 1995). but few microsatellite shifts
(Drummond et al., 1995). A further MSH2 homologue. hMSH3 (the human homologue of
yeast MSH3) appears to play a limited role in repair of some base/base mismatches and may
be more important in repair of insertion/deletion mutations, though its precise role in the latter
is still unclear (Risinger et al., 1996). As in yeast. MSH3 and MSH6 are partially redundant
in mismatch repair (Risinger et al., 1996).
There are three human homologues of bacterial MutL. hMLHl (homologous to yeast
MLF11), hPMS2 (homologous to yeast PMS1) and hPMSl. hMLHl is thought to act in a
similar manner to its bacterial homologue MutL. facilitating the formation of the final effector
complex. Hence, although mismatch binding is normal in cells lacking hMLHl (Branch et
al.. 1995). such cells exhibit a similar phenotypc to those deficient for hMSH2. displaying an
extensive mutator phenotype with shifts in di-, tri- and tctranuclcotidc repeats and high
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numbers of point mutations (Bhattacharrya et al.,1994; Parsons et al., 1993; Umar et al.,
1994). Cell lines lacking hPMS2 display a higher rate of point mutation than those with
defective hMLHl (Glaab et al., 1997) and lines lacking both hMLHl and hPMS2 display a
very high mutation rate (750-fold higher than a mismatch repair proficient control and 50-fold
higher than that in hMLHl-deficient cells). hPMS 1 has been implicated in mismatch repair
because of the identification of a germ-line mutation in a patient with HNPCC (Nicolaides et
al.. 1994). but its biochemical role is not yet understood. Many aspects of mismatch repair in
human cells, such as the method of strand-specific recognition and elements downstream of
hMSH2/hMSH6 in the repair pathway, are still unknown.
Other mechanisms ofmismatch repair
In addition to MutHLS-type repair. E.coli is equipped with base-specific mismatch
repair mechanisms, the very short patch (VSP) repair pathway and the MutY-dependent
pathway (Reviewed in Kolodner. 1995). VSP repair primarily corrects G-T mispairs to G-C,
(but also repairs G-U at lower efficiency) and requires MutS. MutL, Vsr. DNA polymerase I
and ligasc. The MutY-dependent repair pathway is one of three systems that can repair
oxidative damage to guanine, also correcting A-G and A-C mispairs to C-G and G-C at a
lower rate, and involves MutY, MutT. MutM (Fpg). DNA polymerase I and ligasc. It is
likely that base-specific mismatch repair similar to that in E.coli exists in eukaryotic cells; the
fact that cukaryotcs preferentially repair G-T mismatches to G-C implies that they have a
pathway that plays the same role as E.coli VSP repair, although the mechanism is likely to be
different. Similarly, the existence of a human MutT homologue implies that a MutY-like
pathway exists (reviewed in Kolodner. 1996). The existence of these pathways in human cells
has not been established and these mechanisms will not be discussed further.
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Figure 2
A/w/HLS-type mismatch repair in E.coli, S.cerevisiae and man.
A. Mismatch repair in E. coli
This diagram (based on Kolodner, 1996) illustrates the action of the E.coli MutHLS
mismatch repair system on a mispair at a replication fork. Repair is initiated when a base
mismatch incorporated by DNA polymerase escapes the polymerase's proofreading ability. A
protein encoded by the gene MutS binds the mismatch (Su & Modrich, 1986) and is bound by
a homodimer of the MutL product (Grilley et al., 1989). MutL does not become part of the
final effector complex, but acts to facilitate the formation of a stable structure between MutS
and a third protein. MutH, which binds a hemimethylated GATC site either upstream or
downstream of the mismatch. Thus, a stable complex forms with several thousand nucleotides
of DNA containing the mismatch looped out. Daughter strand recognition occurs by virtue of
the hemimcthylated state of newly-synthesised DNA; MutH nicks the unmcthylated strand and
excision and repair take place with the aid of DNA helicase II (uvrD gene product), DNA
single-stranded binding protein. DNA polymerase III holoenzvme, DNA ligase and one of the
single-stranded DNA exonucleases (Reviewed in Modrich. 1991 and Kolodner, 1996). Repair
can occur in either direction from the mismatch, and the molecular requirements are much the
same (Cooper et al., 1993).
B. Mismatch repair in S.cerevisiae
Show n here is an illustration of the mismatch repair pathway in S. cerevisiae (from
Marsischky et al., 1996). Repair of single base substitution mispairs is thought to occur
through binding of mismatched DNA by the MutS homologue MSH2 in complex with MSH6,
whilst either MSH6 or MSH3 can interact with MSH2 in the repair of insertion/deletion
mispairs. Two MutL homologues . MLH1 and PMS1 form a hcterodimer and complex with
MSH2. The downstream elements of this process are poorly understood, but are thought to
involve exonuclcases, helicases and enzymes required for DNA synthesis.
C. Mismatch repair in man
hMSH2. a human homologue of MSH2, binds single base mismatches in complex
with hMSH6. A further MSH2 homologue. hMSH3, is probably involved in repair of
insertion/deletion mutations, and may play a limited role in repair of some single base
mismatches. hMLH 1 and hPMS2 facilitate the formation of the final repair complex.
Elements downstream of the MSH2 and MLH1 homologues are still unknown.
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Mismatch repair in man





1.3.11.3. Mismatch repair gene products in human tumours
In human tumours, the mismatch repair genes usually behave as classical tumour
suppressor genes in their requirement for homozygous loss of function, with almost all RER+
tumour cell lines exhibiting complete lack of normal product from one mismatch repair gene
(Boyer et al.. 1995). However, a heterozygous repair effect has been demonstrated in some
RER+ cells in vitro (Parsons et al., 1993). Unlike other tumour suppressor genes, loss of
heterozygosity is not a common mechanism of gene deletion in sporadic colorectal cancer
(Aaltonen et al., 1993; Hemminki et al.. 1994). although loss of hMLHl does sometimes occur
(Tomlinson et al., 1996). Expression of hMSH2 in the large intestine is normally restricted to
the epithelium in the lower half of the crypts of Lieberkiihn where cell proliferation occurs.
This localisation is lost in at least some colonic neoplasms, which show intense staining
throughout the crypt, though the authors do not state the mismatch repair status of the
tumours studied (Leach et al., 1996). Dysplastic crypts also lose compartmentalism of Ki67.
a marker of cell proliferation, w hich is normally localised in the lower third of the cry pt, and
p21, normally in the upper non-proliferating third of the crypt. It is suggested that APC, also
localised in the upper part of the crypt and the only know n early genetic lesion in colorectal
cancer, may control the compartmentalism of hMSH2. p21 and Ki67 within the colorectal
epithelium (Polyak et al., 1996a).
An intriguing function of mismatch repair in vivo is its apparent association with
control of DNA methylation. Human cancer cells with functional mismatch repair are
methylation-proficicnt. and thus have the ability to transcriptionally deactivate genes, whereas
mismatch repair-deficient cells arc methylation-deficient and cannot deactivate genes
(Lengauer et al.. 1997a). It is not yet known which pattern is 'normal', nor whether the
phenotype is a direct result of mismatch repair deficiency, but it is clear that inability to
undergo appropriate DNA methylation could have enormous consequences for control of cell
growth.
1.3.11.4. Mouse models ofmismatch repair gene defects
Mice lacking Msh2 are healthy at birth and fertile, but in the first year develop RER+
tumours, mainly metastasizing lymphomas of T-cell origin (de Wind el al.. 1995; Rcitmar et
al.. 1995). Later in adulthood, most mice develop intestinal tumours and some also develop
skin tumours (Reitmair et al., 1996a). In culture, cells from these mice show microsatellitc
instability and lose hcterology-depcndcnt suppression of recombination. Thus, the murine
model supports the hypothesis that Msh2 mutation contributes to genomic instability in two
ways, firstly, by elevation of the rate of point mutations by failure to bind and correct
mismatched nucleotides, and secondly, by promoting chromosomal rearrangements through
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loss of recombination specificity. A further feature ofMsh2-/- cells is their 20-fold resistance
to the methylation agent MNNG compared with wild type cells, discussed below.
Mice deficient in Msh6 develop a spectrum of tumours similar to that ofMsh2-
deficicnt mice, but at a later stage in development, with 65% dead by 12 months (Edelmann et
al., 1997). Cells from these mice are deficient in single nucleotide mismatch repair but not in
repeat insertion/deletion repair, and therefore tumours from these mice do not develop
microsatellite instability.
Like Msh2 null mice, C/w.sA-dcficicnt mice arc prone to sarcomas and lymphomas,
with 40% developing tumours within the first year (Baker et al., 1995). Tumour tissue
exhibits MSI and evidence from the examination of two animals suggests that up to 8.9% of
normal cells (including germ cells) are also genetically unstable. The lack of gut tumours in
these animals may simply be because sarcomas and lymphomas develop earlier and. given
time, f/m'2-deficient mice would follow a similar course to Mv/72-deficient animals.
However, at least one mechanism of tumorigenic development which occurs in humans,
removal of TGFp-mcdiatcd growth restraint through mutation of a repetitive sequence within
the TGFP-receptor subunit II gene (Markowitz et al., 1995), is not effective in mice because
the murine TGFpRII gene does not contain a repetitive sequence. Whilst /7w.v2-deficient
females are fully fertile, males are infertile, exhibiting a low sperm count and producing only
grossly abnormal spermatozoa. This is thought to be due to aberrant homologue pairing at
meiosis 1. a phenotype consistent with the analogous phenotype in S.cerevisiae.
Mice deficient in Mlhl exhibit microsatellite instability in normal tissue (Baker et al.,
1996; Edelmann et al., 1996) and are probably susceptible to tumours (though in these reports
the mice were too young to be sure). Both sexes are infertile; spermatocytes exhibit high
levels of prematurely separated chromosomes, arresting in the first division of meiosis, whilst
oocytes appear normal, but fail to develop beyond the single cell stage. Since Mlhl was found
to localise to sites of crossing over on meiotic chromosomes, the evidence suggests that Mlhl
exerts it's effect on chromosome stability by facilitating the formation or stabilisation of
normal levels of chiasmata.
1.3.11.5. Methylation tolerance in mismatch repair deficient cells
Mismatch repair-deficient cell lines derived from human and murine RER+ tumours
demonstrate marked resistance to methylating agents such as N-methyl-N'nitro-N-
nitrosoguanine (MNNG) (Parsons et al.. 1993; Bhattacharyya et a/.. 1994; Aquilina et al.,
1995; Branch et al.. 1995; Reitmair et al., 1995; de Wind et al., 1995). The sensitivity of
normal cells to methylating agents is attributed to successive rounds of unsuccessful mismatch
repair. Unless methylated guanine residues (0''-McG) are repaired, the mismatch repair
system attempts to repair G-T mispairs but replaces mispaired thymines with the same and a
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single-strand nick occurs where repair cannot be completed. Replication results in double-
strand breaks and subsequent cell death. 06-MeG residues are normally repaired by the
methyl-guaninc methyl transferase (MGMT) enzyme, and it is interesting to note that the
colon has low levels of MGMT. perhaps one reason for the tissue-specificity of HNPCC.
1.3.11.6. Replication errors in the normal tissue ofHNPCCpatients
Most HNPCC patients do not exhibit replication errors in their normal tissue, even
under conditions that increase requirement for repair (Parsons et al., 1995; Tomlinson et
al.,\991). However, in one study, single-cell amplification of microsatellite sequences
identified two patients, one with a hPMS2 mutation and one with a hMLHl mutation, in
which a significant proportion of non-neoplastic cells exhibited replication errors (Parsons et
al., 1995). Furthermore, replication error-induced mutation appeared to be partially tissue-
specific: colonic and urinary tract cpitheha from the hPMS2-deficient patient demonstrated a
much higher error rate than did non-epithelial colonic tissue. Analysis of normal tissue from
other patients with known constitutive mismatch repair gene mutations, including one patient
with a different hMLHl mutation and others with mutations in hPMSl and hMSH2, revealed
no such instability. These results have clear clinical implications; therapeutic agents which
target mismatch repair-deficient cells would probably be lethal to non-tumorigenic cells in a
subset of patients.
It is puzzling that patients with such compromised mismatch repair, as well as mice in
which mismatch repair is totally lacking, do not develop large numbers of tumours as
mutations accumulate, as would be expected if accumulation of mutations were the only rate-
limiting step. Exposure to mutagens at doses sufficient to induce a comparably high mutation
rate would be expected to result in large numbers of tumours. Kinzler and Vogelstein (1996)
propose that this may be because mutations occurring in growth-controlling genes as a result
of a mutator phenotype produce conflicting signals within the cell, resulting in death of the cell
by apoptosis. They suggest that, in contrast, exposure of the gut to mutagens causes not only
mutation but also substantial cell death, and any regeneration which follows gives rise to cells
in which the apoptosis-promoting signals are necessarily switched off. It is these cells which
are susceptible to uncontrolled growth if they acquire, or have previously acquired, mutations
in growth-controlling genes. Thus, the authors speculate that irritant, rather that mutagenic,
dietary substances may be largely responsible for colorectal carcinogenesis, through induction
of tissue regcration. Changes in dietary habits, especially decreased intake of fibre, which
may absorb irritants, could account for the gradual lowering in age of onset of HNPCC.
1.3.11. 7. The genetic basis ofmicrosatellite instability in sporadic colorectal cancer
MSI is generally found to occur in around 15% of sporadic colorectal cancers
(Lothe et al., 1993; Young et al., 1993b: Kim et al.. 1994a: Aaltoncn et al., 1994; Bubb et al.,
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1996 and Chapter 3). though has been reported in as many as 28% of sporadic colorectal
cancers (Thibodcau et al.. 1993). It is rarely observed in sporadic colorectal adenomas, and
has thus been associated with the transition from adenoma to carcinoma in this disease
(Aaltonen el al., 1994; Young el al., 1993). Very striking parallels exist between clinical,
pathological and genetic features of such tumours and those from HNPCC patients,
suggesting that the diseases may share a common genetic basis. These features are discussed
in detail in chapter 3. but. most importantly, include a tendency to be located in the proximal
colon, show characteristic histological features, have diploid or near-diploid karyotype, show
a negative correlation with abnormalities of p53 and demonstrate a marked increase in patient
survival. Furthermore, the incidence of MSI is high (58%) in patients 35 years of age and
under with apparently sporadic cancer, indicating a possible genetic basis to a proportion of
the cancers occurring within this group (Liu el al., 1995a). Mutation analysis has so far
demonstrated few mutations of the mismatch repair genes frequently involved in HNPCC
development in RER+ sporadic cancers (Liu ct al., 1995b; Borresen et al., 1995; Bubb et al.,
1996; Konishi et al., 1996; Moslein et al., 1996; Herfarth et al.. 1997). Although hMLHl
and hMSH6 do account for a proportion of sporadic cases (Herfarth et al., 1997; Drummond
et al., 1995; Palombo el al., 1995; Papadopoulos el al., 1995), the dearth of mutations of the
genes principally responsible for HNPCC indicates either inappropriate mutation detection
techniques or the involvement of further components of mismatch repair in RER+ sporadic
cancer.
1.3.11.8. Defective mismatch repair as a mechanism ofcolorectal tumorigenesis
The high levels of deletion/insertion mutation associated with defective mismatch
repair may facilitate tumour progression by mutating other oncogenes or tumour suppressor
genes. Several genes show evidence of a substantially increased mutation rate in cancers with
defective mismatch repair. The TGFp receptor subunit II is very often disrupted by mutations
in an intragenic repetetive tract (Markowitz el al., 1995; Togo et al.. 1996) whilst about half
of all such tumours have mutation of a polvguanine tract in the apoptosis-promoting gene Bax
(Rampino el al.. 1997). Mutations of this sort also occur in a polynucleotide tract of hMSH6
in about 30% of RER+ cancers, although the significance of these mutations to mismatch
repair is not known (Malkhosyan el al., 1996a). A relatively high number of mutations at
repetitive nucleotide units is associated with mutator phenotype status in the p53 gene (Jego el
al., 1993; Greenblatt et al., 1996; Sood el al., 1997). the Hprt locus (Eshlcman et al., 1996;
Malkhosyan et al., 1996b). the insulin-like growth factor II receptor (IGFIIR) (Souza et al.,
1996) and APC (Huang et al., 1996b). Mutations of this type in APC are particularly
intriguing since APC is the earliest known genetic lesion to occur in sporadic tumours. This
implies that an underlying and undetectable low -level defect of mismatch repair may be
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present in some individuals, causing APC mutation early in development, perhaps resulting in
mutational mosaicism. This hypothesis is supported by the observation that extracolonic
features of FAP (caused by germ-line mutations in the APC gene) are present in a
significantly higher proportion of patients with microsatellite-unstable sporadic colon cancers
than stable tumours (Dunlop et al., 1996).
1.3.12. Chromosomal aberrations in colorectal cancer
1.3.12.1. Cytogenetic studies ofsporadic colorectal cancer
The majority of sporadic colorectal cancers display a grossly abnormal chromosome
content. Cytogenetic studies and. recently, comparative genomic hybridisation, have identified
the most common clonal changes to be loss of chromosomes 17p and 18, whilst loss of
chromosomes 1 (p3). 4q. 5(q2). 8p. 9p. 10(q2). 14, 15. 21 and Y. and gain of chromosomes 7,
8q. 13, 20 and X are also widely reported (Reichmann et al, 1981; Muleris et al. 1988 &
1990; Yaseen et al., 1990; Konstantinova et al., 1991; Bardi et al., 1993b; Barletta et al.,
1993; Herbergs et al.. 1994; Gcrdes et al.. 1995; Schlegel et al... 1995; Ried et al., 1996).
Structural abnormalities arc common, most often involving chromosomes 1, 5 and 17 (Gerdes
et al.. 1995). although no specific structural abnormality is prevalent in colon cancer and
balanced rearrangements arc rare (Muleris et al., 1990).
There is a striking progressive increase in chromosomal number and structural
rearrangement in the transition from proximal to distal large bowel (Reichmann et al,. 1982;
Muleris et al. 1990; Bardi et al., 1995). Classification of tumours according to the
chromosomal abnormalities they possess suggests that at least two distinct types of abnormal
karyotype arise, possibly indicating the presence of separate underlying mechanisms of
tumour development (Reichmann et al., 1982; Mulcris et al., 1988). These groups have been
termed 'Monosomic type' (MT) and 'Trisomic type' (TT) by Muleris et al. (1990). MT
tumours comprise 70% of colorectal cancers, and are characterised by loss of chromosome 18
and 17p. ability to undergo endoreduplication. low expression of the thymidvlate synthase
(TS) gene (Lasserrc et al., 1994). stable microsatcllite sequences (Remvikos et al., 1995),
frequent abnormal p53 function (Remvikos et al., 1997) and location in the distal colon or
rectum. In contrast. TT tumours characteristically gain whole chromosomes but never
undergo loss of both chromosome 17p and 18 or endoreduplication, occur predominantly in
the rectum, frequently display microsatellite instability and have high TS expression (Lasserre
et al.. 1994). Additionally, a small proportion (around 7%) of cancers have apparently normal
karyotype (termed NT), and are associated with significantly lower age of diagnosis than
those with abnormal karyotype, proximal location in the bowel, microsatellite instability
(Remvikos et al.. 1995; Schlegcl et al., 1995) and improved patient survival (Wolley et
al.. 1982; Kouri et al., 1990; Armitage et al., 1990; Rognum et al., 1991). The mechanisms
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driving each type of karyotypic evolution are not understood, but may reflect differences in
local environment such as carcinogen content throughout the colon, or. since
endoreduplication can occur as a consequence of hypoxic conditions, degree of angiogenesis
(Loffler et al., 1987). Alternatively, differences in fundamental molecular characteristics
associated with each karyotypic group may drive the acquisition of different chromosomal
abnormalities.
Chromosomal abnormalities in adenomas
Flow cytometry detects ancuploidv in 6% of adenomas (Quirke et al., 1986). whereas
more sensitive cytogenetic and in situ hybridisation techniques detect clonal abnormalities in
half to two-thirds of all adenomas (Reichmann et al., 1985; Longy et al., 1990 & 1993;
Griffin et al.. 1993: Muleris et al., 1994a; Ricd et al., 1996). Karyotypic abnormalities arc
more pronounced in larger adenomas (Quirke et al., 1986; Longy et al., 1993; Ried et al.,
1996), and these abnormalities tend to follow a TT pattern (Mulcris et al.. 1994a). suggesting
that TT carcinomas develop from adenomas more frequently than do MT cancers.
Histological evidence refutes this hypothesis, as the proportion of cancers containing remnants
of adenomatous tissue reflects the distribution of NT. MT and TT cancers (Muleris et
al.. 1994a). Rather. MT cancers which arise from adenomas may develop new chromosomal
aberrations, whilst TT cancers maintain their original adenomatous pattern of karyotypic
abnormality.
Trisomy 7 is a frequent abnormality associated with both malignant and adenomatous
proliferating cells, but has also been shown to occur in several cell types in vitro, including
cells from the stroma adjacent to colonic tumours (Bardi et al., 1993b). This may be a
feature of cells from the immune system participating in host response to the tumour (Bardi et
al., 1993b). an hypothesis supported by the fact that it is detectable in subpopulations of
tumour-infiltrating lymphocytes in renal tumours and surrounding kidney tissue (Dal Cm et
al., 1992).
1.3.12.2. Mechanisms ofchromosomal instability
Defects in DNA replication. DNA repair, telomere stability or chromosome
segregation may all potentially result in chromosome instability. Once the process has been
initiated, resultant chromosomal breakage or aberrant gene expression through mutation,
amplification, gene fusion or changes in regulatory control may result in self-perpetuation of
the instability state. Possible mechanisms by which instability occurs arc described briefly
below7.
Numerical chromosome changes
Degeneration of p53-mediated cell cycle control is thought to be an important means
by which cancer cells can achieve aneuploidy, structural abnormalities and amplifications.
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The process by which loss of p53 function leads to numerical chromosomal instability,
probably involving a spindle checkpoint through associations with microtubules and
centrosomc control, has already been discussed (1.3.2.1 & 1.3.2.2). However, a further
mechanism of numerical chromosome aberration which is suggested to be p53-independent
has recently been described (Lcngauer et al., 1997b). Lengauer et al. discovered that, in
vitro, cells from most colorectal tumours generate chromosome gains or losses as a dominant
trait at a high rate, estimated to be 1 ()~- per chromosome per generation (equivalent to a gain
or loss eveiy 5 cell generations). The mechanism by which this occurs is not yet known, and
although it does not appear to correlate absolutely with p53 status, the presence of a novel
mechanism of numerical chromosome instability remains to be proved categorically.
Structural chromosome changes
McClintock (1951) described two closcly-relatcd methods by which structural
chromosomal instability can occur. In the first, the chromatid type breakage-fiision-bridge
(BFB) cycle, newly broken chromatid ends can undergo sister chromatid fusion, giving rise to
a chromatid bridge configuration at anaphase. Further cycles of breakage, fusion and bridge
formation ensue until the broken end 'heals', presumably by the chance arrival at the broken
end of a stabilising sequence such as telomere-likc repeats. In a related process, the
chromosome type breakagc-fusion-bridge cycle, formation of a dicentric chromosome through
aberrant recombination at or near telomeres results in similar formation of an anaphase
bridge, repeated breakage and recombination until the chromosome becomes stable.
Several events may initiate the BFB cycle. Firstly, it may occur through the
acquisition of DNA strand breaks, in which case abrogation of normal p53 function, with
resulting loss of appropriate G1 cell cycle arrest, apoptotic response, and fully functional
DNA repair and replication, may play an important role. Defective components of nucleotide
excision repair, such as the genetic defect present in patients with Bloom's syndrome, can also
result in high levels of DNA breaks and genomic instability (Korn & Ramkissoon, 1995).
Secondly, there is evidence that intra-chromosomal telomerc-like sequences are hotspots for
recombination, breakage and chromosome fusion events that may initiate instability (discussed
in Hastic & Allshirc, 1989 and Morgan et al., 1996). Thirdly, loss of telomeric sequences
might initiate structural chromosome instability. Telomeres comprise multiple stretches of G-
rich repeats that function in chromosome replication and protect against end-to end fusions.
In germ cells, telomere length is maintained by the enzyme telomerasc. but in all other somatic
tissue the gene encoding this enzyme is not expressed (Kim et al., 1994b), resulting in
progressive reduction in telomere length with age (Hastie et al., 1990). It is thought that
severely shortened telomeres may signal a cell to enter senescence, providing a 'mitotic clock'
which counts the number of cell divisions. Telomere length is substantially reduced by about
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the same extent in both colorectal adenomas and colorectal carcinomas when compared to
normal colonic and blood tissue (Hastie et al., 1990), potentially increasing the risk of
chromosome fusions, dicentric formation, and subsequent acquisition of the breakage-fusion-
bridge cycle. However, maintenance of telomere length to some degree could be a critical
event in the progression to colorectal malignancy, allowing cells to avoid the acquisition of a
senescence signal associated with substantially shortened telomeres. Expression of
telomerase, though not present in colorectal adenoma, is detectable in colorectal carcinoma
(Chadcncau el al., 1995) and recent evidence suggests that telomere length can be maintained
in tumour cells without apparent telomerase activity (Bryan et al., 1997).
Gene amplification
In mammalian cells, the ability to amplify genes is restricted to genetically unstable
transformed or tumorigenic cells (Otto et al., 1989; Tlsty et al., 1990) and is a recessive trait
(Tlsty et al., 1992). Cytologically, amplified sequences may be present either
intrachromosomally, as homogcnously-staining regions (HSR's) or extrachromosomally, in the
form of double minutes (DM's). Both DM's and HSR's are rare in primary bowel cancers
(Ms M.Gerbault-Seureau. personal communication), although presence of DM's has been
demonstrated in vitro in one study (Briidcrlein et al.. 1990) and metastases of colorectal
cancers often contain DM's (Reichmann et al.. 1981).
In mammalian cells, sequences that contain amplified genes are not simple repeats and
often appear at a new chromosomal locations, suggesting that their generation involves several
steps (Stark & Wahl, 1984). Several models for gene amplification have been proposed. The
unequal exchange model proposes that recombination between DNA sequences on two
misaligned chromatids results in a duplication within one chromatid and a deletion within
other. Subsequent events are required to resolve the structure, which then becomes stable
(Stark & Wahl. 1984). However, this model does not predict that movement of DNA should
be associated with amplification. The rereplication model proposes that multiple initiation of
DNA synthesis during one cell cycle lead to an 'onionskin' structure which contains many
copies of the same DNA sequences (Stark & Wahl, 1984). Such multiple initiations of
replication have not been observed in mammalian cells (Windle & Wahl. 1992). A further
model suggests that DNA breakage can induce the breakagc-fusion-bridge cycle, leading to
chromosomal instability and gene amplification. Relaxation of cell cycle checkpoints, such as
in p53-dcficicnt cells, does indeed result in generalised genomic instability including an ability
to undergo gene amplification (Livingstone et al., 1992; Yin et al., 1992). The breakage-
fusion-bridge series of events appears to predominate in rodent cells selected for daig-induced
amplification of the dihydrofolatc reductase gene (DHFR), adenylate deaminase (AMPD) and
CAD. suggested by the observation that tclomeric and centromeric sequences arc found close
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to amplified regions within rearranged chromosomes (Bertoni et al., 1994). Alternatively, the
events following DNA breakage may include the generation of small acentric molecules that
can increase in copy number through unequal segregation on cell division (Windle et al.,
1991). and there is evidence that extrachromosomal amplification can precede integration into
the genome (Stark et al., 1989 & 1993; Wahl et al., 1989; Hamlin et al., 1991). Hypoxia,
which occurs when tumours outgrow their vascular supply, has been demonstrated to facilitate
gene amplification (Rice et al.. 1986), and this has been postulated to be due to the induction
of endonuclcasc activity, which may potentiate break-related genomic instability (Stoler et al.,
1992; Russo et al., 1995).
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1.4 Summary
Colorectal cancer arises as a result of a complex series of interactions between dietary
and genetic factors. This chapter has discussed current knowledge of aetiological factors, the
genetic abnormalities characteristic of colorectal cancer and the mechanisms involved in
initiating and perpetuating instability within the cancer genome. The genes known to be
involved in colorectal cancer development arc summarised in Table 1. overleaf.
Several lines of evidence suggest that sporadic colorectal cancers evolve along
different pathways according to the type of underlying genomic instability they possess. On
the basis of clinical, pathological and molecular features, two general groups can be defined,
one characterised by widespread microsatcllite instability, low levels of p53 abnormality,
near-diploid DNA content, proximal location, mucinous histology and better prognosis, the
other tending toward abnormal chromosome content, abnormalities of p53 function, distal
location and poor prognosis. Tumorigenesis in the first cancer type is thought to occur
because of defects of mismatch repair, whilst there is evidence that the second may be driven
by abnormalities of p53 (Carder et al., 1993 & 1995). Investigation of the nature and
coexistence of these types of instability forms the basis of this thesis.
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Table 1





Possible role in cancer cell
Methylation changes 100% Up-regulation of oncogenes, down-regulation
of tumour suppressor genes
APC mutation or loss >60% (but possibly
nearer 100%)
Disruption of cell adhesion and possibly





75% Loss of control of genomic stability through














Loss of TGFp-mediated growth control
Ki-ras mutation 50% Disruption of signal transduction
c-myc overexprcssion 50% Increased cell proliferation
Defects of mismatch
repair
15% Loss of control of genomic stability through
loss of replication fidelity
TGFpRIl mutation 60% of RER+
canccrs
Loss ofTGFp-mcdiated growth control
Bax mutation >80% of RER+
cancers
Loss of apoptosis promotion
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1.5. Aims of this study
The aim of this project was to investigate aspects of the microsatellite instability
phenotype. its genetic basis, and its interaction with chromosomal instability and defects of
p53. Firstly, the microsatellite instability phenotype was studied in more detail. Its
prevalence was determined in a large series of sporadic colorectal cancers from a Scottish
population, and related to clinical and pathological features in order to try to define a group of
cancers with a distinct biological basis. Also, the gene defect underlying this phenotype was
investigated by mutation analysis of a likely candidate gene. hMSH2. Secondly, the
behaviour of stable and unstable microsatellites over time was then studied in vivo through
analysis of tumours grown as xenografts in mice. These investigations are recorded in
chapters 3 and 4. Thirdly, the coexistence of microsatellite instability and p53 defects with
chromosomal abnormalities in human sporadic colorectal cancer was examined. Analysis of
patterns of chromosomal change was undertaken using Comparative Genomic Hybridisation
(CGH). a powerful DNA analysis technique which detects regions of genomic amplification or
deletion by simultaneous hybridisation of differently-labelled DNA derived from normal and
test tissue onto a normal mctaphase spread (Kallioniemi et a/., 1992; du Manoir et al., 1993).
A fluorescence ratio along the length of the chromosome is generated and changes in
chromosome copy number arc detected as a change in the ratio of green to red fluorescence.
This technique was used in order to try to define, firstly, the number of chromosome
abnormalities associated with each of these putative pathways of tumorigenesis and, secondly,
any unique patterns of chromosomal gain or loss associated w ith each molecular defect.
Tumours employed in this study were grown for one or two passages as subcutaneous
xenografts in SCID mice in order to eliminate stromal contamination. Similar methods were
then applied to a related study of transgenic mice lacking p53 and/or the mismatch repair gene
Msh2, in order to define levels of chromosomal change and MSI associated with these defects
in a system lacking the complicating factors present in human tumours.
A deeper understanding of these mechanisms of instability and their interactions is
crucial to ascertaining the nature and extent of heterogeneity within this disease. In the short
term, this may prove to be clinically important as it could help to determine appropriate
chemotherapcutic treatment, avoiding ineffective or harmful approaches. In the longer term, it




Suppliers of reagents arc listed in appendix I and II.
2.1 Tissue samples
Tissues were harv ested fresh from consecutive sporadic colorectal carcinomas
removed at operation between 1988-1994 at Edinburgh Royal Infirmary, and frozen at -70°C.
For all samples, representative portions of tumour were paraffin-proccsscd and stained with
haematoxylin and eosin in the Department of Pathology. University of Edinburgh, following
standard methodology. DNA was extracted as in 2.3.1. and xenografts were established
whenever resources permitted according to the method described below. Relevant clinical,
pathological and genetic details for primary and xenografted tumours included in this study
are given in Appendix 5.
2.2 Establishment of xenografts
Xenografted tumours were grown subcutaneouslv in severe combined
immunodeficiency syndrome (SCID) mice. These mice are deficient in both B and T
lymphoevte function due to an inability to correctly rearrange the immunoglobulin and T-cell
receptor genes by site-specific [ V(D)J] recombination (Bosma et al.. 1983). and thus do not
reject implanted foreign material. SCID mice do. however, retain non-specific macrophage-
mediated immune response, useful for removal of bacterial contamination from implanted
tumours.
Xenografts were established by implantation of two pieces of primary tumour
<5mm-3, first rinsed in cold wash solution (Glasgow medium supplemented with penicillin,
streptomycin. HEPES and 10% serum), through a small dorsal incision. Tumours were
allowed to grow until an externally visible diameter of about 1cm was reached, or when signs
of poor health were apparent, a usual duration of 28-56 days. Mice were then killed and
tumours either snap frozen in liquid nitrogen, frozen for future passage in a Glasgow
medium/dimethyl sulphoxide (DMSO) mix. or immediately implanted into another mouse.
2.3 Extraction of DNA
2.3.1 DNA extraction from frozen tissue
DNA was extracted from frozen tissue according to the method of Goelz et al.,
(1985b). Frozen tissue was chopped into small pieces in 0.5ml TE-9 SDS and 0.5mg/ml
proteinase K and incubated for 48 hours at 48°C. mixing occasionally. An equal volume of
water-saturated phenol was added, mixed and centrifugcd at 10000 x g for 2 minutes. The
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top layer was removed and an equal volume of PC-9 added to it, mixed and spun again. The
top layer was removed and an equal volume of 24:1 chloroform: isoamyl alcohol was added,
mixed and spun. The top layer was once again removed and 0.5 volume 7.5M ammonium
acetate and 2x volume cthanol added, mixed and left overnight at -20°C. This was
ccntrifuged at 4°C and 10000 x g for 20 minutes, the supernatcnt drained and the pellet
vacuum dried. The DNA was resuspended in 250pl TE, dissolved at 4°C for 3 hours and an
OD reading taken at 260nm. Concentration was adjusted to lmg/ml.
TE-9 SDS: PC-9: TE:
500mMTrispH8 50ml water-saturated phenol lOmMTris.
20mM EDTA 50ml chloroform ImM EDTA.
lOrnM NaCl
1% SDS
2,3,2 DNA extraction from blood
Blood samples were collected in 1% EDTA to prevent clotting. Blood was lysed in an
equal volume of lysis buffer for 30 minutes at room temperature, and equal volume of water-
saturated phenol added, mixed and centrifuged at 10000 x g for 20 minutes. The top layer
was removed and 0.5 x volume 7.5M ammonium acetate and 2 x volume cold isopropanol
added. This was left at -20°C overnight, spun at 8000 x g for 30 minutes and the pellet
drained until dry. The pellet was then resuspended in 250pl TE, dissolved for 3 hours at 4°C
and an OD reading taken at 260nm. Concentration was adjusted to lmg/ml.





2.4 Agarose gel electrophoresis
Agarose gels were prepared by adding 3g electrophoresis-gradc agarose to 150ml lx
Tris-borate-EDTA buffer (TBE) and heating to boiling in a microwave oven, with regular
mixing, to dissolve the agarose. The gel was stirred and allowed to cool to approximately
55°C before adding 20 ng/ml ethidium bromide and pouring into a 12x16cm gel mould with a
20-well comb. For checking PCR products, 8pi product was added to I pi loading dye before
loading. Products were run against 500ng of a suitable molecular weight marker, usually
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marker V (Boehringer-Mannheim Ltd). For larger fragments, cpX174 RF DNA/7/aeIII or lkb
ladder (Life Technologies Ltd) were used. Where quantitation of the product was required,
products were run against 4pl DNA mass ladder (Life Technologies Ltd). Details of
molecular weight markers are given in Appendix 3. Electrophoresis was carried out at 125V
in lxTBE buffer for variable lengths of time; for most purposes, migration of the
bromophenol blue dye approximately 5cm through the gel was sufficient. Gels were
visualised and photographed on a UV box.
IOxTBE:
107.8g Tris (0.89M)
55g Boric acid (0.89M)
7.44g Na2EDTA (0.02M)
in 11 DDW




0.25% xylene cyanol FF
2.5 Flow cytometry
2,5,1 Preparation of cells
Tissue was prepared for flow cytometry according to the method of Vindelov et al.
(1983). Tumour samples approximately 4mm^ were macerated using a sterile scalpel and
resuspendcd in 200 ul citrate buffer. 1 OOpil of this solution was added to 450pil Solution A to
lyse the cells, mixed gently and incubated at room temperature for 10 minutes. This solution
was then neutralised by incubation for 10 minutes at room temperature with 325|iil of solution
B. and cells were stained by the addition of 250pil of propidium iodide, Solution C, on ice for
10 minutes. The cell solution was then drawn through a syringe needle several times to

























in 21 DDW, pH 7.6
11 76g trisodium citrate
dissolved in 800ml DDW
50ml DMSO added and volume made to 1 litre with
DDW. pH 7.6.
2,5.2 Flow cytometry and analysis
Flow cytometry was performed on a Coulter EPICS-XL flow cytometer at an
excitation w avelength of 488nm. Before each use, the alignment of the laser was checked
using Immuno-Chcck allignment flourospheres (Coulter Electronics Ltd). Half-peak
coefficients of variation were typically less than 2%. At least 10,000 nuclei were analysed in
each sample, and tumour DNA content estimated by comparison with identical analyses of
normal tissue.
2.6 Immunocytochemical detection of stabilised p53
Stabilised p53 protein can readily be detected by immunohistochemical methods,
whereas the short half-life of the wild-type protein normally renders it undetectable by such
methods (Oren et ai, 1985). Immunocytochemistry was carried out using two antibodies,
pAb 1801 and D07. The pAb 1801 epitope is located between amino acids 45 and 91, and the
antibody is capable of reacting with both w ild-type and mutant p53. D07 also recognises an
amino terminal epitope and reacts similarly.
Slides were prepared in the Department of Pathology, University of Edinburgh, by
cutting 3gm sections from tissue stored in periodate-lysine-paraformaldehyde-dichromate
(PLPD) and embedded in paraffin wax. Sections were placed onto poly L-lysine (PLL)-
treated microscope slides.
Samples were deparaffinised by placing in xylene for 10 minutes, absolute ethanol for
1 minute. 740P for 1 minute and 640P for 1 minute and then rinsed in water. Endogenous
peroxidase activity was blocked by treatment in 3% hydrogen peroxide for 15 minutes. This
was followed by washing for 5 minutes in DDW and 5 minutes in phosphate buffered saline
(PBS). Slides were then wiped to remove excess fluid and marked around the area of the
section with a wax pen to retain solutions. lOOpl normal rabbit serum (NRS) diluted 1/5 in
PBS was added and left for 20 minutes. This was then drained and the slides incubated
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overnight at 4°C in a 1/100 dilution of either Do-7 or pAbl801 antibody in 1/5 NRS/PBS
After overnight incubation, the slides were washed twice for 5 minutes in PBS before
applying the secondary antibody. Biotinylated rabbit anti-mouse immunoglobulins (Dako
Ltd) were diluted 1/400 in the above NRS/PBS solution and lOOpl added to the slide and
incubated for 30 minutes at room temperature. Meanwhile, an avidin/biotinylated horseradish
peroxidase (HRP) complex (ABC kit, Dako Ltd) was made up by adding 1 drop of avidin and
1 drop of biotinylated horseradish peroxidase to 5ml PBS and allowing 30 minutes for the
reagents to conjugate. After incubation, the slides were washed twice in PBS for 5 minutes
and lOOgl ABC complex was added. Slides were incubated for 30 minutes at room
temperature then again given two 5 minute washes in PBS. They were then incubated for 3
minutes in diaminobenzidine (DAB) solution at room temperature to allow formation of brown
colouration through oxidation of DAB by HRP. washed for 5 minutes in DDW and
counterstaincd for 6 seconds in haematoxylin. They were washed until the water was clear
and dehydrated through 1 minute in 640P. 1 minute in 740P, 1 minutes in absolute ethanol
and 10 minutes in xylene. Slides were mounted with DPX mountant and examined under
lOOx magnification on a light microscope. Slides were scored positive if any nuclei stained
positive and extent of staining, which varied considerably, was noted. Although strength of









made to 50ml with Sorcnsen's phosphate buffer (0.05M, 0.24g KH7PO4
pH7.4).
5% potassium dichromate in 50ml DDW added
immediately before use




DAB solution: DAB buffer:
24ml 02.M Tris
38ml 0. IN HC1
100 pi 1/30 hydrogen peroxide solution 0.068 lg imidazole
DDW to 100ml, pH adjusted to 7.6
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2.7 Analysis of microsatellite instability
2 7.1 Polymerase Chain Reaction (PCR) of microsatcllite sequences for non-isotopic analysis.
The following microsatellite markers were analysed for evidence of genetic instability
in DNA from primary and xenografted tumours: D2S119. D3S1293. D8S282, D13S160,
D15S132. D17S849 (Gyapav el al. 1994) and are detailed in Table 2. At least four sites
were examined in each patient. Reactions were carried out in a 96-well plate and conditions
consisted of a final concentration of lx buffer. 20()pM each dNTP. 0.5 p.M each primer, 0.625
units Taq DNA polymerase and 25ng genomic DNA template. Magnesium ion concentrations
and annealing temperatures for each primer set are indicated in Table 2. Reaction volume
was made up to 25 pi with distilled deionised water (DDW) and one drop of paraffin oil was
overlaid to prevent evaporation. 30 cycles of amplification were carried out with each cycle
consisting of 1 minute denaturation at 95°C. 1 minute annealing at variable temperature
(Table 2) and 2 minutes extension at 72°C. Reactions were checked on a 2% agarose gel as
in 2.4.
PCR buffer (Buffer IV. Advanced Biotechnologies Ltd):















AFM077yb7 D2S119 2mM 55 214-232 CTTGGGGAACAGAGGTCATT
GAGAATCCCTCAATTTCTTTGGA
Al-M093xh3 D2S123 2mM 58 210-240 AAACAGGATGCCTGCCTTTA
GGACTTTCCACCTATGGGAC
AFM200zal D3S1293 2mM 50 116-144 ACTCACAGAGCCTTCACA
CATGGAAATAGAACAGGGT
AFM234vf4 D8S282 1.5mM 50 260-274 GGGCACAGGCATGTGT
GGCTGCATTCTGAAAGGTTA
AFM157xal 1 D13S160 1.5mM 55 229-241 CGGGTGATCTAAGGCTTCTA
GGCAGAGATATGAGGCAAAA
AFM265xf9 D15S132 ImM 55 69-83 CTGATAATAAAACCAGGAAGACAC
TATTGGCCTGAAGTGGTG
AFM234wg3 D17S849 ImM 50 144-174 CAATTCTGTTCTAAGATTATTTTGG
CTCTGGCTGAGGAGGC
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2.7.2 Analysis of microsatellites by silver staining
2.7.2. 1 Preparation ofdenaturing gel
35x50cm glass plates for vertical gel electrophoresis were thoroughly cleaned with
cream cleaner, rinsed well and wiped with 70% ethanol. In order to carry out silver staining
in situ, the gel was bound to the large glass plate by first treating with y-
methacryloxypropyltrimcthoxysilane ("bind silane"). Five microlitres of bind silane was added
to 1ml 95% ethanol. 0.05% acetic acid and spread over one plate. This was left to dry for 5
minutes and then cleaned twice with 95% ethanol before pouring the gel. The other plate was
treated by wiping with Gel Slick (AT Biochem), leaving for 5 minutes and cleaning with 70%
ethanol. 0.4mm spacer and square-well or shark's tooth combs were used. 200pi TEMED
and 200pl 10% ammonium persulphate were added to 60ml acrylamidc solution immediately
before pouring, the gel poured and left to set for at least one hour. The combs were removed,
the wells rinsed w ith 0.5x TBE and the gel preain at 70W in 0.5x TBE for one hour prior to
loading in order to heat to about 55°C.
Acrylamide solution: 1 x TBE buffer:
75ml 19:1 acrylamide:bis acrylamide 'Instagel' (Severn see 2.4
Biotech Ltd)
250g 500ml urea (7M)
50ml 1 Ox TBE
175ml DDW
stored protected from light at 4°C
2.7.2.2 Electrophoresis
Five microlitres of PCR product was denatured at 95°C for 5 minutes in 0.5X volume
short tandem repeat (STR) loading solution on a thermal heating block then placed on ice.
After rinsing the wells of the polyacrylamide gel w ith 0.5X TBE, 6pi of treated PCR product
were loaded into each well and electrophoresis carried out at constant power (70W) until the
xylene cyanol marker in the loading dye reached to bottom of the gel (about 4 hours).





0.05% xylene cyanol FF
49
2.7.2.3 Silver staining ofmicrosatellite gels
Gels were stained on a rocking platform according to the method of Bassam et al.
(1991). as detailed in Promcga's DNA Silver Staining System protocol. Ultrapure DDW
(UDDW) was used throughout. The plates were separated and the gel, attached to one plate,
was placed in fix solution for 20 minutes, washed three times in UDDW for 2 minutes and
placed in staining solution for 30 minutes. The gel was then washed for 10 seconds in
UDDW and placed in chilled developer solution until bands appeared. The reaction was
stopped with 10% glacial acetic acid for 5 minutes, the gel washed for 2 minutes in UDDW
and then read and photographed on a light box. For re-use, plates were soaked in 5M sodium
hydroxide for one hour and cleaned with detergent and 70% ethanol. Spent silver nitrate was








made to 1 litre with Ultrapure
water
Developer Solution:




made to 1 litre with Ultrapure
water
2 .7 ,3 Radioactive detection of microsatellite sequences
2.7.3.1 Radioactive isotope labelling
PCR reactions were carried out in a thermal cycler using 96-well plates. The
reactions were labelled with y-[33p]dATP and the products separated by vertical
electrophoresis in 6% denaturing polyacrylamide gel.
Oligonucleotide primer sequences were diluted with sterile distilled water before use,
giving a final concentration of lOng/pl. The CA strand primer in each reaction was 5' end-
labelled with y33p dATP. using T4 polynucleotide kinase. Labelling was performed prior to
each PCR reaction. lOng of oligonucleotide (lOng/pl) was added to 2 pi of 5x buffer, 6.2pl of
sterile distilled water. 0.3pl of y33p dATP (equivalent to 3pCi) and placed on ice. 0.53pl (5U)
of T4 polynucleotide kinase was then added giving a total volume of lOpl and the reaction
placed in a water bath at 37°C for one hour. This amount was sufficient for up to 10 PCR
reactions.
5X T4 polynucleotide kinase buffer:





2.7.3.2 Preparation of PCRs
Polymerase chain reactions were carried out as in section 2.7.1, except that prior to
amplification an additional 1 pi labelled primer was added to each reaction. After
amplification. 5pi stop solution was added to 5pi PCR product, the mixture boiled for 3





0.1% xylene cyanol FF
2.7.3.3 Polyacrylamide pel electrophoresis of raclio-lahelled microsatellite sequences
A 6% denaturing polyacrylamide gel was used in vertical sequencing gel apparatus
with 0.5xTBE buffer. Gels were prepared in 35cm x 50cm vertical DNA sequencing
electrophoresis plates. Plates were thoroughly cleaned with 'Decon' detergent, rinsed with
water and finally wiped with 70% alcohol. One plate was siliconised by wiping with 3ml Gel
Slick, air drying and removing excess with water. Plates were assembled with 0.4mm spacers
and combs. Sixty microlitrcs of TEMED and 60pl 25% ammonium persulphate (APS) were
added to 60ml stock acrylamide immediately prior to pouring and the gel was allowed to
polymerise for 1 hour. The gel was pre-run for an hour in 0.5xTBE at 70W to reach 55°C.
5pi of combined PCR product and stop solution denatured as described above were
added to the wells after rinsing w ith TBE to disperse urea. The gel was then run at 70W for
3-6 hours or until the xylene cyanol marker dye approached the end of the electrophoresis
plate. It was then fixed for 10 minutes in a solution of 10% methanol and 10% acetic acid,
transferred to Whatman No 17 paper and dried on a vacuum gel drier. Autoradiography was








2.7.4 Microsatcllite analysis with automated laser fluorescence (ALF) DNA sequencer
An Automated Laser Fluorimeter (ALF) DNA sequencer was used in the assessment
of microsatellitc instability in tumour DNA from primary sporadic colorectal cancers. This
work was carried out by Mr C.Cunningham and will be described only briefly.
PCR was carried out under standard conditions with the inclusion of one
fluorescently-labclled primer. Appropriate internal standards were added and samples were
alkali and heat denatured and rapidly cooled prior to electrophoresis on a 7M urea 6% MDE
gel (AT Biochem) using an ALF DNA sequencer. Microsatellite instability in tumour DNA
was determined by a shift of the allele peak to a new position when compared with
corresponding normal DNA.
2.8 Mutation detection in hMSH2
2.8,1 Mutation detection by single-stranded conformational polymorphism analysis
The hMSH2 gene covers about 73kb of genomic DNA and spans 16 exons (Kolodner
el al.. 1994). Primers were designed to amplify each exon separately, including splice sites
where possible. Mutation screening was carried out using a combination of SSCP and
heteroduplex analysis of PCR-generated DNA fragments. Initially, SSCP analysis was
carried out on exons 2-15, for which the intron-exon boundaries were known (Dr K.Kinzler,
personal communication). Each exon was amplified separately by PCR using primers which
included most 5" and 3" splice sites. Some exons, particularly 3, 12 and 15 proved difficult or
impossible to resolve by this method, producing cither smearing or only a single band on the
gel. The inability of these fragments to form discrete secondary structures that can easily be
resolved on an acrylamide gel may be related to the high A-T content of the gene, although the
problematic fragments did not differ in their A-T content from other resolvable hMSH2 PCR
fragments. Where SSCP analysis did not produce a satisfactory result, heteroduplex analysis
was carried out. Exons 1 and 16, when their sequences became available, were examined by
heteroduplex analysis only as this proved to be somewhat faster than SSCP. Samples which
showed an abnormal banding pattern by either method were sequenced using a modified
dideoxy chain termination method.
2.8.1.1 Polymerase Chain Reaction ofthe hMSH2 gene.
All 16 exons of hMSH2 were amplified using the primers described in Table 3.
Sequences of the intron-exon boundaries were kindly provided by Dr K.Kinzler. Primers were
designed to amplify each exon separately, including splice sites where possible. Reactions
consisted of 50pl volumes containing lOOng genomic DNA and a final concentration of 0.25
to 0.5pM each primer. 200pM each dNTP, 2.5mM magnesium chloride (except exons 15 and
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I. which contained 15mM), lx buffer and solutions were overlaid with one drop of paraffin
oil. This was heated to 95°C for 5 minutes, cooled to 80°C and 1.25U of thermostable DNA
polymerase added to 'hot start" the reaction, a technique found to significantly improve
reaction specificity in many cases. PCR was carried out for 30 cycles at variable annealing
temperatures (Table 3) with the initial 2 cycles annealing at higher temperature than
subsequent cycles (as described in the footnotes to Table 3) in order to promote specific target












Printer sequences (5' to 3')
1 44 302 GCGCATTTTCTTCAACCAGG
AAAGGAGCCGCGGCCACAA
2 44 236 ACATGTAATATCTCAAATCTG
AAATAAGTAAATTAAAAAGGAAG
3 55 376 AAAGTATGTTCAAGAGTTTGT
ATCTCCTCTATCACTAGACT
4 44 212 TTATTCCTTTTCTCATAGTAG
TTGTAATTCACATTTATAATCC
5 46u 241 TGGCTATAGGAAATCTTCG
AACCATTCAACATTTTTAACC
6 55 225 ACTAATGAGCTTGCCATTC
AACTGCAGGTTACATAAAAC
7 44 225 AAATATTTTACATTAATTCAAG
GTATGIGTTGAAGGAAAAC
8 49 279 GATCTTTTTATTTGTTTG
AAAAATAACTACTGCTTA
9 50c 191 GGATTTTGTCACTTTGTTC
TAGGACAAAAGAATTATTCC
10 48 195 TGGTAGTAGGTATTTATGG
CATTTAGGGAATTAATAAAG
11 54 250 ACTGTTATTTCGATTTGCAG
CCAGGTGACATTCAGAAC
12 54 159 TTTATTATTCAGTATTCCTGTG
CCACAAAGCCCAAAAACCA
13 48 325 AGAAAGAAGTTTAAAACTTGC
CTATCTTCAAGGGACTAGG
14 44 281 TACCACATTTTATGTGATG
TACTGAATTTAGAGTACTC
15 48u 325 GCTGTCTCTTCTCATG
TAATAATAGAGAAGCTAAG
16 50 270 AGAIATTTTAATTACTAATGGG
AATATCTTATTAAGTTGATAGC
a
Unless otherwise stated, the first two PGR cycles were carried out at annealing temperatures 2°C higher than
the following 28, which were at the temperature stated in table 2.
^
Annealing for 1 cycle at 52°C followed by stepdown by 1°C each cycle, ending with 26 cycles at 44°C.
c
Annealing for 1 cycle at 54°C followed by stepdown by 1°C each cycle, ending with 28 cycles at 50°C.
^
Annealing for 1 cycle at 52°C followed by stepdown by 1°C each cycle, ending with 28 cycles at 48°C.
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2.8.1.2 SSCP electrophoresis ofhMSH2 PCR products
Gels were poured in 16x20cm vertical electrophoresis plates with 0.75mm spacers
and 20-wcll combs. To 30ml 0.5xMDE gel solution, 120ptl 10% ammonium persulphate and
12)0.1 TEMED were added, the solution mixed and poured immediately. It was allowed to
polymerise at 30°C for one hour. Five microlitres of PCR product were denatured for 5
minutes at 50°C in 1 pi denaturing solution. Three microlitrcs of stop solution were added to
each tube and the samples loaded quickly onto the gel. after rinsing the wells with lxTBE.
Electrophoresis was carried out at up to 30W cooled to approximately 20°C by a circulating
water bath. Running time varied according to fragment size; good fragment separation was
achieved when samples were run such that the xylene cyanol marker dye had migrated
between 20 and 60cm throught the gel. Electrophoresis buffer was lxTBE.
0.5xMDE gel solution: Denaturing solution: lOxTBE:
7.5ml MDE gel 0.5M sodium hydroxide See 2.4
1.5ml glycerol lOmM EDTA
3ml lOxTBE
18ml DDW
2.8.1.3 Silver staining ofSSCP gels
Silver staining of SSCP gels was carried out in a shallow glass dish on a gently
shaking platform, carefully pouring off used solutions. Ultrapure water was used throughout.
Staining was done using the BioRad silver stain kit.
The gel was removed from both plates and placed in 40% methanol for 30 minutes,
followed by two 15 minute washes in 10% ethanol. The gel was then treated with oxidiser
solution for 3 minutes and then repeatedly washed for two minutes with water until absolutely
colourless. It was then placed in staining solution for 15 minutes, washed twice for 30
seconds in water and then treated with developer solution until a brown precipitate formed.
The developer was replaced with fresh and the gel left until bands appeared. The reaction was
stopped with 5% glacial acetic acid for 5 minutes and the gel transferred onto 3MM paper and
dried at 80°C for one hour on a gel dryer.
BioRad silver stain kit components (exact composition not given):
Oxidiser solution: Staining solution: Developer solution:
potassium dichromatc silver nitrate solution sodium carbonate and paraformaldehyde
solution in Ultrapurc water in Ultrapure water solution in Ultrapure water
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2.8.1.4 Restriction enzyme digestion ofhMSH2 exon 5 and exon 2 PCR products
Twenty-one products generated from exon 5 were abnormal by SSCP and sequencing
revealed changes in the length of a polyadenine tract within intron 5 (see Chapter 3, Results).
In order to eliminate the possibility of other mutations in the exon, this portion was cleaved
away with Tru 11 and the remaining exonic fragment reanalysed by SSCP. Similarly, 8
products generated from exon 2 which were abnormal by SSCP but revealed only a length
change in an intronic polynucleotide tract by sequencing, were cleaved with Pst I to allow
reanalysis of the exonic portion by SSCP. Reactions were carried out by adding 10U enzyme
(usually 1 pi) to lOpl PCR product and 1 x concentration of appropriate buffer in a total
volume of 3()pl. mixing and incubating for at least 2 hours at 37°C for Pstl or 65°C for
Trull. Samples were then cthanol-precipitated by adding 3 x volume of ice-cold ethanol and
one tenth volume of 7.5M ammonium acetate and leaving at -70°C for 30 minutes. They were
then centrifuged at 10000 x g for 15 minutes, the supematent removed and the pellet washed
in 70% cthanol. Finally, the pellet was centrifuged at 10000 x g for 15 minutes at 4°C, the
supematcnt removed, the pellet air dried and resuspended in lOpl TE buffer. Half of this
quantity was then used for SSCP analysis as in 2.8.1.2.
1 Ox Pstl buffer: 10 x Trull buffer: TE:
500mM Tris-HCl (pH8.0) lOOmM Tris-HCl (pH8.5) 10mMTrispH8
lOOmM MgClg lOOmM MgClg ImM EDTA
500mM NaCl 1MKC1
lmg/ml BSA
2.8,2 Restriction digest assay for hMSH2 exon 13 polymorphism
A previously-reported polymorphism in hMSH2 intron 12 (Fishel et al., 1993; Hall et
al., 1994). a T-C change at the -6 position of the intron 12 3" splice site, was found in three
patients by sequencing samples with heteroduplex bands (see Chapter 3, Results). In order to
confirm its presence in other samples, a restriction digest assay for the polymorphism was
designed. Sfcl was chosen for the assay as it cuts at CTPuPyAG; thus, the T-C change creates
the site, cleaving 40 base pairs from the 281 base pair product. All DNA samples were
checked by this method. One unit of Sfcl was added to 5pl PCR product, 1 pi lOx buffer, 100
pg/ml bovine serum albumin (BSA) and the volume made to I Opl with DDW. Digestion was
allowed to proceed for one hour at 37°C and the reaction was stopped by heating to 65°C for
10 minutes. Digestion products were separated by electrophoresis on a 3% agarose gel
containing 50 ng/ml ethidium bromide in lxTBE against 500ng marker V (Boehringcr
Mannheim Ltd) and gels photographed on a UV box.
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2 8 3 Restriction digest assay for polymorphism in the hMSH2 untranslated region 5' to the
exon 1 coding sequence
A frequent abnormality in the exon 1 PCR fragment was detected by the presence of
an extra band by hcteroduplex analysis and a consistent SSCP banding pattern (See Chapter,
Results, and figure 6). Sequencing revealed a C->G substitution at the +9 position of intron
1. a change which destroys a Ben J cleavage site. DNA samples from 106 healthy blood
donors were screened by restriction enzyme digest assay to ensure that the sequence alteration
was present in the normal population and to assess the frequency of the alteration in the
population. Restriction enzyme digests of hMSH2 exon 1 PCR product (obtained as in
2.8.1.1) contained lOpl PCR product, 10U Ben J and lx buffer in a final volume of 20pl and
were carried out at 37°C for at least 2 hours. This was followed by electrophoresis on a 20%
polyacrylamidc gel. 10ml gel was prepared by mixing 5ml of 40% 29:1 acrylamide:bis
acrylamide with 1ml lOxTBE and made to 10ml with DDW. Just before pouring, 20pl 10%
APS and 5pi TEMED were added to the gel solution, mixed and poured between 6x10cm
glass plates separated by 0.8mm spacers and combs (BioRad Mini-Protean Gel System). The
gel was allowed 30 minutes to polymerise, after which the wells were rinsed with lxTBE and
the samples, mixed with 0.5x volume loading dye, were loaded into the wells. Electrophoresis
was carried out in lxTBE at 100V until the xylene cyanol had migrated to the bottom of the
gel. The gel was then removed, stained for 15 minutes in 50pg/ml ethidium bromide in
lxTBE and visualised under UV. This work was carried out by Mr R. Morris.
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2,8.4 Heteroduplex analysis of hMSH2 PCR products
2.8.4.1 Preparation ofPCR samples
PCR reactions were carried out as above (section 2.8.1). PCR product was heated to
95°C to denature double-stranded DNA and then cooled slowly to 37°C over 30 minutes,
allow ing reannealing of single strands. Where mutant alleles are present, these form
heteroduplexes with normal alleles. Since heteroduplex molecules tend to be retarded in
comparison with homoduplexes on running through polyacrylamide gel, they are readily
detectable by electrophoresis. Cooled samples were prepared for electrophoresis by adding 4p
1 to 2pl loading dye (see 2.4).
2.8.4.2 Electrophoresis
35x50cm glass plates for vertical gel electrophoresis were used with 0.4mm spacers
and square or shark's tooth combs. Both were pre-treated: the first was wiped with 3ml Gel
Slick, allowed to dry for 5 minutes then wiped with 70% cthanol. The second was treated
with 20pl gamma-methacryloxypropyl-trimethoxysilane in 5ml distilled water (pH 3.5 with
acetic acid) in order to attach the gel to the plate for staining and dried for ten minutes before
wiping four times with 95% ethanol. A lxMDE gel was prepared by addition of 240pl 10%
ammonium persulphate and 24pl TEMED to 60ml gel mix. The gel was poured and allowed
to set for 1 hour before use. 5pi PCR product and loading dye prepared as above was loaded
onto the gel along with 0.5 pg of a molecular weight marker, Marker V (Boehringer Mannheim
Ltd), and a control sample known to separate into heteroduplex and homoduplex bands.
Electrophoresis was carried out at 0.71 to 0.8kV for 16 hours in 0.6x TBE running buffer.
This slow running of the gel ensured that it remained cool.
MDE gel mix: lOxTBE:





2.8.4.3 Silver staining of heteroduplex gels
Gels prepared w ith MDE modified acrylamide. such as those used for heteroduplex
analysis, were found to dissociate from bind silane-treated plates on addition of the acetic acid
solution fixative stage of a standard silver staining protocol (section 2.7.2.3). Therefore,
heteroduplex gels were stained using a different silver staining protocol. Minor modifications
to this method resulted in high quality silver staining.
The entire protocol was carried out on a gently rocking platform using Ultrapure
water (UDDW). The glass plates were separated and the gel soaked for 10 minutes in 10%
ethanol followed by 10 minutes in 1% nitric acid It was then rinsed for 5 minutes in UDDW
and placed in staining solution for 20 minutes. After rinsing for 10 seconds with UDDW, the
gel was placed in developer solution until a brown precipitate appeared, when the developer
was replaced with fresh. When bands appeared, the reaction was stopped with 0.1M citric
acid for 10 minutes, the gel rinsed in UDDW for a further 5 minutes and then interpreted and
photographed on a light box. For re-use, plates were soaked in 5M sodium hydroxide for one
hour and cleaned with detergent and 70% ethanol. Spent silver nitrate was treated with
sodium chloride to precipitate the silver before disposal.
Staining solution: Developer solution:
2.04g silver nitrate in 11 UDDW 160g sodium carbonate (decahydrate)
lml 37% formaldehyde
in 21 UDDW
2.9 Sequencing of mutations
2,9,1 Strategy
All tumours showing aberrantly migrating bands by SSCP or heteroduplex analysis of
hMSH2 were sequenced along with their corresponding normal DNA using the dideoxy chain
termination method (Sequenase version 2.0, United States Biochemicals). Exon 1 was
sequenced directly from PCR product. Exons 2, 10. 12, 13, 15 and 16 were not amenable to
direct sequencing and so were first made blunt-ended, cloned into a vector and sequenced as
either single or pooled colonies. For exons 3 and 5, biotinylated primers were available,
allow ing sequencing to be carried out after separation of the DNA into single strands using
Dynabeads (Dynal Ltd). Further sequencing was carried out using high-fidelity polymerase
where single Tctq polymerase-amplified clones had been analysed, as the rate of Taq
polymerase-induced errors was found to be high.
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2.9.2 Cloning and sequencing of blunt-ended PCR products
2.9.2.1 PCR reactions and creation of blunt-ended DNA
PCR was carried out as described in section 2.8.1.1 to produce 200pl of each sample
to be sequenced. Surplus reaction reagents were removed using a fine sephadex G50 Quick
Spin column (Boehringer-Mannhcim Ltd). The column was first inverted to resuspend the
sephadex and then spun at 6000 x g for two minutes to dry. 100pi PCR product was added to
the top of the column and it was spun at 6000 x g for 4 minutes and the drops collected. This
was repeated with the remaining lOOpl product. The cleaned PCR product was precipitated in
20pl 7.5M ammonium acetate and 400pl cold absolute ethanol (-20°C) at -70°C for 30 min,
spun at 10000 x g for 15 min at 4°C. washed in 400pl cold 70% ethanol and spun again at
4°C for 15 minutes. The pellet was drained, vacuum dried for 15 min and resuspended in
16.5pi DDW. Taq polymerase-gcnerated products were then treated with the Klenow
fragment of DNA polymerase 1 to produce blunt-ended fragments. PCR product was
incubated at room temperature with 5U Klcnow in a final concentration of lx buffer and
0.5mM dNTPS. The reaction was stopped after 30 minutes by adding 1 pi 0.5mM EDTA
pH8 and the DNA spun through a G50 Quick Spin column (Boehringer-Mannheim Ltd), as in
2.9.2.1. to remove unincorporated dNTPs. DNA was quantitated by electrophoresis of 5pl
sample against 2pi quantitative DNA mass ladder on a 2% agarose gel containing as in 2.4
and checked under UV.
Klenow buffer:
Any restriction enzyme buffer can be used (eg Pst 1 buffer, see section 2.8.1.4)
2.9.2.2 Preparation of vector
2pg pGEM 7zf+ vector was linearised with 10U Smal at 25°C overnight in lx buffer
and surplus reagents removed using a G50 Quick Spin column (Boehringer Mannheim Ltd) as
in 2.9.2.1 Digestion was checked by electrophoresis of 500ng DNA on a 0.8% agarose gel
containing 50ng/ml ethidium bromide and run in lxTBE against 500ng uncut vector and A,
DNA/Hindlll molecular weight marker (Boehringer-Mannheim Ltd). The gel was checked on
a UV box.
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lOx Smal buffer: lx TBE:
33()mM Tris acetate see 2.4
1 OOmM magnesium acetate
660mM potassium acetate
50mM dithiothreitol
pH 7.9 at 37°C
2.9.2.3 Ligation reactions
For each sample to be sequenced 2 ligation reactions were set up, one with a 3:1 and
one with a 10:1 molar ratio of insert:vector. Reactions consisted of lOOng vector, 30ng or
lOOng blunt-ended PCR product, lx buffer and 5U T4 ligase in 20pl volume. A negative
control, containing everything except ligase, was also included. Ligations were carried out at
16°C overnight.






25% (w/v) polyethylene glycol-8000
2.9.2 4 Transformation ofcompetent cells
Transformations were carried out in DH5a competent E coli cells. These cells
undergo cx-complementation of the (1-galactosidase gene when transformed with an
appropriate plasmid and can therefore be used for blue/white colony screening when grown in
the presence of X-gal.
Ligation reactions, including the positive and negative control, were diluted 1/5 with
DDW and 1 pi (about l-2ng) added to 20pi competent cells (thawed on ice) and gently mixed.
After 30 minutes on ice, the cells were heat shocked at 42 °C for 40 seconds then placed
immediately on ice again. 80pl SOC medium was added to each and the tubes were shaken at
37°C at 300rpm for one hour. The entire cell suspension was then plated onto a 50pg/ml L-
Amp agarose plate spread with 800pg X-Gal and 800pg IPTG in 1ml L-broth for blue-white
screening. Plates were inverted and incubated overnight at 37°C. Remaining competent cells
were refrozen at -70°C by first placing in a methanol/dry ice bath for five minutes. Cells were







autoclavcd and cooled before adding:
lOmM MgCl2.6H20 (filter sterilised)





Initially, all samples were grown as minipreparations as pooled clones by picking
between 20 and 100 separate large white colonies (containing insert) from each plate using
sterile pipette tips. All colonies were put into 10ml L-broth containing 50gg/ml ampicillin and
incubated at 37°C. shaking at 300rpm. overnight. It later became necessary to sequence single
colonies (see section 2.9.1), and these were grown up in exactly the same way but adding only
one colony to each miniprep. Colonies were only used if the concurrent control plates
appeared correct, ie positive control showed blue colonies and negative control showed no (or
very few) colonies.
Extraction of DNA was carried out using the Wizard Miniprep kit (Promega Ltd).
3ml broth was spun at 10000 x g to pellet cells. The pellet was resuspended in 200gl
resuspension solution and 200gl cell lysis solution added and the tube inverted until the
solution cleared. 200gl neutralization solution was then added and the tube inverted to mix.
The solution was then spun 10000 x g for 5 minutes and the supernatent mixed with 1ml
Wizard Miniprcp DNA Purification Resin and mixed. This was poured into the barrel of a
5ml syringe attached to a Wizard Minicolumn. placed into a vacuum manifold and a vacuum
applied. The vacuum was broken and 2ml column wash added and the vacuum reapplied.
After emptying the tube, the column was dried by applying the vacuum for a further 2
minutes. The syringe barrel was then removed and the column spun at 10000 x g for 20
seconds to remove any residual column wash. Fifty microlitres of TE was added and after 1












50mM Tris-HCl pH 7.5
lOmM EDTA
lOOpg/ml RNAse A
Cell lysis solution: Neutralization solution:
see 2.9.2.4 200mM NaOH 1 32M. potassium
acetate, pH4.81% SDS
Wizard Miniprcps Column wash solution:
DNA Purification 200mM NaCl
Resin: constituents not 20mM Tris-HCl pH7.5
given by manufacturer 5mM EDTA
TE:
See 2.3.1
diluted with 55ml 95% cthanol prior to use
2.9.2.6 Sequencing reactions
Sequencing of cloned PCR fragments was carried out according to the protocol
provided with the Sequcnase Version 2.0 kit (Amcrsham International pic). Double-stranded
plasmid DNA containing insert, obtained as above, was denatured by incubating at 37°C for
30 minutes in 0.1 volume denaturing solution. This was neutralised with 0.1 volume 3M
sodium acetate. pH4.5-5.5, and precipitated with 4x volume ethanol. After 15 minutes at -
70°C, the DNA was centrifuged at 4°C for 15 minutes, washed with 4x volume 70% cthanol,
centrifuged again and vacuum dried. The pellet was resuspended in 7pi DDW, and to it was
added 50pg of appropriate primer in 1 pi volume and 2pl Sequenase buffer. This was mixed
and heated to 65°C for 2 minutes then allowed to cool to <35°C in a waterbath over 15-30
minutes. It was then spun briefly and placed on ice. To it was added lpl 0.1M DTT, 2pl
labelling mix (diluted 1/5 in DDW) 3.2U Sequenase in 2pi dilution buffer and 5pCi 35SdATP.
2.5pl of each termination mix was warmed to 37°C and 3.5 pi of the the above DNA solution
added and mixed thoroughly. After 5 minutes the reaction was stopped by adding 4pl stop
solution and the reactions stored at -20°C for up to one week before use.
The primer used for sequencing was either the T7 promoter for sequencing single
clones, or the appropriate PCR primer, either upstream or downstream, for pooled clones.
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Denaturing solution: 5 x Sequenase buffer:
200mM Tris-HCl pH 7.5
lOOmM MgCl2
250mM NaCl
Labelling mix Termination mix:
(dGTP): 50mM NaCl2M NaOH
2mM EDTA 7.5 pM dGTP 80pM each dNTP
7.5 pM dTTP 8pM of one of
7.5pM dCTP ddGTP, ddATP.
ddTTP or ddCTP
Dilution buffer: Stop solution:
lOmM Tris.HCl pH 7.5 see 2.7.3.2
5mM dithiothreitol
().5mg/ml BSA
2.9.2. 7 Sequencing gels
Sequencing was carried out on BRL S2 sequencing apparatus using 0.4mm spacers
and sharks-tooth combs. Plates were cleaned with cream cleaner, washed thoroughly and
wiped with 70% cthanol. One plate was treated with gel slick as in section 2.7.2.1. 60ml gel
stock solution was polymerised by adding 60pl 25% ammonium persulphate and 60pl
TEMED immediately before pouring. The gel was allowed to polymerise horizontally for 1
hour with inverted combs and then pre-run without combs, after rinsing the well thoroughly
with lxTBE. at 90W for 30-60 minutes in IxTBE until it reached 50°C. Combs were then
replaced to form wells, which were again rinsed thoroughly. Samples were heated to 75°C for
3 min prior to loading and run at 70W until the bromophenol blue marker reached the bottom
of the gel.
The gel was fixed twice in 10% acetic acid 10% methanol for 5 minutes and
transferred onto 3MM paper. It was dried for 2 hours on vacuum gel dryer and exposed to
autoradiography film overnight.
Stock gel solution: lOxTBE:
75ml 19:1 acrylamide:bis acrylamide 'Instagel'(Severn Biotech Ltd) See 2.4
250g 500ml urea (7M)
50ml lOxTBE
175ml DDW
stored protected from light at 4°C
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2.9.3 Sequencing using high-fidelity polymerase
2.9.3.1 Overcoming the problem of Taq polymerase-generated sequence errors in single-
clone sequencing
The error rate of Taq polymerase is high, estimated to range from one error per 400
bases to one per 4-5000 under more optimum conditions (Saiki et ai, 1988; Innis et al.,
1988). Therefore, the method of choice to produce the most reliable data relies on pooling a
large number of cloned PCR products. This reduces the likelihood that a rag-generated error
will be seen in the subsequent DNA sequence, since only errors which occurred at an early
stage of amplification will produce sufficient copies to be detected amid large numbers of
normal copies. However, it requires sequencing reactions to be primed by an oligonucleotide
specific to the PC R-gencratcd fragment rather than one specific to the plasmid, since
orientation of integrated blunt-ended cloned products within the plasmid is random. Primers
designed from such a sequence are not always suitable for sequencing, presumably because
they form inappropriate secondary structure. Consequently, whilst sequencing of pooled
clones produced very clear results for some exons of hMSH2 it was not always successful,
giving many 'stops" across all four lanes of sequencing reaction in some exons. In order to
employ a plasmid-specific primer, single clones had to be sequenced but, not surprisingly,
when this was attempted using cloned Taq-gene fragments, many false mutations were
detected (ie apparent mutations could not be confirmed on multiple repetitions of the
reactions). For exons which could not be sequenced using pooled clones, PCR fragments
were generated using a high-fidelity polymerase, xTth (Perkin-Elmer Ltd), which has
proofreading activity. This resulted in high quality sequence with few spurious results.
2.9.3.2 High Fidelity PCR ofhMSH2
xTth polymerase is a high fidelity proofreading DNA polymerase which produces
fragments with adenine overhangs similar to Taq polymerase-generated fragments. Although
PCR yields tend to be significantly lower than with Taq, similar reaction conditions produce
perfectly adequate results. PCR reactions were carried out in 50ql volumes containing lOOng
DNA. ImM magnesium acetate, 200pM each dNTP, 50pM each primer and lx buffer.
Reactions were 'hot started" by adding 2U xTth DNA polymerase, XL as in the manner
described in section 2.8.1.1. Cycling conditions were the same as in section 2.8.1.1 and Table
3.
xTth buffer:
tncine. potassium acetate, glycerol. DMSO
(concentrations not given by manufacturer)
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2.9.3.3 Cloning intopCRlI
pCRII vector (part of the TA cloning kit, Invitrogen) became available at this stage
and was used in preference pGEM7ZF+ as it is quicker and more efficient. It removes the
need for blunt-end cloning, since the vector. pCRII, is linear and has thymine overhangs,
making it very easy to ligatc to DNA fragments, which have adenine overhangs. vTth
polymerase was used in conjunction with this vector to produce cloned sequences.
The PCR reactions carried out with xTth polymerase were used as soon as possible
after completion, always on the same day. in order to maximise ligation efficiency, since the
adenine overhangs of the PCR product arc displaced over a period of several hours. Ten
microlitres of PCR product was quantified by electrophoresis on a 1.5% agarose gel
containing 5()ng/ml cthidium bromide by running against 2 pi DNA mass ladder (Life
Technologies Ltd). A 1:1 molar ratio of vector:inscrt ligation reaction was set up consisting
of 2pi lOx ligation buffer. 2pi (50ng) pCRII vector, 1 pi (4 units) T4 DNA ligase and 5ng
PCR product (up to 2.5pl) in a final volume of lOpl. If PCR reaction yield was lower than
2ng/pl, 3 pi was added and amount of vector reduced accordingly to retain a 1:1 molar ratio.











2.9.3.4 Transformation of competent cells
Fifty microlitres of One Shot InvocF' competent cells (part of the TA cloning kit) were
thawed on ice and mixed gently by stirring with a pipette tip. Two microlitres of 0.5M p-
mercaptocthanol, followed by 2pi ligation mix (obtained as above), were added, stirring gently
after each. After a 30 minute incubation on ice. cells were heat-shocked for 30 seconds at
42°C and placed on ice for a further 2 minutes. To this was added 450pl SOC medium and
the vials shaken at 225rpm and 37°C for 1 hour. The cells were then placed on ice before
spreading a 50pl and a 200pl aliquot L-amp plates which had previously been spread with
66
800|ag X-Gal in 1ml L-broth. Plates were incubated overnight at 37°C and then stored at
4°C.
SOC medium. L-broth and L-amp plates:
see 2.9.2.4
2.9.3.5 Minpreparations
Minipreparations were carried out as in 2.9.2.5
2.9.3.6 Sequencing reactions and electrophoresis
Sequencing reactions and gels were as in 2.9.2.6-2.9.2.7, using only the T7 promoter
primer. All apparent mutations were confirmed by their presence in at least one other clone.
Generally. 6-8 clones were sequenced per sample.
2,9.4 Sequencing using Dvnabcads
2.9.4.1 Preparation ofsingle-stranded DNA
PCR reactions were carried out as described in 2.8.1.1, substituting the reverse
primer for one biotinylated at it's 5" end. lOOpl product was generated and spun through a
G50 Quick Spin column (Boehringer Mannheim Ltd) (see 2.9.2.1) to remove excess reagents.
It w as then added to an equal volume of wash buffer and 15 pi streptavidin-coated
Dynabeads (Dynal Ltd), left for 10 minutes and placed next to a magnet to separate the beads.
The supcrnatcnt was removed and the beads washed with 100pi wash buffer and the
supernatent removed by magnetic separation. The beads were resuspended in 5pi fresh 0.15M
NaOH and incubated at room temperature for 10 min. placed next to magnet and the
supernatent. containing unbiotinylated DNA strand, removed and stored in cold ethanol. This
step was repeated, the beads washed w ith lOOpl wash buffer followed by lOOpl TE and the
beads resuspended in 10pi DDW. Five microlitres were used for each sequencing reaction.
Wash buffer: TE:
lOmM Tris pH7.5 See 2.8.1.4
ImM EDTA
2M NaCl
2.9.4.2 Sequencing single-stranded DNA prepared using Dynaheads
For each 5pl sample to be sequenced. 1 pi DMSO. lOng of the appropriate upstream
PCR primer and 2pl Scquenasc buffer was added. The DNA was denatured at 95°C for 3
minutes, placed immediately on ice. briefly spun and replaced on ice. Dideoxy termination
mixes (ddGTP. ddATP. ddTTP. ddCTP) were prepared by adding 10% DMSO to each. For
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each sequencing reaction. 2.5jal of each mix was placed at 37°C and allowed to prewarm for
at least 5 minutes.
To each DNA sample, lpl 0.1M dithiothreitol, 2f.il dGTP labelling mix diluted 1/10-
1/20 with DDW. 0.5pl dATP (lOpCi), 2 pi Sequenase 2.0 diluted in Sequenase dilution
buffer to 13U/6pl was added sequentially and mixed. 3.5 pi of this mix was added to the
termination mixes at 37°C, mixing well. After 5 minutes, the reaction was stopped by adding
4pl stop solution.
Stop solution: Other reagents:
see 2.7.3.2 see 2.9.2.6
2.9.4.4 Sequencing gels
Sequencing gels were prepared and run as in section 2.9.2.7.
2,9,5 Cycle sequencing of PCR products
Direct sequencing of PCR products was carried out using the ThermoSequenase radio
labelled terminator cycle sequencing kit (Amersham International pic). This is a method of
cycle sequencing which utilises radio-labelled ddNTP terminators in conjunction with a
thermostable DNA polymerase to produce high quality sequence which is largely free of
background.
2.9.5.1 Pretreatment ofPCR DNA samples
Before sequencing reactions can be carried out, PCR-generated DNA must be
pretrcatcd with exonucleasc I and shrimp alkaline phosphatase (SAP) to remove single-
stranded oligonucleotides, single-stranded PCR-generated DNA and free dNTPs. To do this,
1 pi each enzyme (1OU exonuclease I and 2U SAP) was added to 5 pi PCR product and
incubated at 37°C for 15 minutes. The enzymes were then inactivated by heating to 80°C for
15 minutes. Additionally, an aliquot of untreated DNA sample was quantitated by agarose gel
electrophoresis against a quantitative marker as in 2.4.
2.9.5.2 Sequencing reactions
2pl dGTP termination master mix was mixed with 0.5pl of [a-3JP]ddNTP to produce
a termination mix for each ddNTP. A reaction mixture was made for each test DNA sample
by mixing 50ng (25fmol) treated DNA with 0.5pmol sequence-specific primer (forward-strand
primers as described in Table 3) and 2pl reaction buffer in a final volume of 20pl. 4.5pl
reaction mixture was transferred to each termination tube, mixed and overlaid with one drop
of paraffin oil. The tubes were placed on a thermal cycling block and subjected to 30 cycles
of 95°C for 30s, 57°C for 30s and 72°C for 1 minute. 4pl stop solution was added to each
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tube and the samples heated to 70°C for 2 minutes before loading 3 pi per lane onto a
denaturing polyacrylamide gel.
Reaction buffer: dGTP termination master mix: Stop solution:








Gel electrophoresis and autoradiography were carried out as in 2.9.2.7, except that
glycerol-tolerant buffer was substituted for TBE buffer.




made to 1 litre with DDW
2.9.4.4 Elimination ofcompressions using dITP
Where compressions (uneven band spacing) caused difficulties in reading a sequence,
reactions were repeated substituting dITP termination master mix for dGTP. Reactions were
carried out as above, except that the termination temperature was reduced from 72°C to 60°C
and the time at this temperature increased to 5 minutes.





2.10 Assay for the effect of hMSH2 polymorphisms on transcription of the gene
2,10.1 Strategy
It was postulated that the intronic mutations that were detected within hMSH2 might
affect mRNA splicing by causing aberrant splicing (most likely skipping of the adjacent exon
in the case of mutation affecting a splice donor site or failure to excise an intron in the case of
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mutation affecting a splice acceptor site). Alternatively, they could result in reduced levels of
transcript. In order to investigate this possibility, RNA was extracted from 8 xenografts, 4 of
which were known to have an intronic mutation in their primary tumour (all 4 in intron 5 and
one in intron 1) and 4 of which were non-mutated controls. RNA was not available from
primary tumour. cDNA was produced by reverse transcription and two assays were carried
out. In the first procedure, PCR primers were designed to amplify three regions: across exon
2 from exons 1 and 3, across exon 5 from exons 4 and 6 and across this whole region from
exons 1 and 6. Amplification of these regions was used to look for evidence of aberrant splice
sequences. Secondly, since insufficient tumour material was available for extraction of RNA
in adequate quantities for Northern blotting, a quantitative PCR-based assay was used to
ascertain the level of transcript present in mutated versus normal samples.
2.10.2 Extraction of RNA from frozen tissue
2.10.2.1 TRIzol method
Extraction of RNA from frozen tissue was carried out using two different methods.
The first utilized TRIzol (Life Technologies Ltd), a mono-phasic solution of phenol and
guanidine isothiocyanate which isolates total RNA from cells. Tissue samples were handled
in a class one flow hood using appropriate measures to avoid RNase contamination: all
glassware was sterilised at 180°C before use, plastic was rinsed with diethyl pyrocarbonate
(DEPC)-treatcd water, tips and tubes were from new unopened packets and double gloves
were worn when handling all materials.
A tissue sample at least 5mm3 was taken from the -70°C freezer and stored on dry ice
until needed. The sample was placed into 1ml TRIzol reagent in a 1,5ml tube and macerated
using a small plastic stick. After 5 minutes at room temperature, 0.2ml chloroform was
added, the tube vigorously shaken for 15 seconds and then left at room temperature for a
further 3 minutes. It was spun at 12000g for 15 minutes at 4°C and the upper aqueous layer
which appeared after centrifugation was removed to a clean tube. RNA was precipitated by
adding 0 .5 ml isopropanol, incubating for 10 minutes at room temperature and then spinning at
10000 x g for 10 minutes at 4°C. The RNA pellet was washed by adding 1ml 75% ethanol,
vortexing and spinning at 7500 x g for 5 minutes at 4°C. The supernatant was removed and
the tube left inverted on a clean paper towel for 10 minutes until the pellet was almost dry. It
was then dissolved in 20pi DEPC-treated DDW and incubated at 60°C for 10 minutes. RNA




Shaken and left for 24 hours to destroy RNases, then autoclaved to destroy DEPC.
2.10.2.2 QuickPrep Total RNA Extraction kit method
The QuickPrep Total RNA Extraction kit (Pharmacia Biotech) is an extraction
procedure in which guanidinium thiocyanate (GTC) treatment dissociates cellular components
and inactivate endogenous RNase, and RNA is selectively precipitated by centrifugation in
caesium trifluoroacetate (CsTFA).
Precautions for avoidance of RNase contamination were followed as above
(2.10.2.1). A 5mm3 tissue sample, stored at -70°C then on dry ice immediately before use,
was placed into a 1.5ml tube and homogenised in 150pl extraction buffer and 3pi p-
mercaptoethanol (p-ME) using a small plastic stick. To this was added 350pl lithium chloride
solution, the solution mixed thoroughly and placed on ice. 500pl CsTFA was added, the
sample mixed by vortexing, and then placed on ice for 10 minutes. RNA was pelleted by
centrifuging at 10000 x g at 4°C. the supernatent aspirated, and the tube placed on ice prior to
washing the pellet with 75pl extraction buffer, 175pl lithium chloride solution and 250pl
CsTFA. The sample was vigorously vortexed for 5 pulses to remove any remaining protein
and DNA contaminants from the pellet and tube, and then centrifuged at 10000 x g for 10
minutes at 4°C. The supernatent was aspirated, the tube placed on ice and 1ml 70% ethanol
added. After vortexing for 5 pulses, the samples was again spun at 10000 x g for 5 minutes
at 4°C. the ethanol removed and the pellet air dried for 10-15 minutes. RNA was dissolved in
lOOpl DEPC-treated DDW (see 2.10.2.1) on ice for 30 minutes, vortexed, and then heated to
65°C for 10 minutes with occasional pipetting to aid dissolution of the pellet. Quantitation
and storage was as in 2.10.2.1.
2,10,3 Preparation of first strand cDNA,
First strand DNA synthesis was carried out using the Superscript Preamplification
System with random hexamers (Life Technologies Ltd). Ipg RNA prepared as above was
defrosted on ice and to it was added 500ng random hexamers. The mixture was heated to
70°C for 10 minutes and transferred to ice for 1 minute. To the tube was added 2pi PCR
buffer, 2pi 25mM MgCl2. 1 pi dNTP mix and 2pi 0.1M DTT. This was incubated at 25°C
before adding 1 pi (200U) Superscript II RT, mixing and incubating for a further 10 minutes
at 25°C then for 50 minutes at 42°C. Reactions were terminated by heating to 70°C for 15
minutes and the tubes then chilled on ice. Finally, the newly-synthesised cDNA was incubated





2.10.4.1 Polymerase chain reaction of ItMSH2 cDNA
PCR of hMSH2 cDNA was carried out using the primers shown in Table 4.
Reactions were 'hot started' as in section 2.8.1.1 and reagents were identical to those
described in section 2.8.1.1. with substitution of 2pl cDNA product for genomic template.
Cycling conditions were 30 rounds of 30 seconds at 94°C, 30 seconds at 50°C (exons 1-3) or
54°C (exons 4-6) and 1 minute at 72°C. In addition, the forward primer for exon 2
amplification and the reverse primer for exon 5 amplification (Table 4) were used to amplify a
sequence from exon 1 to exon 6. For this reaction, annealing temperature was 56°C and
predicted normal product was 1072bp.
Table 4






Primer sequence (5' to 3') PCR
annealing
temperature
2 610 455 GCGCATTTTCTTCAACCAGG
GAGGAGAGCCTCAAGATTG
56°C
5 324 510 TATCAGGACCTCAACCGG
CCACTGGTTAACAAGTCTTT
52°C
2.10.4.2 Detection of amplified cDNA sequence by polyacrylamide gel electrophoresis
PCR-amphfied DNA was electrophorescd on a 2% agarose gel (as in section 2.4) and
the fragment sizes visualised and photographed under UV light. For more accurate
determination of band sizes, the fragments were then electrophoresed on a 5% (exon 2) and
8% (exon 5) acrylamide minigel. This was as in 2.8.3, except that 1.25ml or 2ml,
respectively, of 40% 29:1 acrylamide:bis were used.
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2.10.5 Assay 2
2.10.5.1 Quantitative PCR of hMSH2
PCR has been shown to be a reliable method for quantitation of mRNA (Wang et al.,
1989). In the assay used here, the relative amount of hMSH2 mRNA transcript present in
tumours bearing sequence alterations in introns 1 and 5 and those with no sequence change
was compared using a quantitative PCR assay (Wei et al., 1995). The amount of hMSH2
transcript was measured in relation to p actin transcript, which was co-amplificd as an
internal standard, and quantitatcd against cDNA from normal colonic tissue.
cDNA (produced in step 2.10.3) was amplified using the primers shown in Table 5.
Because the amount of p actin transcript is many times greater than that of hMSH2. the
method of Wei et al. rccomments addition of p actin primers after 11 cycles, in order to
ensure that the reaction remains in log phase. This was found to work for cDNA generated
from TRIzol-extracted RNA, but had to be modified to addition after 7 cycles for cDNA
derived from Pharmacia-extracted RNA because levels of P actin product, though consistent,
were generally lower. This was presumably due to the earn -over of very low levels of
extraction reagents into cDNA. which is only likely to be problematic when primers are
insufficiently pure (Dr S. Bader. personal communication). Resynthesis of higher quality
oligonucleotides would probably eliminate this difficulty. Despite this minor problem. cDNA
produced from RNA extracted by the Pharmacia kit method was found to produce more
consistent results on quantitative PCR analysis, and therefore only RNA extracted by this
method was used for quantitation.
PCR reactions consisted of l.SpM each hMSH2 primer, 2.5U Taq polymerase,
1.2mM MgClg. lx PCR buffer. 0. ImM of each dNTP and lpl cDNA in a final volume of 45
pi. overlaid with one drop of paraffin oil. Cycling was carried out for 11 cycles of 95°C for
30 seconds. 59°C for 30 seconds and 72°C for 1 minute. After this, 45pM of each p actin
primer was added to make a final volume of 50pl. and a further 19 cycles carried out at the
same temperatures. Products were visualised on a 2% agarose gel as in 2.4. Quantitation
was carried out using the BioRad Gel Doc system and Molecular Analyst software.





Primer sequences for quantitative hMSH2 cDNA assay.







2.11 Mutation analysis of the p53 gene
Mutation analysis of the p53 gene was performed on some tumours with low or
negative immunohistochemical p53 staining in order to exclude the possible presence of
mutation not detectable by IHC (see Chapter 5. Results). Analysis was carried out using
single-stranded conformational polymorphism analysis (SSCP) of exons 4-8, in which 90% of
all mutations arc located (Levine et al., 1991). Four samples with high levels of p53 staining
had already been assessed in this manner by Ms J. Scheler and Ms K. Cripps, and found to
harbour mutations within this region of the gene. Analysis of a further 20 tumours which
were either negative or showed a low level of staining by immunocytochemistry with anti-p53
antibodies was carried out. The four samples with known mutations were included as positive
controls.
2.11.1 PCR of p53 exons 4-8
PCR was carried out in four separate reactions using the primers listed in Table 6.
Reactions were carried out in 5()pl volumes consisting of lOOng genomic DNA, 0.5pM each
primer, 200pM each dNTP. 1.5mM MgCl2 and 1 x buffer solution, overlaid with one drop of
paraffin oil. Reactions were 'hot-started' with 1.25U thermostable Taq polymerase as in
2.8.1 1 and cycled 30 times at 94°C for 30 seconds. 58°C for 30 seconds and 72°C for 1
minute. Reactions were checked on a 2 % agarose gel as in 2.4 before SSCP analysis.
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Table 6
Primer sequences for amplification of p53.









2.11.2 SSCP analysis of p53
SSCP analysis of PCR fragments generated in 2.1.3.1 was carried out as in 2.8.1.2.
2.12 DNA fingerprinting
DNA fingerprinting was undertaken in selected cases in order to confirm that DNA
from xenograft tissue corresponded to that of the primary tumour and normal tissue from
which it had been taken (see Chapter 4, Results). The probe chosen for DNA fingerprinting
was 29C1. a sequence which recognises a highly polymorphic region of human telomeric
DNA located in the pairing regions of the short arms of the sex chromosomes (Cooke et al.,
1985). Where insufficient DNA was available for Southern blotting, or in cases which
produced equivocal results [as discussed below], a second fingerprinting method was used.
This was a PCR-based protocol for analysis of a highly polymorphic Alu sequence within the
3' end of intron 1 of the p53 gene (Futrcal et al., 1991).
2,12.1 Fingerprinting using p29C 1
2.12.1.1 Southern blotting
Electrophoresis and DNA transfer
lOpg genomic DNA prepared as in section 2.3.1 was digested overnight at 37°C with
30U EcoRI and lx enzyme buffer in a 50pl volume. A 0.8% 20x20cm horizontal gel was
prepared by boiling 2.4g agarose in 300ml lxTBE buffer, adding 5pl lOmg/ml cthidium
bromide and pouring when the gel had cooled to 55°C. 5pl bromophcnol blue loading dye was
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added to each sample and electrophoresis was carried out at 80mA in lxTBE until the dye had
migrated 20cm. lpg of a DNA molecular weight marker lkb ladder (Life Technologies Ltd)
was run alongside the samples. The gel was photographed on a UV box alongside a
fluorescent ruler for scale.
The gel was prepared for blotting by shaking gently for 45 minutes in 500ml sodium
hydroxide solution, washing twice for 15 minutes in DDW and neutralised by shaking for a
further 45 minutes in 500ml 1M Tris-Cl (pH5 .5). It was then carefully transferred to the
blotting apparatus which consisted of a 20x35cm 17MM paper wick placed over a perspex
plate which was suspended over a tank of 20xSSC. The wick was soaked in 20xSSC and
carefully rolled flat before placing the gel on top. A sheet of Hybond N+ nylon membrane cut
to the size of the gel and clearly marked for orientation was soaked in DDW then 20xSSC,
placed on top of the gel and rolled flat to remove bubbles. On top of this was placed a pile of
paper towels, a perspcx plate and a 1kg weight. Clingfilm was placed around the edges of the
gel to prevent evaporation and aberrant buffer flow and the apparatus was left overnight for
the DNA to transfer to the membrane. After this time the membrane was soaked for 45
minutes in neutralising solution and then dried and stored between two sheets of blotting paper
until hybridisation.
lOx EcoRI buffer: Sodium hydroxide solution: Neutralising solution:
500mM Tris HC1 (pH8.0) 0.5M NaOH 0.5M Tris pH7.4
1 OOmM MgCl2 1,5M NaCl 3M NaCl
5()()mM NaCl
20xSSC: Bromophenol blue loading
88.2g sodium citrate dye:
175.3g NaCl see 2.4
Preparation ofprobe
The insert from plasmid p29C 1 was cut out using the Pstl restriction enzyme. 20U
enzyme were added to 4pg plasmid DNA and lx Pstl buffer and the volume made to lOOpl
with DDW. Digestion was done for 3 hours at 37°C, after which 5pi bromophenol blue
loading dye (sec 2.4) was added to each sample. The insert was isolated by electrophoresis on
a 1% agarose gel against the Ikb ladder molecular weight marker (Life Technologies Ltd).
The gel was prepared by adding 0.5g low melting point agarose in 50ml lxTBE, boiling and
adding cthidium bromide to lpl 50pg/ml before pouring into a 5x10cm mould at 55°C. After
electrophoresis at 100V in lxTBE to 8cm migration of the dye, the 1.7kb insert was
visualised briefly under UV light (to minimise DNA damage), cut out of the gel using a
scalpel and placed into a pre-wcighed 1,5ml tube. DDW was added at 300pl per lOOpg of gel
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and the agarose melted by heating to 65°C for 5 minutes. Concentration was estimated from
the original known quantity of plasmid digested. 25-50ng of insert was taken for labelling.
lOxPstl buffer:





Labelling using random primers
Probe DNA was labelled using the Prime-It RmT kit (Stratagene Ltd). Briefly, 50ng
of probe in agarose prepared as above was added to a single-use reaction tube containing
random 9-mers. nucleotides, buffer and co-factors for use with a32PdCTP and the volume
made to 42pl with DDW. This was boiled for 5 minutes and briefly spun to collect
condensation. To this tube was added 5pl (50qCi) a32PdCTP and 3ql Magenta DNA
polymerase (4U/ql), the contents mixed and incubated at 37°C for 30 minutes. After this time
the reaction was terminated by the addition of 2pi stop mix (0.5M EDTA (pH8.0).
Unincorporated oligonucleotides and isotope were removed by passing the probe through a
drained G50 Sephadex nick column that had been rinsed with TE. The column was then
cleaned by running 3ml TE through it. Probe was added along with 400pi TE and allowed to
pass into the column bed. A further 400pl TE was added and the drops collected from the
bottom of the column. An approximate measure of isotope incorporation into the probe was




The nylon membrane was was placed onto a square nylon mesh, rolled and placed
into a hybridisation bottle. 20 ml hybridisation buffer was added the bottle placed on a
rotating wheel in a 65°C oven for 4 hours to prchybridisc. After this time, probe prepared as
above w as denatured by boiling for 3 minutes. The hybridisation buffer was poured out of the
bottle, the denatured probe added and the buffer returned to the bottle for overnight incubation
rotating at 65°C.
The filter was washed by pouring out the hybridisation buffer, replacing it with 50ml
prewarmcd 2x SSC and replacing the bottle in the oven at 65°C for 30 minutes. The same
was done with 2x SSC/1% SDS and then 0.5x SSC/1% SDS. The filter was then removed
from the bottle, placed into 0. lxSSC at room temperature and soaked for 30 minutes. It was
w rapped in Clingfilm and placed next to a piece of autoradiography film in cassette containing
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intensifying screens, placed at -70°C for two days and then developed using an automatic
developing machine.
After autoradiography, the filter was stripped of hybridised probe by boiling for 20
minutes in 0. lx SSC/1% SDS, dried and stored.
2.5ml 20% SDS
heated to 65 °C.
Immediately before use. 1 Omg salmon sperm DNA denatured by
boiling for 5 minutes before adding to above buffer at 65 °C.
pH to 7, DDW to 11
2.12.2 Fingerprinting using an Alu polymorphism within the p53 gene
2.12.2.1 Polymerase chain reaction
Polymerase chain reaction was carried out in two parts. Initially, specific primers
were used to amplify p53 intron 1, then a nested primer was used to amplify the internal Alu
repeat (Table 7). In the initial round of amplification. PCR was carried out in 50pl volume
reactions containing 1 x reaction buffer, 1.5mM magnesium chloride, 200mM each dNTP,
0.5pM each primer and lOOng genomic DNA template overlaid with drop mineral oil. This
was heated to 94°C for 5 minutes, cooled to 80°C and 1.25U Taq polymerase added to each
reaction. Cycling reactions were 30 cycles of 30 seconds at 94°C, 30 seconds at 55°C and 30
seconds at 72°C.
The second round of amplification was carried out using as template lOpl of PCR
product from the previous reaction. This was added to 0.8 x buffer, 150mM each dNTP,
0.7mM magnesium chloride, 2.5pM Alu primer and 1.25U Taq polymerase in a final volume
of 50pl. overlaid with a drop of paraffin oil and amplification carried out for ten cycles of
94°C for 30 seconds, 55°C for 30 seconds and 72°C 30 seconds. PCR product was checked
on a 2% agarose gel as in 2.4 before final analysis on a silver-stained denaturing
polvacrylamide gel by the same method as for microsatelhte sequences (2.7.2). Allele sizes
were 140. 130. 125, 120. 115 and 105 bases.
Hybridisation buffer:
5g dcxtran sulphate dissolved in 25ml DDW at 65°C for 30









Primer sequences for amplification of p53 intron 1 Alu region.
Primer sequence (5'-3')
1st reaction upstream primer GCACTTTCCTCAACTCTACA
1 st reaction downstream primer AACAGCTCCTTTAATGGCAG
Alu primer CCACTTGCACTCCAGCCTGGG
2.13 Comparative Genomic Hybridisation
Comparative Genomic Hybridisation (CGH) was carried out on a series of 29
xenografited human colorectal tumour samples and three primary tumours (see Chapter 5,
Materials and Methods). CGH was also carried out on DNA from mouse tumours, and this is
described in 2.14.
2.13.1 Preparation of Metaphasc Chromosome Spreads
2.13.1.1 Blood culture
10 ml of fresh blood donated by a healthy male volunteer was collected in a Lithium
heparin tube. RPMI medium (Dutch modification) was supplemented with 10% foetal bovine
serum, phytohcmagglutinin and L-glutamine and filtered through a 0.2pm filter. 10ml was
placed into a flat-bottomed 25cm- plastic tissue culture flask. 0.75 ml blood was inoculated
into this, swirled to mix, and cultures were incubated at 37°C for 72 hours. 1 hour before
harvesting (at 71 hours). lOOpl of lOpg/ml colcemid was added and the incubation continued.
Cultures were transferred into 10ml centrifuge tubes and spun at 500 x g for 5 minutes to
pellet cells. The supernatent was removed and the pellet resuspended in prewarmed (37°C)
0.075M KC1 hypotonic solution and incubated in a 37°C waterbath for 10 minutes. The tubes
were then spun again at the same speed, the supernatent removed and the pellet tapped to
loosen it. Cells were fixed dropwise with gentle vortexing to a final volume of 5ml with fresh
ice-cold fixative solution, placed at -20°C for one hour and spun at 500 x g for 5 minutes.
Fixing and spinning was repeated twice to obtain a white pellet. Mctaphase preparations were
stored in 5ml fix at -20°C for up to a year.
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RPMI medium (Dutch modification)
containing:
10% foetal bovine serum (heat inactivated)
9pg/ml phytohcmagglutinin-M
Fixative solution:




Filtered through 0.2pm filter before use.
2.13.1.2 Preparation ofSlides
Microscope slides were soaked overnight in 10% Decon detergent, rinsed for 1 hour
in water and transferred to 100% ethanol containing a few drops of concentrated hydrochloric
acid for storage. Metaphase preparation solutions were spun at 500 x g for 5 minutes to
pellet cells, the supernatent discarded and the pellet resuspended in a few drops of fix to form
a milky solution. Slides were polished with a soft lint-free cloth just before use and one drop
of fixed chromosome preparation dropped directly on top. The position of the drop was
marked with a diamond pencil. Slide quality was checked on a phase contrast microscope at
x40 magnification. If necessary, spreading of chromosomes was facilitated by either
increasing the dropping height, placing slides at -20°C for 2 minutes before use or by gently
blowing on the drop of metaphase suspension.
Slides for CGH were stored at room temperature in a vacuum desiccator for 1-2
weeks. Each batch was tested for suitability for CGH before setting up large numbers. Slides
for G-banding were aged by baking at 80°C for one hour and stored on the bench.
2.13.1.3 G-Banding ofMetaphase Chromosome Spreads
Normal karotype of the control samples was confirmed by G-banding. Slides for G-
banding were left for at least 24 hours after baking before staining.
Slides were treated with fresh 0.005% trypsin in PBS for 20-40 seconds and then
rinsed with cold PBS. They were placed into Giemsa staining solution for 5 minutes, rinsed
with DDW and mounted with DPX under a clean cover slip. Karyotype analysis of 10
mctaphases was carried out under xlOO magnification.
PBS: Giemsa staining solution:
2,13 ,2 Extraction of control DNA
Control DNA for counter-hybridisation was obtained from lymphocytes obtained
from two healthy male volunteers. 10ml peripheral blood was collected in 1% EDTA and
DNA extracted as described in section 2.3.2. Metaphase chromosome preparations from
Sec 2.6 Gurf s Giemsa in PBS pH 6.8
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these individuals were made from a separate blood sample (section 2.13.1.1) and normal
karyotype was confirmed by G-banding of metaphase chromosomes (see section 2.13.1.3).
2 .13 ,3 Nick Translation Of Control And Test DNA
Normal male DNA and either primary tumour or xenograft DNA were labelled by
incorporation of digoxygenin-11-dUTP (normal) or biotin-16-dUTP (test samples) by nick
translation. The method of Kallioniemi et al (1992) suggests that optimal hybridisation can
be achieved using labelled probes of 600-1000bp. In this study, it was found that fragment
lengths of between 100 and lOOOkb, assessed by running single-stranded DNA on an agarose
gel, provided optimal hybridisation, with chromosomes appearing fuzzy if fragments were too
small and poor hybridisation occurring if fragments were too large.
For nick translation. DNasel (lOu/pl) was diluted 1/12000 in ice-cold DDW. One
1,5ml microfuge tube per sample was placed on ice to cool and the following mixture added to
each:





20pM digoxygenin-11-dUTP (control) or biotin-16-dUTP (test sample)
4pil of lOx nick translation buffer
DDW to 38pi
lpl (10U) DNA polymerase I
1 pi diluted DNAse I
The mixture was mixed gently, centrifuged and incubated at 16°C for 1 hour. It was
then placed on ice and lOpl removed in order to check fragment size. This aliquot was boiled
for 2 minutes, placed on ice for 2 minutes, pulse-centrifuged and then fragments separated by
electrophoresis against a lkb ladder molecular weight marker (Life Technologies Ltd) on a
1% agarose gel (1% agarose in lxTBE. otherwise as in section 2.4) until the bromophenol
blue had migrated 6cm. If any fragment was bigger than lkb. a further lpl DNasel was
added to the reaction tube and the 16°C incubation continued for 10-20 minutes. When
fragments were between 100 and 1000 nucleotides long, the reaction was stopped by adding
2pl 0.2mM EDTA/1%SDS. The DNA was then cleaned through a Quick Spin column to
remove unincorporated nucleotides (Boehringer Mannheim Ltd) (as in 2.9.2.1) and stored at -
20°C until required.
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lOx nick translation buffer:
0.5M Tris pH 7.5
0.1M MgS04,
ImM dithiothrcitol
500pg/ml bovine serum albumin fraction V.
2.13.3.1 Verification ofDNA labelling
At first, nick translation reactions were always checked to ensure that sufficient
incorporation of labelled nucleotide had occurred. However, the reactions were found to be
extremely reliable and were thereafter only verified if a new reagent was used. The assay was
done using a colorimctric assay, coupling alkaline phosphastase (AP). via streptavidin or anti-
digoxygenin antibody, to biotin or digoxygenin incorporated into DNA and detecting with an
AP substrate. The substrates used. 5-bromo-4-chloro-3-indoyl phosphate (BCIP) and nitro
blue tetrazolium (NBT), develop an intensely dark blue-purple insoluble reaction product on
exposure to AP.
Nick translated DNA was quantitated against biotinylated PBR322 or digoxygenin-
labelled lambda standards. One microlitre of neat, 1/10 and 1/100 dilutions of labelled DNA
were dotted onto a small charged nitrocellulose membrane (Hybond N+), along with
concentrations ranging from l-100pg of the appropriate standard. The filter was allowed to
dry and then shaken for 5 minutes in buffer 1 followed by 30 minutes in buffer 2. After a
further rinse in buffer 1, the filter was incubated for 10 minutes in 10ml buffer 1 containing
lOpl strcptavidin alkaline phosphatase (to test biotin-labellcd DNA) or anti-digoxygenin
alkaline phosphatase (to test digoxygenin-labelled DNA). shaken for two 15 minute washes in
buffer 1 and then for 5 minutes in buffer 3. Alkaline phosphatase substrate BCIP/NBT was
obtained in kit form and prepared according the manufacturer's instructions (Dako Ltd). It
was incubated with the filter in a scaled plastic bag in the dark until colour developed (up to 2
hours), the test samples compared with the standard, and concentration of labelled DNA
estimated.
Buffer 1: Buffer 2: Buffer 3:
0.1M Tris O.lMTris 0.1M Tris pH9.5
0.15M NaCl 0.15M NaCl
pH7 .5 0.5% blocking agent (Amcrsham International pic),




Several variations of the CGH technique were attempted in order to find optimal
hybridisation conditions. The method found to work most consistently was a modification of
the method of Kallioniemi et al (1992). including changes incorporated from the methods of
Verma and Babu and from a method provided by Dr H.Morrison at the Human Genetics Unit,
MRC. Edinburgh.
2.13.4.1 Prohe preparation
50()ng of normal male genomic DNA labelled with digoxygenin was mixed with
5()0ng of biotin-labellcd test DNA and lOpg human Cot-1 DNA. The mix was precipitated in
lOOpl ice cold ethanol at -70°C for 1 hour and then dried by spinning at 1000 x g in a vacuum
centrifuge. At this point, slide preparation (see below) was begun. The DNA pellet was
resuspended in 7.5pl CGH buffer, vortexed and left at room temperature for one hour. 7.5pi
dcioniscd formamide was added, mixed, pulse-centrifuged and the DNA denatured for 5
minutes at 70°C. Following denaturation, DNA was allowed to reanncal for between 30
minutes and 2 hours at 37°C before being added to the prepared slide.
CGH buffer:
20% dcxtran sulphate (diluted from autoclaved 50% stock)
4xSSC see 2.12.1.1
2.13.4.2 Slide preparation
Hybridisation of labelled genomic DNA prepared as above (2.13.4) was carried out
on normal male mctaphase chromosome preparations which had been stored desiccated for 1 -
2 weeks (section 2.13.1.2). Treatment was carried out either in 50ml-capacity Coplin jars,
moving slides using forceps, or 200ml-capacity glass staining dishes using a slide rack,
according to the number to be processed. Use of smaller numbers of slides and Coplin jars
was generally found to produce more satisfactory results.
Slides were treated by placing first in RNase A solution at 37°C for 1 hour, washing
in 2xSSC at room temperature for 2 minutes and dehydrating through 70%, 90% and 100%
ethanol for 2 minutes each. Slides were then warmed on a hotplate to 70°C and placed into
70% formamide solution at 70°C in a fume cabinet for 3 minutes, using a thermometer to
keep a constant check on the formamide temperature. This was always carried out in Coplin
jars, adding no more than 4 slides at a time to each jar, as this was found to be the best way to
maintain a constant solution temperature. Slides were then plunged immediately into ice-cold
70% cthanol and left for 5 minutes before dehydrating through the ethanol series as before.
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Finally, they were placed into proteinase K solution at 37°C for 2.5 minutes, washed for 2
minutes in proteinase K buffer at room temperature and dehydrated through ethanol as before.
Prior to adding the probe, slides were placed on a hotplate at 37°C along with small
(20mm2) covershps which had been thoroughly cleaned with ethanol. Each DNA mix was
placed onto a cover slip, taking care to ensure that the temperature did not drop below 37°C,
and the slide placed chromosome-side down on top. The cover slip was sealed with rubber
solution and slides were place in a humidified chamber at 37°C for 2-3 days.
RNase A solution:




Proteinase K buffer: Proteinase K formamide solution:
0.02M Tris pH 7.5 solution: 35ml deionised
0.002M calcium lOOng/ml proteinase formamide
chloride K in proteinase K 2xSSC
buffer
Dcioniscd formamide:
500ml formamide added to 25g ion-exchange resin beads, stirred
for 45 minutes, then filtered through a paper filter. Stored at -
20°C.
2.13.4.3 Antibody detection of labelled probes
After incubation, slides were removed from the chamber the rubber sealant carefully
removed. They were washed four times for 3 minutes in 50% formamide/2xSSC at 45°C,
allowing the cover slips to float off in the first wash. This was followed by four 3 minutes
washes in 2xSSC at 45°C and then four 3 minutes washes in 0. lxSSC at 45°C. The slides
were then washed for 2 minutes in 0.1% Tween 20/4xSSC at room temperature prior to the
addition of antibody.
lOOpl blocking buffer was added to each slide and covered with a clean large cover
slip. After 5 minutes this was drained and lOOpl fluorescein/rhodaminc solution added in the
same manner. Slides were incubated for 30 minutes in the dark at 37°C in a damp chamber.
They were then drained and washed three times for 2 minutes in 0.1% Tween 20/4xSSC at
37°C. The slides were drained and lOOpl biotinylated anti-avidin (BAA) secondary antibody
added and incubated under a cover slip for 30 minutes as before. Slides were washed again
three times in 0.1% Tween 20/4xSSC. drained and 100pi fluorescein solution added for a
further 30 minutes as before. The slides were then washed three times in 0.1% Tween
20/4xSSC as before, drained and allowed to dry. They were mounted in 35pl DAPI/antifade






made to 10ml with DDW and heated to 50°C to
dissolved, aliquoted into 1.5ml tubes and spun at




Spun 10000 x g for 15 minutes at 4°C
DAPI/antifade solution:
0.75pg/ml DAPI in Vectashield antifade
solution
2.13 ,5 Aialvsis of CGH
Hybridisations were analysed using the Apple Macintosh-based quantitative image
analysis software MacProbe (Perceptive Scientific Instruments. Ltd). This system uses a
standard Leica fluorescence microscope equipped with a charged coupled device (CCD)
camera. P-l filter set and computer-controlled filter wheel for image acquisition. Each
fluorochrome is excited separately using a single band-pass excitation filter and gray-level
images are captured through a triple bandpass emission filter at xlOOO magnification, overlaid
and displayed in pseudo-colour. A single colour DAPI image is used for chromosome
identification. Between five and ten metaphase spreads were analysed for each tumour.
Green/red ratios were generated for all undamaged and non-overlapping chromosomes and an
average profile was generated for each chromosome using a minimum of 5 autosomes and 3
sex chromosomes. Green/red ratio cut-off points of 1.125 and 0.875 were chosen for scoring
of chromosome copy number changes. This was the level at which copy number changes
could easily be visualised, and is equivalent to a loss or gain of one chromosome in 25% of
cells in a diploid karyotype. Batches were only used if the standard deviation of the sample
and the normal control were small. Telomeres, pericentric regions and heterochromatic
regions sometimes fell out of range because of the blocking effect of the Cot-1 DNA. and were
excluded from analysis.




Spun at 10000 x g for 15 minutes at 4°C





Spun at 10000 x g for 15 minutes at 4°C
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Fluorescein 490 520 Green
Rhodamine 545 575 Red
2.14 Analysis of tumours from knockout mice
Tumours from mice deficient in Msh2, p53, or both, were assessed for chromosomal
abnormalities by CGH (see Chapter 6). In addition, the status of a number of these tumours
was assessed for microsatellitc instability. These methods arc described below.
2.14.1 Generation of nullizygous mice
A large cohort ofMsh2 +/+, Msh2 +/- and Msh2 -/- animals were generated on an
outbrcd background segregating for a variety of genomes including 129/Ola. SWR and
C57BL/6J. These mice were bred from a singleMsh2 +/- male, in which removal ofMsh2
activity was achieved by insertion of an intragenic neo cassette (de Wind et al., 1995). Msh2
-/- mice were interbred with p53 -/- mice (Clarke et al., 1993) to generate animals mutant for
both genes. Mice were maintained under non-barrier conditions and given a standard diet.
Genotype was confirmed by Dr N.Toft and Mr O.Sansom using PCR-based assays specific
for targeted and wild-type alleles for both p53 (Malcomson et al., 1997) and Msh2 (Dr
N.Toft. unpublished). On tumour development (see Chapter 6, Results), mice were killed, the
tumour removed and DNA extracted as in 2.3.1.
Generation of mice was carried out under the direction of Dr Alan Clarke.
2.14.2 Comparative Genomic Hybridisation
2.14.2.1 Cell lines and metaphase preparation
Normal mctaphases for CGH were obtained from the murine embryonic stem cell line
E14, derived from mouse strain 129/Ola (Hooper et al., 1987). Cells were grown in CM5-5
medium in 75cm^ flasks. For metaphase preparation, culture medium was changed 24 hours
before cells were 50% confluent (in log-phase growth) to achieve a degree of synchronisation.
One hour before harvesting, colcemid was added to the culture medium to a final
concentration of 0.1 jug/ml. After this time, the medium was removed and kept, and the cells
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rinsed twice with PBS. Sufficient TVP was added to cover the bottom surface of the flask,
and when cells had disaggregated (about 5 minutes), they were dislodged from the flask by
tapping. The spent medium was then added to the cells again to neutralise the trypsin, and the
cell suspension spun at 1000 x g for 5 minutes in a 50ml polypropylene tube. The cells were
then gently tapped to resuspend. 50ml 0.075M KC1 added and incubated for 10 minutes at
room temperature. Cells were centrifuged as before, resuspended in a single drop of
supernatant by tapping, and fixed by the dropwise addition of 50ml of ice-cold fix (2 parts
methanol to one part glacial acetic acid). The cell suspension was incubated on ice for 30
minutes, centrifuged and resuspended in 50ml of fresh fix. After a five minute incubation, the
cell suspension was spun again and resuspended in a small volume of fix to make a milky
solution. Slides were prepared and stored as in 2.13.1.2.
TVP: PBS:
0.025% (w/v) trypsin see 2.6
ImM EDTA
1% chick serum (Life Technologies) in PBS.
Sterilised by filtration through 0.2(.im filter.
Stored at -20°C.
2.14.2.2 Chromosome counts.
In order to check chromosome number, slides were stained for 30 minutes in 5%
Gicmsa prepared in PBS. Twenty metaphase spreads were selected at random and the number
of chromosomes counted in each spread.
PBS:
see 2.6
2.14.2.3 Nick translation ofmurine DNA
Nick translation reactions to label test DNA with biotin were carried out as in 2.13.3
Similarly, an equal amount of DNA from normal mouse tail tissue, extracted as in 2.3.1., was
labelled with digoxygenin. Reaction product sizes were checked on an agarose gel as in 2.4.
2.14.2.4 Hybridisation and antibody detection of labelled DNA
500ng mouse tumour DNA labelled with biotin was mixed with 500ng normal mouse
DNA labelled with digoxygenin and 20pg mouse Cot-1 DNA, precipitated, and prepared for
hybridisation as in 2.13.4.1. Meanwhile, slides were denatured, dehydrated, and treated with
proteinase K and RNase prior to hybridisation with labelled DNA as in 2.13.4.1. Antibody
detection of labelled DNA and DAPI countcrstaining was as described in 2.13.4.3.
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2.14.2.5 Ana lysis of CGH
Hybridisations were analysed using the Apple Macintosh-based Quantitative Image
Processing System (QUIPS) software (Vysis. UK. Ltd). The system is based on a normal
fluorescent microscope (Zeiss Axioskop) equipped with a CCD camera (Sensys) and triple
bandpass filter set for rhodamine. fluorescein and DAPI very similar to the system described
in 2.13.5. Because mouse karyotyping software was not available, kary otyping was carried
out manually onto a human karyotype template (using only chromosome templates 1-19. X
and Y). and thereafter proceeding as in 2.12.5 for generation of green:red ratio profiles.
Between four and eight metaphase spreads were analysed for each tumour. Green/red ratio
cut-off points of 1.2 and 0.8 were chosen for scoring of chromosome copy number changes.
Telomeres and centromeres were excluded from analysis.
2,14,3 Microsatellite analysis of mouse tumours
In order to assess the status of microsatellite instability in selected tumours compared
with paired normal tail tissue, four highly polymorphic microsatellite lock DIMitT D7Mitl7,
D10Mit2 and D14Mitl5 were examined. Primers sequences for these loci were obtained from
the Whitehead Institute for Biomedical Research/Massachusetts Institute of Technology
Centre for Genome Research website at http://www.genome.wi.mit.edu and are shown in
Table 9. Reactions were carried out in a 96-well plate and conditions consisted of a final
concentration of lx buffer. 1.5mM MgClg, 200p.M each dNTP. 0.5p.M each primer. 0.625
units Taq DNA polymerase and 25ng DNA template. Reaction volume was made up to 25pl
w ith distilled deionised water (DDW) and one drop of paraffin oil was overlaid to prevent
evaporation. After an initial 2 minute denaturation at 95°C. 30 cycles of amplification were
carried out with each cycle consisting of 30 seconds denaturation at 95°C, 30 seconds
annealing at 57°C and 30 seconds extension at 72°C. followed by final extension at 72°C for
9 minutes. Microsatellite instability was assessed on a 6% denaturing polvacrylamide gel
with silver staining as in 2.7.2.
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MICROSATELLITE INSTABILITY AND THE ROLE OF HMSH2 IN
SPORADIC COLORECTAL CANCER.
3.1. Introduction
Tumours from hereditary non-polyposis colorectal cancer (HNPCC) patients are
characterised by the presence of multiple replication errors (Ionov et al., 1993; Aaltonen et
al., 1993). As a consequence of defects in the mismatch repair pathway in such tumours,
mutations remain unrepaired. Within microsatellite sequences such replication slippage is
manifest as an alteration in length, termed microsatellite instability (MSI), and tumours are
termed replication error positive (RER+) when instability occurs at more than one locus
(Aaltonen et al., 1993). MSI has also been demonstrated in sporadic colorectal cancers
(Thibodeau et al.. 1993) and subsequently in many other cancers, including pancreatic (Han et
al., 1993), gastric (Han et al.,\993\ Peltomaki et o7.,1993; Mironov et al., 1994; Rhyu et
al., 1994; Chong et al.. 1994), prostatic (Gao et al., 1994), endometrial (Risinger et al., 1993;
Peltomaki et al.. 1993), breast (Patel et al., 1994), non-small cell (Shridhar et al., 1994; Fong
et al.. 1995) and small cell lung cancers (Merlo et al., 1994) and in Muir-Torre syndrome
(Honchel et al., 1993).
Up to 86% of tumours from HNPCC patients exhibit instability at multiple
microsatellite sites (Aaltonen et al., 1993 & 1994; Wu et al., 1994). The proportion of
sporadic colorectal cancers which demonstrate the same phenomenon, though much lower
(around 17% in most studies), nevertheless accounts for a significant number of cancer
patients (Aaltonen et al., 1993 & 1994; Ionov et al., 1993; Lothe et al., 1993; Young et
al., 1993b; Thibodcau et al., 1993; Kim et al., 1994a). Sporadic tumours with microsatellite
instability have characteristics in common with HNPCC tumours. They are usually located in
the proximal colon (Ionov et al., 1993; Thibodcau et al., 1993; Lothe et al., 1993; Aaltonen et
al., 1993; Kim et al., 1994a), associated with extracellular mucin production (Kim et al.,
1994a). poor differentiation (Ionov et al., 1993; Lothc et al., 1993; Kim et al., 1994a) and
near-diploid DNA content (Aaltonen et al., 1993; Lothe et al., 1993; Remvikos et al., 1995;
Schlcgel et al., 1995). They also show a negative correlation with mutation (Ionov et
al., 1993) or immunochemical stabilisation of p53 (Kim et al., 1994a) and Ki-ras mutation
(Ionov et al.. 1993). In addition, loss of heterozygosity at known tumour suppressor gene loci
on chromosomes 5q. 17p and 18q is relatively less frequent in tumours with MSI compared to
those without (Thibodeau et al., 1993). Finally, these tumours show a tendency towards
increased patient survival (Thibodeau et al., 1993; Lothe et al., 1993).
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Recently, a number of genes that participate in human mismatch repair have been
identified, namely hMSH2 (Fishel et al., 1993; Leach et al., 1993), hMLHl (Bronner et
al., 1994; Papadopoulos et al., 1994). hPMSl and hPMS2 (Nicolaides et al., 1994), hMSH6
|also calledpl60or GTBP] (Palombo etal., 1995; Drummond et al., 1995; Papadopoulos et
<7/.,1995) and hMSH3 (Risinger et al., 1996). The roles of these genes were inferred from
their homology with bacterial and yeast mismatch repair genes (Prolla et al., 1994), and germ-
line mutations have been found in HNPCC families. The most frequently involved are
hMSH2, where mutations account for at least 50% of HNPCC kindreds (Peltomaki et al.,
1993; Liu et al., 1994; Nystrom-Lahti et al., 1994; Wijnen el al., 1995; Liu et al., 1996a), and
hMLHl, which accounts for up to 40% (Han et al., 1996; Liu et al., 1996a). Mutations in
these genes may also play a role in the development of sporadic colorectal cancer. However,
mutations have only been demonstrated in a small percentage of sporadic cancers or cell lines
derived from colorectal carcinomas so far (Liu et al., 1995b; Borresen et al., 1995; Bubb et
al., 1996; Moslein et al., 1996; Hcrfarth etal., 1997).
The aim of this study was to clarify the prevalence of mismatch repair deficiency in a
large unselected series of 215 Scottish sporadic colorectal cancer cases and relate this to
clinico-pathological factors. Secondly, to delineate the role of a specific mismatch repair gene
known to be important in hereditary cancers, extensive mutation analysis of hMSH2 was
carried out on selected cases. In the course of this, mutations were identified not only in
hMSH2 exons, but also in adjacent intronic sequence. A further series of experiments was
carried out to establish whether these intronic mutations were likely to be purely secondary to
mismatch repair (engendered by defects in some other gene) or might affect the function of
hMSH2. perhaps through altered splicing.
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3.2. Materials and Methods
3,2.1. Outline of methods
3.2.1.1 Analysis ofmicrosatellite instability
The initial part of this study examined microsatellite instability in a large series of
215 sporadic colorectal carcinoma patients, comparing tumour with matching normal tissue.
Each tumour was examined for instability in at least four microsatellite loci, using a
combination of automated laser fluorescence (ALF). silver staining and radioactive isotope
labelling. Detailed methods can be found in 2 .7. Clinical and pathological features of these
tumours (Dukes' stage, tumour site, p53 status by immunocytochemistry [see 2.6],
histological features) were assessed and their incidence in cancers with unstable
microsatellites versus those with stable microsatellites tested. Patient survival in these two
groups was also compared using the Cox proportional hazard method.
3.2.1.2 Statistical analysis
The effect on post-operative survival of all relevant factors was investigated by
analysis with the Cox proportional hazards method, using the Cox Regression routines of
SPSS for Windows 6.0. Post-operative survival was established by perusal of death
certificates held by the Registrar General for Scotland. Those patients who did not appear in
the registry on the census date were traced through hospital records to confirm survival by
continuing out-patient attendance or by letter to their family practitioner. The censoring date
for survival was taken as 31.12.93; thus, all who survived later than this date were treated as
iast known alive" at this time. Factors investigated as possible predictors of survival were
age. tumour side. p53 status, gender, shift status and Dukes stage. Deaths from all causes
were considered.
3.2.1.3 Mutation analysis of hMSH2
Details of methods arc presented in 2.8 and 2.9. Following identification of 39
cancers with microsatellite instability, 36 were taken for mutation analysis of hMSH2, which
was carried out using a combination of single strand conformation polymorphism (SSCP)
analysis and hcteroduplex analysis. Exonic and. where possible, splice site sequences were
analysed by one or both of these methods. A restriction digest assay was used to detect a
previously reported polymorphism in hMSH2 intron 12 (Fishel et al., 1993; Hall et al., 1994)
and a new polymorphism in exon 1 All tumours showing aberrantly migrating bands by
SSCP or hcteroduplex analysis and their corresponding normal DNA were sequenced using
the dideoxy chain termination method, either directly from PCR product, from a PCR product
made singlc-strandcd by use of a biotinvlatcd primer and strcptavidin-coated magnetic beads
or after cloning into a vector (sec 2.9). In cases where single Taq polymerase-amplificd
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clones were analysed, further sequencing was carried out using high-fidelity polymerase as the
rate of Taq polymerase-induccd errors was found to be high.
Two intronic regions of the hMSH2 gene were found to harbour frequent mutations in
repetitive sequences, postulated to affect mRNA by causing aberrant splicing or reducing the
levels of transcript. Although frozen tissue was not available from these tumours for RNA
analysis, this possibility was investigated by extraction of RNA from xenografted tumours
derived from primary lesions known to contain an intronic mutation, as well as wild-type
controls. cDNA was produced by reverse transcription and two assays were carried out. In
the first procedure. PCR primers were designed to amplify three regions spanning the
mutations to search for evidence of aberrant splicing. Secondly, since insufficient tumour
material was available for extraction of RNA in adequate quantities for Northern blotting, a
quantitative PCR-based assay was used to ascertain the level of transcript present in mutated
versus normal samples. Methods are detailed in 2.10.
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3.3. Results.
3.3,1. Microsatellite Instability Analysis
3.3.1.1 Characteristics of tumours with microsatellite instability
A total of 215 patients diagnosed as having primary sporadic colorectal cancer were
included in this study. This group was unselected, and included patients with more than one
tumour and those with cancer at other sites (either synchronous or asynchronous) who did not
fit the criteria for HNPCC (Percesepe et al., 1994). When patients had more than one
carcinoma, each lesion was analysed separately if DNA was available. Thus, a total of 219
carcinomas were analysed, four patients each having 2 synchronous cancers. Relevant
clinical, pathological and genetic details for these patients, as well as their study number for
cross-referencing, are given in Appendix 5.
These 219 cancers were staged as follows: 25 Duke's Stage A, 100 Duke's Stage B
and 94 Duke's Stage CD (for these purposes stages C and D were amalgamated as
information regarding distant metastasis was not always available). The average age was 70
years, range 28-95 years, with one patient of unknown age. The group comprised 46.5%
(100/215) males and 53.5% (115/215) females.
All samples were analysed for genetic instability at a minimum of 4 microsatellite
loci. 16.4% (36/219) exhibited instability at one or more loci. The average age of this group
was 68.75 years, range 37-93 years. This is not significantly different from the age of the
group without evidence of MSI (70.02 years, range 28-95). During the course of this study a
polyadenine tract located in the 5' region ofhMSH2 intron 5 was identified (Figures 5 and 6)
which exhibited replication errors in 58% (19/33) of samples showing microsatellite
instability at other loci. When instability at this locus was included, a further 3 patients were
found whose tumours showed evidence of MSI, one ofwhich appeared to show instability at
another locus but despite repetition had not given an unequivocal result. Thus, in total, 17.8%
(39/219) of sporadic colorectal cancers in this series exhibited MSI. When the more stringent
requirement of instability at 2 or more loci (including intron 5 ofhMSH2) was applied, a
criterion often used to define a replication error positive (RER+) phenotype (Aaltonen et
al., 1993), the incidence of MSI was 10.5% (23/219).
3.3.1.2 Microsatellite instability in relation to clinicopathologicalfeatures
The relationship between microsatellite instability and site of tumour, p53
stabilisation and Duke's stage was examined (Table 10). 59% (23/39) of lesions with
instability at one or more loci were in the proximal or right side of the bowel (ie proximal to
and including the splenic flexure). This was significantly different (x,^ =7.73, p<0.01) from
the distribution of those without MSI (non-shifters), where 35% (63/180) were right-sided,
similar to the general distribution of all colorectal cancers in the UK of which 28% are right-
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sided (Cancer Research Campaign, 1993). Of lesions with at least 2 unstable sites, 74% were
proximal (xi=12.93, p<0.001). When proximal tumours alone were considered, 27% (23/86)
demonstrated microsatellite instability at one or more loci, and 17/86 (20%) were RER+, as
compared with only 12% (16/133) of distal cancers.
When evidence of p53 stabilisation was examined in this series of tumours [scored
positive if any tumour nucleus in the section stained (Purdie et al., 1991)], 56.4% (22/39) of
tumours with MSI at one or more loci stained positively for p53 protein (Figure 4), which was
not significantly different from those without MSI, in which 60% (108/180) had evidence of
stabilised p53 {j} = 0.43, p>0.5). However, a significant inverse relationship was seen
between MSI status and p53 staining in tumours with instability at more than one loci (x^
=4.43, p<0.05). Fifty-nine percent of the total population had positively stained nuclei. When
the site of lesion was considered 54% ofproximal tumours and 64.5% of distal tumours had
evidence of stabilised p53. These results were compared to data generated from the analysis
of a subset of these cases for loss ofheterozygosity (LOH) at 17p using three restriction
fragment length polymorphic (RFLP) markers intragenic to p53 (Dr C.A.Purdie, personal
communication). 125 lesions were analysed for intragenic loss ofp53, ofwhich 49 were
informative at one or more loci. Ofthese informative cases, 19 had allele loss involving p53
and in 3 (16%) of these we demonstrated MSI, all located on the left side of the bowel. Of the
30 lesions where heterozygosity in p53 appeared to be retained, 9 (30%) exhibited MSI; of
these 6 were located on the right side of the colon. Thus there is an apparent trend for
tumours that exhibit MSI to retain heterozygosity in p53, but this difference was not
statistically significant. There was no significant difference between Duke's Stage and MSI
status in tumours with MSI at one or more locus (x^ = 2.37, p>0.3) or at more than one loci
(X^ = 2.028, p>0.3) (Table 10), although lesions with MSI appeared to be less common
within the Duke's A group.
Histological examination of the 39 tumours with MSI revealed that 41% (16/39) of
these tumours contained large lakes of extracellular mucin mixed with tumour cells and could
thus be classified as mucinous carcinomas (Rosai, 1996). This is a much higher proportion
than in the unselected Scottish population of sporadic colorectal cancers; in such a series
overlapping with the present study only 17% (59/346) mucinous carcinomas were observed.
Examples of histological tumour types are shown in Figure 3. Degree of differentiation was
found to show substantial heterogeneity throughout the tumour, and therefore the sample
taken for DNA could not be reliably assessed for this factor.
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Table 10
Characteristics of tumours with MSI.
MSI STATUS
UNSTABLE > 1 LOCUS UNSTABLE > 1 LOCUS (RER+) "stable
SIDE
LEFT 16(41%) 6 (26%) 117 (65%)
RIGHT 23 (59%) 17(74%) 63 (35%)
DUKES STAGE
A 2 (5%) 1 (4.5%) 23 (13%)
b 21 (54%) 13 (56.5%) 79 (44%)
CD 16 (41%) 9 (39%) 78 (43%)
p53 STATUS
bICC POSITIVE 22 (56%) 9 (39%)
d 108 (60%)
ICC NEGATIVE 17 (44%) 14 (61%) 66 (37%)
CUNKNOWN 6
TOTAL 39 23 180
ano alteration in length seen at loci tested, ^immunocytochemistry CPLPD fixed tissue unavailable
3 samples included with strong cytoplasmic staining, nuclei were not stained.
Figure 3
Examples of haemotoxylin and eosin (H&E) staining of sections of paraffin-embedded
formalin fixed colonic tissue.
(A) Normal colonic epithelium.
(B) Well- to moderately-differentiated adenocarcinoma.
(C) Poorlv-differentiatcd adenocarcinoma.




Immunohistochemical detection of p53 protein.
Immunohistochemistry of sporadic colorectal carcinomas using DAB-detection of anti-p53
antibodies D07 and pAB 1801. Bound antibody is stained brown, background cells are
stained purple with haemotoxylin.
(A) Tumour negative for the presence of stabilised p53 detected by D07.
(B) Strongly positive staining of stabilised p53 by D07.
(C) Tumour showing occasional positive staining with D07. Arrows indicate examples of
positive cells.
(D) Tumour negative for the presence of stabilised p53 detected by pAB1801.

















































































































































Survival analysis was carried out on 169 patients for whom full information on test
criteria (described in 3.2.1.2) was available. Analysis was carried out using the Cox
proportional hazards method. Thirty-five of the 169 tumours (20.7%) exhibited replication
errors at one or more microsatellite loci. Survival of patients from whom these cancers were
resected was markedly above that of patients whose tumours diplayed no such instability
(77% at 3 years compared with 43%). The most significant predictor of survival was Duke's
stage (x2=38.4. p<0.0001) followed by age (x2=9T 1. p=0.0025). MSI (x2=7.83, p=0.0051)
and side (x =6.35. p=0 012). The hazard ratio of patients with tumours showing MSI to
those without was estimated to be 0.39 (95% C.I. 0.19-0.82). Thus, at any point in time after
diagnosis, a patient whose tumour showed MSI had a risk of dying which was estimated to be
about 39% of that of a patient with a tumour without MSI, even after allowing for the
influence of other predictive factors. The results arc presented as an estimated survival curve
(Figure 5). p53 immunohistochemical status and sex showed no association with prognosis.
Cancers arising in the proximal bowel were associated with better prognosis than
those arising in the distal bowel, though this effect was less significant than the effects of
microsatellite instability. When analysis was repeated excluding 'site of tumour', those with




Survival analysis of sporadic colorectal cancer patients with and without MSI.
Estimated survival probabilities for patients with MSI (—) and those without (—) by
days post-operation using the Cox proportional hazards method. Probabilities are plotted for
a hypothetical set of patients with the same mean effects of Duke's stage, tumour side and age
as observed in the study sample. The number of patients with and without MSI surviving at
1100 days were six and 29 respectively.
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3.3.3. Mutation Analysis of hMSH2
3.3.3.1. Mutations within hMSH2
A total of 36 tumours with microsatellite instability at one or more loci (including
hMSH2 intron 5) were analysed for mutations in the hMSH2 gene using either SSCP
mutation analysis, heteroduplex analysis or both methods (Figure 6). In addition, 32 tumours
without MSI were analysed as controls. Germ-line exonic mutations were found in only two
cases (Table 11 and Figures 7&8). Both of these were mis-sense mutations and both occurred
in the control group, one in a 74-ycar old patient with no family history of disease and one in a
49 year-old with a family history of pancreatic cancer. Both cancers occurred in the proximal
colon. Only one tumour with MSI was found to carry any exonic mutation, a frameshift
creating a new stop codon. This tumour also showed a reduction in length of a polyadenine
tract located 3 nucleotides downstream of the 3' end of exon 5, a change which was found in
an additional 21 tumours (Figure 6, 7 & 8 and Table 11). Of these 21 tumours, the
polyadenine tract length alteration was found to be somatic in 20 cases but occurred in both
the tumour and normal tissue of one patient. These alterations were initially detected by
abnormal banding on SSCP gels, but were later found to be easily detectable on denaturing
polyacrylamidc gels. Abnormal allele lengths ranged from 10 to 23 bases compared with
matching normal tissue which had 25 adenine nucleotides in this tract, which differs from the
previously published sequence of 26 residues (Liu et aI., 1994). This change has been
reported by others to occur frequently in colorectal cancers with microsatellite instability
(Hoang et al., 1997).
A further tumour with MSI had an intronic transition-type point mutation, an
alteration of unknown function, as well as the length reduction in intron 5 and a second
reduction in the length of intron 1. Seven other tumours had this somatic reduction in the
length of the polythymine tract located 3' in intron 1, predicted to be part of the splice site.
Whereas in normal tissue this tract extends for 12 or 13 nucleotides, this was reduced to as
few as 9 base pairs in some tumours. Analysis of 6 cancer-free control samples demonstrated
that 12 or 13 bases was a normal polymorphic variation (Dr V.J. Bubb, personal
communication). Removal of this polynucleotide tract by Pst I digestion and repetition of
SSCP on the residual 176 nucleotide fragment (containing 90% of the exonic sequence)
revealed no further mutations.
When these results were combined. 15 tumours had a single change in the hMSH2
gene. 8 tumours had 2 alterations and one had three. Thus, a total of 61% (22/36) of tumours
with MSI had an alteration in hMSH2 compared to 6% (2/32) of non-shifters analysed.
However, in only one tumour with MSI was there a hMSH2 mutation within an exon.
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3.3.3.2. Polymorphisms within hMSH2
Two alleles were detected by heteroduplex analysis in intron 1, which sequencing
revealed to be a C-»G substitution at the +9 position (Figures 6&7). This destroyed a Ben I
cleavage site, permitting use of a PCR-RFLP assay to calculate allele frequency in 106
unselected healthy blood donors. The allele frequencies were Al= 0.38 and A2= 0.62 in this
local population. The same frequency for each allele was found for the cases analysed for
hMSH2 mutation in our study population. Thus this polymorphism does not appear to
influence susceptibility to sporadic colorectal cancer.
Twenty-seven percent of patients with MSI were heterozygous for a previously
described C/T polymorphism at the -6 position of intron 12 (Fishel el al., 1993; Hall et
aI., 1994) [Figure 7], Two patients carried both the polymorphism described at +12 position
of intron 10 (Wijncn et al.. 1994) and the polymorphism described at -9 position of intron 9,
GTCGTT-GTCATT (Borresen et al., 1995) [Figure 7|.
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Mutation detection methods in hMSH2
Examples of mutation detection of (A) a deletion of 15 adenine bases from the polyadenine
tract of
intron 5 and (C) a polymorphic C/G base change within intron 1 (sequence from normal tissue
of two individuals, homozygotes for A1 and A2, are shown).
(B) shows SSCP analysis of intron 5 for three normal/tumour pairs, where sample 1 is the
same pair as shown in A. sample 2 has no mutation and sample 3 (patient no.9 in the study)
carries a germ-line change.
(D) SSCP analysis of the polymorphism shown in C, where samples 1 and 8 are
heterozygous, samples 2. 4 and 5 are homozygous for A2 and samples 3. 6 and 7 are
homozy gous for A1.
(E) Heteroduplex analysis of the first 3 samples shown in D. with the heteroduplex band
marked by an arrow.
(F) The same 3 samples detected by Bcn\ digest. Allele sizes for Ben 1 digests are 8lbp (Al)
and 57bp (A2). The lower 48bp and upper 152bp bands are constant. A 2 lbp constant band
is not shown.
M=lkb ladder DNA molecular weight marker (Life Technologies Ltd).




Sequencing of hMSH2 mutations and polymorphisms.
Dideoxy chain termination sequencing of all mutations (A-F) and polymorphisms (G-J) in
hMSH2 detected in this study (see table 11 and Figure 8).
(A) Sequencing of a single cloned allele showing a germ-line C-G transversion at codon 21,
exon 1. in tumour (right) and normal (left) tissue from patient 33.
(B) T-C transition at the -19 position of the 3' end of intron 1 in the tumour (right) from
patient 19. not present in matched normal tissue (left). This patient also has a 4bp reduction
in the length of the intron 1 polvthymine tract, illustrated in another patient in (E).
(C) Germ-line A-G transition in codon 102, exon 3, in patient 69 (normal tissue on the left,
tumour on the right).
(D) Single thymine deletion in codon 818. exon 15. in tumour (right) of patient 15, creating
frameshift and stop codon.
(E) Somatic deletion of two thymines in the polvthymine tract at the 3' end of intron 1 in
patient no. 85 (tumour on right, normal tissue on left).
(F) Deletion of 15 adenines in the polyadenine tract at the 5' end of intron 5 in tumour material
(right) from patient no. 34.
(G) C/G polymorphism at the +9 position of intron 1 shown in homozygote A1 (patient 38.
left) and homozygote A2 (patient 6, right).
(H) Normal tissue from patient 84, heterozygous for an A/T polymorphism at the +12
position of intron 10 (Wijnen et al., 1994).
(I) Reverse strand sequencing of normal tissue from patient 84, heterozygous for a G/A
polymorphism at the -9 position of intron 9 (Borresen et al., 1995).
(J) Normal tissue from patient 81. heterozygous for a C/T polymorphism at position -6 of






































Location of mutations and polymorphisms within hMSH2





Exon1 codon21 CAC-CAG His-GIn
1MSI-patient (germ-line)
Exon3 codon102 AAT-AGT Asn-Ser
1MSI-patient (germ-line)




INTRONIC Intron1 Reductioninle g hof polythyminetractt3'end 8MSI+patients (somatic) Intron1 TtoC-19p sition,3'end 1MSI+patient (somatic)
INTRONIC Intron9
GtoA-9p sition,3'end and Intron10
GtoA+12positionfintr n10,5'end 2MSI+patients (germ-line)
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EXONIC Exon15 codon818 deletedT createsstop
1MSI+patient (somatic) hMSH2
INTRONIC Intron5 Reductioninle g hof polyadeninetractt5'en 22MSI+patients (21somatic,1ger -line)
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3.3.3.3. Intronic sequence alterations in HMSH2 and transcription
The two most common intronic sequence alterations detected in hMSH2. the
polynucleotide tract length changes in mtrons 5 and 1 (Table 11 and Figures 6.7 & 8). were
investigated for their effects on transcription of the hMSH2 gene. Xenografted tumours were
used for this analysis, since RNA was not available from primary tumour tissue. RNA from
at least 3 tumours with sequence alterations in intron 5 (EVMU. MACA. MEMcG), one of
which also had an alteration in intron 1 (ANKE). and at least 3 control tumours with normal
hMSH2 sequences (ROPE. SHCH. GEHA. BUCH) was analysed to assess amount and
length of hMSH2 transcript. RNA was reverse transcribed and then subjected to three PCR
reactions using primers spanning the regions of interest (exon 2, exon 5 and exons 2-5),
followed by a quantitative PCR assay using p-globin as an internal control. Results are
illustrated in Figure 9.
No difference was detected between hMSH2 transcript length across the three
amplified regions in tumour samples with intronic mutations compared with non-mutated
controls, suggesting that the common intronic mutations do not cause aberrant splicing of
hMSH2. Transcript length across exons 2 and 5 was shown to be normal in all tumours,
although amplification of the longer PCR product across exons 2-5 produced a weak larger
band in all samples, possibly due to the presence of low levels of an alternatively-transcribed
gene product.
Quantitation of the hMSH2 transcript relative to the P-actin transcript yielded
surprising results (Figure 9). The 3 control tumours (ROPE, SHCH, GEHA) showed levels
of hMSH2 transcript ranging between 97% and 72% of the total reaction product (taking
average from reactions done in triplicate). Compared with these tumours, samples with
mutations in intron 5 (EVMU. MACA) or both intron 2 and 5 (ANKE) showed lower levels
of hMSH2 transcript, ranging from 34% to 57%. However, levels of hMSH2 transcript in 2
normal colonic tissue samples (N1. N2) were even lower, at 21% and 24%. Thus, whilst the
amount of hMSH2 transcript present in tumours with intronic hMSH2 mutations appears to
be lower than those without, transcript levels in all tumours were higher than in normal
colonic tissue.
Repetition of the quantitation reaction on another occasion using the same cDNA
yielded consistent results. However, cDNA produced from TRIzol-extracted RNA produced
widely variable results (not shown), and was excluded from analysis.
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Figure 9
Analysis of hMSH2 cDNA.
Agarose gel electrophoresis of cDNA amplification products from xenografted tumours
known to contain intronic sequence alterations hMSH2, amplified to check for transcript
length changes (A-C) and quantitatively (D).
(A) Amplification of exon 2 from primers within exons 1 and 3. Lanes 1 and 10 contain
molecular weight markers cpX174 RF DNA///neIII and Marker V (Boehringer-Mannheim
Ltd), respectively. Lane 2, blank; lane 3, tumour with mutation in intron 5 (MACA); lane 4,
tumour with mutation in intron 1 and intron 5 (ANKE); lanes 5-9, control tumours without
intronic mutations (ROPE. GEHA. BUCH, SHCH. ANBA).
(B) Amplification of exon 5 from primers within exons 4 and 6. Lane 1 contains molecular
weight marker lkb ladder (Life Technologies Ltd). Lanes 2 & 3, tumours with mutations in
intron 5 (EVMU & MACA); lane 4, mutant for both introns 2 and 5 (ANKE); lanes 5-9,
control tumours without mutations as in (A). Lane 10. Marker V (Boehringer-Mannheim
Ltd).
(C) Amplification of exons 2-5 from primers within exons 1 and 6. Lanes 1 & 2, tumours
with mutations in intron 5 and introns 1 and 5, respectively (MACA, ANKE); lanes 3-7,
control tumours without mutations as in (A). Marker in lane 8 is cpX174 RF DNA/T/nelll.
(D) Example of quantitative PCR of hMSH2 cDNA from xenografted tumour samples. The
top band is the amplification product of the internal control, p-actin, and the bottom band is
the PCR product from hMSH2. Lanes 1-3, control samples (ROPE, SFICH, GEHA) with no
hMSH2 mutation; lanes 4-6. tumours with somatic mutations of the hMSH2 intron 5
polyadeninc tract (ANKE, EVMU, MACA). Tumour ANKE also has a mutation of the
polythymine tract of intron 1. Lanes 7-8, normal colonic tissue. Lane 9, DNA molecular
weight marker V (Boehringcr Mannheim).
(E) Quantitative analysis of the above experiment, done in triplicate. Bars represent mean
hMSH2 product expressed as a percentage of total PCR product (ie hMSH2 plus P actin)



















































3.4.1 MSI and clinicopathological features of sporadic colorectal cancer
This study has identified a group comprising a sixth of a population of Scottish
sporadic colorectal cancer patients that exhibit microsatellite instability. This proportion is in
agreement with the incidence of MSI identified by others in sporadic CRC from other
geographic locations, including Lothe et al.( 1993)-[ 16.5%]; Aaltonen et al. (1993) [13%] and
Kim et al., 1994a 113%]. This tumour group includes a number of cases where only one locus
is altered, a phenomenon which has been previously noted in colorectal cancer (Peltomaki et
al., 1993; Lothe et al., 1993) [discussed below].
Other clinico-pathological factors that may distinguish this group from the general
population of colorectal cancer patients were examined. Although there was found to be no
significant difference between microsatellite unstable and stable tumours for age of onset.
Duke's Stage or gender distribution, the data did confirm the proximal location of colonic
lesions with MSI. which has been noted by others (Lothe et al., 1993; Kim et al., 1994a;
Thibodeau et al., 1993). The results of the Cox analysis indicate a highly significant
favourable effect of MSI status on post-operative survival, even after allowing for the effects
of age. Duke's stage, sex and tumour side. Paradoxically, histological features generally
associated with aggressive tumour behaviour are common in MSI tumours; in this series 41%
were mucin-secreting.
The characteristic clinical and pathological profile of tumours with microsatellite
instability, common to both sporadic and hereditary cancers, is intriguing. It has been
suggested that the survival advantage stems from an enhanced host immune response to
cancer cells arising as a result of a high mutation rate of tumour-associated antigens (Kim et
al., 1994a): the rate of frameshift mutation at repeated DNA units and the rate of point
mutation in cell lines deficient in hMSH2 or hMLHl is estimated to be about a thousand times
greater that that of mismatch repair-proficient cells (Parsons et al., 1993; Bhattacharyya et
al., 1994; Shibata et al., 1994). However, a recent study indicates that mismatch repair-
deficient cancers often acquire frameshift mutations in the beta 2-microglobulin (beta 2M)
gene, which encodes a protein important in antigen recognition in cytotoxic T cell-mediated
killing, and are thus more likely to escape immune surveillance (Bicknell et al., 1996). An
alternative explanation is that the tumour reaches a situation where it can no longer survive
with such a mutation burden if. for example, it compromises the function of essential
housekeeping genes. Exactly how the survival advantage comes about remains to be resolved,
and it will be of particular interest to discover the means by which host immune response to
tumour cells w ith replication error phenotype is moderated. The abundance of tumours with
MSI which secrete mucin might be explained by the notion that such tumours, by retaining the
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ability to secrete mucin, retain a more normal phenotype than those which have lost this
ability (probably as a result of massive genomic disruption). Alternatively, one consequence
of the high mutation rate in cells with defective mismatch repair may be disregulation of genes
controlling mucin production, and hence overproduction of mucin.
The frequent initiation of tumours with unstable microsatellites and characteristic
pathology in the proximal colon may indicate that factors present in the local environment
favour growth of cells with the characteristics of defective mismatch repair. Although the
carcinogenic burden is believed to be higher in the left colon due to slower passage of faecal
material, constitutive genetic differences exist between the left and right colon which may
increase the concentration of certain mutagens in the proximal colon. For instance, certain
polymorphic variants of drag metabolizing enzymes appear to confer susceptibility to
colorectal cancer in general, but to proximal lesions in particular. Two such examples are the
increased incidence in colorectal cancer patients compared to non cancer-bearing control
individuals of a 'slow metabolizing' polymorphism of epoxide hydrolase, an enzyme
responsible for detoxification of reactive epoxides (Dr S .Hubbard, personal communication),
and of a null mutation of an enzyme which detoxifies polycvclic aromatic hydrocarbon
metabolites, glutathione S-transferase mu (GSTM1) (Zhong et al., 1993). Inefficient
metabolism of specific mutagens present in the diet, or delayed removal of mutagenic
intermediate products of metabolism, may result in particularly high levels of certain
carcinogenic substances within the proximal bowel, favouring growth of one or more cells in
which a mismatch repair-associated activity is defective. The initial mismatch repair gene
mutation may be caused by the carcinogen itself, by other dietary components or by-products
of metabolism, or may be already present in the germ-line. Although mismatch repair genes
are believed to require homozygous mutation in order to lose repair function, a heterozygous
effect of such mutations has been demonstrated in vitro (Parsons et al., 1993), and it is
possible that such cells maintain growth with a somewhat increased rate of mutation and a
level of resistance to damage-induced apoptosis characteristic of cells with such defects.
Mismatch repair function is incapacitated when a second allele is affected, after which tumour
suppressor genes rapidly acquire mutations and accelerated progression to carcinoma status
ensues. Kinzler and Vogelstein (1996) propose that mutations occurring in growth-controlling
genes produce conflicting signals within the cell and normally cause the cell to die by
apoptosis. However, exposure of the gut to mutagens causes not only mutation but also
substantial cell death, and the regeneration which follows gives rise to cells in which the
apoptosis-promoting signals are necessarily switched off. They suggest that only in these
conditions arc cells which acquire, or have already acquired, mutations in growth-controlling
genes, susceptible to uncontrolled growth.
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Determination of the MSI status of a colorectal lesion could be important not only as
a predictor of prognosis but also in terms of potential cancer therapy. Mismatch repair
deficiency confers resistance to certain alkylating agents such as N-methyl-N'nitro-N-
nitrosoguanine (MNNG), N-mcthyl-N-nitrosurea (MNU) and the chemotherapeutic drug
temozolomide (Branch et al., 1993 & 1995; Kat et al., 1993; de Wind et al., 1995; Liu et al.,
1996b) and. to a lesser extent, to cisplatin (Aebi et al., 1996; Drummond et al., 1996; Fink et
al., 1996; Mello et al., 1996). However, such cells retain sensitivity to chloroethylating
agents (Liu et al., 1996b). The potential to tailor chemotherapeutic regimens to a tumour's
molecular status in order to maximise anti-tumour effect whilst avoiding inappropriate
treatment of resistant tumours (which may actually exacerbate the disease process by
increasing the cancer's mutational burden) offers real promise of effective drug treatment for a
significant number of cancers. Further, mutations induced by mismatch repair deficiency
could provide targets for corrective gene therapy (Benson & Wells, 1995). Recent insights
into the mechanism of development of tumours with MSI suggest that mutation of an
intragenic 'target' polynucleotide repeat within the TGF P receptor subunit II (TGFp RII)
renders colorectal tumour cells insensitive to TGFp-mediated growth inhibition (Markowitz et
al., 1995). Mutations at similar repetitive units within the insulin-like growth factor II
receptor (IGF-IIR) probably compromise the same pathway of growth inhibition in a subset of
mismatch-repair deficient gastrointestinal cancers (Souza et al., 1996), and very frequent
mutations of a polynucleotide tract within the apoptosis-promoting gene Bax are predicted to
render many cancers with MSI less liable to undergo apoptosis (Rampino et al., 1997).
Surprisingly, such mutations are not detected at random; repetitive nucleotide units within
many other oncogenes and tumour suppressor genes undergo no such alterations in mismatch
repair-deficient cancers (Simms et al., 1997), suggesting a strong selective pressure in favour
of mutation of only certain genes critical for inhibition of cancer development.
In addition to the distinct clinical and pathological profiles of this group of tumours,
there was a significant inverse relationship between p53 stabilisation and MSI status in
tumours with instability at more than one locus (ie those tumours which were RER+). This
relationship has also been reported by others (Ionov et al., 1993), although without indication
whether the tumours analyzed were sporadic or hereditary in nature. Furthermore, MSI
tumours were about twice as common within the group of tumours which had retained both
alleles of p53. Thus, the results of this study provide further evidence that distinct genetic
defects drive different pathways of colorectal carcinogenesis. A very recent study provides in
vitro evidence for the existence of two such mechanisms in colorectal cancer, one involving
defects in the mismatch repair process with concurrent instability at microsatellite loci and a
second leading to extensive chromosomal instability (Lengauer et al., 1997b).
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3 .4.2 The role of hMSH2 in sporadic colorectal cancer
Although sporadic colorectal cancers with MSI demonstrate replication slippage in a
similar manner to HNPCC lesions and share similar biological characteristics, there are clear
differences. Unlike the situation seen in sporadic colorectal cancer, microsatellite instability
occurs as an early event in HNPCC adenomas (Young et al., 1993; Aaltonen et al., 1994), as
it does in Barrett's oesophagus, oesophageal adenocarcinoma (Meltzer et al., 1994) and
ulcerative colitis-associated lesions (Suzuki et al., 1994). Furthermore, it is clear that the role
of hMSH2 is different. Only three percent (1/36) of unstable tumours and 6% (2/32) of stable
tumours had one or more mutation in the exonic portions of hMSH2. Thus, this study
concurs w ith the results of the analysis of similar series of sporadic tumours (Borresen et al.,
1995; Konishi et al., 1996; Herfarth et al., 1997) and is akin to the incidence of hMSH2
mutation in 20 cell lines derived from sporadic colorectal cancers with MSI (Liu et al.,
1995b). However, it is in direct contrast to HNPCC where analysis of these regions identifies
a mutation incidence of up to 40% (Liu et al., 1994; Wijnen et al., 1995).
In this series of sporadic cancers, frequent mutations occurred in non-coding regions
of hMSH2. All but one of these occurred within two polynucleotide repeat tracts, a
polythymine tract of the intron 1 splice donor site and a polyadenine tract repeat within intron
5, suggesting that they may be the effect, rather than the cause, of a generalised mutator
phenotype. Although not directly affecting the coding sequence, mutations of this nature,
located within or close to splice sites, can cause inefficient or aberrant splicing (Wieringa et
al., 1984; Chu et al., 1993). However, the great majority of hMSH2 mutations were in this
class; it would be surprising, if hMSH2 were critical for microsatellite instability in sporadic
cancer, for the predominant mechanism of inactivation to be one that does is not observed in
HNPCC. Moreover, analysis of RNA from such tumours suggests that these sequence
alterations arc unlikely to to exert a profound effect upon hMSH2 transcription, since lesions
with and without such intronic mutations showed that only normal length hMSH2 transcript
was detectable. A certain amount of caution must be exercised in interpreting these data,
since, in some circumstances, incorrectly spliced mRNA can be degraded more rapidly than
normal (for review see Beclman & Parker, 1995) and could remain undetected. Results of
quantitative RNA analysis, though inconclusive, did suggest a possible effect of such
mutations on transcription, as the amount of hMSH2 transcript was somewhat lower in
tumours carrying such intronic mutations compared to those without. Difficulties with
reproducibility of quantitative PCR. discussed in 3.3 .3 .3, probably mean that collection of
new samples (primary or xenografted tumour) would be necessary for reliable confirmation of
these data by Northern analysis. In addition, it is clear that a larger number of tumours needs
to be studied. All tumours exhibited a level of hMSH2 transcript higher than that of normal
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tissue, suggesting that the gene could be up-regulated in colonic tumours. This may be due to
the increased rate of cell division in tumour tissue compared with normal, since levels of
hMSH2 have been shown to be higher during active stages of the cell cycle compared with
resting cells (Marra et al., 1996).
In this study, a proportion of hMSH2 mutations may have escaped detection as SSCP
analysis cannot detect all mutations, although the efficacy of the technique for detecting point
mutations and small insertions and deletions has been demonstrated in our laboratory in the
study of other genes (Curtis et al., 1994; Morris et al., 1996). Mutations in the promotor
region, large losses or methylation changes could not have been detected by this method.
Perhaps this indicates inactivation of the gene by a mutation not detectable by the methods
used in this study, or by another mechanism altogether. However, despite limitations of
mutation detection, extensive examination of the known components of the mismatch repair
system, hMSH2, hMLHl. hPMSl. hPMS2 and GTBP, by several laboratories using diverse
methods have yielded few gene mutations or protein malfunctions. GTBP and hMLHl
mutations do account for microsatellite instability in several cases of sporadic cancer
(Papadopoulos et al., 1995; Malkhosyan et al., 1996b; Herfarth et al., 1997) and errors of
DNA replication itself arc at fault in a small proportion of cases; a small number of mutations
in the proof-reading domain of polymerase 5 have been identified in sporadic cancers (da
Costa et al., 1995). The cause of the mutator phenotype in sporadic cancers could be another,
as yet unidentified, component of the mismatch repair pathway; no homologue of the E. colt
MntH gene has yet been identified, for example. Another possibility could be a gene product
such as proliferating cell nuclear antigen (PCNA), a protein which enhances the processivity
of pol5 and pole and is essential for replication. In S.cerevisiae, PCNA has been directly
implicated in mismatch repair, and missense mutations of POL30, the gene encoding PCNA,
can give rise to destabilisation of a GT repeat (Johnson et al., 1996b). It is of interest that a
mutation of hMSH3 has been detected in endometrial cancer with microsatellite instability
(Risinger et al.. 1996); this gene could be important in the genesis of a similar phenotype in
sporadic colorectal cancer. Given the identical mutator phenotype and shared clinico-
pathological features of HNPCC and sporadic cancers with microsatellite instability, it seems
unusual that the putative defect in sporadic disease accounts for virtually no cases of HNPCC
(since almost all are caused by defects in hMSH2, hMLHl, hPMS 1 and hPMS2). This might
suggest that the dcfect(s) occurring in sporadic cancer result in embryonic lethality when
present in the germ-line. Although this appears unlikely in view of the relatively normal
development of mice totally deficient \x\Msh2, Pmsl and Mlhl (Baker et al., 1995 & 1996;
Reitmair et al., 1995; de Wind et al., 1995), the component may be one which is also
fundamental to other cellular processes, for instance a helicase, a polymerase or PCNA. The
fact that sporadic endometrial adenocarcinomas (which also occur commonly in HNPCC
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patients) displaying microsatellite instability also harbour very few mutations in the mismatch
repair genes hMSH2. hMLHl. hPMSl and hPMS2 (Katabuchi et al., 1995; Kowalski et al.,
1997) supports the assumption that the major cause of microsatellite instability in sporadic
cancer remains to be determined.
The overall incidence of hMSH2 mutation in this population of sporadic colorectal
cancers is at least 11%, with only 1% having exonic mutations. Amongst this population of
patients with apparently sporadic colorectal cancer, three carried germ-line mutations in
hMSH2. This small subset of patients may be thought to represent hereditary, rather than
sporadic, colorectal cancers which do not fit the criteria for HNPCC. Only one of these 3
patients had any family history of cancer. Interestingly, this patient was identified from the
group of cancers without MSI. He was younger (49 years) than the average age-group, had a
Duke's C carcinoma in the ascending colon, and had a family history of pancreatic cancer.
This individual may belong to the class of familial RER+ tumours including lung, breast and
pancreas, with less prevalent microsatellite alterations (Liu et al., 1995b) although this has not
previously been associated with hMSH2 mutation. A second patient with no family history or
evidence of microsatellite instability, aged 74 and with a cancer of the caecum, was also found
to have a germ-line hMSH2 mutation. Both of these mutations were mis-sense and therefore
predicted to compromise protein function. The third germline mutation was the shortened
polyadcnine tract in intron 5; found in a patient whose tumour demonstrated MSI. These
observations support the view that a wide range of phenotypes are associated with germ-line
hMSH2 mutation (Kolodner et al., 1994; Mary et al.. 1994).
3.5. Conclusions
Two major conclusions can be drawn from this work. Firstly, although MSI is
clearly a significant factor in the clonal expansion of around one in six of all sporadic
colorectal cancers, exonic hMSH2 defects are associated with this instability in a very much
lower proportion of tumours than in HNPCC. Indeed, when mutations in the intronic
sequences of hMSH2 are excluded from consideration, hMSH2 mutation in sporadic tumours
with MSI is no more frequent than in other tumours. Therefore, it appears that the genetic
basis of microsatellite instability in sporadic and inherited colorectal cancer is different.
Secondly, the data (from a large series of patients with extensive follow-up) clearly
demonstrate a survival advantage for patients who have a tumour exhibiting MSI. It will be
of great interest to determine the mechanism by which such genetic instability imparts




Temporal evolution of microsatellite instability in sporadic
colorectal cancer xenografts
4.1. Introduction
Cells in which mismatch repair is defective exhibit high mutation rates at
microsatelhte loci. In vitro studies show that cell lines derived from colorectal tumours with
microsatellite instability continue to generate de novo mutations in di- and trinucleotide repeat
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sequences at each round of replication at a rate of 5x10 to 10 per allele per cell replication
(Shibata et al, 1994). Furthermore, primary cancers with unstable microsatellites usually
(though not always) display heterogeneity of novel microsatellite alleles throughout the
tumour, suggesting that the generation of new mutations often persists throughout tumour
growth in vivo (Shibata et al.. 1994). This study aimed to test directly whether the replication
error phenotype persists throughout prolonged carcinoma growth in vivo through analysis of
microsatellite loci in a series of human colorectal tumours growing as xenografts.
It is not known whether MSI can be acquired spontaneously during carcinoma
growth. The very low incidence of MSI in sporadic colorectal adenomas compared with
carcinomas (Aaltoncn el al., 1994; Young et al., 1993) implies that it might be associated
with the transition from adenoma to carcinoma, but it could alternatively be is a feature of a
carcinoma type which is not preceded by an adenomatous stage. MSI does arise, however, in
conjunction with drug resistance in cancer cell lines challenged with cisplatin or doxorubicin
(Anthoney et al., 1996). Acquisition of such a mutator phenotype at a later stage in a real
tumour could have implications for tumour management, as MSI is associated with sensitivity
to certain chemothcrapeutic drugs but resistance to others (discussed in Chapter 2, section
2.5). Thus, a further aim of this study was to examine replication-competent sporadic
colorectal carcinomas over time in order to determine whether the mutator phenotype can arise
spontaneously.
In vivo study of grow ing human tumour tissue is only possible through subcutaneous
implantation as xenografts into SCID mice. Such tumours retain remarkably similar
pathological and genetic features to the primary tumour, including histological pattern
(McQueen et al, 1991), deletion or mutation status of p53, DCC. APC and Ki-ras (Lefranqois
et al., 1989; McQueen et al., 1991; Ms S. White, personal communication), stability of p53
by immunohistochemistry (Ms S.White, personal communication). DNA ploidy (Ms S. White,
125
personal communication) and karyotype (Lefran?ois et al, 1989), although an increased
tendency towards polyploidisation has been noted. To date, the behaviour of microsatellite
loci in these tumours has not been studied.
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4.2. Materials and methods
4 2.1 Outline of methods
Xenografts were established and harvested, and DNA extracted from normal, primary
tumour, early xenograft and late xenograft tissue samples as described in 2.2-2.3. Samples
were deemed to be early passage when they had been passed through not more than 3 mice
and late passage when they had been passed through at least four mice (approximately 4
months). Tumours were assessed for instability using a PCR/silver staining method at four
microsatellite loci. D2S123. D3S1293. D8S282 andD13S160 as described in 2.7.1-2.7.2.
Initially, 33 xenografted tumours were available for assessment of microsatellite
instability status at late passage (see Appendix 5). All but 2 were also available for
assessment at early passage, and in two others, primary tumour tissue was not available. A
further five tumours were available only at early passage. In most cases, tumours were
examined after 1 and 6 passes. Tumours in which microsatelhte instability occurred
underwent DNA fingerprinting by at least one of two methods. Southern analysis of a variable
number tanden repeat (VNTR) or PCR-based analysis of an Alii repeat, to ensure that no
sample ntixup had occurred.
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4.3. Results
Thirty-three xenografted tumours from which late passage tumour DNA was
available were initially included in this study. All were examined at the earliest available
passage (usually pass 1. occasionally pass 2 or 3) and the latest available passage (pass 4 to
7. and passes 18 and 23 in one case). Examples are illustrated in Figure 10. Nine
demonstrated microsatellite instability at one or more loci, although four were unusual,
demonstrating apparent instability- in the xenografted tumours but not the corresponding
primary- tumour (in one case only in the late passage xenograft) suggesting the onset of
instability during xenograft progression. DNA fingerprinting of all unstable tumours
demonstrated the presence of novel alleles at two different regions (one VNTR and one Alu
repeat sequence) in these 4 samples when compared with the DNA from their matching
normal tissue (Figure 11) and thus excluded these samples from the series. The other 5
tumours with MSI showed concordance between normal and tumour tissue on fingerprinting.
Thus, a total of 5 out of 29 (17%) xenografted tumours included in the assessment of
microsatellite instability at late passage demonstrated microsatellite instability. Details of
allele shifts and passage numbers for these tumours are shown in Table 12. In all 5 cases the
instability was apparent in both primary tumour and xenograft samples. Instability was
always apparent at 2 or more loci, therefore all could be termed RER+ (see 1.3.11.1).
None of 24 xenografted tumours whose primary cancer had stable microsatellite
sequences developed MSI. even, in one case, where the tumour had been passed 23 times
through mice over a period of approximately 2 years.
A further 6 tumours (including one which was excluded from the original series
because fingerprinting demonstrated the late passage xenograft to be erroneous) were only
available for study at early passage. Data from these tumours were in keeping with that of the
main series of cancers; 4 demonstrated stability in the primary tumour and xenograft, whilst 2
showed instability in the primary tumour and xenograft, one at one microsatellite locus and
one at all 4 loci (Table 12).
Microsatellite allele shift did not occur within every locus at every pass. Novel
alleles, of different lengths to those in normal tissue, demonstrated subsequent stable
transmission at up to three loci in 5 of the 7 xenografted tumours with MSI (Table 12). The
majority of mutations at microsatellites were 2 or 4 nucleotide insertions or deletions although
changes of up to 12 nucleotides were observed in two tumours (ANKE and MEMCG late
passage xenografts).
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Figure 10
Microsatellite instability in xenografted colorectal carcinomas
Silver stained polyacrylamide gel analysis of PCR products generated from four
microsatellite loci, (A) D13S160. (B) D8S282, (C) D3S1293 and (D) D2S123, in normal (N),
primary tumour (T). early xenograft (XE) and late xenograft (XL) tissue from two patients,
GEHA and MEMcG. GEHA demonstrates no microsatellite allele shifts, whereas MEMcG
shows instability at all four loci. Early xenografts were at passage number 1 for both GEHA
and MEMcG. late xenografts at passage 6 and 4. respectively.




DNA fingerprinting of xenografted tumour samples
(A) Southern analysis with probe 29C1 (Cooke et al., 1985) of normal (N), primary tumour
(T) and late xenograft (XL) material from three individuals, GEHA, MEMcG and JOLO.
GEHA and MEMcG show the same allele pattern in all samples analysed. JOLO contains
novel bands in late xenograft tissue compared with the corresponding normal and primary
tumour, indicating a likely sample mixup. This sample was excluded from the series.
(B) The same samples analysed by PCR amplification of an Alu repeat within the p53 gene.
Again. GEHA and MEMcG show concordant banding patterns, whereas JOLO shows loss of
Al in XL.
M=lkb ladder DNA molecular weight marker (Life Technologies, Ltd).
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4.4. Discussion and Conclusions
The data presented here demonstrate that the replication error phenotype of sporadic
colorectal tumours grown as xenografts is maintained over a prolonged period of time. New
microsatellite alleles arise continually during growth (though not at every locus with every
passage), consistent with the presence of underlying defects in the process of mismatch repair
rather than a transient mutational event at the onset of carcinoma. This is concordant with the
work of Shibata et al. (1 994) who demonstrated maintenance of this phenotype in vitro and
evidence suggestive of its maintenance in vivo. Additionally, a recent study used
microdissection of RER+ gastric tumours to demonstrate intratumoral clonal heterogeneity of
microsatellitcs. suggesting that evolution of such sequences can occur in vivo (Ottini et al.,
1997). Similarly, primary cancers in which microsatellite sequences were stable, maintained
replication fidelity when grown as xenografts over an extensive period (growth for up to 2
years in one case), demonstrating that spontaneous onset of the replication error phenotype
during cancer progression is a rare event. Thus, the data suggest that the mutator status of a
colorectal tumour, as assessed after surgical resection, is fixed.
These data are compatible with the current hypothesis that the mutator phenotype
represents one of at least two tumorigenic processes responsible for the development of
colorectal cancer (Kinzler & Vogelstein, 1996; Lengauer et al., 1997b). Lengauer et al.
(1997b) have demonstrated a second mutagenic process in cell lines derived from colorectal
cancer in which spontaneous chromosomal anomalies occur very frequently (termed CIN, for
chromosomal instability). Although the two mutagenic pathways can coexist, the authors
believe that only one is required for cancer progression and the CIN phenotype is dominant.
Conceivably, the stable cancers in this series do spontaneously generate microsatellite
instability but growth of such cells is not favoured, perhaps due to the preexistence of a potent
alternative tumorigenic pathway. The in vitro acquisition of a mutator phenotype in response
to cisplatin and doxorubicin (Anthoney et al., 1996) implies that certain circumstances do
favour growth of clones with replication errors. An investigation of the effects of several anti¬
cancer drugs on selected tumours from this series is currently underway and should yield
interesting results.
The results of this study provide an additional demonstration of the value of
xenografts as tools for the study of colorectal cancer. The status of replication fidelity at
microsatellite sequences can be added to the many genetic and histological features which
remain constant during xenograft growth, further confirming these tumours to be legitimate
representations of the primary colorectal carcinoma from which they arise. In addition,
examination of microsatellite loci through serial passage has shown that, at least with the 4
loci used in this series, characterisation of the primary tumour alone is not always sufficient
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for accurate classification as RER- and RER+. Aaltonen et al. (1993) originally divided
tumours according to whether they were unstable at one (classed as RER-) or at more than
one (RER+) microsatellite. and found only the latter group to be associated with certain
distinctive clinical and pathological characteristics. These criteria have subsequently been
widely, though arbitrarily, employed, since the specificity and number of microsatellites used
to define this status varies. In this series, data from the primary tumour alone would have
resulted in misclassification as RER- of one tumour (JEGA), in which underlying instability
was clearly present. Conversely, the classification employed early in the discovery of this
phenomenon (see Chapter 2), in which a tumour with instability at any locus was deemed
unstable, would have resulted in misclassification as unstable of another tumour (CODR),
which remains stable throughout passage. The allele shift observed on only one occasion in
this tumour may be explained by the suggested low level of background microsatellite
instability thought to occur in certain repeat types (Weber et al., 1993). In the light of these
results, it seems preferable to choose the cautious classification suggested by Aaltoncn et al.
in order to avoid false assignment of essentially stable tumours to the small group of lesions
which have intrinsically unstable microsatellites. In future, correct classification might be
better achieved by examination of a larger number of selected microsatellite loci, as suggested




Chromosomal instability in sporadic colorectal cancer
5.1. Introduction
Cytogenetic and comparative genomic hybridisation (CGH) studies have
determined a number of specific chromosomal abnormalities which occur very frequently in
colorectal cancer (Reichmann et al., 1981; Muleris et al. 1988 & 1990; Yaseen et al., 1990;
Konstantinova et al., 1991; Bardi et al., 1993b; Barletta et al., 1993; Herbergs el al., 1994;
Gerdes et al., 1995; Schlcgel et al., 1995; Ricd et al., 1996). However, recent evidence
indicates that at least one of the distinct mechanisms of genomic instability which drive
sporadic colorectal carcinogenesis might not necessarily result in chromosomal instability.
This mechanism is associated with generalised microsatellite instability caused by defects in
the process of mismatch repair and is associated with distinct clinico-pathological features
(discussed in Chapter 2). Several studies have demonstrated that in such tumours there is
seldom evidence for major abnormalities in chromosome structure or number (Aaltonen et
al., 1993; Lothe et al.,1993; Shibata et al., 1994; Remvikos et al., 1995; Branch et al., 1995;
Schlcgcl et al., 1995). A second putative mechanism, which is a feature of the large
majority of sporadic colorectal carcinomas, is characterised by defects of p53 function.
Numerous studies link p53 defects with chromosomal abnormalities (Bischoff et al., 1990;
Livingstone et al., 1992; Yin et al., 1992; Carder et al., 1993 & 1995; Agapova el al.,
1996; Remvikos et al., 1997) and, furthermore, disruption of p53 function has been shown
to precede aneuploid clonal divergence in colorectal cancer (Carder et al., 1993 & 1995).
Several reports suggest an inverse correlation between aberrant p53 function and the
microsatcllite instability phenotype (Ionov et al., 1993; Kim et al.. 1994a; Cottu et al., 1997;
Radford et al., 1997; Rcmvikos et al., 1997), implying that these two abnormalities
represent independent tumorigcnic mechanisms. In vitro evidence also suggests that high
levels of chromosomal instability and microsatellite instability are features of independent
tumorigenic mechanisms in colorectal cancer (Lengauer et al., 1997b). The latter study
suggests that the two processes are not mutually exclusive, though either one is sufficient to
drive carcinogenesis.
This investigation set out to determine the extent of chromosomal abnormalities in
relation to defects of p53 and microsatellite instability in sporadic colorectal cancer. CGH
(Kallioniemi et al., 1992; du Manoir et al., 1993) was used to evaluate chromosomal copy
number abnormalities in a scries of such tumours, and flow cytometry was employed to
determine DNA ploidy abnormalities. Further to this, patterns of chromosomal abnormalities
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were examined in order to identify' specific common regions of amplification or deletion,
which may indicate the presence of an oncogene or tumour suppressor gene, associated with
defects of either putative tumorigenic pathway. The study employed tumours grown through
one or two passages as subcutaneous xenografts in SCID mice, which are advantageous in
their elimination of human stromal contamination from tumour material. As noted in Chapter
4, tumours grown through serial passage in this way display a remarkable adherence to many
genetic (S.Whitc, unpublished data; Lefrangois et al., 1989; McQueen et al., 1991) and
histological features (S.Whitc. unpublished data; McQueen et al, 1991) of the primary tumour
from which they were established, although a degree of karyotypic evolution does occur
(Lefrangois et al, 1989). The results of analysis of DNA ploidy, p53 status and chromosomal
changes presented here shed further light on the value of xenografted tumours as study models
for colorectal cancer.
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5.2. Material and methods
5 2.1. Comparative Genomic Hybridisation
CGH detects changes in copy number of whole or partial chromosomes (Kallioniemi
et al., 1992: du Manoir el aI.. 1993) through simultaneous hybridisation onto a normal
metaphase spread of DNA derived from normal and test tissue, differentiated by fluorescent
coloured labels. A fluorescence ratio is plotted along the length of each chromosome and any
regions of amplification or deletion are detected as a change in ratio of green to red
fluorescence. Hybridisation on to normal metaphases makes the technique particularly
suitable for analysis of tumour genomes, since good quality metaphases for use with
conventional cytogenetic techniques are notoriously difficult to obtain. In addition, as it
provides information about the whole genome at once it is considerably more powerful than
conventional deletion/amplification study methods which are limited to single loci. However,
though it provides an excellent method for detection of amplification and deletion relative to
the entire DNA content of the test sample, it cannot detect translocations or pure
polyploidisation.
In this study, test DNA was extracted from 29 cancers, 28 derived from primary
colorectal cancers and one from a lymph node metastasis from a patient with colorectal
cancer, all of which had been grown as xenografts in SCID mice (2.1-2.2) through one or two
passages (approximately one or two months) before analysis. The latter tumour was excluded
from statistical analysis. Clinical and pathological details for these tumours are presented in
Table 13.
CGH was carried out according to the protocol described in 2.13. Tumour DNA was
labelled with biotin by nick translation and counter-hybridised against digoxygenin-labelled
normal DNA and Cot-1 DNA onto a normal male metaphase spread for 2-3 days. A
rhodamine-conjugatcd anti-digoxygenin antibody and fluorescein-conjugated avidin were used
to visualise hybridised normal and tumour DNA. Each experiment included a normal control
hybridisation consisting of normal male DNA labelled with biotin vs normal male DNA
labelled with digoxygenin. Hybridisations were analysed using the Apple Macintosh-based
quantitative image analysis software MacProbe (Perceptive Scientific Instruments, Ltd).
Between five and ten mctaphase spreads, or a minimum of 5 autosomes and 3 sex
chromosomes, were analysed for each tumour. Green/red ratio cut-off points of 1.125 and
0.875 were chosen for scoring of chromosome copy number changes. This was the level at
which copy number changes could easily be visualised, and is equivalent to a loss or gain of
one chromosome in 25% of cells in a diploid karyotype. A chromosome arm was scored 'lost'
or 'gained' if any region w ithin it (other than excluded areas) reached the appropriate cut-off
point, and scored as both 'lost and gained' if both cut-off points were reached.
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5.2.2 Analysis of p53 status and microsatellite instability
Immunohistochemical staining of p53 was carried out on all primary and 14 xenograft
tumour sections as in 2.6 using two antibodies, pAblSOl and D07, both of which recognize
both normal and mutant forms of the protein. Immunohistochemistry (IHC) using these
antibodies in a series of tumours often yields a wide inter-tumoral variation in the number and
intensity of positive nuclei. Generally, there is an excellent correlation between positive
staining with D07 in >30% of nuclei and mutation within the p53 gene (Baas et al., 1994).
However, some tumours containing less than 30% positive nuclei also carry a mutation in the
p53 gene. Negative IHC usually indicates normal p53 function, but a subset of tumours with
mutations of p53, usually either nonsense mutations or point mutations within exon 6, are
associated with lack of protein stabilisation (Cripps et al., 1992; Remvikos et al., 1997).
Thus, in order to clarify the status of p53 in tumours in which numbers of IHC-positive nuclei
were low or negative. SSCP mutation analysis of the gene was carried out (see 2.11 for
method). Analysis was restricted to the mutational 'hotspot' region of p53, exons 5-9, where
the vast majority of mutations occur (Levine et al., 1991). pAbl801 often produced lower
levels of staining relative to DO 7, and so low level staining with this antibody was not
considered to be sufficient to justify classification as a low-level staining tumour.
Microsatellite instability was assessed using PCR, polyacrylamide gel electrophoresis
and silver staining (2.7) in the same manner as in Chapters 3 & 4.
5 2 3 Analysis of DNA ploidv
Because CGH cannot detect polyploidisation, DNA ploidy was assessed by flow
cytometry (see 2.5). Tissue was available for flow cytometry from 26 tumour samples.
Where available (in 22 cases) both primary tumour and xenograft samples were analysed.
Three tumours were only available as primary tumours and one only as xenograft material.
Aneuploid tumours were assigned an arbitrary status of hyperdiploid or hypotetraploid
according to the proximity of the peak to the predicted diploid and tetraploid position.
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5.3. Results
5.3.1 Assessment of p53 status
p53 immunohistochcmistry status was assessed in 28 primary sporadic colorectal
cancers and one lymph node metastasis from which the early passage xenografts samples in
this study derived. Of these, 21 (including the lymph node) stained positive for stabilised p53
protein with pAb 1801. D07 or both, and 8 did not stain with either antibody (see examples in
Figure 4). The percentage of immunohistochemically positive nuclei per positive tumour
varied from < 1 % to >90%. This large variation in staining level is well reported, and is
strongly associated with mutation of the gene when >30% or more of cells stain positive (Baas
et al., 1994; Midgley et al.. 1992). Fourteen xenografted tumours were also assessed for p53
status by IHC. producing no discrepancies with the primary tumour results.
Of 8 IHC-negative tumours and 11 tumours with low to moderate levels of IFIC
staining which were assessed for mutation within exons 5-8 of p53, three showed evidence for
mutation. Two of these, samples CORU and ELWI, which showed evidence for mutation in
exon 5 and exon 6, respectively, were immunocytochemically negative for p53 with both D07
and pAb 1801. The remaining lesion, MACA. with a mutation in exon 8, demonstrated a low
level of staining with D07 but was not assessed for 1801. Thus, taking both IHC and
mutation analysis together, a total of 23 tumours (including the lymph node metastasis)
showed evidence for defective p53 function. p53 status and clinico-pathological features for
these tumours are shown in Table 13.
p53 status, defined by IHC and mutation status, did not appear to define a group of
cancers with clear-cut clinico-pathological characteristics; Dukes' stage and tumour side were
not significantly different in p53 defective tumours when compared with those in which p53
was apparently normal (0= 0.173 and p= 1.00, respectively).
5.3.2 Assessment of microsatellite instability status
Six tumours demonstrated microsatellite instability at 2 or more loci, and were thus
termed RER+. Of these, five showed shifts in allele size at 2 or more loci in the primary
tumour and one showed instability at only one locus in the primary tumour, but demonstrated
widespread shifts in the early passage xenograft (tumour JEGA, see Chapter 4 for details of
microsatellite instability in this tumour). A further tumour showed a shift in allele size at one
locus in the primary tumour, but demonstrated no further change at any locus through passage
(tumour CODR. see Chapter 4) and was thus classified as RER- (Aaltonen et al., 1993).
Results are summarised in Table 13.
The characteristics of the cancers in this series with widespread microsatcllite
instability conform with the predicted phenotype, discussed in Chapter 2, in that they are all
derived from the proximal colon (compared with RER-, p=0.016, 2-tailed Fisher's exact test).
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The proportions of cancers which were Dukes' stage A or B compared with C/D were similar
in RER+ and RER- tumours (p= 0.173).
5,3,3 Flow cytometry
Of 26 samples assessed for DNA ploidy, 8 were near-diploid and 18 were aneuploid
(of which 9 were assigned the arbitrary status hypcrdiploid. 7 were designated hypotctraploid
or tctraploid. and 2 were known only to be aneuploid). Most were assessed in both the
primary tumour and xenograft, with only one discrepancy: passage 1 xenograft ANKE was
tetraploid. whilst its primary tumour was diploid, implying that endoreduplication had
occurred. This tumour was classified 'unknown' for purposes of statistical analysis. Flow
cytometry results are shown in Table 13 and Figure 12.
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Table 13 Clinicopathological, molecular and immunocytochemical data for colorectal
cancer xenografts
Tumour MSI p53 status DNA content Age Side Site Dukes Xeno.
name status stage pass used
for CGH
JEGA RER+ Defective Near-diploid 68 Right Asc B 3
AGSC RER+ Defective Near-diploid 71 Right Cae C/D3 5
ANKE RER+ Defective Near-diploid/tctraploid^ 82 Right Asc B 1
MACA RER+ Defective NK 81 Right Cae B 1
EVMU RER+ Normal Near-diploid 49 Right Cae B 1
MEMCG RER+ Normal Near-diploid 65 Right Cae B 1
ANWO RER- Defective Hyperdiploid 77 Right Asc B 1
SAGR RER- Defective Near-diploid 39 Right Cae B 1
ROPE RER- Defective Near-diploid 83 Right Cae C/D3 1
ELW1 RER- Defective Hypotetraploid 84 Right Cae C/D3 4
JAMU2 RER- Defective Aneuploid2 85 Right Asc C/D3 1
EDLA RER- Defective Hypotetraploid 48 Right Asc C/D3 1
BUCH RER- Defective Hyperdiploid 81 Right Asc C/D3 3
PAMCI RER- Defective Hypotetraploid 65 Left Rec C/D3 1
THLE RER- Defective Hyperdiploid 66 Left Rec C/D3 2
JOCR RER- Defective Hyperdiploid 36 Left Sig C/D3 3
CORU RER- Defective Tetraploid 40 Left Sig C/D3 1
DUMA RER- Defective Near-diploid 68 Left Des B 2
EDDO RER- Defective Hyperdiploid 78 Left Sig B 1
GEHA RER- Defective Aneuploid2 86 Left Sig B 1
JOLO RER- Defective Hyperdiploid 56 Left Sig B 2
ANBA RER- Defective NK 61 Left Sig C/D3 3
CODR RER- Defective Hypotetraploid 40 Left Rec C/D3 1
CADU RER- Defective Hyperdiploid 95 Left Sig B 2
HIDE RER- Normal Hypotetraploid 71 Right Asc C/D3 1
GRZBO RER- Normal NK 87 Left NK A 1
JEDO RER- Normal Hyperdiploid 68 Left Sig B 1
WITO RER- Normal Hypotetraploid 76 Left Sig A 1
ANSA RER- Defective Hyperdiploid 73 Left1 LN na 2
1 location of primary cancer
2 data obtained from Ms J Scheler; further details not available.
•3
J See Chapter 2 for discussion of classification of tumours as Dukes' C/D
4 Primary tumour diploid, passage 1 xenograft tetraploid. This tumour classified 'unknown' for statistical
analysis.
Cae = caecum. Asc = ascending colon. Dcs = descending colon, Sig = sigmoid. Rec = rectum,
LN = lymph node.
NK = unknown, na = not applicable.
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Figure 12
Flow cytometric analysis of sporadic colorectal cancers xenografts
Flow cytometry of tumour cells from the following sources:
(A) Primary tumour corresponding to xenograft SAGR,
(B) 1st passage xenograft SAGR, showing large near-diploid peak,
(C) Primary tumour corresponding to xenograft HIDE,
(D) 3rd passage xenograft HIDE with large aneuploid peak, and
(E) normal colonic tissue.
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5.3.4 Assessment of chromosomal changes by Comparative Genomic Hybridisation
5.3.4.1 Chromosomal copy number changes detected by CGH
DNA copy number changes were assessed by CGH in xenografted tumours derived
from 28 primary colorectal tumours and one lymph node metastasis. Examples of CGH
hybridisations and ratio profiles are shown in Figure 13. and a summary of the chromosomal
anomalies detected in all tumours is presented in Figures 14 and 16. The vast majority of
abnormalities were deletions or amplifications of either whole chromosomes or entire
chromosome arms. Duplications and deletions which involved interstitial breakpoints are
presented in Figure 15. The most frequently observed changes, occurring in over half of all
tumours, were deletion of chromosomes 8p and 18q and duplication of chromosomes 8q, 13q
and 20q (Figures 14 & 16). These chromosomal abnormalities were notable in that they could
often still be observed when the ratio cut-off point was increased to the equivalent of loss or
gain of one chromosome in 75% diploid cells, indicating their presence as the majority clonal
population. Also very frequent were duplications of chromosome 7q and 7p and deletions of
17p. occurring in around half the series. Deletions of lp, 5q, 18p and 15q were also common
(Figures 14, 15 & 16). Sex chromosome anomalies were also fairly frequent, with loss of X
in 7 tumours and loss of Yp in 7/28 tumours (25%). However, because males were assumed
to be less likely to lose their single X chromosome than females were to lose one copy
(supported by the fact that all 7 tumours with X chromosome loss were from female patients),
sex chromosomes were omitted from statistical analysis.
Kallioniemi et al. (1994) suggest that some chromosomal regions, namely lp32-pter.
16p. 19 and 22. can give aberrant results, probably because of their high guanine/cytosine
content. In this study, normal versus normal controls, which were included in each
experiment, usually demonstrated even hybridisation of DNA to all chromosomes, although
chromosome 19 occasionally gave aberrant results. Reversal of the usual red to green
labelling of tumour and normal DNA demonstrated chromosome 19 to be the only region of




Example of Comparative Genomic Hybridisation.
Comparative Genomic Hybridisation of one xenografted tumour, CADU, and normal control:
(A) Raw, unaltered metaphase image, CADU.
(B) The same metaphase after karyotyping and background subtraction.
(C) Ratio profile of an average of 6 CADU metaphases.































































































































Summary of chromosomal abnormalities in sporadic colorectal cancer xenografts
This graph illustrates the number of deletion (red) and amplification (green) events
occurring on each chromosome arm. These events always involved the entire chromosome
arm unless shown as an interstitial deletion/amplification in Figure 15.
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Discrete deletions and amplifications in colorectal cancer xenografts
Amplifications and deletions necessarily involving non-centromeric interstitial
breakage occurred in twelve tumours, and are shown here. Deletions are shown to the left of














































5.3.4.2 Chromosome abnormalities assessed by CGH in relation to DNA ploidy
Chromosomal copy number changes assessed by CGH are relative to the total DNA
content of the sample and do not take into account overall DNA content. Tumours which had
been assessed as aneuploid or ncar-diploid by flow cytometry were compared to determine
whether numbers of relative copy number changes w ithin them, detected by CGH, differed.
When the number of chromosomal losses in diploid and aneuploid tumours was compared, no
significant difference was found (p=0.7499. Mann-Whitney test). However, significantly
fewer chromosomal gains occurred in ncar-diploid tumours (p=0.0008, Mann-Whitney test).
5.3.4.3 Chromosome abnormalities and microsatellite instability status
Four of 5 RER+ cancers available for assessment by flow cytometry were near-
diploid. compared with only 3/22 RER- tumours (p=0.016. 2-tailed Fisher's exact test). One
RER+ cancer apparently underwent endoreduplication between the primary tumour and time
of harvesting as xenograft, and was excluded from statistical analysis.
When numbers of chromosomal changes detected by CGH in RER+ cancers were
compared with RER-, RER+ lesions were significantly less likely to incur chromosomal gains
(p=0.0426, Mann-Whitney test). The total number of changes occurring per tumour was not
significantly different in RER+ tumours, nor were the total number of losses (p=0.1035 and
p=0.1959, respectively, Mann-Whitney test).
A striking pattern of chromosomal abnormalities was observed in RER- cancers
compared with RER+. At least two of the frequent chromosomal abnormalities, deletion of
chromosome 8p and 18q, and duplication of 8q. 13q and 20q, were present in 21/22 RER-
cancers. Only one of the six RER+ cancers had more than one of these abnormalities, despite
displaying changes in other chromosomes (although three other RER+ tumours had one of
these abnormalities each), a difference which was highly significant (p=0.0004, Fisher's exact
test). RER+ cancers showed no loss of chromosome 8p or 18q at all. compared with one or
both changes in 20/22 RER- cancers (p<0.0001, Fisher's exact test), despite the overall levels
of loss being comparable.
5.3.4.4 Chromosome abnormalities andp53 status
Classification of p53 status proved complicated. Flow cytometric analysis revealed
no significant difference in DNA ploidy between the group of 6 tumours (HIDE, WITO,
GRZBO. JEDO. EVMU and MEMCG) in which p53 was apparently normal on the grounds
of negative IHC and absence of mutation and those in which p53 was mutated or stabilised;
2/5 tumours in which p53 was normal by IHC and mutation analysis were near-diploid,
compared with 5/19 where p53 was abnormal (p=0.642, 2-tailed Fisher's exact test).
Similarly, there was no significant difference between occurrence of chromosome loss or gain
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detected by CGH in tumours with defective p53, defined by the same criteria, and those in
which p53 was apparently normal.
However, CGH analysis revealed clear loss of 17p, the chromosomal region
containing p53, in three cancers which had been classified by IHC and mutation analysis as
normal for p53. Loss of 17p is strongly correlated with mutations of the remaining allele of
the p53 gene and abnormalities ofprotein function (Baker et al., 1990; Cunningham et al.,
1992). When these three tumours were reclassified as defective for p53, only three remained
which could be classified as 'p53 normal', GRZBO, JEDO and MEMCG. These three
tumours had very few chromosomal changes, and when the test was repeated including only
these three cancers as 'p53 normal', a significantly higher number of chromosomal gains and
losses were seen in p53 defective tumours compared with p53 normal (p=0.0399 and
p=0.0153, Mann-Whitney test). Moreover, a further two tumours in this series (JEGA and
SAGR) displayed very low levels of immunohistochemical staining for p53, where the
percentage ofnuclei staining positive with D07 was 1% or less, and had no detectable
mutation of the p53 gene. Low levels of immunohistochemical staining ofp53 correspond
very infrequently with mutation of the p53 gene (Cripps et al., 1992), and therefore the
positive nuclear staining in these tumours may represent high levels ofwild-type protein
(discussed in Wynford-Thomas, 1992; Hall & Lane, 1994). The test was repeated including
as 'p53 normal' tumours with low levels of IHC staining as well as those with no evidence of
mutation or loss of 17p. The number of chromosomal gains and losses were significantly
lower in these tumours compared to those with higher levels of staining or mutation of p53
(p=0.0019 and p=0.0055, Mann-Whitney test).
No pattern of chromosomal abnormality was associated with either p53 status; all of
the common anomalies described in 5.3.4.1 occurred in both p53 defective and p53 normal
cancers.
In this series, loss of chromosome 17p did not correlate with detected positive
immunocytochemical p53 status as has been demonstrated in another series of colorectal
cancers (Cunningham et al., 1992). Loss of 17p occurred in 9/20 IHC positive lesions and
4/8 IHC-negative tumours. Although not all tumours were assessed for p53 mutation, only
2/6 with mutation had detectable loss of 17p material. However, losses of this region were
not examined by methods more sensitive than CGH.
5.3.4.5 Chromosome abnormalities and clinicopathologicalfeatures
The numbers of chromosomal losses and gains were examined in relation to the side
of the bowel in which the primary cancer was located, and to Dukes' stage. There was no
difference between the number of chromosomal changes in left-sided compared with right-
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sided cancers, or in Dukes' A & B compared with Dukes' C & D cancers. Furthermore, no
pattern of chromosomal change predominated in any of these groups.
5.3.4.6 Chromosome abnormalities in a lymph node metastasis
CGH analysis of the tumour derived from a lymph node metastasis showed a high
number of chromosomal changes, including two of the common alterations, gain of 20q and
8q. However, this cancer did not demonstrate loss of 18q. an event suggested by others to
occur ubiquitously in metastatic colorectal cancer (Ookawa et al., 1993; Frank et al., 1997).
5.3.4. 7 Comparison ofxenografted and primary tumour
In order to confirm that chromosomal abnormalities in xenografted tumours were
comparable with those of the original primary tumour, CGH was carried out on three primary
tumours from which early passage xenografts were derived. In one case (WITO). the primary
tumour was essentially identical to the early passage xenograft, except for a more marked loss
of chromosome 20p in the xenograft. Xenograft CADU represented all the main changes
present in the primary tumour (loss of 8p. 15q. 17p and 18 and gain of 8q, 13q and 20q), but
appeared to have undergone three further events: pronounced loss of 3p, duplication of 3q and
loss of 20p. Xenograft JOCR appeared to represent a subclone of the original tumour,
showing more marked appearance of certain chromosome abnormalities evident in the primary
tumour; conversely, certain other changes that were prominent in the primary tumour (gain of
12p and some of 12q. gain of 18p and loss of 22q) were present at lower levels in the
xenograft. Interestingly, striking loss of 8p was present in both primary tumour and
xenograft, indicating that this event must have preceded the divergence represented by the
differences between primary tumour and xenograft. Three lesions unequivocally present in the
primary tumour corresponding to xenograft JOCR could not be detected at all in the
xenograft: 18q loss, 20q gain and Yp loss.
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Figure 16
Chromosomal abnormalities in xenografted sporadic colorectal cancers according to
RER and p53 status.
Chromosome deletions (red) and amplifications (green) are shown for each
xenografted colorectal tumour from the scries of 28. Each horizontal row represents a
tumour, each vertical column a chromosome arm. A chromosome arm was scored red if it all
or part of it reached the threshold for deletion (0.875), as green if all or part of it reached the
threshold for amplification (1.125), or as red and green if both amplification and deletion
occurred.
RER status is given as positive (+) or negative (-). p53 status is given as follows:
defective by either positive IHC at >1% nuclei and/or mutation analysis (D); defective only by
positive IHC at <1% of nuclei, but with no detectable mutation (D*); normal by IHC and
mutation analysis and showing no deletion of 17p material (N); normal by IHC and mutation
analysis but showing loss of chromosome 17p by CGH (N*). The xenograft derived from a
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5.4 Discussion
Genomic instability is intrinsic to carcinoma development, and numerous types of
instability have been demonstrated in colorectal neoplasms. The present study has used CGH
to examine the complex chromosomal abnormalities which have evolved in a series of such
tumours in relation to putative mechanisms of instability: defects of p53 and of mismatch
repair, inferred by the presence of microsatellitc instability.
The chromosomal deletions and amplifications found here conform with many other
cytogenetic and CGH studies of colorectal carcinomas (Reichmann et al., 1981; Muleris et
a/.1988. 1990; Yaseen el al., 1990; Konstantinova et al., 1991; Bardi et al., 1993b; Barletta
et al., 1993; Herbergs et al., 1994; Gerdes et al., 1995; Schlegel et al., 1995; Ried et al.,
1996). In addition, others have shown that RER+ colorectal cancers tend to remain near-
diploid (Aaltonen et al., 1993; Lothe et al., 1993) and the RER+ cancers in this series
conform with this finding (although one case. ANKE, was unusual and is discussed below).
However, whilst global DNA ploidy generally remains near-normal in RER+ tumours, the
CGH analysis presented here demonstrates that chromosomal changes do occur: the number
of chromosomal deletion events in RER+ tumours are similar to those of the RER- group,
although significantly lower numbers of individual chromosome duplications are present in
RER+ tumours. Thus, it appears that a mechanism by which chromosomal stability is
maintained may be deficient in at least some RER+ tumours. A similar CGH study found
smaller numbers of chromosomal abnormalities, especially duplications, in RER+ colorectal
cancers compared with RER- (Schlegel et al., 1995). Although numbers in the study by
Schlegcl et al. were small and direct comparison is difficult because the authors do not give
details of their threshold for scoring chromosomal changes, these data appear to be in keeping
with this study. Somewhat at odds with these results, cytogenetic analysis of colorectal
cancers found the RER+ phenotvpe to be associated with either normal or 'trisomic type'
karyotype, in which duplications are common but structural rearrangements rare (Remvikos et
al., 1995). This discrepancy is difficult to explain, but may partly be accounted for by the
small numbers involved in each study and the inability to distinguish structural
rearrangements, and thus 'karyotypic type', by CGH (Muleris et al., 1990). Despite some
differences, taken together, these studies suggest that the number of chromosomal
abnormalities is lower, though by no means absent, in RER+ colorectal cancers. There is
some evidence that defective mismatch repair itself could contribute to chromosomal
instability (dc Wind et al.. 1995; Baker et al.. 1995 & 1996; Reitmair et al., 1995; Edelmann et
al., 1996). but compelling in vitro data shows that chromosomal instability exists as a distinct
phenomenon which can coexist with microsatellite instability in colorectal cancer cells
(Lcngauer et al., 1997b).
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Whilst mechanisms driving some level of chromosomal instability appear to be active
in RER+ cancers, a remarkable 95% of RER- tumours from this series demonstrated a
distinctive pattern of deletion and amplification rarely observed in RER+ tumours. These
abnormalities involved a combination of at least two of the following changes: deletion of 8p
and 18q and duplication of 8q. 13q and 20q. More striking still. 8p and 18q deletion, at least
one of which was present in 91% of RER- cancers, was not observed in any of the RER+
tumours. These patterns provide a tantalising insight into the underlying mechanisms of
instability and selection in colorectal cancer. The pattern of chromosomal abnormalities
observed in RER- cancers is probably the result of selective pressure in favour of cells in
which such anomalies have disrupted genes critical to tumorigenic development. These clonal
abnormalities do not arise in RER+ cancers, and this could be because any chromosomal
instability present does not predispose to such changes, or because clonal selection for them is
not favoured. Clonal selection for these particular chromosomal abnormalities might not be
favoured if frameshift and point mutations occur so frequently that they invariably cause
mutations within critical genes, making the RER+ phenotype effectively dominant. A current
hypothesis suggests that a similar, though probably not identical, combination of oncogenes
and tumour suppressor genes are important to the development of all colorectal cancers, but
the way in which these genes arc mutated differs, occurring predominantly through frameshift
and point mutations in RER+ and through larger chromosomal events in RER- (Kinzler &
Vogelstein. 1996). It is not possible to discern from these results why this pattern of
chromosomal loss and gain is not observed in RER+ tumours, but mutation analysis in RER+
tumours of the putative tumour suppressor genes located in these regions may help to explain.
The tumour suppressor genes DCC (Vogelstein et al., 1988; Fearon et al., 1990; Itoh et al.,
1993; Cho el al., 1994) DPC4 (Takagi et al., 1996; Thiagalingam et al., 1996) and JV18
(Riggins et al., 1996) are all located on the frequently lost chromosome 18q, whilst the
frequent deletion of chromosome 8p supports evidence from molecular studies for the presence
of at least one. and probably two. tumour suppressor genes in this region (Cunningham et al.,
1993; Fujiwara et al., 1993; Yaremko et al., 1994; Farrington et al., 1996). The significance
of duplication of chromosomes 8q. 13q and 20q to the cancer phenotype is not clear, since the
regions of amplification include such large portions of the genome in which no genes of known
importance in colorectal cancer are located.
How do chromosomal anomalies arise? Although numerical and structural
chromosomal anomalies do not necessarily arise through similar mechanisms, abnormality of
a single gene product with multiple functions in chromosome stability regulation, such as p53,
could allow both types of instability to arise simultaneously. Structural chromosomal
instability can be initiated by a small number of events (such as strand breakage or telomere
loss), resulting in activation of the breakage-fusion-bridge (BFB) mechanism, in which sister
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chromatid- or aberrant chromosomal fusion is followed by a sequence comprising repeated
breakage and fusion which eventually leads to stable, though abnormal, chromosomes
(McClintock, 1951). Generation of stable chromosomes may occur if breakage events have
occurred within intrachromosomal telomere-like repeats or centromeric sequences, when such
sequences are brought to the end of chromosomes. If preferential breakpoints are present
w ithin the chromosomes in which chromosome arms often show loss or gain, especially
chromosome 8. these could facilitate the acquisition of anomalies involving these
chromosomes through frequent generation of stable abnormal structures. Removal of a DNA
damage surveillance component could allow accumulation of the type of damage capable of
initiating this cycle, as well as propagation of cells in which DNA damaged by the BFB cycle
is allowed to replicate.
Could p53 defects account for the generation of chromosomal anomalies? Very few
chromosomal changes were seen in three tumours where no p53 defect could be detected by
immunohistochemistry and mutation analysis and where loss of 17p was not visible.
Similarly, tumours in which very low levels of IHC staining were present, where positive
staining may be due to over-expression of wild-type protein in response to elevated levels of
DNA damage (Maltzman et al., 1984; Barnes el al.. 1992; Vojstek & Lane, 1993), and no
mutation or loss of the gene occurred, had very low levels of chromosomal abnormality. Both
of these categories are likely to define cancers in which there is no underlying defect of p53,
and so these data probably suggest, in keeping with many other studies (Bischoff el al., 1990;
Livingstone et al., 1992; Yin et al.. 1992; Carder et al.. 1993 & 1995; Agapova et al., 1996;
Rcmvikos et al., 1997), that wild-type p53 activity is associated with low levels of
chromosomal abnormality. However, finding an appropriate definition of normal and
abnormal p53 status clearly presents problems. Lesions with no IHC staining for p53 could
harbour p53 abnormalities which render the p53 protein undetectable by immunocytochemical
methods by the formation of epitopes not detectable by either antibody D07 or pAbl801,
through truncation (Remvikos el al., 1997) or altered conformation (Cripps et al., 1992) of
the protein. Conversely, stabilisation of the protein is not absolutely correlated with missense
mutation (Gannon et al., 1990; Cunningham et al.. 1992; Cripps et al., 1992; Baas et al.,
1994), and several factors other than gene mutation, including binding to viral proteins (Lane
et al., 1990; Levine et al.. 1991) and to cellular factors such as Mdm2 (Wu et al., 1993) can
lead to inefficient protein breakdown and stabilisation of the protein. In addition, selection
against deletion of 17p in tumours classified as normal for p53 introduces bias, since this this
involves some selection against the process of chromosomal instability in its own right.
However p53 status is defined, the association between anomalies of p53 and presence of
chromosomal defects is not absolute; it is possible for few chromosomal changes to be present
in conjunction with abnormal p53 stabilisation, and chromosomal anomalies occur to some
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degree in tumours without p53 deficiency, though the methods used do not rule out mutations
elsewhere in the gene.
Most chromosomal abnormalities detected in this study involved either whole
chromosome loss/gain or apparent centromeric breakage. One exception was deletion of
chromosome 1 p. in which recurrent loss occurred in patterns consistent with the presence of at
least two tumour suppressor genes (Figure 15). This conforms with data from more detailed
loss of heterozygosity studies, in which lp has been suggested to harbour at least 3 tumour
suppressor genes involved in colorectal cancer development (Leister et al., 1990; Bardi et al.,
1993a; Praml et al., 1995a). Smaller interstitial losses, such as deletions within chromosome
5q. may be under-represented because slight errors in measurement of signal position along
the chromosome, caused by small differences in chromatin condensation between metaphases,
can lead to damping down of small, sharp peaks in the fluorescence ratio. In the case of
chromosome 5q, interstitial deletions which reached the chosen ratio cut-off level were present
in only two tumours, whereas four others showed evidence of loss not reaching this level in
their fluorescence ratios. Data from this laboratory indicate that a high frequency of relatively
small deletions do indeed occur in this region (Ashton-Rickardt et al., 1989 & 1991; Curtis et
al., 1994). Software under development employs band-by-band chromosome measurement,
rather than the current end-to-end method, and should provide more accurate analysis. Small
discrete amplifications were extremely rare, indicating that, unlike other tumour types such as
cancer of the breast (Muleris et al., 1994b), discrete gene amplification probably does not
represent an important mechanism of oncogene activation in colorectal tumorigenesis.
The investigation has provided further evidence of the value of xenografted tumour
material as a study model representative of the progenitor primary tumour. Although the
comparison of three primary tumours with corresponding xenografts presented here clearly
demonstrates that some degree of chromosomal evolution can occur during growth, as would
be expected if the underlying process of chromosomal instability is a dynamic one (Lengauer
et al., 1997b). the major chromosomal lesions present in the primary tumour are usually
retained. Complete concordance between primary tumour and xenograft was observed with
p53 immunohistochemistry. and only one discrepancy occurred with the results of flow
cytometry. In this case, tumour ANKE appeared to have undergone endoreduplication,
changing from a diploid state in the primary tumour to tetraploid in the xenograft.
Xenografted colorectal tumours have been suggested to be somewhat more prone to
cndoreduplication than primary tumours (Lcfranyois et al., 1989), but the close adherence of
the chromosomal anomalies detected here to the patterns seen in many larger studies suggests
that xenograftcd tumours do not undergo significant changes as a consequence of
transposition into the mouse environment. In addition, preliminary data from six late passage
xenografts suggests that very little chromosomal evolution occurs between early and late pass
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tumours. The fact that this study includes cancers of all Dukes stage, tumour site, tumour
type, histological differentiation, ploidy level, p53 status and RER status supports data
indicating that tumorigenicity in nude mice is independent of many, though not all, prognostic
factors (Jessup et al., 1988; Lefranqois et al., 1989).
Despite retaining characteristics of the primary tumour, subcutaneous xenografts
undergo infrequent invasion and metastasis (McQueen et al., 1991). However, injection of
colon cancer cells into the caecal wall of athymic nude mice results in lymphatic and vascular
invasion and a pattern of metastasis similar to that seen in human colonic cancer (Bresalier et
al.. 1987a & b), suggesting the involvement of tissue-specific factors in the modulation of
tumour development. Investigation of alternative methods of implantation may lead to the
development of a tumour model still more representative of primary colorectal cancer than the
subcutaneous grafts used here.
5.5 Conclusions
In summary, this study has addressed the relationship between chromosomal
abnormalities and two putative mechanisms by which tumorigenesis is driven, namely
replication error defects and abnormalities of p53. Clear differences between chromosomal
abnormalities in RER+ and RER- cancers have emerged, and. though there appears to be an
association between abnormal p53 status and high levels of chromosomal abnormalities,
difficulties of assigning p53 status mean that this cannot be said with certainty. In addition,
further confirmation of the value of xenografts as good study models for colorectal cancer has
been provided. The need for analysis of larger numbers of tumours is evident, and this
investigation provides the basis for a larger study of colorectal tumours, currently underway,
in which it is hoped the patterns of chromosomal change demonstrated here will be confirmed.
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Chapter 6
Genetic instability in murine tumours deficient in p53 and
Msh2
6.1. Introduction
Defects of p53 and of the mismatch repair pathway occur frequently in human
colorectal cancer, and are thought to be fundamental to tumour progression. The generation
by gene targeting of mice w ith defects of both p53 and components of mismatch repair
provides a relatively uncomplicated system in which to study the contribution of each factor to
development and tumorigenesis. Mice in which p53 is homozygously defective are
developmentally normal but succumb to tumours, predominantly lymphomas, by the age of 9-
10 months (Donehower et al., 1992; Harvey et al., 1993a; Purdie et cil., 1994). In vitro, cells
derived from such mice have very unstable karyotypes, with a strong tendency to increase
their ploidy levels during growth (Harvey et al., 1993b; Purdie et al., 1994) and an ability to
undergo gene amplification (Livingstone el al., 1992; Yin et al., 1992). Heterozygous mice
acquire a somewhat different spectrum of tumours, predominantly lymphomas and sarcomas,
at a later age (Harvey et al., 1993a; Purdie et al., 1994). Mice with homozygous deletion of
Msh2 are also healthy at birth, but around one third develop tumours, mainly metastasizing
lymphomas of T-cell origin, in the first year (de Wind et al., 1995; Reitmair et al., 1995).
Development of intestinal tumours is common in older mice with lymphoma, and skin lesions
are sometimes found (Rcitmair et al., 1996a). Both tumour tissue and non-tumorigenic cells
from Msh2 null mice (though not normal tissue in vivo) frequently display widespread
microsatcllite instability in culture, and cells have been shown to lose heterology-dependent
suppression of recombination in vitro. Mice with heterozygous loss ofMsh2 have functional
mismatch binding and do not develop any more tumours than wild-type controls (Reitmair et
al., 1995 & 1996a). Thus, the mutational events occurring in cells from such mice are largely
consistent with those of human cells with comparable genotype, where p53-deficiency
apparently predisposes to gross chromosomal abnormalities whilst lack of hMSH2 favours
acquisition of point mutations and microsatellite instability.
Interbreeding of mice deficient in genes of importance in tumour development could
prove invaluable to our understanding of how genetic events contribute to cancer initiation and
progression. Mv/72-dcficicncy has been shown to accelerate the rate of adenoma formation in
Apc+/~ mice, apparently through point mutation of the remaining Ape allele (Reitmair et al.,
1996b). Interbreeding of mice deficient in both Msh2 and p53 also accelerates tumorigenesis,
suggesting the two defects to be co-operative for tumorigenesis (Cranston et al., 1997; Toft
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et al., 1998). One report demonstrates female embryonic lethality for this genotype, with
female embryos exhibiting massive levels of global apoptosis (Cranston et al., 1997), though
liveborn females were present in animals bred in our laboratory (Toft et al., 1998). Tumour
tissue from mice deficient in both p53 and Msh2 function displays microsatellite instability at
a similar rate to that in Ms/i2-deficient tumours alone (Cranston et al., 1997). but
chromosomal instability in such lesions has not yet been studied.
This chapter extends the analysis of the p53- and mismatch repair-deficient phenotype
presented in Chapter 5 by examining microsatellite instability and chromosomal abnormalities
in mice with known deficiencies of both p53 and Msh2. The examination of these traits in
human tumours can be problematic, and analysing these defects in murine systems avoids
numerous difficulties, notably those associated with the intervention of many other genetic
events in the cancer phenotype and the considerable difficulties of accurate classification of
p53 status (discussed in Chapter 5). In addition to mice with null genotypes for both genes,
study of the effects of heterozygosity at either locus was made possible by the availability of
tumour tissue from animals with heterozygosity at one locus and homozygosity at the other.
The aim. in keeping w ith that of the previous chapter, was to examine the interaction of the
two tumongenic pathways and to determine which pathway, if any, produces the predominant
pattern of genomic instability.
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6.2. Materials and methods
Unless otherwise stated, the methods employed in this chapter are described in 2.14.
Msh2-/~ mice were interbred with p53-/- mice to generate F2 animals mutant for both genes.
Genotype was confirmed using a PCR-based assay. Following DNA extraction from
lymphomas arising in these animals. CGH was carried out on a series of 42 tumours using a
protocol almost identical to that employed with human DNA. using a similar software
package but with manual karyotyping. Hybridisation quality was verified by the correct
identification of sex according to X chromosome copy number. A green/red (tumour/normal)
ratio cut-off point of 1.2 was chosen for delineation of amplifications and 0.8 for deletions,
representing gain or loss of chromosomal material in 40% of cells. This ratio, somewhat
higher than that chosen for CGH analysis of human chromosomes, was chosen in order to be
certain of scoring only genuine aneuploidy; intrinsic properties of the software occasionally
resulted in generalised skewing of the euchromatin ratio away from the ratio= 1 line due to
extreme green/red ratios in the heterochromatic regions, which are more abundant in the
mouse than in the human genome. This skewing, though uniform, resulted in difficulties of
interpretation, particularly if aneuploidy was apparent. Additionally, no tumours of known
karyotype were available as positive controls, and karyotypes have not previously been
published for tumours arising in these mice, so a higher ratio cut-off point was felt to be safer.
Consequently, chromosomal changes may be underestimated.
Matched normal tissues were not available for many of the tumours analysed for
CGH. Analysis of microsatellite sequences was carried out on 20 matched normal/tumour
pairs, using four polymorphic microsatellite loci, DlMit4, D7Mitl7. D10Mit2 and
D14Mitl5, as in 2.14.3. 8 of these tumours were assessed by CGH.
Flow cytometry was performed on a set of 28 tumours not included in the CGH study,
using the method of Vindelov (1993) as described in 2.5.1. In addition, loss of heterozygosity
analysis ofp53 and Msh2 was undertaken using same the PCR-based assays that were used
for genotyping (2.14), and DNA sequencing was carried out on three tumours using a dideoxy
chain termination method (2.9.2).
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6.3. Results
6.3.1. Tumour development in knockout mice
The median age at which mice null for Msh2 alone (Msh2-/- p53+/+) died or were killed
because of tumour development was 142 days. For p53 null animals (Msh2+/+ p53-/~) it was
significantly earlier, at 121 days (p<0.0006. log rank test). Mice totally deficient for both p53
and Msh2 (Msh2-I- p53-/-) died at 65 days, earlier than those null for either defect (p<0.0006. log
rank test), indicating that p53 and Msh2 are co-operative for tumorigenesis.
Animals heterozygous for p53 deficiency but with homozygous loss ofMsh2 function
(Msh2-/- p53+/-) had a median age of death of 99 days, earlier than homozygous deficiency of
Msh2 alone (p<0.00001. log rank test) whilst those totally lacking in p53 and heterozygous for
Msh2 (Msh2+/~ p53- -) died at 109 days, which was not significantly earlier than p53-/- mice
(p>0.09, log rank test). Figures were based on a cohort of 199 animals. Statistical tests were
carried out by the Department of Medical Statistics. University of Edinburgh.
The large majority of tumours which arose in all genotypes were lymphomas of T-cell
origin, and. for simplicity, only this tumour type was used for genetic analysis. Some differences
in the tumour spectrum were seen: 12% ofMsh2+/+p53-/- mice developed sarcoma rather than
lymphoma, whilst 40% ofMsh2- '-p53+/+ mice developed intestinal lesions in addition to
lymphoma. The distribution of lymphoma origin also varied: Msh2-/~ p53+/+ mice developed
thymic and extra-thymic lymphomas in approximately equal proportions, as did Msh2-/- p53+/~
animals. whereas Msh2+/+ p53- - mice succumbed predominantly to thymic lymphomas. Mice
homozygously lacking both genes (Msh2-/- p53-/-) developed lymphomas which were exclusively
thymic, and tumours from Msh2+/- p53-/~ mice were exclusively extra-thymic.
6.3.2. CGH analysis of chromosomal changes in murine tumours
Results of CGH analysis of lymphomas are presented in Table 14 and Figures 17, 18 and
19. Ten tumours from this series showed signs of chromosomal change. The number of
chromosomal locations at which change was scored varied from one to four per tumour. The data
(Table 14) indicate that the majority of lesions from Msh2+ + p53-/- mice showed at least one
chromosomal change (details shown in Figure 18). In contrast, chromosomal anomalies were
rarely seen in mice of all other genotypes.
Chromosomes 4 and 15 were over-represented in four tumours, chromosome 11 in three
and chromosomes 9 and 14 in two (Figure 18 & 19). Amplifications occurred much more
frequently than deletions, w ith 18 chromosomal amplifications noted (in 9 tumours) and only three
deletions. Whole chromosome copy number changes occurred at approximately the same
frequency as partial chromosome duplication (Figure 18).
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Figure 17
Examples of Comparative Genomic Hybridisation analysis of murine lymphomas.
(A) Normal mouse kary otype with DAPI banding, and (B) corresponding control
hybridisation of normal female vs normal female mouse DNA. visualised using rhodamine and
fluorescein.
(C) Average ratio profile for 5 mctaphases from the above control hybridisation experiment.
(D) Normal mouse karyotype with DAPI banding, and (E) corresponding hybridisation of
normal female mouse DNA (red) vs murine lymphoma DNA (green) from a male
Msh2-/-p53-/~ mouse.
(F) Average ratio profile for 5 metaphases from the hybridisation shown in (D) and (E),
showing aneuploid DNA content.


































































































































































































Diploid and aneuploid DNA content in murine tumours by CGH
Genotype No. diploid tumours No. aneuploid tumours
Msh2 +/+ p53 -/- 4 6
Msh2 -/- p53 +/+ 5 1
Msh2 -/- p53 -/- 6 1
Msh2 -/- p53 +/- 12 1
Msh2 +/- p53 -/- 5 1
6.3.3. Analysis ofDNA content ofmurine tumours by flow cytometry
Overall DNA content was measured by flow cytometry in a subset of tumours
different from that used for CGH (Table 15). Results were largely consistent with those
obtained by CGH; in this case, all tumours were demonstrated to show near-diploid DNA
content except two in which p53 alone was deficient.
Table 15
DNA content of tumours from Msh2- and /i5i-deficient mice measured by flow
cytometry.
Genotype No. near-diploid tumours No. aneuploid tumours
Msh2 +/+ p53 -/- 5 2
Msh2 -/- p53 +/+ 7 0
Msh2 -/- p53 -/- 7 0
Msh2 -/- p53 +/- 7 0
6.3.4. Microsatellite instability in murine tumours
Analysis of four microsatellite loci in 20 tumours revealed instability in 11 tumours.
Results are presented in Table 16. Microsatellite instability occurred in 9/9 lymphomas with
both Msh2 and p53 deficiency, even when the p53 deficiency was heterozygous, compared
with only 1/4 tumours deficient \x\Msh2 alone. Interestingly, 1/5 tumours with heterozygous
loss ofMsh2 and homozygous loss ofp53 showed microsatellite instability at one locus. This
tumour was found to have undergone deletion of the wild-type allele ofMsh2.
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Table 16
Microsatellite instability in tumours from mice deficient in p53, Msh2 or both.
Genotype






6.3.5. Analysis of the second allele ofp53 in Msh2-/~ p53+/~ mice.
Animals with the genotype Msh2-/- p53+/- develop tumours earlier than those
homozygous for Mv/?2-deficiency alone, implying that heterozygous deletion of p53
accelerates tumorigenesis. In order to investigate whether this occurred because of loss of
wild-type p53 function, the remaining p53 allele was investigated. Loss of heterozygosity
(LOH) was searched for in 7 tumours from animals homozygous for mutation ofMsh2 and
heterozygous for mutation ofp53 but was not detected in any tumour. Thus, loss of the
second allele of p53 by large deletion appears to be a rare event. Three thymic lymphomas
without detectable LOH at the p53 locus were chosen for detailed sequence analysis of the
second allele ofp53. In these tumours, exons 5-9 ofp53, the region of the gene where
mutations are most frequently found (Levine et al., 1991), were sequenced. One tumour




Chromosomal abnormalities in murine tumours detected by Comparative Genomic
Hybridisation
All duplications and deletions of chromosomal material detected by CGH in murine tumours are
depicted in this diagram. Deletions are shown to the left of each chromosome with a thin line,








































Chromosomal abnormalities in aneuploid murine tumours
This figure indicates the chromosomes affected by the duplications (green) or deletions (red)





















































The phcnotypic effects of defective p53 and Msh2 in mice have been reported previously,
but only recently have mice with combined defects been bred. The generation of mice lacking
both p53 and Msh2 in this laboratory and elsewhere (Cranston et a/., 1997) indicates that the
combination of these genetic deletions accelerates tumorigenesis, demonstrating a co-operative
effect of the two genes on tumour development. The nature of this synergistic effect has been
addressed using analysis of the genetic events known to be associated with each independent
defect, microsatellite instability and chromosomal abnormalities, with a view to determining the
dominant pathway of genomic instability in tumour development.
The data presented here clearly demonstrate the dominance of the Msh2-/- phenotype in
driving genomic instability in tumours null for both Msh2 and p53. In this study, MSI occurred in
all lymphomas in which homozygous loss ofMsh2 was present in combination with any defect of
p53, whilst the chromosomal anomalies common in p53-/- tumours were rare in all Msh2-I-
tumours, even those completely lacking p53. Furthermore, deficiency ofp53 in Msh2-/- mice
increased to 100% the proportion of tumours in which MSI was detectable compared with Msh2-
/- mice. Thus, whilst the acceleration of tumorigenesis in animals lacking both Msh2 and p53
implicates both gene defects in tumour development, the mechanism through which p53
contributes to tumorigencsis in these mice is distinct from its role in p53-/- animals, which
involves the generation of chromosomal instability.
Why do tumours from animals lacking both Msh2 and p53 acquire mutations in
microsatellites at a higher rate to that in Msh2-/- mice but fail to show chromosomal instability?
The most plausible explanation is that the microsatellite instability phenotype arises earlier in
these mice and thus precedes and preempts chromosomal lesions, resulting, instead, in the
development of a tumour in which microsatellite instability is widespread. Chromosomal
instability in tumours from mice deficient in p53 alone may be due to a number of essential
functions of p53: inability to produce growth arrest at G1 in response to DNA damage, incorrect
centrosome formation, lack of a G2 spindle checkpoint or inability to trigger apoptosis in response
to DNA damage (discussed in detail in Chapter 1). Mice deficient in p53 alone display frequent
abnormal centrosomc formation in a variety of cell types (Fukasawa et al., 1997) suggesting that
some chromosomal lesions are a spontaneous and inevitable consequence of p5 3-deficiency,
although others may be incurred as a result of exogenous DNA damage. A potent Msh2-driven
mutagenic pathway which causes multiple mutations in oncogenes and tumour suppressor genes
could precede such chromosomal instability if a cell lacks one or more of the functions of p53
which prevent the clonal expansion of cells harbouring multiple frameshift and point mutations.
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The mechanism through which rapid expansion of clones with the microsatellite
instability phenotype occurs is likely to be the loss of p53-dependent apoptosis. an increase in the
mutation rate at microsatellitc sequences, or both. In the first case, /OJ-dcficiency could result in
failure to respond to apoptotic signals such as Mv/72-induced mutations which lead to
inappropriate expression of oncogenes (Hermeking & Eick, 1994; Lowe el al., 1994),
inappropriate expression of factors involved in G1 arrest (Gottlieb & Oren, 1996), or possibly the
presence of mismatches themselves (Lee et al., 1995). Widespread Ms7?2-induccd mutation may
facilitate the disruption of other genes involved in apoptotic pathways, thus speeding the
tumorigenic process further. If reduced apoptosis occurs in these tumours, then My/z2-deficient
tumours in which a high mutation rate is accompanied by p53 inactivity would be expected to
contain lower numbers of apoptotic cells than Msh2-/- tumours. Examination of normal cells
from the small intestines of these mice demonstrates that the basal level of apoptosis is low but
does not differ from that of other genotypes (Dr N.Toft. personal communication). Levels of
apoptosis in lymphoma tissue have not been measured, though have been observed to be generally
high in all genotypes (Dr N.Toft. personal communication).
Alternatively, lack of p53 in Msh2-deficient tumours may contribute to an increase in the
rate of framcshift mutation through direct involvement in repair of mismatches, and the apparent
exacerbation of the defective mismatch repair phenotype by lack of p53 could be due to lack of
repair of some insertion/deletion mutations. There is evidence that p53 plays a direct role in
recognition of insertion/deletion mismatches (Lee et al., 1995), and p53 has been shown to be
capable of binding the promoter region of Msh2. It is conceivable, then, that p53 is involved in
recognition of insertion/deletion mutations and mismatch repair either through its interaction with
Msh2 or independently. The fact that loss of p53 appears to exacerbate the MSI phenotype in
Msh2-/~ tumours suggests that its role, if any, in mismatch repair is not exclusively due to
interaction with Msh2. but it is possible that p53 could partially substitute for Msh2 where Msh2
is completely lacking. If this were true, then it is likely to occur only in the absence of Msh2,
since the rate of point mutations, including insertion/deletion mutations, is not increased in p53-/~
mice (Nishino et al., 1995; Sands et al., 1995).
Chromosomal instability occurs through routes other than the p53-mediated pathway; a
recent study suggests that chromosomal instability can arise as a dominant trait independently of
p53, at least in human colorectal cancer cells (Lengauer et al., 1997b). It is possible that a
further explanation for the lack of chromosomal instability in Msh2-/-p53-/- mice is that
activation of such a process is favoured in the p53 null environment, whereas the high rate of
frameshift and point mutations within the Msh2-/- background favour its inactivation. However,
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unless evidence is produced to the contrary, the simpler hypotheses based on rates of apoptosis
and mutation within such tumours seem more probable. In summary, it appears that the role of
p5 3-deficiency in Msh2-/- p53-/- mice is primarily to facilitate the growth cells with Msh2-
deficiency-type genomic instability, though without further experiment it is not possible to
conclude by what mechanism this occurs. Determination of both levels of apoptosis and the rate
of insertion/deletion mutation within Msh2-/~ p53-/~ tissue provides the basis for future
investigation.
An additional point of interest in these data is the accelerated tumorigenesis in mice
heterozygous for p53 but null for Msh2. These lesions develop approximately 20 days later than
those in the double nulls, but significantly earlier than in the p53-deficient and Msh2-deficient
animals, again implying a co-operative interaction between the two pathways in the same manner
as the double homozygotes. p53 is conventionally thought to require functional loss of both
alleles in order lose its tumour suppressor activity, either through mutation/deletion or through a
dominant negative effect, and the majority of tumours developing in p53+/- mice show loss of the
remaining p53 allele (Purdie et al., 1994). However, a dosage effect of p53 has been
demonstrated in the intermediate in vitro growth rates and radiation- and UV-induced apoptotic
responses of cells derived from p53 +/- mice (Clarke et al., 1993; Ms S .Corbet, personal
communication), suggesting that loss of just one gene copy ofp53 could permit expression of a
rapid growth phenotvpe in the lymphoid tumours. Loss of heterozygosity ofp53 did not occur in
any of the Msh2-/~ p53+/- tumours examined here, though point mutation of the wild-type allele
w ould be a more likely on an Mv/72-deficicnt background. Point mutation of the second allele was
only detected in one of three such tumours, which might indicate that heterozygosity ofp53 is
sufficient to cause accelerated tumour onset. However, sequencing analysis did not include the
whole gene, so mutation cannot be excluded. A functional assay for p53 activity is currently
underway in these tumours and should provide a definitive answer.
The appearance of recurrent duplications within chromosomes 4, 11 and 15 in ancuploid
tumours suggest the presence in these regions of factors conferring growth advantage. Trisomy
15 has previously been shown to be a frequent event in murine lymphomas (Spira et al., 1979).
The regions of amplification are mostly large, and each contain regions of homology with several
human chromosomes, making it impossible to delineate any common regions of loss and gain in
mouse and man. Analysis of larger numbers of tumours is necessary in order to confirm this
finding and determine any other regions of non-random change.
Finally, the aim of studying animal models is to aid our understanding of the tumorigenic
process in man. This data presented here clarify the role ofMsh2 and p53 on lymphoma
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development in mice, and clearly demonstrate the dominance of the M?/i2-associated phenotypc as
a mechanism of genomic instability in tumorigenesis. Data from human cancers (Chapter 5) was
less easy to interpret, probably for a number of reasons: difficulties of interpretation of patterns of
p53 expression, the undoubted contribution of other genetic events to the tumour phenotype, and
the fact that the major cause of microsatellite instability in sporadic colorectal cancer has yet to be
identified and may constitute more than one gene defect, resulting in a range of phenotypes
associated with microsatellite instability. Nevertheless, reassessment of the human tumours in the
light of data from Msh2- and pij-deficient mice does indicate a possible similarity between the
phenotype of human and murine tumours according to genotype. Combined data from flow
cytometry and CGH demonstrated that human cancers with defective p53 (defined as all tumours
in which abnormalities of p53 were detected by mutation analysis, loss of 17p or strongly positive
immunocytochemistry) and functional mismatch repair were entirely aneuploid, whilst genotypes
in which mismatch repair was defective were predominantly diploid regardless of p53 status.
Clearly, numbers of human tumours are very small when divided into four genotypes and analysis
of a larger series would be essential to confirm this observation. However, data from this study
suggest that the observation that p53 abnormalities precede, and probably facilitate, the formation
of ancuploid clones in human colorectal tumours (Carder et al., 1993 & 1995) may be dependent
upon the presence of functional mismatch repair.
6.5. Conclusions
This stud}' has analysed a unique set of tumours arising in mice deficient in the tumour
suppressor genes p52, Msh2, or both. Tumours from mice deficient in p53 alone exhibit frequent
chromosomal anomalies, and common regions of amplification on chromosomes 4, 11 and 15
have been identified. A proportion of tumours in mice lacking Msh2 but with normal p53 exhibit
microsatcllite instability, though this is lower than in tumours from Msh2-/~ p53-/- mice where
microsatellite instability occurs ubiquitously. Furthermore, Msh2-/- p53-/- tumours rarely display
chromosomal lesions. The data suggest that the role of p53 is different in Msh2-/- p53-/- and
p53-/~ tumours. In the latter. p53 deficiency results in chromosomal instability. In the former,
p53 accelerates the development of tumours which evolve primarily through a pathway of Msh2-
driven multiple point mutations, either through the abolition of p5 3-dependent apoptosis or
through an increase in the rate of point mutation. Comparison with the data from human
colorectal tumours obtained in Chapter 5 suggests that a similar relationship may exist between
abnormalities of p53 and mismatch repair and chromosomal and microsatcllite instability in





This thesis has examined aspects of microsatellite instability, chromosomal instability
and defects of p53 from two sources: primary and xenografted human sporadic colorectal
cancers, and lymphomas from mice deficient in p53 and the mismatch repair gene Msh2. A
number of conclusions can be drawn.
Firstly, the phenotvpe associated with defects of mismatch repair, microsatellite
instability, is present in around one sixth of the Scottish population of sporadic colorectal
cancers and is associated with a series of characteristic features: proximal tumour location,
lack of abnormality of p53, and, most strikingly, improved patient prognosis. These features
resemble those shown by tumours in the familial condition FINPCC, in which a mutated
version of hMSH2 or hMLHl is usually inherited in the germ-line, prompting a search for
mutations in hMSH2 in these sporadic tumours. The number of exonic mutations within
hMSH2 in sporadic colorectal cancers with microsatellite instability is very small, indicating
that hMSH2 is rarely important in the generation of this phenotype in sporadic colorectal
cancer. Mutations within repetitive intronic sequences of hMSH2 are frequent but are
probably secondary to the mutator phenotype. though they might affect transcriptional
efficiency, possibly exacerbating the mutator phenotype. The major cause of this phenotype
in sporadic cancer remains to be determined.
Secondly, study of colorectal cancers xenografted into SCID mice demonstrates the
microsatcllite instability phenotype to be retained through serial passage. Conversely, the
phenotypc is never acquired by previously stable tumours during passage. This, as well as
conservation in the xenograft of a number of other primary tumour characteristics such as
ploidy and p53 protein stability provide further support that xenografts are good study models
for colorectal cancer.
Thirdly, a striking pattern of chromosomal change is associated with the rer-
phenotype in sporadic colorectal tumours, involving deletion of chromosome 8p and 18q and
gain of 8q, 13q and 20q. In contrast, cancers in which microsatellite instability occurs do not
display this pattern of chromosomal anomaly, although some degree of chromosomal
abnormality does occur. This probably reflects the different mechanisms of mutagenesis
occurring in each tumour type, though further study may determine whether target genes in
these regions are affected by a different spectrum of mutation in each tumour type.
Finally, deficiency of the mismatch repair gene Msh2 in mice predisposes to
lymphoma in which microsatellite sequences arc often unstable but chromosomal content is
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usually normal whilst deficiency ofp53 gives rise to lymphoma containing stable
microsatellitcs but abnormal chromosomal content. The combination of both defects
accelerates development of chromosomally normal lymphomas in which microsatellite
instability is very frequent, indicating the dominant pathway of genomic instability in these
tumours to be driven by Msh2 and suggesting the role of p53 in tumorigenesis to be dependent
upon mismatch repair function. Further study will be required to confirm the observation that
human colorectal tumours with equivalent p53 and mismatch repair status conform to a
similar pattern of chromosomal and microsatellite instability.
7.2 Future prospects
A series of colorectal cancer xenografts have been characterised for many genetic
features including defects of p53 and of the mismatch repair pathway. These tumours, as well
as cancer-prone mice deficient in genes involved in these pathways, should provide a valuable
means of determining the effect of new and existing chemotherapeutic drugs in relation to the
genetic constitution of the tumour.
At present, little is known about factors determing response to chemotherapy.
Chemotherapeutic treatment of colorectal cancer affords an increase in survival of only about
15%. and administration of such treatment largely disregards the biology of the tumour.
However, it is becoming clear that many biological factors may influence response to
chemotherapy. These include the ability to regulate intracellular drug concentration, achieved
in part by expression of the MDR gene product, the nature of the interaction between drug and
cellular target and the presence of factors involved in response to damage caused by
chemothcrapeutic agents. Mismatch repair deficiency has also been shown to confer
sensitivity to chloroethylating agents (Liu et al., 1996b) but resistance to tcmozolomide,
alkylating agents and cisplatin (Branch et al., 1993 & 1995; Kat et al., 1993; de Wind et al.,
1995; Aebi et al., 1996; Drummond et al., 1996; Fink et al., 1996; Liu et al., 1996b; Mello
et al., 1996), at least in some cases through failure to initiate apoptosis (Dr N.Toft, personal
communication). Similarly, deficiency of p53 can result in resistance to certain drugs
including the topoisomerasc Il-inhibitor etoposide (Clarke et al., 1993; Lowe et al., 1993) and
doxorubicin (Aas et al., 1996). probably because damage fails to initiate apoptosis in the
absence of DNA repair. Moreover, at least some cells survive with incorrectly repaired
damage, to generate mutated subclones (Griffiths et al., 1996).
Thus, the combination of genetic defects present within a tumour can be critical in
determining response to drug treatment, and characterising the genotype-dependent response
of colorectal tumours to current chemotherapy drugs might facilitate the design of treatment
appropriate to individual needs. Furthermore, the use of both genetically characterised
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xcnografted human tumours and murine models in which genetic defects are known precisely
may aid our understanding of the pathways by which chemotherapeutic drugs kill tumour
cells, thus helping in the design of novel compounds affecting these pathways. Defective gene
products could themselves provide targets for new drugs, such as compounds capable of
converting mutant p53 to wild-type (Kinzler & Vogelstein, 1993). Use of the resources
characterised in this study could provide an invaluable vehicle for such experiments.
186
Bibliography
Aaltonen. L.A., Peltomaki, P.. Leach, F.S., Sistonen, P.. Pylkkanen, L., Mecklin, J.P., Jarvinen, H.,
Powell, S.M., Jen, J., Hamilton, S.R., Petersen, G.M., Kinzler, K.W., Vogelstein, B., and de la
Chapelle, A. Clues to the pathogenesis of familial colorectal cancer. Science 260:812-816, 1993.
Aaltonen, L.A., Peltomaki, P., Mecklin, J.P., Jarvinen, H., Jass, J.R., Green, J.S., Lynch, H.T.,
Watson, P., Tallqvist. G.. Juhola, M., Sistonen, P., Hamilton, S.R., Kinzler, K.W., Vogelstein, B..
and de la Chapelle, A. Replication errors in benign and malignant tumors from Hereditary Non-
Polyposis Colorectal Cancer patients. Cancer Research 54:1645-1648. 1994.
Aas, T., Borresen, A.L., Geisler, S., Smith-Sorensen, B.. Johnsen, H., Varhaug, J.E., Akslen, L.A.,
and Lonning, P.E. Specific p53 mutations are associated with de novo resistance to doxorubicin in
breast cancer patients. Nature Medicine 2:811-814, 1996.
Acharya, S., Wilson, T., Gradia, S„ Kane, M.F., Guerrette. S., Marsischky, G.T.. Kolodner. R.. and
Fishel, R. hMSH2 forms specific mispair binding complexes with hMSH3 and hMSH6. Proceedings
OfThe National Academy OfSciences Of The United States OfAmerica 93:13629-13634, 1996.
Aebi, S., Kurdihaidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R.D., Boland, C.R..
Koi. M., Fishel, R.. and Howell, S.B. Loss of DNA mismatch repair in acquired resistance to
cisplatin. Cancer Research 56:3087-3090, 1996.
Agapova, L.S., Ilyinskaya, G.V., Turovets, N.A., Ivanov, A.V., Chumakov, P.M., and Kopnin, B.P.
Chromosome changes caused by alterations of p53 expression. Mutation Research-Fundamental And
Molecular Mechanisms OfMutagenesis 354:129-138, 1996.
Agarwal, M.L., Agarwal, A., Taylor, W.R., and Stark, G.R. p53 controls both the G2/M and the G1
cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proceedings Of
The National Academy OfSciences OfThe United States OfAmerica 92:8493-8497, 1995.
Akiyama, Y., Sato, H., Yamada, T., Nagasaki, H., Tsuchiya, A., Abe, R., and Yuasa, Y. Germ-line
mutation of the hMSH6/GTBP gene in an atypical Hereditary Non-Polyposis Colorectal Cancer
kindred. Cancer Research 57:3920-3923, 1997.
Anthoney, D.A., Mcllwrath, A.J., Gallagher, W.M., Edlin, A.R.M., and Brown, R. Microsatellite
instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Research
(56): 1374-1381, 1996.
Aquilina, G., Hess, P., Fiumicino, S., Ceccotti, S., and Bignami, M. A mutator phenotype
characterizes one of 2 complementation groups in human cells tolerant to methylation damage.
Cancer Research 55:2569-2575, 1995.
Armitage, N.C., Ballantyne, K.C., Evans, D.F., Clarke, P., Sheffield, J., and Hardcastle, J.D. The
influence of tumor cell DNA content on survival in colorectal cancer - a detailed analysis. British
Journal OfCancer 62:852-856, 1990.
Ashton-Rickardt. P.G., Dunlop, M.G., Nakamura, Y., Morris, R.G., Purdie, C.A., Steel, C.M.,
Evans, H.J., Bird. C.C., and Wyllie, A.H. High frequency of APC loss in sporadic colorectal
carcinoma due to breaks clustered in 5q21-22. Oncogene 4:1169-1174. 1989.
Ashton-Rickardt. P.G., Wyllie, A.H., Bird, C.C., Dunlop, M.G., Steel, C.M., Morris. R.G., Piris, J.,
Romanowski. P., Wood, R., White, R.. and Nakamura, Y. MCC, a candidate familial polyposis gene
in 5q.21, shows frequent allele loss in colorectal and lung cancer. Oncogene 6:1881-1886. 1991.
187
Baas, I.O., Mulder, J.W.R., Qfferhaus, G.J.A., Vogelstein, B., and Hamilton. S.R. Evaluation of 6
antibodies for immunohistochemistiy of mutant p53 gene product in archival colorectal neoplasms.
Journal OfPathology 172:5-12, 1994.
Baker, S.J., Preisinger, A.C., Jessup, J.M., Paraskeva, C., Markowitz, S., Willson, J.K.V., Hamilton,
S., and Vogelstein, B. p53 gene mutations occur in combination with 17p allelic deletions as late
events in colorectal tumorigenesis. Cancer Research 50:7717-7722, 1990.
Baker, S.M., Bronner, C.E.. Zhang, L.. Plug, A.W., Robatzek, M., Warren, G., Elliott, E.A., Yu,
J.A., Ashley, T., Arnheim, N., Flavell, R.A., and Liskay, R.M. Male mice defective in the DNA
mismatch repair gene Pms2 exhibit abnormal chromosome synapsis in meiosis. Cell 82:309-319,
1995.
Baker, S.M., Plug, A.W., Prolla, T.A., Bronner, C.E., Harris. A.C., Yao, X., Christie, D.M., Monell,
C., Arnheim, N., Bradley, A., Ashley, T.. and Liskay, R.M. Involvement of mouse Mlhl in DNA
mismatch repair and meiotic crossing-over. Nature Genetics 13:336-342, 1996.
Barbacid, M. Ras genes. Annual Review OfBiochemistry 56:779-827, 1987.
Bardi. G., Pandis. N., Fenger, C., Kronborg, O.. Bomme, L., and Heim, S. Deletion of lp36 as a
primary chromosomal aberration in intestinal tumorigenesis. Cancer Research 53:1895-1898. 1993a.
Bardi, G., Johansson, B., Pandis, N., Mandahl, N., Bakjensen, E., Lindstrom. C., Tornqvist, A.,
Frederiksen, H., Andren-Sandberg, A., Mitelman, F., and Heim, S. Cytogenetic analysis of 52
colorectal carcinomas - nonrandom aberration pattern and correlation with pathological parameters.
International Journal OfCancer 55:422-428, 1993b.
Bardi, G., Sukhikh, T., Pandis, N., Fenger, C.. Kronborg, O., and Heim, S. Karyotypic
characterization of colorectal adenocarcinomas. Genes Chromosomes & Cancer 12:97-109, 1995.
21. Bardot, V., Luccioni, C., Lefrangois, D., Muleris, M., and Dutrillaux, B. Activity of thymidylate
synthetase, thymidine kinase and galactokinase in primary and xenografted human colorectal cancers
in relation to their chromosomal patterns. International Journal OfCancer 47:670-674, 1991.
Barletta, C., Scillato, F., Sega. F.M., and Mannella, E. Genetic alteration in gastrointestinal cancer -
a molecular and cytogenetic study. Anticancer Research 13:2325-2329. 1993.
Barnes, D.M., Hanby. A.M., Gillett, C.E., Mohammed, S., Hodgson, S., Bobrow. L.G., Leigh, I.M.,
Purkis, T., MacGeoch, C., Sprnr, N.K., Bartek, J., Vojtesek, B.. Picksley, S.M., and Lane, D.P.
Abnormal expression of wild-type p53 protein in normal cells of a cancer family patient. Lancet 340:
259-263, 1992.
Bassam, B.J., Caetanoanolles, G., and Gresshoff, P.M. Fast and sensitive silver staining of DNA in
polyacrylamide gels. Analytical Biochemistry 196:80-83, 1991.
Beelman, C.A. and Parker, R. Degradation of messenger RNA in eukaiyotes. Cell 81:179-183, 1995.
Bell, S.M., Scott, N., Cross. D., Sagar, P.. Lewis, F.A., Blair. G.E., Taylor, G.R.. Dixon, M.F., and
Quirke, P. Prognostic value of p53 overexpression and c-ki-ras gene-mutations in colorectal cancer.
Gastroenterology 104:57-64, 1993.
Benchimol, S., Lamb, P., Crawford, L., Sheer, D., Solomon, E., Shows, T., Brans, G., and Peacock,
J. Human p53 is on the short arm of chromosome 17. Cytogenetics And Cell Genetics 40:580-581,
1985.
188
Benson, J.R. and Wells, K. Microsatellite instability and a TGF-beta receptor - clues to a growth
control pathway. Bioessavs 17:1009-1012, 1995.
Bertoni. L., Attolini, C., Tessera, L., Mucciolo, E., and Giulotto. E. Telomeric and non-telomeric
(TTAGCC)(n) sequences in gene amplification and chromosome stability. Genomics 24:53-62, 1994.
Bhattacharyya, N.P., Skandalis, A., Ganesh, A., Groden, J., andMeuth, M. Mutator phenotypes in
human colorectal carcinoma cell lines. Proceedings Of The NationalAcademy OfSciences OfThe
United States OfAmerica 91:6319-6323, 1994.
Bicknell. D C., Kaklamanis, L., Hampson, R.. Bodmer, W.F., and Karran. P. Selection for beta(2)-
microglobulin mutation in mismatch repair-defective colorectal carcinomas. Current Biology
6:1695-1697, 1996.
Bischoff, F.Z., Yim, S O., Pathak, S., Grant, G., Siciliano, M.J., Giovanella, B.C., Strong, L.C., and
Tainsky, M.A. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni
cancer syndrome - aneuploidy and immortalization. Cancer Research 50:7979-7984, 1990.
Blagosklonny, M. V. Loss of function and p53 protein stabilization. Oncogene 15:1889-1893, 1997.
Bocker, T., Diermann, J., Friedl, W., Gebert, J., Holinski-Feder, E., Karner-Hanusch, J., von Knebel-
Doeberitz, M., Koelble, K., Moeslein, G., Schackert, H.K., Wirtz, H.C., Fishel, R., and Ruschoff, J.
Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer
Research 57:4739-4743, 1997.
Bomme. L., Bardi, G., Pandis, N., Fenger, C., Kronborg, O., and Heim, S. Clonal karyotypic
abnormalities in colorectal adenomas - clues to the early genetic events in the adenoma-carcinoma
sequence. Genes Chromosomes & Cancer 10:190-196, 1994.
Boolbol. S.K., Dannenberg, A.J., Chadburn, A., Martucci, C., Guo, X.J., Ramonetti, J.T.,
Abreugoris, M., Newmark, H.L., Lipkin, M.L., Decosse, J.J., and Bertagnolli, M.M.
Cyclooxygenase-2 overexpression and tumor formation are blocked by Sulindac in a murine model of
Familial Adenomatous Polyposis. Cancer Research 56:2556-2560, 1996.
Borresen, A.L., Lothe, R.A., Meling, G.I., Lystad, S., Morrison, P., Lipford. J., Kane, M.F.,
Rognum, T O., and Kolodner, R.D. Somatic mutations in the hMSH2 gene in microsatellite unstable
colorectal carcinomas. Human Molecular Genetics 4:2065-2072, 1995.
Bos, J.L., Fearon, E.R., Hamilton, S.R., Verlaan deVries, M., VanBoom, J.H., VandeReb, A.J., and
Vogelstein, B. Prevalence of ras gene mutations in human colorectal cancers. Nature 327:293-297,
1987.
Bosnia. G.C., Custer, R.P., andBosma, M.J. A severe combined immunodeficiency mutation in the
mouse. Nature 301:527-530. 1983.
Boyer, J.C., Umar, A., Risinger, J.I., Lipford, J.R., Kane, M., Yin, S., Barrett. J.C., Kolodner, R.D.,
and Kunkel, T.A. Microsatellite instability, mismatch repair deficiency, and genetic defects in
human cancer cell lines. Cancer Research 55:6063-6070, 1995.
Branch, P., Hampson, R., and Karran, P. DNA mismatch binding defects, DNA-damage tolerance,
and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Research 55:2304-2309,
1995.
Bresalier, R.S.. Hujanen. E.S.. Raper. S.E.. Roll, F.J., Itzkowitz, S.H., Martin, G.R., and Kim. Y.S.
An animal model for colon cancer metastasis - establishment and characterization of murine cell
lines with enhanced liver-metastasizing ability. Cancer Research 47:1398-1406, 1987.
189
Bresalier. R.S.. Raper, S.E., Hujanen. E.S., and Kim, Y.S. A new animal model for human colon
cancer metastasis. International Journal OfCancer 39:625-630, 1987.
Bronner, C.E.. Baker, S.M., Morrison, P.T., Warren, G., Smith, L.G., Lescoe, M.K., Kane, M.,
Earabino, C., Lipford, J., Lindblom, A., Tannergard, P., Bollag, R.J., Godwin, A.R., Ward, D.C.,
Nordenskjold. M., Fishel, R., Kolodner. R., and Liskay, R.M. Mutation in the DNA mismatch repair
gene homolog hMLHl is associated with Hereditary Non-Polvposis Colon Cancer. Nature 368:258-
261, 1994.
Briiderlein. S., VanderBosch, K., Schlag, P., and Schwab, M. Cytogenetics and DNA amplification
in colorectal cancers. Genes Chromosomes & Cancer 2:63-70, 1990.
Bryan, T.M., Englezou, A., DallaPozza, L., Dunham, M.A., and Reddel, R.R. Evidence for an
alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell
lines. Nature Medicine 3:1271-1274, 1997.
Bubb, V.J., Curtis, L.J., Cunningham, C., Dunlop, M.G., Carothers, A.D., Morris, R.G., White, S.,
Bird, C.C., and Wyllie, A.H. Microsatellite instability and the role of hMSH2 in sporadic colorectal
cancer. Oncogene 12:2641-2649, 1996.
Burkitt. D.P. Epidemiology of cancer of the colon and rectum. Cancer 28:3-13, 1971.
Cajot, J.F., Sordat, I., Silvestre, T., and Sordat. B. Differential display cloning identifies motility-
related protein (MRPl/cd9) as highly expressed in primary compared to metastatic human colon
carcinoma cells. Cancer Research 57:2593-2597. 1997.
Campo, E„ De la Callemartin, O., Miquel, R., Palacin, A., Romero, M., Fabregat, V., Vives, J.,
Cardesa, A., and Yague, J. Loss of heterozygosity of p53-gene and p53-protein expression in human
colorectal carcinomas. Cancer Research 51:4436-4442. 1991.
Cancer Research Campaign Factsheet 18. Cambridge:Cancer Research Campaign, 1993.
Carder, P., Wyllie, A.H., Purdie, C.A., Morris, R.G., White, S., Piris, J., and Bird, C.C. Stabilized
p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 8:1397-1401, 1993.
Carder, P.J., Cripps. K.J., Morris, R., Collins, S., White, S., Bird, C.C., and Wyllie, A.H. Mutation
of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. British Journal Of
Cancer 71:215-218, 1995.
Chadeneau, C., Hay, K., Hirte, H. W., Gallinger. S., and Bacchetti, S. Telomerase activity associated
with acquisition of malignancy in human colorectal cancer. Cancer Research 55:2533-2536, 1995.
Cho, K.R., Oliner, J.D., Simons, J.W., Hedrick, L., Fearon. E.R., Preisinger, A.C., Hedge, P.,
Silverman, G.A., and Vogelstein. B. The DCC gene - structural analysis and mutations in colorectal
carcinomas. Genomics 19:525-531, 1994.
Chong, J.M., Fukayama. M., Hayashi, Y., Takizawa, T., Koike, M.. Konishi, M.. Kikuchi-
Yanoshita, R., and Miyaki, M. Microsatellite instability in the progression of gastric carcinoma.
Cancer Research 54:4595-4597, 1994.
Chu, C.S., Trapnell, B.C., Curristin, S., Cutting, G.R., and Crystal, R.G. Genetic basis of variable
exon 9 skipping in cystic fibrosis transmembrane conductance regulator messenger RNA. Nature
Genetics 3:151-156, 1993.
190
Clarke, A.R., Purdie, C.A., Harrison, D.J.. Morris, R.G., Bird. C.C., Hooper. M.L., and Wyllie. A.H.
Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852,
1993.
Clarke. A.R., Howard, L.A., Harrison. D.J., and Winton, D.J. p53, mutation frequency and apoptosis
in the murine small intestine. Oncogene 14:2015-2018, 1997.
Cohn, K.H., Wang, F.S., Desoto-laPaix, F., Solomon, W.B., Patterson. L.G., Arnold, M.R., Weimar,
J., Feldman. J.G., Levy, A.T., Leone, A., and Steeg, P.S. Association of nm23 allelic deletions with
distant metastases in colorectal carcinoma. Lancet 338:722-724, 1991.
Cooke, H.J. and Brown, W.R.A. A highly polymorphic X- and Y-homologous DNA probe.
Cytogenetics And Cell Genetics 40:607, 1985.
Cooper, D.L., Lahue, R.S., and Modrich, P. Methyl-directed mismatch repair is bidirectional.
Journal OfBiological Chemistry 268:11823-11829, 1993.
Cotran, R.S., Kumar, V., and Robbins. S.L. (Editors) Robbins pathologic basis ofdisease. W.B.
Saunders Company, Philadelphia. 1994
Cottu, P.H., Muzeau, F., Estreicher. A., Flejou, J.F., Iggo, R., Thomas, G., and Hamelin, R. Inverse
correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene
13:2727-2730, 1996.
Couturier-Turpin. M.H., Esnous, C., Louvel, A., Poirier, Y., and Couturier, D. Chromosome 1 in
human colorectal tumors - cytogenetic research on structural changes and their significance. Human
Genetics 88:431-438, 1992.
Cranston, A., Bocker, T., Reitmair, A., Palazzo, J., Wilson, T., Mak, T., and Fishel, R. Female
embryonic lethality in mice nullizygous for both Msh2 and p53. Nature Genetics 17:114-118, 1997.
Cripps. K.J., Purdie, C.A., Carder, P.J., White, S., Komine. K., Bird, C.C.. and Wyllie, A.H. A study
of stabilization of p53 protein versus point mutation in colorectal carcinoma. Oncogene 9:2739-
2743, 1994.
Cross, S.M., Sanchez, C.A., Morgan. C.A., Schimke. M.K., Ramel, S., Idzerda, R.L., Raskind,
W.H.. and Reid, B.J. A p53-dependent mouse spindle checkpoint. Science 267:1353-1356, 1995.
Cunningham, J., Lust, J.A., Schaid, D.J., Bren. G.D., Carpenter, H.A., Rizza. E„ Kovach, J.S., and
Thibodeau, S.N. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Research
52:1974-1980. 1992.
Cunningham, C.. Dunlop, M.G., Wyllie, A.H., and Bird, C.C. Deletion mapping in colorectal cancer
of a putative tumor suppressor gene in 8p22-p21.3. Oncogene 8:1391-1396, 1993.
Cunningham, C. and Dunlop. M.G. Genetics of colorectal cancer. British Medical Bulletin 50:640-
655, 1994.
Cunningham. C., Dunlop, M.G., Bird. C.C., and Wyllie, A.H. Deletion analysis of chromosome 8p
in sporadic colorectal adenomas. British Journal OfCancer 70:18-20, 1994.
Curtis, L.J., Bubb. V.J., Gledhill, S., Morris, R.G., Bird, C.C., and Wyllie, A.H. Loss of
heterozygosity of MCC is not associated with mutation at the retained allele in sporadic colorectal
cancer. Human Molecular Genetics 3:684, 1994.
191
Da Costa, L.T., Liu, B., El-Deiry, W.S., Hamilton, S.R., Kinzler, K.W., Vogelstein, B., Markowitz,
S., Willson, J.K. V., de la Chapelle, A., Downey, K.M., and So, A.G. Polymerase delta variants in
RER colorectal tumors. Nature Genetics 9:10-11. 1995.
Dal Cin, P., Aly, M.S., Delabie, J., Ceuppens, J.L., van Gool, S., van Damme, B., Baert, L., van
Poppel, H., and van den Berghe, H. Trisomy 7 and trisomy 10 characterize subpopulations of tumor-
infiltrating lymphocytes in kidney tumors and in the surrounding kidney tissue. Proceedings OfThe
National Academy OfSciences Of The United States OfAmerica 89:9744-9748, 1992.
Debustros, A., Nelkin, B.D., Silverman, A., Ehrlich, G., Poiesz, B., and Baylin, S.B. The short arm
of chromosome 11 is a hot spot for hypermethylation in human neoplasia. Proceedings OfThe
National Academy OfSciences OfThe United States OfAmerica 85:5693-5697, 1988.
Delhanty, J.D.A., Davis, M.B., and Wood. J. Chromosome instability in lymphocytes, fibroblasts,
and colon epithelial-like cells from patients with Familial Polyposis Coli. Cancer GeneticsAnd
Cytogenetics 8:27-50, 1983.
DeWind, N., Dekker, M., Berns, A., Radman, M., and Riele, H.T. Inactivation of the mouse Msh2
gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and
predisposition to cancer. Cell 82:321-330, 1995.
Dietmaier, W., Wallinger, S.. Bocker, T., Kullmann, F., Fishel, R., andRuschoff, J. Diagnostic
microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer
Research 57:4749-4756, 1997.
Dietrich, W.F., Lander, E.S., Smith, J.S., Moser, A.R., Gould, K.A., Luongo, C., Borenstein, N., and
Dove. W. Genetic identification ofMom-1, a major modifier locus affecting /win-induced intestinal
neoplasia in the mouse. Cell 75:631-639, 1993.
Dileonardo, A., Linke, S.P., Clarkin, K., and Wahl, G.M. DNA damage triggers a prolonged p53-
dependent G1 arrest and long- term induction of Cipl in normal human fibroblasts. Genes &
Development 8:2540-2551, 1994.
DiLeonardo, A., Khan, S.H., Linke, S.P., Greco, V., Seidita, G., and Wahl, G.M. DNA re-replication
in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or
pRb function. Cancer Research 57:1013-1019, 1997.
Diller, L., Kassel, J., Nelson. C.E., Gryka, M.A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk. M.,
Baker, S.J., Vogelstein, B., and Friend, S.H. p53 functions as a cell cycle control protein in
osteosarcomas. Molecular And Cellular Biology 10:5772-5781, 1990.
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A.K., Moore, M., Finlay, C., andLevine, A.J.
Gain of function mutations in p53. Nature Genetics 4:42-46, 1993.
DiVinci, A., Infusini, E., Peveri, C., Risio, M., Rossini, F.P., and Giaretti, W. Deletions at
chromosome lp by fluorescence in-situ hybridization are an early event in human colorectal
tumorigenesis. Gastroenterology 111:102-107, 1996.
Donehower, L.A., Harvey, M., Slagle. B.L., McArthur, M.J., Montgomery, C.A., Butel, J.S., and
Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous
tumors. Nature 356:215-221, 1992.
Donehower. L.A., Godley, L.A., Aldaz, C.M., Pyle, R., Shi, Y.P., Pinkel, D., Gray, T., Bradley, A.,
Medina, D., and Varmus, H.E. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1
transgenic mice and promotes chromosomal instability. Genes & Development 9:882-895, 1995.
192
Drummond, J.T., Li, G.M., Longley, M.J., andModrich, P. Isolation of an hMSH2-pl60 heterodimer
that restores DNA mismatch repair to tumor cells. Science 268:1909-1912, 1995.
Drummond. J.T., Anthoney, A., Brown, R., and Modrich, P. Cisplatin and adriamycin resistance are
associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line. Journal Of
Biological Chemistry 271:19645-19648, 1996.
DuManoir, S., Speicher, M.R., Joos, S., Schrock, E.. Popp, S., Dohner, H., Kovacs, G., Robert-
Nicoud. M., Lichter, P., and Cremer, T. Detection of complete and partial chromosome gains and
losses by comparative genomic in situ hybridization. Human Genetics 90:590-610, 1993.
Dunlop, M.G., Farrington, S.M., Bubb, V.J., Cunningham, C., Wright, M., Curtis, L.J., Butt, Z.A.,
Wright, E., Fleck, B.W., Redhead, D., Mitchell. R., Rainey, J.B., Macintyre, I.M.C., Carter, D.C.,
and Wyllie, A.E1. Extracolonic features of Familial Adenomatous Polyposis in patients with sporadic
colorectal cancer. British Journal OfCancer 74:1789-1795, 1996.
Dunn, S.E., Kari, F.W., French, J., Leininger, J.R., Travlos, G., Wilson, R., and Barrett, J.C. Dietary
restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation,
and tumor progression in p53-deficient mice. Cancer Research 57:4667-4672, 1997.
Edelmann, W., Cohen, P.E., Kane, M., Lau, K., Morrow, B., Bennett, S., Umar, A., Kunkel, T.,
Cattoretti, G., Chaganti, R., Pollard, J. W., Kolodner, R.D., and Kucher-Lapati, R. Meiotic pachytene
arrest in Mlhl-deficient mice. Cell 85:1125-1134, 1996.
Edelmann, W., Yang, K., Umar, A., Heyer, J., Lau, K., Fan, K., Liedtke, W., Cohen, P.E., Kane,
M.F., Lipford J.R., Yu, N., Crouse, G.F., Pollard, J.W., Kunkel, T., Lipkin, M., Kolodner, R., and
Kucher-Lapati, R. Mutation in the mismatch repair gene MSH6 causes cancer susceptibility. Cell
91:467-477, 1997.
El-Deiry, W.S., Harper, J.W., Oconnor, P.M., Velculescu, V.E., Camnan, C.E., Jackman, J.,
Pietenpol, J.A., Burrell, M., Hill, D.E., Wang, Y.S., Wiman, K.G., Mercer, W.E., Kastan, M.B.,
Kohn, K.W., Elledge, S.J., Kinzler, K.W., and Vogelstein, B. Wafl/Cipl is induced in p53-mediated
G1 arrest and apoptosis. Cancer Research 54:1169-1174, 1994.
Eliyahu, D., Goldfinger, N., Pinhasikimhi, O., Shaulsky, G., Skurnik, Y., Arai, N., Rotter, V., and
Oren, M. Meth-A fibrosarcoma cells express 2 transforming mutant p53 species. Oncogene 3:313-
321, 1988.
Eppert, K., Scherer, S.W., Gzcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L.C., Bapat, B.,
Gallinger, S., Andrulis, I.L., Thomsen, G.H., Wrana, J.L., and Attisano, L. MadR2 maps to 18q21
and encodes a TGF beta-regulated Mad-related protein that is functionally mutated in colorectal
carcinoma. Cell 86:543-552, 1996.
Eshleman, J.R., Lang, E.Z., Bowerfind G.K., Parsons, R., Vogelstein, B., Willson, J.K.V., Veigl.
M.L., Sedwick, W.D., and Markowitz, S.D. Increased mutation-rate at the HPRT locus accompanies
microsatellite instability in colon cancer. Oncogene 10:33-37, 1995.
Evan, G.I., Wyllie, A.H., Gilbert, C.S., Littlewood T.D., Land H., Brooks, M., Waters, C.M., Penn,
L.Z., and Hancock, D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119-128,
1992.
Farrington, S.M., Cunningham, C., Boyle. S.M., Wyllie. A.H., and Dunlop, M.G. Detailed physical
and deletion mapping of 8p with isolation of YAC clones from tumor suppressor loci involved in
colorectal cancer. Oncogene 12:1803-1808, 1996.
193
Fearon, E.R. and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61:759-767,
1990.
Fearon, E.R., Cho, K.R., Nigro, J.M., Kern, S.E., Simons, J.W., Ruppert, J.M., Hamilton, S.R.,
Preisinger, A.C., Thomas, G., Kinzler, K.W., and Vogelstein, B. Identification of a chromosome 18q
gene that is altered in colorectal cancers. Science 247:49-56, 1990.
Findlay. M.P.N., Cunningham, D., Morgan, G., Clinton, S., Hardcastle, A., and Aherne, G.W. Lack
of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent
response to chemotherapy. British Journal OfCancer 75:903-909, 1997.
Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R.D., and Howell, S.B. The
role of DNA mismatch repair in platinum drug resistance. Cancer Research 56:4881-4886, 1996.
Finlay, C.A.. Hinds, P.W., Tan, T.H., Eliyahu, D., Oren, M., and Levine, A.J. Activating mutations
for transformation by p53 produce a gene product that forms an Hsc70-p53 complex with an altered
half-life. MolecularAnd Cellular Biology 8:531-539, 1988.
Fishel, R., Lescoe, M.K., Rao, M.R.S., Copeland, N.G., Jenkins, N.A., Garber, J., Kane, M., and
Kolodner, R. The human mutator gene homolog MSH2 and its association with Hereditary Non-
Polyposis Colon Cancer. Cell 75:1027-1038, 1993.
Fishel, R., Ewel, A., Lee, S., Lescoe. M.K., and Griffith, J. Binding of mismatched microsatellite
DNA sequences by the human MSH2 protein. Science 266:1403-1405, 1994.
Fong, K.M., Zimmerman. P.V., and Smith, P.J. Microsatellite instability and other molecular
abnormalities in non-small cell lung cancer. Cancer Research 55:28-30, 1995.
Ford, J.M. and Hanawalt. P.C. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are
deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV
resistance. Proceedings Of The National Academy OfSciences OfThe United States OfAmerica
92:8876-8880, 1995.
Forrester, K., Almoguera, C., Han, K.Y., Grizzle, W.E., and Perucho, M. Detection of high-
incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327:298-303, 1987.
Frank, C.J., McClatchey, K.D., Devaney, K.O., and Carey, T.E. Evidence that loss of chromosome
18q is associated with tumor progression. Cancer Research 57:824-827, 1997.
Fuchs. E.J., McKemia, K.A., and Bedi. A. p53-dependent DNA damage-induced apoptosis requires
Fas/APO-1 -independent activation of CPP332 beta. Cancer Research 57:2550-2554, 1997.
Fujiwara, Y., Emi, M., Ohata. H., Kato, Y., Nakajima, T., Mori, T., and Nakamura, Y. Evidence for
the presence of 2 tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer
Research 53:1172-1174, 1993.
Fukasawa. K., Choi, T., Kuriyama, R., Rulong, S., and Vandevoude. G.F. Abnormal centrosome
amplification in the absence of p53. Science 271:1744-1747, 1996.
Fukasawa, K., Wiener, F., VandeWoude, G.F.. and Mai, S.B. Genomic instability and apoptosis are
frequent in p53 deficient young mice. Oncogene 15:1295-1302, 1997.
Futreal, P.A., Barrett, J.C., and Wiseman, R.W. An Alu polymorphism intragenic to the tp53 gene.
Nucleic Acids Research 19:6977, 1991.
194
Gallick, G.E., Kurzrock, R.. Kloetzer, W.S.. Arlinghaus. R.B., and Gutterman. J.U. Expression of
p21rasin fresh primary and metastatic human colorectal tumors. Proceedings OfThe National
Academy OfSciences OfThe United States OfAmerica 82:1795-1799, 1985.
Gannon, J.V., Greaves, R., Iggo, R., and Lane, D.P. Activating mutations in p53 produce a common
conformational effect - a monoclonal antibody specific for the mutant form. Embo Journal 9:1595-
1602, 1990.
Gao, X.A.. Wu, N., Grignon. D., Zacharek, A., Liu, H., Salkowski, A., Li, G.Y., Sakr. W., Sarkar,
F.. Porter, A.T., Chen, Y.Q., and Honn, K.V. High-frequency of mutator phenotype in human
prostatic adenocarcinoma. Oncogene 9:2999-3003, 1994.
Garkavtsev, I., Grigorian. I.A., Ossovskaya, V.S., Chernov, M.V., Chumakov, P.M., and Gudkov.
A.V. The candidate tumour suppressor p33 (ING1) cooperates with p53 in cell growth control.
Nature 391:295-298, 1998.
Gerdes. H.. Chen, Q.G., Elalii, A.H., Sircar, A., Goldberg. E., Winawer, D., Urmaclier, C.,
Winawer, S.J., and Jhanwar, S.C. Recurrent deletions involving chromosome 1, chromosome 5,
chromosome 17, and chromosome 18 in colorectal carcinoma -possible role in biological and clinical
behavior of tumors. Anticancer Research 15:13-24, 1995.
Glaab, W.E. and Tindall, K.R. Mutation rate at the HPRT locus in human cancer cell lines with
specific mismatch repair gene defects. Carcinogenesis 18:1-8. 1997.
Goelz, S.E., Vogelstein, B., Hamilton, S.R., and Feinberg, A.P. Hypomethylation of DNA from
benign and malignant human colon neoplasms. Science 228:187-190, 1985a.
Goelz, S.E., Hamilton. S.R., and Vogelstein, B. Purification of DNA from formaldehyde fixed and
paraffin embedded human tissue. Biochemical And Biophysical Research Communications 130:118-
126, 1985b.
Gottlieb, T.M. and Oren, M. p53 in growth control and neoplasia. Biochimica Et Biophysica Acta-
Reviews On Cancer 1287:77-102, 1996.
Graeber, T.G., Peterson, J.F., Tsai, M., Monica, K., Fornace. A.J., and Giaccia, A.J. Hypoxia induces
accumulation of p53 protein, but activation of a G1 phase checkpoint by low oxygen conditions is
independent of p53 status. Molecular And Cellular Biology 14:6264-6277, 1994.
Greenblatt, M.S., Bennett, W.P., Hollstein, M., and Harris, C.C. Mutations in the p53 tumor
suppressor gene - clues to cancer etiology and molecular pathogenesis. Cancer Research 54:4855-
4878, 1994.
Greenblatt. M.S., Grollman, A.P., and Harris, C.C. Deletions and insertions in the p53 tumor
suppressor gene in human cancers - confirmation of the DNA-polymerase slippage misalignment
model. Cancer Research 56:2130-2136, 1996.
Griffin, C.A., Lazar, S., Hamilton. S R., Giardiello, F.M., Long, P., Krush, A.J., and Booker, S.V.
Cytogenetic analysis of intestinal polyps in polyposis syndromes - comparison with sporadic
colorectal adenomas. Cancer Genetics And Cytogenetics 67:14-20, 1993.
Griffiths, S.D., Clarke, A.R., Healy, L.E., Ross, G., Ford. A.M., Hooper, M.L., Wyllie, A.H., and
Greaves, M. Absence of p53 permits propagation of mutant cells following genotoxic damage.
Oncogene 14:523-531, 1997.
Grilley, M., Welsh, K.M., Su, S.S., and Modrich, P. Isolation and characterization of the
Escherichia coli MutL gene product. Journal OfBiological Chemistry 264:1000-1004, 1989.
195
Groden. J., Thliveris, A., Samowitz, W., Carlson, M., Gelbert, L„ Albertsen, H., Joslyn, G., Stevens,
J., Spirio, L.. Robertson, M., Sargeant, L., Krapcho, K., Wolff, E., Burt, R., Hughes, J.P.,
Warrington, J., McPherson. J., Wasmuth, J., LePaslier, D.. Abderrahim, H., Cohen. D., Leppert, M.,
and White, R. Identification and characterization of the Familial Adenomatous Polyposis coli gene.
Cell 66:589-600, 1991.
Guillouf, C., Rosselli, F.. Krishnaraju, K.. Moustacchi. E.. Hoffman. B.. and Liebermann, D.A. p53
involvement in control of G2 exit of the cell cycle - role in DNA damage-induced apoptosis.
Oncogene 10:2263-2270, 1995.
Gvapay, G., Morissette, J., Vignal, A., Dib, C., Fizames, C., Millasseau, P., Marc, S., Bernardi, G.,
Lathrop, M., and Weissenbach, J. The 1993-94 genethon human genetic-linkage map. Nature
Genetics 7:246-339, 1994.
Hall, P. A. and Lane, D.P. p53 in tumor pathology - can we trust immunohistochemistry? -revisited!
Journal OfPathology 172:1-4, 1994.
Hall, N.R., Taylor, G.R., Finan, P.J., Kolodner, R.D., Bodmer, W.F., Cottrell, S.E., Frayling, I., and
Bishop, D.T. Intron splice acceptor site sequence variation in the Hereditary Non-Polyposis
Colorectal Cancer gene hMSH2. European Journal OfCancer 30A: 1550-1552, 1994.
Hamelin, R., Laurent-Puig, P., Olschwang, S., Jego, N., Asselain, B.. Remvikos, Y., Girodet, J.,
Salmon. R.J., and Thomas, G. Association of p53 mutations with short survival in colorectal cancer.
Gastroenterology 106:42-48. 1994.
Hamlin. J.L., Leu. T.H., Vaughn, J.P., Ma, C., andDijkwel, P.A. Amplification of DNA sequences
in mammalian cells. Progress In Nucleic Acid Research And Molecular Biology 41:203-239. 1991.
Han, H.J., Yanagisawa, A., Kato, Y., Park, J.G.. and Nakamura, Y. Genetic instability in pancreatic
cancer and poorly differentiated type of gastric cancer. Cancer Research 53:5087-5089, 1993.
Han. H.J., Yuan, Y„ Ku. J.L., Oh, J.H., Won, Y.J., Kang, K.J., Kim. K.Y., Kim, S., Kim. C.Y.,
Kim, J.P., Oh, N.G., Lee. K.H., Choe, K.J., Nakamura, Y., and Park. J.G. Germline mutations of
hMLHl and hMSH2 genes in Korean Hereditary Non-Polyposis Colorectal Cancer. Journal OfThe
National Cancer Institute 88:1317-1319, 1996.
Harvey, M., McArthur, M.J., Montgomery, C.A.. Butel, J.S., Bradley, A., and Donehower, L.A.
Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genetics 5:225-
229, 1993a.
Harvey, M., Sands, A.T., Weiss, R.S., Hegi, M.E., Wiseman, R.W., Pantazis, P., Giovanella, B.C.,
Tainsky, M.A., Bradley, A., and Donehower, L.A. In vitro growth characteristics of embryo
fibroblasts isolated from p53-deficient mice. Oncogene 8:2457-2467, 1993b.
Hastie, N.D. and Allshire, R.C. Human telomeres - fusion and interstitial sites. Trends In Genetics
5:326-331, 1989.
Hastie, N.D., Dempster, M„ Dunlop, M.G., Thompson, A.M., Green, D.K., and Allshire. R.C.
Telomere reduction in human colorectal carcinoma and with aging. Nature 346:866-868. 1990.
Haupt, Y., Maya, R., Kazaz, A., and Oren. M. Mdm2 promotes the rapid degradation of p53. Nature
387:296-299, 1997.
196
Haut, ML, Steeg, P.S., Willson, J.K.V., and Markowitz, S.D. Induction of nm23 gene expression in
human colonic neoplasms and equal expression in colon tumors of high and low metastatic potential.
Journal OfThe National Cancer Institute 83:712-716, 1991.
Hawn, M.T., Umar. A., Carethers, J.M., Marra, G., Kunkel, T.A., Boland, C.R., andKoi, M.
Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint.
Cancer Research 55:3721-3725, 1995.
Hedrick. L., Cho, K.R., Fearon, E.R., Wu, T.C., Kinzler. K.W., and Vogelstein, B. The DCC gene
product in cellular differentiation and colorectal tumorigenesis. Genes & Development 8:1174-1183,
1994.
Heikkila, R.. Schwab. G., Wickstrom, E., Loke. S.L.. Pluznik, D.H., Watt, R., and Neckers, L.M. A
c-myc antisense oligodeoxynucleotide inhibits entry into S-phase but not progress from GO to Gl.
Nature 328:445-449, 1987.
Hemminki, A., Peltomaki, P., Mecklin, J.P., Jarvinen, H., Salovaara, R., Nystrom-Lahti, M., de la
Chapelle, A., and Aaltonen, L.A. Loss of the wild-type MLH1 gene is a feature of Hereditary Non-
Polyposis Colorectal Cancer. Nature Genetics 8:405-410, 1994.
Herbergs, J., Debruine, A.P., Marx, P.T.J., Vallinga, M.I.J., Stockbrugger. R.W., Ramaekers. F.C.S.,
Arends, J.W., and Hopman, A.H.N. Chromosome aberrations in adenomas of the colon - proof of
trisomy 7 in tumor cells by combined interphase cytogenetics and immunocytochemistry.
International Journal OfCancer 57:781-785, 1994.
Herfarth, K.K.F., Kodner, I.J., Whelan, A.J., Ivanovich, J.L., Bracamontes, J.R., Wells, S.A., and
Goodfellow, P.J. Mutations in MLH1 are more frequent than in MSH2 in sporadic colorectal cancers
with microsatellite instability. Genes Chromosomes & Cancer 18:42-49, 1997.
Hermeking. H. and Eick. D. Mediation of c-myc-induced apoptosis by p53. Science 265:2091-2093,
1994.
Hoang, J.M., Cottu. P.H., Thuille. B., Salmon. R.J., Thomas. G., andHamelin, R. BAT-26, an
indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Research
57:300-303, 1997.
Hollstein, M., Sidransky. D., Vogelstein. B., and Harris, C.C. p53 mutations in human cancers.
Science 253:49-53, 1991.
Honchel, R., Hailing, K.C., Schaid. D.J., Pittelkow, M., and Thibodeau, S.N. Microsatellite
instability in Muir-Torre syndrome. Cancer Research 54:1159-1163, 1994.
Hooper, M., Hardy, K., Handyside, A., Hunter, S., and Monk, M. HPRT-deficient (Lesch-Nyhan)
mouse embryos derived from germline colonization by cultured cells. Nature 326:292-295, 1987.
Huang, L.C., Clarkin, K.C., and Wahl, G.M. Sensitivity and selectivity of the DNA damage sensor
responsible for activating p53-dependent Gl arrest. Proceedings OfThe National Academy Of
Sciences Of The United States OfAmerica 93:4827-4832, 1996a.
Huang, J., Papadopoulos, N., McKinley, A.J., Farrington, S.M., Curtis. L.J., Wyllie, A.H., Zheng, S.,
Willson. J.K.V., Markowitz, S.D.. Morin, P., Kinzler, K.W., Vogelstein, B., and Dunlop, M.G. APC
mutations in colorectal tumors with mismatch repair deficiency. Proceedings OfThe National
Academy OfSciences OfThe United States OfAmerica 93:9049-9054, 1996b.
Ilett, K.F., David. B.M., Detchon, P., Castleden, W.M., and Kwa, R. Acetylation phenotype in
colorectal carcinoma. Cancer Research 47:1466-1469, 1987.
197
International multicentre pooled analysis of colon cancer trials investigators. Efficiency of adjuvant
fluorouracil and folinic acid in colon cancer. Lancet 345:939-944. 1995.
Ionov. Y„ Peinado. M.A., Malkhosyan. S.. Shibata. D.. and Perucho. M. Ubiquitous somatic
mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature
363:558-561. 1993.
Isobe. M.. Emanuel. B.S.. Givol. D., Oren. M.. and Croce. C.M. Localization of gene for human p53
tumor antigen to band 17p 13. Nature 320:84-85, 1986.
Itoh. F.. Hinoda. Y., Ohe. M.. Ohe. Y.. Ban. T.. Endo. T.. Imai. K.. and Yachi. A. Decreased
expression of DCC messenger RNA in human colorectal cancers. International Journal OfCancer
53:260-263, 1993.
Jayaraman, L. and Prives, C. Activation of p53 sequence-specific DNA binding by short single
strands of DNA requires the p53 C-terminus. Cell 81:1021-1029. 1995.
Jego, N., Thomas, G„ and Hamelin, R. Short direct repeats flanking deletions, and duplicating
insertions in p53 gene in human cancers. Oncogene 8:209-213, 1993.
Jen, J., Powell, S.M.. Papadopoulos, N., Smith, K.J., Hamilton. S.R., Vogelstein, B., andKinzler,
K. W. Molecular determinants of dysplasia in colorectal lesions. Cancer Research 54:5523-5526,
1994a.
Jen, J., Kim. H.G., Piantadosi, S„ Liu, Z.F., Levitt, R.C., Sistonen, P., Kinzler, K.W., Vogelstein. B.,
and Hamilton, S.R. Allelic loss of chromosome 18q and prognosis in colorectal cancer. New England
Journal OfMedicine 331:213-221, 1994b.
Jessup, J.M., Giavazzi. R., Campbell, D., Cleary, K., Morikawa, K., andFidler, I.J. Growth potential
of human colorectal carcinomas in nude mice - association with the preoperative serum
concentration of carcinoembryonic antigen in patients. Cancer Research 48:1689-1692, 1988.
Johnson, R.E., Kowali. G.K., Prakash, L., and Prakash. S. Requirement of the yeast MSH3 and
MSH6 genes for MSH2-dependent genomic stability. Journal OfBiological Chemistry 271:7285-
7288, 1996a.
Johnson. R.E., Kowali, G.K., Guzder, S.N., Amin, N.S., Holm, C., Habraken. Y., Sung, P., Prakash,
L.. and Prakash. S. Evidence for involvement of yeast proliferating cell nuclear antigen in DNA
mismatch repair. Journal OfBiological Chemistry 271:27987-27990, 1996b.
Johnston. P.G., Lenz, H.J.. Leichman, C.G., Danenberg, K.D., Allegra. C.J., Danenberg, P.V., and
Leichman, L. Thymidvlate synthase gene and protein expression correlate and are associated with
response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Research 55:1407-1412.
1995.
Joslyn. G., Carlson, M.. Thliveris. A., Albertsen. H.. Gelbert. L., Samowitz, W.. Groden. J., Stevens.
J., Spirio, L.. Robertson, M., Sargeant. L., Krapcho. K., Wolff, E.. Burt. R.. Hughes, J.P..
Warrington, J.. Mcpherson. J., Wasmuth, J., Lepaslier. D.. Abderrahim. H.. Cohen. D., Leppert. M..
and White, R. Identification of deletion mutations and 3 new genes at the familial polyposis locus.
Cell 66:601-613, 1991.
Joslyn, G., Richardson, D.S., White, R.. and Alber. T. Dimer formation by an N-terminal coiled coil
in the APC protein. Proceedings Of The National Academy OfSciences Of The United States Of
America 90:11109-11113, 1993.
Kafatos, F.C., Orr, W., and Delidakis. C. Developmentally regulated gene amplification. Trends In
Genetics 1:301-306, 1985
198
Kaghad. M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.C., Valent, A., Minty, A., Chalon, P.,
Lelias, J.M., Dumont. X., Ferrara, P., McKeon, F., and Caput. D. Monoallelically-expressed gene
related to p53 at lp36, a region frequently deleted in neuroblastoma and other human cancers. Cell
90:809-819, 1997.
Kakiuchi, H., Watanabe. M., Ushijima, T., Toyota, M., Imai, K., Weisburger. J.H., Sugimura, T.,
and Nagao, M. Specific 5'-GGGA-3'-5'-GGA-3' mutation of the APC gene in rat colon tumors
induced by 2-amino-l-methyl-6-phenylimidazo[4,5-b]pyridine. Proceedings OfThe National
Academy OfSciences OfThe United States OfAmerica 92:910-914, 1995.
Kaklamanis, L., Gatter, K.C.. Mortensen, N., Baigrie, R.J., Heryet, A., Lane, D P., and Harris, A.L.
p53 expression in colorectal adenomas. American Journal OfPathology 142:87-93, 1993.
Kallioniemi, A., Kallioniemi, O.P., Sudar, D., Rutovitz, D., Gray, J.W., Waldman, F., and Pinkel, D.
Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science
258:818-821, 1992.
Kallioniemi, O.P.. Kallioniemi, A., Piper, J., Isola, J., Waldman, F.M., Gray, J.W., and Pinkel. D.
Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes
in solid tumors. Genes Chromosomes & Cancer 10:231-243, 1994.
Kargman, S.L., Oneill, G.P., Vickers, P.J., Evans, J.F., Mancini, J.A., and Jothy, S. Expression of
prostaglandin G/H synthase-1 and synthase-2 protein in human colon cancer. Cancer Research
55:2556-2559, 1995.
Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R.W. Participation of p53
protein in the cellular response to DNA damage. Cancer Research 51:6304-6311, 1991.
Kastan, M.B., Zhan, Q.M., Eldeiry. W.S., Carrier, F., Jacks, T., Walsh. W.V., Plunkett, B.S.,
Vogelstein. B.. and Fornace, A.J. A mammalian cell cycle checkpoint pathway utilizing p53 and
GADD45 is defective in ataxia telangiectasia. Cell 71:587-597, 1992.
Kat, A., Thilly, W.G., Fang, W.H., Longley, M.J., Li, G.M., andModrich, P. An alkylation-tolerant,
mutator human cell line is deficient in strand-specific mismatch repair. Proceedings Of The National
Academy OfSciences Of The United States OfAmerica 90:6424-6428, 1993.
Katabuchi, H., Van Rees, B., Lambers, A.R., Ronnett, B.M., Blazes. M.S., Leach, F.S., Cho, K.R.,
and Hedrick, L. Mutations in DNA mismatch repair genes are not responsible for microsatellite
instability in most sporadic endometrial carcinomas. Cancer Research 55:5556-5560, 1995.
Keino-Masu, K., Masu. M., Hinck, L., Leonardo. E.D., Chan, S.S.Y., Culotti, J.G., and Tessier-
Lavigne, M. Deleted in colorectal cancer (DCC) encodes a netrin receptor. Cell 87:175-185, 1996.
Kikuchi-Yanoshita, R., Konishi, M., Ito, S., Seki, M., Tanaka, K., Maeda, Y., lino, H., Fukayama,
M., Koike, M., Mori, T., Sakuraba. H., Fukunari, H.. Iwama, T.. and Miyaki, M. Genetic changes of
both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in
Familial Adenomatous Polyposis and nonFamilial Adenomatous Polyposis patients. Cancer
Research 52:3965-3971, 1992.
Kim, H.G., Jen, J., Vogelstein, B., and Hamilton, S.R. Clinical and pathological characteristics of
sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. American
Journal OfPathology 145:148-156, 1994a.
Kim, N.W., Piatyszek, M.A., Prowse, K.R.. Harley, C.B., West, M.D., Ho, P.L.C., Coviello. G.M.,
Wright, W.E., Weinrich, S.L., and Shay, J.W. Specific association of human telomerase activity
with immortal cells and cancer. Science 266:2011-2015. 1994b.
199
Kinzler, K.W., Nilbert, M.C., Su, L.K., Vogelstein, B., Bryan, T.M., Levy, D.B., Smith, K.J.,
Preisinger, A.C., Hedge, P., McKechnie, D., Finniear, R., Markham. A., Groffen, J., Boguski, M.S.,
Altschul, S.F., Horii, A., Ando, H., Miyoshi, Y., Miki, Y., Nishisho, I., and Nakamura, Y.
Identification of FAP locus genes from chromosome 5q21. Science 253:661-665, 1991a.
Kinzler, K.W., Nilbert, M.C., Vogelstein, B., Bryan, T.M., Levy, D.B., Smith, K.J., Preisinger, A.C.,
Hamilton. S.R., Hedge, P., Markham, A., Carlson, M., Joslyn, G., Groden, J., White, R., Miki, Y.,
Miyoshi, Y., Nishisho, I., and Nakamura, Y. Identification of a gene located at chromosome 5q21
that is mutated in colorectal cancers. Science 251:1366-1370, 1991b.
Kinzler, K. W. and Vogelstein, B. Clinical implications of basic research - cancer therapy meets p53.
New EnglandJournal OfMedicine 331, 49-50, 1994.
Kinzler, K.W. and Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87:159-170, 1996.
Knudson, C.M. Mutation and cancer: statistical study of retinoblastoma. Proceedings OfThe
National Academy OfSciences OfThe United States OfAmerica 68(4):820-823, 1971.
Knudson. C.M.. Tung, K.S.K., Tourtellotte, W.G., Brown, G.A.J., and Korsmeyer. S.J. Bax-deficient
mice with lymphoid hyperplasia and male germ cell death. Science 270:96-99, 1995.
Kolodner, R.D., Hall. N.R.. Lipford, J.. Kane, M.F., Rao. M.R.S., Morrison, P., Wirth, L., Finan,
P.J., Burn. J.. Chapman, P.. Earabino, C., Merchant, E., and Bishop. D.T. Structure of the human
MSH2 locus and analysis of 2 Muir-Torre kindreds for MSH2 mutations. Genomics 24:516-526,
1994.
Kolodner, R. Biochemistry and genetics of eukaryotic mismatch repair. Genes & Development
10:1433-1442, 1996.
Kolodziej, P.A., Timpe, L.C., Mitchell, K.J., Fried, S.R., Goodman, C.S., Jan, L.Y., and Jan, Y.N.
Frazzled encodes a drosophila member of the DCC immunoglobulin subfamily and is required for
CNS and motor axon guidance. Cell 87:197-204, 1996.
Kolodziej, P. A. DCC's function takes shape in the nervous system. Current Opinion In Genetics &
Development 7: 87-92, 1997.
Konishi, M., Kikuchi-Yanoshita. R.. Tanaka, K., Muraoka. M.. Onda. A., Okumura, Y., Kishi, N.,
Iwama, T., Mori, T., Koike, M., Ushio, K., Cliiba. M., Nomizu, S., Konishi, F., Utsunomiya, J., and
Miyaki, M. Molecular nature of colon tumors in Hereditary Non-Polyposis Colon Cancer, familial
polyposis, and sporadic colon cancer. Gastroenterology 111:307-317, 1996.
Konstantinova, L.N., Fleischman, E.W., Knisch, V.I., Perevozchikov, A.G., andKopnin, B.P.
Karyotype peculiarities of human colorectal adenocarcinomas. Human Genetics 86:491-496, 1991.
Kora, R. and Ramkissoon, Y. Blooms syndrome - mapping to the point. Nature 378:557-558, 1995.
Kouri. M., Pyrhonen, S., Mecklin, J.P., Jarvinen, H.. Laasonen, A., Franssila. K., and Nordling. S.
The prognostic value of DNA ploidy in colorectal carcinoma - a prospective-study. British Journal
OfCancer 62:976-981, 1990.
Kowalski. L.D., Mutch, D.G., Herzog, T.J., Rader, J.S., and Goodfellow, P.J. Mutational analysis of
MLH1 and MSH2 in 25 prospectively acquired RER+ endometrial cancers. Genes Chromosomes &
Cancer 18:219-227, 1997.
200
Kraiss, S., Spicss. S., Reihsaus, E„ and Montenarh. M. Correlation of metabolic stability and altered
quaternary structure of oncoprotein p53 with cell transformation. Experimental Cell Research
192:157-164, 1991.
Kramer, P.R., Pearson, C.E., and Sinden, R.R. Stability of triplet repeats of myotonic dystrophy and
fragile X loci in human mutator mismatch repair cell lines. Faseb Journal 10:D 30, 1996.
Kuerbitz, S.J., Plunkett. B.S., Walsh, W.V., and Kastan, M.B. Wild-type p53 is a cell cycle
checkpoint determinant following irradiation. Proceedings OfThe National Academy OfSciences Of
The United States OfAmerica 89:7491-7495, 1992.
Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M.,
and Attali. P. Sulindac causes regression of rectal polyps in Familial Adenomatous Polyposis.
Gastroenterology 101: 635-639, 1991.
Laird. P.W., Jacksongrusby, L., Fazeli, A., Dickinson, S.L., Jung. W.E., Li, E., Weinberg, R.A., and
Jaenisch, R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81:197-205, 1995.
Lalle, P., Moyret-Lalle, C., Wang, Q., Vialle, J.M., Navarro, C., Bressac-dePaillerets, B., Magaud,
J.P., and Ozturk, M. Genomic stability and wild-type p53 function of lymphoblastoid cells with
germ-line p53 mutation. Oncogene 10:2447-2454, 1995.
Lane, N. The Precursor Tissue of Ordinary Large Bowel Cancer. Cancer Research 36:2669-2672,
1976.
Lane. D.P. and Benchimol, S. p53 - oncogene or anti-oncogene? Genes & Development 4:1-8, 1990.
Lane, D.P. Cancer - p53, guardian of the genome. Nature 358:15-16, 1992.
Lasserre. C., Sabatier, L., Beaumatin, J., Luccioni, C., Lefrangois. D., Muleris, M., and Dutrillaux,
B. Gene dosage and expression, and enzyme activity of thymidine kinase and thymidylate synthase in
xenografted colorectal adenocarcinomas. International Journal OfCancer 56:506-511, 1994.
Laurent-Puig, P., Olschwang, S., Delattre, O., Remvikos, Y., Asselain, B.. Melot, T., Validire, P.,
Muleris. M., Girodet, J., Salmon, R.J., and Thomas, G. Survival and acquired genetic alterations in
colorectal cancer. Gastroenterology 102:1136-1141, 1992.
Leach, F.S., Nicolaides, N.C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R.. Peltomaki, P.,
Sistonen, P., Aaltonen, L.A., Nystrom-Lahti, M., Guan, X.Y.. Zhang. J., Meltzer, P.S., Yu, J.W.,
Kao, F.T., Chen, D.J., Cerosaletti, K.M., Fournier, R.E.K., Todd, S., Lewis, T., Leach, R.J., Naylor,
S.L., Weissenbach, J., Mecklin, J.P.. Jarvinen. H., Petersen, G.M., Hamilton, S.R., Green, J., Jass. J.,
Watson, P., Lynch, H.T., Trent, J.M., de la Chapelle. A.. Kinzler. K.W., and Vogelstein, B.
Mutations of a MutS homolog in Hereditary Non-Polyposis Colorectal Cancer. Cell 75:1215-1225.
1993.
Leach. F.S., Polyak, K„ Burrell, M„ Johnson, K.A., Hill, D„ Dunlop, M.G.. Wyllie, A.H..
Peltomaki, P., de la Chapelle, A., Hamilton, S.R., Kinzler, K.W., and Vogelstein, B. Expression of
the human mismatch repair gene liMSH2 in normal and neoplastic tissues. Cancer Research 56:235-
240. 1996.
Lee, S., Elenbaas, B., Levine, A., and Griffith, J. p53 and its 14 kDa C-terminal domain recognize
primary DNA damage in the form of insertion/deletion mismatches. Cell 81:1013-1020, 1995.
Lefrangois, D., Olschwang, S., Delattre, O., Muleris, M., Dutrillaux. A.M., Thomas, G., and
Dutrillaux. B. Preservation of chromosome and DNA characteristics of human colorectal
adenocarcinomas after passage in nude mice. International Journal OfCancer 44:871-878, 1989.
201
Leister. I., Weith, A., Bruderlein, S., Cziepluch, C., Kangwanpong, D., Schlag, P.. and Schwab, M.
Human colorectal cancer - high-frequency of deletions at chromosome lp35. Cancer Research
50:7232-7235, 1990.
Lengauer, C., Kinzler. K. W., and Vogelstein. B. DNA methylation and genetic instability in
colorectal cancer cells. Proceedings OfThe National Academy OfSciences OfThe United States Of
America 94:2545-2550, 1997a.
Lengauer, C., Kinzler, K.W., and Vogelstein, B. Genetic instability in colorectal cancers. Nature
386:623-627, 1997b.
Leone, A., Mcbride, O.W., Weston, A., Wang, M.G., Anglard, P., Cropp, C.S., Goepel. J.R..
Lidereau, R., Callahan, R., Linehan, W.M., Rees, R.C., Harris, C.C., Liotta, L.A., and Steeg, P S.
Somatic allelic deletion of nm23 in human cancer. Cancer Research 51:2490-2493, 1991.
Levin, K.E. and Dozois, R.R. Epidemiology of large bowel cancer. World Journal OfSurgery
15:562-567, 1991.
Levine, A.J., Momand, J., and Finlay, C.A. The p53 tumor suppressor gene. Nature 351:453-456,
1991.
Lewis, J. and Bird. A. DNA methylation and chromatin structure. Febs Letters 285:155-159, 1991.
Li, F.P. and Fraumeni. J.F. Soft-tissue sarcoma, breast cancer and other neoplasms. A familial
syndrome? Ann.Intern.Med. 71:747-749, 1969.
Li, R., Waga, S., Hannon, G.J., Beach, D., and Stillman, B. Differential effects by the p21 cdk
inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537, 1994.
Li, Y.J.. Laurent-Puig. P., Salmon, R.J., Thomas, G., and Hamelin, R. Polymorphisms and probable
lack of mutation in the Wafl-Cipl gene in colorectal cancer. Oncogene 10:599-601, 1995.
Lin, D., Shields, M.T., Ullrich, S.J., Appella, E., and Mercer, W.E. Growth arrest induced by wild-
type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proceedings Of
The National Academy OfSciences Of The United States OfAmerica 89:9210-9214, 1992.
Linke, S.P., Clarkin, K.C., Dileonardo, A., Tsou, A., and Wahl, G.M. A reversible, p53-dependent
G0/G1 cell-cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA
damage. Genes & Development 10:934-947, 1996.
Little, J., Logan, R.F.A., Hawtin, P.G., Hardcastle, J.D., and Turner, I.D. Colorectal adenomas and
diet - a case-control study of subjects participating in the Nottingham fecal occult blood screening
program. British Journal OfCancer 67:177-184, 1993.
Liu, B., Parsons, R.E., Hamilton, S.R.. Petersen, G.M., Lynch, H.T., Watson. P., Markowitz, S.,
Willson, J.K.V., Green, J., de la Chapelle, A., Kinzler, K.W., and Vogelstein, B. liMSH2 mutations
in Hereditary Non-Polyposis Colorectal Cancer kindreds. Cancer Research 54:4590-4594, 1994.
Liu, B., Farrington, S.M., Petersen, G.M., Hamilton, S R., Parsons, R., Papadopoulos, N., Fujiwara.
T., Jen, J., Kinzler, K. W., Wyllie, A.H., Vogelstein. B., and Dunlop, M.G. Genetic instability occurs
in the majority of young patients with colorectal cancer. Nature Medicine 1:348-352, 1995a.
Liu, B., Nicolaides, N.C., Markowitz, S., Willson, J.K.V.. Parsons, R.E., Jen, J., Papadopolous, N.,
Peltomaki. P., de la Chapelle. A., Hamilton, S.R., Kinzler, K.W., and Vogelstein. B. Mismatch
202
repair gene defects in sporadic colorectal cancers with microsatellite instability. Nature Genetics
9:48-55, 1995b.
Liu. B., Parsons, R.. Papadopoulos, N., Nicolaides, N.C., Lynch. H.T., Watson, P., Jass, J.R.,
Dunlop, M., Wyllie, A., Peltomaki, P., de la Chapelle, A., Hamilton, S R., Vogelstein, B., and
Kinzler. K. W. Analysis of mismatch repair genes in Hereditary Non-Polyposis Colorectal Cancer
patients. Nature Medicine 2:169-174, 1996a.
Liu. L.L., Markowitz, S., and Gerson, S.L. Mismatch repair mutations override alkyltransferase in
conferring resistance to temozolomide but not to 1,3-bis (2-chloroethyl) nitrosourea. Cancer
Research 56:5375-5379, 1996b.
Livingstone, L.R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T.D. Altered cell-cycle
arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935, 1992.
Loftier, M. Restimulation of cell-cycle progression by hypoxic tumor cells with deoxynucleosides
requires ppm oxygen tension. Experimental Cell Research 169:255-261. 1987.
Longy, M., Saura, R., Schouler, L., Mauhin, C., Goussot, J.F., Grison, O., and Couzigou, P.
Chromosomal analysis of colonic adenomatous polyps. Cancer Genetics And Cytogenetics 49:249-
257, 1990.
Longy, M., Saura. R., Dumas. F., Leseve, J.F., Taine. L.. Goussot. J.F., and Couzigou, P.
Chromosome analysis of adenomatous polyps of the colon - possible existence of 2 differently
evolving cytogenetic groups. Cancer Genetics And Cytogenetics 67:7-13, 1993.
Lothe, R.A., Peltomaki, P., Meling, G.I., Aaltonen, L.A., Nystrom-Lahti, M., Pylkkanen, L..
Heimdal, K., Andersen, T.I., Moller, P., Rognum, T.O., Fossa. S.D., Haldorsen, T., Langmark, F.,
Brogger. A., de la Chapelle, A., andBorresen. A.L. Genomic instability in colorectal cancer -
relationship to clinicopathological variables and family history. Cancer Research 53:5849-5852,
1993.
Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A., and Jacks, T. p53 is required for radiation-
induced apoptosis in mouse thymocytes. Nature 362:847-849, 1993a.
Lowe, S.W., Ruley, H.E., Jacks, T., andHousman, D.E. p53-dependent apoptosis modulates the
cytotoxicity of anticancer agents. Cell 74:957-967, 1993b.
Lowe, S.W., Jacks, T., Housman, D.E., and Ruley, H.E. Abrogation of oncogene-associated apoptosis
allows transformation of p53-deficient cells. Proceedings OfThe National Academy OfSciences Of
The United States OfAmerica 91:2026-2030. 1994.
MacPhee, M., Chepenik, K.P., Liddell, R.A., Nelson. K.K., Siracusa, L.D.. andBuchberg, A.M. The
secretory phospholipase-A2 gene is a candidate for the Mom-1 locus, a major modifier of APC (min)-
induced intestinal neoplasia. Cell 81:957-966, 1995.
Malcomson, R.D.G., Clarke. A.R., Peter, A., Coutts, S.B., Howie, S.E.M.. and Harrison. D.J.
Apoptosis induced by gamma irradiation, but not CD4 ligation, of peripheral T lymphocytes in vivo
is p53-dependent. Journal OfPathology 181: 166-171, 1997.
Malkhosyan, S., Rampino, N., Yamamoto, H., and Perucho. M. Frameshift mutator mutations.
Nature 382:499-500, 1996a.
Malkhosyan, S., McCarty, A., Sawai, H.. and Perucho, M. Differences in the spectrum of
spontaneous mutations in the HPRT gene between tumor-cells of the microsatellite mutator
phenotype. Mutation Research-DNAging Genetic InstabilityAndAging 316:249-259, 1996b.
203
Maltzman, W. and Czyzyk. L. UV irradiation stimulates levels of p53 cellular tumor antigen in non-
transformed mouse cells. Molecular And Cellular Biology 4:1689-1694, 1984.
Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L.Z., Lutterbaugh, J., Fan, R.S., Zborowska,
E., Kinzler, K.W., Vogelstein, B., Brattain, M., and Willson, J.K.V. Inactivation of the type-II TGF-
beta receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338, 1995.
Marra, G., Chang, C.L., Laghi, L.A., Chauhan, D.P., Young, D., andBoland, C.R. Expression of
human MutS homolog-2 (hMSH2) protein in resting and proliferating cells. Oncogene 13:2189-
2196, 1996.
Marsischky, G.T., Filosi, N., Kane, M.F., and Kolodner, R. Redundancy of saccharomyces
cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes & Development 10:407-
420, 1996.
Mary, J.L.. Bishop, T., Kolodner, R., Lipford, J.R., Kane, M., Weber, W., Torhorst, J., Muller, H.,
Spycher. M., and Scott, R.J. Mutational analysis of the hMSH2 gene reveals a 3-base-pair deletion in
a family predisposed to colorectal cancer development. Human Molecular Genetics 3:2067-2069,
1994.
McBride. O.W., Merry, D., and Givol, D. The gene for human p53 cellular tumor antigen is located
on chromosome 17 short arm (17pl3). Proceedings Of The National Academy OfSciences Of The
United States OfAmerica 83:130-134, 1986.
McClintock, B. Chromosome organization and genie expression. Cold Spring Harbor Symposia On
Quantitative Biology 16:13-47, 1951.
McQueen, H.A., Wyllie, A.H., Piris, J., Foster, E., and Bird, C.C. Stability of critical genetic lesions
in human colorectal carcinoma xenografts. British Journal OfCancer 63:94-96, 1991.
Meling, G.I., Lothe, R.A., Borresen. A.L., Hauge, S., Graue, C., Clausen, O.P.F., andRognum. T O.
Genetic alterations within the retinoblastoma locus in colorectal carcinomas - relation to DNA ploidy
pattern studied by flow cytometric analysis. British Journal OfCancer 64:475-480, 1991.
Meling, G.I., Lothe, R.A., Borresen, A.L., Graue, C., Hauge, S., Clausen, O.P.F., and Rognum. T O.
The tp53 tumor suppressor gene in colorectal carcinomas .2. Relation to DNA ploidy pattern and
clinicopathological variables. British Journal OfCancer 67:93-98, 1993.
Mello, J.A., Acharya, S., Fishel, R., and Essigmann, J.M. The mismatch repair protein hMSH2 binds
selectively to DNA adducts of the anticancer drug cisplatin. Chemistry & Biology 3:579-589, 1996.
Mellon. I., Rajpal, D.K., Koi, M., Boland. C.R., and Champe, G.N. Transcription-coupled repair
deficiency and mutations in human mismatch repair genes. Science 272:557-560, 1996.
Meltzer. S.J., Yin, J., Manin, B., Rhyu, M.G., Cottrell, J., Hudson, E., Redd. J.L., Krasna, M.J.,
Abraham, J.M., and Reid, B.J. Microsatellite instability occurs frequently and in both diploid and
aneuploid cell populations of Barretts-associated esophageal adenocarcinomas. Cancer Research
54:3379-3382, 1994.
Mercer. W.E., Shields, M.T., Lin, D., Appella. E„ and Ullrich, S.J. Growth suppression induced by
wild-type p53-protein is accompanied by selective down-regulation of proliferating cell nuclear
antigen expression. Proceedings Of The National Academy OfSciences OfThe United States Of
America 88:1958-1962. 1991.
204
Merlo. A., Mabry, M., Gabrielson, E., Vollmcr. R.. Baylin. S.B.. and Sidransky, D. Frequent
microsatellite instability in primary small cell lung cancer. Cancer Research 54:2098-2101, 1994.
Midgley, C.A., Fisher, C.J., Bartek, J., Vojtesek. B., Lane, D., and Barnes, D.M. Analysis of p53
expression in human tumors - an antibody raised against human p53 expressed in Escherichia coli.
Journal OfCell Science 101:183, 1992.
Miki, Y., Nishisho, I., Miyoshi, Y., Horii, A., Ando. H., Nakajima, T., Utsunomiya, J., and
Nakamura, Y. Frequent loss of heterozygosity at the MCC locus on chromosome 5q21-22 in sporadic
colorectal carcinomas. Japanese Journal OfCancer Research 82:1003-1007, 1991.
Milner, J. and Medcalf, E.A. Cotranslation of activated mutant p53 with wild-type drives the wild-
type p53 protein into the mutant conformation. Cell 65:765-774, 1991.
Mironov, N.M., Aguelon, M.A.M., Potapova, G.I., Omori, Y., Gorbunov, O.V., Klimenkov, A.A.,
and Yamasaki, H. Alterations of (CA)n DNA repeats and tumor-suppressor genes in human gastric
cancer. Cancer Research 54:41-44, 1994.
Miyaki, M., Konishi, M., Tanaka. K., Kikuchi-Yanoshita, R., Muraoka, M., Yasuno, M., Igari, T.,
Koike, M., Chiba, M., and Mori, T. Germline mutation of MSH6 as the cause of Hereditary Non-
Polyposis Colorectal Cancer. Nature Genetics 17:271-272, 1997.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H.G., Lin, H.K., Liebermann, D.A., Hoffman,
B., and Reed, J.C. Tumor suppressor p53 is a regulator of Bcl-2 and Bax gene-expression in-vitro
and in-vivo. Oncogene 9:1799-1805, 1994.
Miyoshi, Y., Ando, H., Nagase, H., Nishisho, I., Horii. A., Miki, Y., Mori, T., Utsunomiya, J., Baba.
S., Petersen. G., Hamilton, S.R., Kinzler, K.W., Vogelstein, B., and Nakamura, Y. Germ-line
mutations of the APC gene in 53 Familial Adenomatous Polyposis patients. Proceedings OfThe
National Academy OfSciences Of The United States OfAmerica 89:4452-4456, 1992a.
Miyoshi, Y., Nagase, H.. Ando, H., Horii, A., Ichii, S., Nakatsuru, S., Aoki, T.. Miki, T., Mori, T.,
and Nakamaki, T. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region
in the APC gene. Human Molecular Genetics 1:229-233, 1992b.
Modrich, P. Mechanisms and biological effects of mismatch repair. Annual Review OfGenetics
25:229-253, 1991.
Morgan, W.F., Day, J.P., Kaplan, M.I., McGhee, E.M., and Limoli, C.L. Genomic instability
induced by ionizing radiation. Radiation Research 146:247-258, 1996.
Morin, P.J., Vogelstein, B., and Kinzler, K.W. Apoptosis and APC in colorectal tumorigenesis.
Proceedings OfThe National Academy OfSciences Of The United States OfAmerica 93:7950-7954,
1996.
Morris, R.G., Curtis, L.J., Romanowski, P.. Hardcastle, J.D., Jenkins. D.A., Robinson, M., Wyllie,
A.H., and Bird, C.C. Ki-ras mutations in adenomas: a characteristic of cancer-bearing colorectal
mucosa. Journal OfPathology 180:357-363, 1996.
Moser. A.R., Pitot, H.C., and Dove. W.F. A dominant mutation that predisposes to multiple
intestinal neoplasia in the mouse. Science 247:322-324, 1990.
Moser, A.R., Dove, W.F., Roth, K.A., and Gordon. J.I. The min (multiple intestinal neoplasia)
mutation - its effect on gut epithelial cell differentiation and interaction with a modifier system.
Journal OfCell Biology 116:1517-1526, 1992.
205
Moslein, G., Tester, D.J., Lindor, N.M., Honchel, R., Cunningham, J.M., French, A.J., Hailing.
K.C., Schwab, M., Goretzki, P.. and Thibodeau, S.N. Microsatellite instability and mutation analysis
of hMSH2 and hMLHl in patients with sporadic, familial and hereditary colorectal cancer. Human
Molecular Genetics 5:1245-1252, 1996.
Muleris, M., Salmon, R.J., and Dutrillaux. B. Existence of 2 distinct processes of chromosomal
evolution in near- diploid colorectal tumors. Cancer Genetics And Cytogenetics 32:43-50, 1988.
Muleris, M., Salmon, R.J., and Dutrillaux, B. Cytogenetics of colorectal adenocarcinomas. Cancer
Genetics And Cytogenetics 46:143-156, 1990.
Muleris, M., Zafrani, B., Validire, P., Girodet, J., Salmon, R.J., and Dutrillaux. B. Cytogenetic study
of 30 colorectal adenomas. Cancer Genetics And Cytogenetics 74:104-108, 1994a.
Muleris, M., Almeida, A., Gerbault-Seurcau, M., Malfoy, B.. and Dutrillaux, B. Detection of DNA
amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified
comparative genomic hybridization technique. Genes Chromosomes & Cancer 10:160-170, 1994b.
Munemitsu, S., Souza, B., Muller, O., Albert. I., Rubinfeld. B.. andPolakis, P. The APC gene
product associates with microtubules in vivo and promotes their assembly in vitro. Cancer Research
54:3676-3681, 1994.
Muto. T., Bussey, H.J.R., and Morson, B.C. The evolution of cancer of the colon and rectum. Cancer
36:2251-2270, 1975.
Nagase, H., Miyoshi, Y., Horii, A., Aoki, T., Ogawa, M., Utsunomiya, J., Baba, S., Sasazuki, T., and
Nakamura, Y. Correlation between the location of germ-line mutations in the APC gene and the
number of colorectal polyps in Familial Adenomatous Polyposis patients. Cancer Research 52:4055-
4057, 1992.
Nagase, H. and Nakamura, Y. Mutations of the APC (Adenomatous Polyposis Coli) gene. Human
Mutation 2:425-434, 1993.
Narayanan, R., Lawlor, K G., Schaapveld, R.Q.J., Cho, K.R., Vogelstein, B., Tran, P.B.V., Osborne,
M.P., and Telang, N.T. Antisense RNA to the putative tumor-suppressor gene DCC transforms rat-1
fibroblasts. Oncogene 7:553-561, 1992.
Nathke, I.S., Adams, C.L., Polakis, P., Sellin, J.H.. and Nelson, W.J. The Adenomatous Polyposis
Coli tumor suppressor protein localizes to plasma membrane sites involved in active cell migration.
Journal OfCell Biology 134:165-179, 1996.
Nelson, W.G. and Kastan, M.B. DNA strand breaks - the DNA-template alterations that trigger p53-
dependent DNA damage response pathways. Molecular And Cellular Biology 14:1815-1823, 1994.
Newbold, R.F. and Overell, R. W. Fibroblast immortality is a prerequisite for transformation by c-
Ha-ras oncogene. Nature 304:648-651. 1983.
Newland, R.C., Chapuis, P.H., Pheils, M.T., and MacPherson, J.G. The relationship of survival to
staging and grading of colorectal carcinoma - a prospective-study of 503 cases. Cancer 47:1424-
1429, 1981.
Nicolaides, N.C., Papadopoulos, N., Liu, B., Wei, Y.F., Carter, K.C., Ruben. S.M., Rosen, C.A.,
Haseltine, W.A., Fleischmann, R.D., Fraser, C.M., Adams, M.D., Venter, J.C.. Dunlop. M.G.,
Hamilton, S.R.. Petersen, G.M.. de la Chapelle, A., Vogelstein, B., andKinzler, K.W. Mutations of 2
PMS homologs in Hereditary Non-Polyposis Colon Cancer. Nature 371:75-80, 1994.
206
Nigro, J.M., Baker. S.J.. Preisinger, AC., Jessup. J.M., Hostetter, R., Cleary, K., Bigner. S.H.,
Davidson, N., Baylin. S., Devilee, P., Glover, T., Collins, F.S., Weston. A.. Modali. R., Harris. C.C.,
and Vogelstein, B. Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-
708, 1989.
Nishino. H., Knoll, A., Buettner, V.L., Frisk, C.S.. Maruta, Y., Haavik, J., and Sommer, S.S. p53
wild-type and p53 nullizygous big blue transgenic mice have similar frequencies and patterns of
observed mutation in liver, spleen and brain. Oncogene 11:263-270, 1995.
Nishisho, I., Nakamura, Y., Miyoshi. Y., Miki, Y., Ando, H., Horii, A., Koyama, K., Utsunomiya. J.,
Baba, S., Hedge, P., Markham, A., Krush, A.J., Petersen, G., Hamilton, S.R., Nilbert. M.C., Levy,
D.B., Bryan, T.M., Preisinger, A.C., Smith, K.J., Su, L.K., Kinzler, K.W., and Vogelstein, B.
Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253:665-669,
1991.
Nystrom-Lahti, M., Parsons, R., Sistonen, P., Pylkkanen, L., Aaltonen, L.A., Leach, F.S., Hamilton,
S.R., Watson, P.. Bronson, E., Cavalieri, J., Lynch, J., Lanspa, S., Smyrk, T., Lynch, P., Drouhard,
T., Kinzler, K.W., Vogelstein, B., Lynch, H.T., de la Chapelle, A., and Peltomaki, P. Mismatch
repair genes on chromosomes 2p and 3p account for a major share of Hereditary Non-Polyposis
Colorectal Cancer families evaluable by linkage. American Journal OfHuman Genetics 55:659-665,
1994.
O'Connell, J., O'Sullivan. G.C., Collins, J.K., and Shanahan. F. The Fas counterattack - Fas-
mediated T-cell killing by colon cancer cells expressing Fas ligand. Journal OfExperimental
Medicine 184:1075-1082, 1996.
Qfner, D.. Riehemann. K., Maier, H., Riedmann, B., Nehoda, H., Totsch. M., Bocker. W.. Jasani, B.,
and Schmid. K.W. Immunohistochemically detectable Bcl-2 expression in colorectal carcinoma -
correlation with tumor stage and patient survival. British Journal OfCancer 72:981-985, 1995.
Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L., and Vogelstein, B. Amplification of a gene
encoding a p53-associated protein in human sarcomas. Nature 358:80-83, 1992.
Olschwang, S., Tiret, A., Laurent-Puig, P., Muleris, M., Pare, R., and Thomas, G. Restriction of
ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis-coli
patients. Cell 75:959-968, 1993.
Olsen, J.. Kronborg, O., Lynggaard, J., and Ewertz, M. Dietary risk-factors for cancer and adenomas
of the large intestine - a case-control study within a screening trial in Denmark. European Journal
OfCancer 30A:53-60. 1994.
Ookawa, K., Sakamoto, M., Hirohashi, S., Yoshida. Y., Sugimura, T., Terada. M., and Yokota, J.
Concordant p53 and DCC alterations and allelic losses on chromosomes 13q and 14q associated with
liver metastases of colorectal carcinoma. International Journal OfCancer 53:382-387, 1993.
Oren. M. The p53 cellular tumor antigen - gene structure, expression and protein properties.
Biochimica Et Biophysica Acta 823:67-78, 1985.
Oshima. M., Dinchuk. J.E., Kargman, S.L., Oshima, H., Hancock, B., Kwong. E., Trzaskos, J.M.,
Evans, J.F., and Taketo, M.M. Suppression of intestinal polyposis in APC (delta-716) knockout mice
by inhibition of cyclooxygenase 2 (Cox-2). Cell 87:803-809, 1996.
Ottini. L., Palli, D., Falchetti, M., Damico, C., Amorosi. A., Saieva, C., Calzolari, A., Cimoli, F.,
Tatarelli, C., DeMarchis, L.. Masala, G., Mariani-Costantini, R.. and Cama. A. Microsatellite
instability in gastric cancer is associated with tumor location and family history in a high risk
population from Tuscany. Cancer Research 57:4523-4529, 1997.
207
Otto, E., McCord, S., and Tlsty, T.D. Increased incidence of CAD gene amplification in tumorigenic
rat lines as an indicator of genomic instability of neoplastic cells. Journal OfBiological Chemistry
264:3390-3396, 1989.
Owen, D. A. Flat adenoma, flat carcinoma, and de novo carcinoma of the colon. Cancer 77, 3-6,
1996.
Owen-Schaub, L.B., Zhang, W., Cusack, J.C., Angelo, L.S., Santee, S.M., Fujiwara. T., Roth. J.A.,
Deisseroth, A.B., Zhang, W.W., Kruzel, E., and Radinsky, R. Wild-type human p53 and a
temperature-sensitive mutant induce Fas/APO-1 expression. Molecular And Cellular Biology
15:3032-3040, 1995.
Palombo, F., Gallinari. P., Iaccarino, I., Lettieri, T., Hughes, M., Darrigo, A., Truong, O., Hsuan,
J.J., and Jiricny, J. GTBP, a 160 kilodalton protein essential for mismatch binding activity in human
cells. Science 268:1912-1914, 1995.
Papadopoulos, N., Nicolaides, N.C., Wei, Y.F., Ruben, S.M., Carter, K.C., Rosen, C.A., Haseltine,
W.A., Fleischmann, R.D., Fraser, C.M., Adams, M.D.. Venter, J.C., Hamilton, S.R., Petersen, G.M.,
Watson. P., Lynch, H.T., Peltomaki. P., Mecklin. J.P., de la Chapelle, A., Kinzler, K.W., and
Vogelstein. B. Mutation of a MutL homolog in hereditary colon cancer. Science 263:1625-1629,
1994.
Papadopoulos, N., Nicolaides, N.C., Liu, B., Parsons, R., Lengauer, C., Palombo, F., Darrigo, A.,
Markowitz, S., Willson, J.K.V., Kinzler, K.W., Jiricny, J., and Vogelstein, B. Mutations of GTBP in
genetically unstable cells. Science 268:1915-1917, 1995.
Parsons, R., Li, G.M., Longley, M.J., Fang. W.H.. Papadopoulos, N., Jen, J., de la Chapelle, A.,
Kinzler, K. W., Vogelstein, B., and Modrich, P. Hypermutability and mismatch repair deficiency in
RER+tumor cells. Cell 75:1227-1236, 1993.
Parsons, R., Li, G.M., Longley, M., Modrich, P., Liu, B., Berk, T., Hamilton, S.R., Kinzler, K.W.,
and Vogelstein, B. Mismatch repair deficiency in phenotypically normal human cells. Science
268:738-740, 1995.
Patel, U., Grundfest-Broniatowski, S., Gupta, M., and Banerjee, S. Microsatellite instabilities at 5
chromosomes in primary breast tumors. Oncogene 9:3695-3700, 1994.
Pearson, C.E., Ewel, A., Acharya, S., Fishel, R.A., and Sinden, R.R. Human MSH2 binds to
trinucleotide repeat DNA structures associated with neurodegenerative diseases. Human Molecular
Genetics 6:1117-1123, 1997.
Peltomaki, P., Aaltonen, L.A., Sistonen, P., Pylkkanen, L., Mecklin, J.P., Jarvinen, H., Green, J.S.,
Jass, J.R., Weber, J.L., Leach, F.S., Petersen, G.M., Hamilton, S.R., de la Chapelle, A., and
Vogelstein, B. Genetic mapping of a locus predisposing to human colorectal cancer. Science
260:810-812, 1993.
Percesepe, A., Deleon, M.P., Anti, M., Marra, G., Armelao, F., Roncucci, L., Pahor, M., Coco, C.,
Canetta, C., and Gasbarrini, G. Underestimation of hereditary non polyposis colorectal cancer
(HNPCC) diagnosis in families with small nuclear size. Gastroenterology 106:A 428, 1994.
Pietenpol, J.A.. Papadopoulos, N., Markowitz, S., Willson, J.K.V., Kinzler, K.W.. and Vogelstein. B.
Paradoxical inhibition of solid tumor-cell growth by Bcl2. Cancer Research 54:3714-3717, 1994.
Polyak, K., Hamilton, SR.. Vogelstein, B., and Kinzler, K. W. Early alteration of cell cycle-regulated
gene expression in colorectal neoplasia. American Journal OfPathology 149:381-387, 1996a.
208
Polyak, K., Waldman. T.. He, T.C., Kinzler, K.W., and Vogelstein, B. Genetic determinants of p53-
induced apoptosis and growth arrest. Genes & Development 10:1945-1952, 1996b.
Powell, S.M., Zilz, N., Beazer-Barclay, Y., Bryan, T.M., Hamilton, S.R., Thibodeau, S.N.,
Vogelstein, B., and Kinzler, K.W. APC mutations occur early during colorectal tumorigenesis.
Nature 359:235-237, 1992.
Praml, C., Finke, L.H., Herfarth, C., Schlag, P., Schwab, M., and Amler, L. Deletion mapping
defines different regions in lp34.2-pter that may harbor genetic information related to human
colorectal cancer. Oncogene 11:1357-1362, 1995a.
Praml, C., Savelyeva, L., Lepaslier, D., Siracusa, L.D., Buchberg, A.M., Schwab, M., and Amler,
L.C. Human homolog of a candidate for the Moml locus, the secretory type- II phospholipase-A2
(Pla2s). maps to lp35-36.1. Cancer Research 55:5504-5506. 1995b.
Prolla, T.A., Christie. D.M.. and Liskay, R.M. Dual requirement in yeast DNA mismatch repair for
MLH1 and PMS1, 2 homologs of the bacterial MutL gene. Molecular And Cellular Biology 14:407-
415, 1994.
Purdie, C.A., Harrison, D.J., Peter, A., Dobbie, L., White, S., Howie, S.E.M., Salter, D.M., Bird.
C.C., Wyllie, A.H., Hooper, M.L.. and Clarke, A.R. Tumor incidence, spectrum and ploidv in mice
with a large deletion in the p53 gene. Oncogene 9:603-609, 1994.
Quirke, P., Fozard, J.B.J., Dixon, M.F., Dyson, J.E.D., Giles, G.R., and Bird, C.C. DNA aneuploidv
in colorectal adenomas. British Journal OfCancer 53, 477-481, 1986.
Radford, G., Smith, I., Buttenshaw, R., Biden, K., Simms, L., Chenevix-Trench, G., You, J., and
Leggett, B. Frequency of p53 mutations in 64 RER+ and RER- sporadic colorectal cancers: further
evidence for separate pathways in tumorigenesis. Gastroenterology 112:A643, 1997.
Rampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., Reed, J.C., andPerucho, M. Somatic
frameshift mutations in the Bax gene in colon cancers of the microsatellite mutator phenotype.
Science 275:967-969, 1997.
Rayssiguier, C., Thaler, D.S., and Radman, M. The barrier to recombination between Escherichia-
coli and salmonella- typhimurium is disrupted in mismatch-repair mutants. Nature 342:396-401,
1989.
Reddy, B.S., Rao, C.V., Rivenson, A., andKelloff, G. Inhibitory effect of aspirin on azoxymethane-
induced colon carcinogenesis in F344 rats. Carcinogenesis 14:1493-1497, 1993.
Reed. J.C. Bcl-2 and the regulation of programmed cell death. Journal OfCell Biology 124:1-6,
1994.
Reenan, R.A.G. and Kolodner, R.D. Characterization of insertion mutations in the Saccharornyces
cerevisiae MSH1 and MSH2 genes - evidence for separate mitochondrial and nuclear functions.
Genetics 132:975-985, 1992a.
Reenan. R.A.G. and Kolodner, R.D. Isolation and characterization of 2 Saccharomyces cerevisiae
genes encoding homologs of the bacterial HexA and MutS mismatch repair proteins. Genetics
132:963-973, 1992b.
Reichmann. A., Martin, P.. and Levin, B. Chromosomes in human large bowel cancer - evidence for
non-random changes. Gastroenterology 80:1259, 1981.
209
Reichmann, A., Levin, B., and Martin, P. Human large-bowel cancer - correlation of clinical and
histopathological features with banded chromosomes. International Journal OfCancer 29:625-629,
1982.
Reichmann, A., Martin, P., and Levin, B. Chromosomes in human large bowel tumors - a study of
chromosome 1. Cancer Genetics And Cytogenetics 12:295-301. 1984.
Reichmann, A., Martin, P., and Levin, B. Chromosomal banding patterns in human large bowel
adenomas. Human Genetics 70:28-31, 1985.
Reitmair, A.H., Schmits, R., Ewel, A., Bapat, B., Redston, M., Mitri, A., Waterhouse, P., Mittrucker.
H.W., Wakeham. A., Liu, B., Thomason, A., Griesser, H.. Gallinger, S., Ballhausen, W.G., Fishel,
R., and Mak, T. W. Msh2-deficient mice are viable and susceptible to lymphoid tumors. Nature
Genetics 11:64-70, 1995.
Reitmair, A.H., Redston, M., Cai, J.C., Chuang, T.C.Y., Bjerknes, M., Cheng, H., Hay, K.,
Gallinger, S., Bapat, B., and Mak, T.W. Spontaneous intestinal carcinomas and skin neoplasms in
Msli2-deficient mice. Cancer Research 56:3842-3849, 1996a.
Reitmair, A.H., Cai, J.C., Bjerknes, M., Redston, M., Cheng, H., Pind, M.T., Hay, K., Mitri, A.,
Bapat. B.V., Mak. T.W.. and Gallinger. S. Msh2 deficiency contributes to accelerated Ape-mediated
intestinal tumorigenesis. Cancer Research 56, 2922-2926, 1996b.
Remvikos, Y., Vogt, N., Muleris, M., Salmon, R.J., Malfoy, B.. and Dutrillaux, B. DNA repeat
instability is associated with colorectal cancers presenting minimal chromosome rearrangements.
Genes Chromosomes & Cancer 12:272-276, 1995.
Remvikos, Y., Muleris, M., Salmon, R.J., and Dutrillaux, B. Colorectal carcinogenesis: from
chromosomal evolution pathways to molecular pathogenesis. Cancer Genetics And Cytogenetics
93:63-73, 1997.
Rhvu, M.G., Park, W.S., and Meltzer, S.J. Microsatellite instability occurs frequently in human
gastric carcinoma. Oncogene 9:29-32, 1994.
Rice. G.C., Hoy, C., and Schimke, R.T. Transient hypoxia enhances the frequency of dihydrofolate
reductase gene amplification in Chinese hamster ovary cells. Proceedings OfThe National Academy
OfSciences OfThe United States OfAmerica 83:5978-5982, 1986.
Ried, T., Knutzen, R., Steinbeck, R., Blegen, H., Schrock, E., Heselmeyer, K., Dumanoir, S., and
Auer, G. Comparative genomic hybridization reveals a specific pattern of chromosomal gains and
losses during the genesis of colorectal tumors. Genes Chromosomes & Cancer 15:234-245, 1996.
Riggins, G.J., Markowitz, S., Wilson, J.K., Vogelstein. B., and Kinzler, K.W. Absence of secretory
phospholipase A2 gene alterations in human colorectal cancer. Cancer Research 55:5184-5186.
1995.
Riggins, G.J.. Thiagalingam, S., Rozenblum, E., Weinstein, C.L., Kern, S.E., Hamilton, S.R.,
Willson, J.K.V., Markowitz, S.D., Kinzler, K.W., and Vogelstein, B. Mad-related genes in the
human. Nature Genetics 13:347-349, 1996.
Risinger. J.I.. Berchuck, A., Kohler, M.F., Watson, P., Lynch, H.T., and Boyd, J. Genetic instability
of microsatellites in endometrial carcinoma. Cancer Research 53:5100-5103, 1993.
Risinger, J.I., Umar, A., Boyd. J., Berchuck, A., Kunkel, T.A., and Barrett, J.C. Mutation ofMSH3
in endometrial cancer and evidence for its functional role in heteroduplex repair. Nature Genetics
14:102-105, 1996.
210
Rodrigues. N R.. Rowan. A.. Smith. M.E.F.. Kerr, I.B.. Bodmer. W.F.. Gannon. J.V.. and Lane. D.P.
p53 mutations in colorectal cancer. Proceedings OfThe National Academy OfSciences Of The
United States OfAmerica 87:7555-7559. 1990.
Rognum. T O.. Lund. E.. Meling, G.I.. and Langmark. F. Near diploid large bowel carcinomas have
better 5-year survival than aneuploid ones. Cancer 68:1077-1081. 1991.
Rosai. J. Ackerman's Surgical Pathology. St Louis: Mosbv. 1996 (8th Ed). Chapter 11. p611.
Ross-Macdonald P. and Roeder. G.S. Mutation of a meiosis-specific MutS homolog decreases
crossing-over but not mismatch correction. Cell 79:1069-1080. 1994.
Rubinfeld B.. Souza. B., Albert. I.. Muller. O.. Chamberlain. S.H.. Masiarz. F.R., Munemitsu. S.,
and Polakis. P. Association of the APC gene product with beta catenin. Science 262:1731-1734.
1993.
Ruley, H.E. Adenovirus early region-lA enables viral and cellular transforming genes to transform
primary cells in culture. Nature 304:602-606, 1983.
Russo, C.A.. Weber, T.K., Volpe. C.M., Stoler. D.L., Petrelli. N.J., Rodriguez-Bigas. M., Burhans.
W.C.. and Anderson, G.R. An anoxia inducible endonuclease and enhanced DNA breakage as
contributors to genomic instability in cancer. Cancer Research 55:1122-1128, 1995.
Saiki, R.K.. Gelfand, D.H., Stoffel, S., Scharf, S.J., Higuchi, R., Horn, G.T., Mullis, K.B., and
Erlich. H.A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.
Science 239:487-491. 1988.
Sands. A.T.. Suraokar, M.B., Sanchez, A., Marth, J.E., Donehower, L.A., and Bradley, A. p53
deficiency does not affect the accumulation of point mutations in a transgene target. Proceedings Of
The National Academy OfSciences OfThe United States OfAmerica 92:8517-8521, 1995.
Sano, H., Kawahito, Y„ Wilder. R.L., Hashiramoto, A., Mukai, S.. Asai, K., Kimura. S.. Kato, H.,
Kondo, M.. and Hla, T. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human colorectal
cancer. Cancer Research 55:3785-3789, 1995.
Sarkar. N.H. and Reddy. B.S. Both dietary calorie and fat affect the growth of transplanted
mammary tumors in R1II/SA mice - the effect of calorie is more profound than the effect of fat.
International Journal OfOncology 6:1149-1157, 1995. CHECK TITLE
Scherer, S.J., Welter, C., Zang, K.D.. and Dooley, S. Specific in vitro binding of p53 to the promoter
region of the human mismatch repair gene hMSH2. Biochemical And Biophysical Research
Communications 221:722-728, 1996.
Schlegel. J„ Stumm. G., Scherthan. H., Bocker, T., Zirngibl. H.. Ruschoff, J., and Hofstadter. F.
Comparative genomic in situ hybridization of colon carcinomas with replication error. Cancer
Research 55:6002-6005, 1995.
Schmid M., Haaf, T., and Grunert. D. 5-azacvtidine-induced undercondensations in human
chromosomes. Human Genetics 67:257-263. 1984.
Scott, N., Sagar. P.. Stewart. J., Blair, G.E., Dixon, M.F., and Quirke. P. p53 in colorectal-cancer -
clinicopathological correlation and prognostic significance. British Journal OfCancer 63:317-319,
1991.
Selva, E.M.. New, L., Crouse, G.F., and Lahue. R.S. Mismatch correction acts as a barrier to
homeologous recombination in saccharomyces cerevisiae. Genetics 139:1175-1188, 1995.
211
Shaw, P., Bovev. R., Tardy, S., Sahli, R., Sordat. B., and Costa, J. Induction of apoptosis by wild-
type p53 in a human colon tumor-derived cell line. Proceedings Of The National Academy Of
Sciences Of The United States OfAmerica 89:4495-4499. 1992.
Sheng, H.M, Shao, J.Y., Kirkland, S.C., Isakson, P., Coffey, R.J., Morrow, J., Beauchamp, R.D.,
and DuBois, R.N. Inhibition of human colon cancer cell growth by selective inhibition of
cyclooxygenase 2. Journal OfClinical Investigation 99:2254-2259, 1997.
Shibata, D., Peinado, M.A., Ionov, Y., Malkhosyan, S., andPerucho, M. Genomic instability in
repeated sequences is an early somatic event in colorectal tumorigenesis that persists after
transformation. Nature Genetics 6:273-281, 1994.
Shirasawa, S., Urabe, K., Yanagawa, Y., Toshitani, K., Iwama, T., and Sasazuki, T. p53 gene-
mutations in colorectal tumors from patients with Familial Polyposis Coli. Cancer Research
51:2874-2878, 1991.
Shirasawa, S., Furuse, M., Yokoyama, N., and Sasazuki, T. Altered growth of human colon cancer
cell lines disrupted at activated Ki-ras. Science 260:85-88. 1993.
Shridliar. V., Siegfried. J., Hunt, J., del Mar Alonso, M.. and Smith, D.I. Genetic instability of
microsatellite sequences in many non-small cell lung carcinomas. Cancer Research 54:2084-2087,
1994.
Sikora, K., Chan, S., Evan, G., Gabra, H., Markham, N., Stewart, J., and Watson. J. c-myc oncogene
expression in colorectal cancer. Cancer 59:1289-1295, 1987.
Silverman, A.L., Park, J.G., Hamilton, S.R., Gazdar, A.F., Luk, G.D., and Baylin, S.B. Abnormal
methylation of the calcitonin gene in human colonic neoplasms. Cancer Research 49:3468-3473,
1989.
Simms, L.A., Zou, T.T., Young, J., Shi, Y.Q., Lei, J.Y., Appel. R.. Rliyu. M.G., Sugimura, H.,
Chenevix-Trench, G., Souza, R.F., Meltzer, S.J., andLeggett, B.A. Apparent protection from
instability of repeat sequences in cancer-related genes in replication error positive gastrointestinal
cancers. Oncogene 14:2613-2618. 1997.
Sivaraman, L., Leatham, M.P., Yee, J., Wilkens, L.R., Lan, A.F., and LeMarchand, L. CYP1A1
genetic polymorphisms and in situ colorectal cancer. Cancer Research 54:3692-3695, 1994.
Smith, K.J., Johnson, K.A., Bryan, T.M., Hill, D.E., Markowitz, S., Willson, J.K.V., Paraskeva, C.,
Petersen. G.M., Hamilton, S R., Vogelstein, B., and Kinzler, K. W. The APC gene product in normal
and tumor cells. Proceedings OfThe National Academy OfSciences OfThe United States Of
America 90:2846-2850, 1993.
Smith. K.J., Levy. D.B., Maupin, P., Pollard, T.D., Vogelstein, B., and Kinzler, K. W. Wild-type but
not mutant APC associates with the microtubule cytoskeleton. Cancer Research 54:3672-3675, 1994.
Smith, M.L., Chen, I.T., Zhan, Q.M.. O'Connor. P.M., andFornace, A.J. Involvement of the p53
tumor suppressor in repair of UV-type DNA damage. Oncogene 10:1053-1059. 1995.
Solomon, E., Voss, R., Hall. V.. Bodmer. W.F., Jass, J R., Jeffreys, A.J., Lucibello. F.C.. Patel, I.,
and Rider, S.H. Chromosome 5 allele loss in human colorectal carcinomas. Nature 328:616-619,
1987.
Sood. A.K., Skilling, J.S., and Buller, R.E. Ovarian cancer genomic instability correlates with p53
fraineshift mutations. Cancer Research 57:1047-1049, 1997.
212
Souza. R.F., Appel. R., Yin. J., Wang, S.N., Smolinski, K.N., Abraham, J.M., Zou, T.T., Shi, Y.Q..
Lei. J.Y., Cottrell, J., Cymes, K., Biden, K., Simms, L., Leggett, B., Lynch, P.M., Frazier, M.,
Powell, S.M., Harpaz. N., Sugimura, H., Young, J., andMeltzer, S.J. Microsatellite instability in the
insulin-like growth factor II receptor gene in gastrointestinal tumors. Nature Genetics 14:255-257,
1996.
Spira, J., Wiener, F., Ohno, S., and Klein. G. Is trisomy cause or consequence of murine T cell
leukaemia development? Studies on Robertsonian translocation in mice. Proceedings OfThe
National Academy OfSciences OfThe United States OfAmerica 76:6619-6621, 1979.
Spirio, L., Olschwang, S„ Groden, J.. Robertson, M., Samowitz, W., Joslyn, G., Gelbert, L.,
Thliveris. A., Carlson, M., Otterud, B., Lynch, H., Watson, P., Lynch, P., Laurent-Puig, P., Burt, R.,
Hughes, J.P., Thomas, G., Leppert, M., and White, R. Alleles of the APC gene - an attenuated form
of familial polyposis. Cell 75:951-957, 1993.
Stark, G.R. and Wahl, G.M. Gene amplification. Annual Review OfBiochemistry 53:447-491, 1984.
Stark, G.R., Debatisse, M., Giulotto, E., and Wahl, G.M. Recent progress in understanding
mechanisms of mammalian DNA amplification. Cell 57:901-908, 1989.
Stark, G.R. Regulation and mechanisms of mammalian gene amplification. Advances In Cancer
Research 61:87-113, 1993.
Starzynska, T., Bromley, M., Ghosh, A., and Stern, P.L. Prognostic significance of p53
overexpression in gastric and colorectal carcinoma. British Journal OfCancer 66:558-562, 1992.
Stoler, D.L., Anderson, G.R., Russo, C.A., Spina, A.M., andBeerman, T.A. Anoxia-inducible
endonuclease activity as a potential basis of the genomic instability of cancer cells. Cancer Research
52:4372-4378. 1992.
Strand, M., Prolla, T.A., Liskay, R.M., and Petes, T.D. Destabilization of tracts of simple repetitive
DNA in yeast by mutations affecting DNA mismatch repair. Nature 368:569, 1994.
Strand, M., Earlev, M.C., Crouse. G.F., and Petes. T.D. Mutations in the MSH3 gene preferentially
lead to deletions within tracts of simple repetitive DNA in Saccharomyces cerevisiae. Proceedings
Of The National Academy OfSciences OfThe United States OfAmerica 92:10418-10421, 1995.
Sturzbecher, H. W., Addison, C., and Jenkins, J.R. Characterization of mutant p53-Hsp72/73 protein-
protein complexes by transient expression in monkev cos cells. MolecularAnd Cellular Biology
8:3740-3747, 1988.
Su, S.S. and Modrich, P. Escherichia coli MutS-encoded protein binds to mismatched DNA base
pairs. Proceedings OfThe National Academy OfSciences OfThe United States OfAmerica 83:5057-
5061, 1986.
Su, L.K., Johnson. K.A., Smith, K.J., Hill, D.E., Vogelstein, B., and Kinzler, K.W. Association
between wild-type and mutant APC gene products. Cancer Research 53:2728-2731, 1993a.
Su, L.K., Vogelstein, B., and Kinzler, K.W. Association of the APC tumor suppressor protein with
catenins. Science 262:1734-1737, 1993b.
Su, L.K., Burrell, M., Hill, D.E., Gyuris, J., Brent, R., Wiltshire, R., Trent, J., Vogelstein, B.. and
Kinzler, K.W. APC binds to the novel protein EB1. Cancer Research 55:2972-2977, 1995.
213
Sun, X.F., Carstensen, J.M., Zhang, H., Stal, O., Wingren, S., Hatschek, T., and Nordenskjold, B.
Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet
340:1369-1373, 1992.
Suzuki, H., Harpaz. N., Tarmin, L., Yin, J., Jiang, H.Y., Bell, J.D., Hontanosas, M., Groisman,
G.M., Abraham, J.M., and Meltzer, S.J. Microsatellite instability in ulcerative colitis associated
colorectal dysplasias and cancers. Cancer Research 54:4841-4844, 1994
Takagi, Y., Kohmura. H., Futamura, M., Kida, H.. Tanemura, H., Shimokawa, K., and Saji, S.
Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology
111:1369-1372,1996.
Tanaka. K., Yanoshita, R., Konislii, M., Osliimura, M., Maeda, Y., Mori, T., and Miyaki, M.
Suppression of tumorigenicity in human colon carcinoma cells by introduction of normal
chromosome lp36 region. Oncogene 8:2253-2258, 1993.
Tannergard, P., Zabarovsky, E., Stanbridge, E., Nordenskjold, M., and Lindblom, A. Sublocalization
of a locus at 3p21.3-23 predisposing to Hereditary Non-Polyposis Colon Cancer. Human Genetics
94:210-214, 1994.
Thiagalingam, S., Lengauer, C., Leach, F.S., Schutte, M., Hahn, S.A., Overhauser, J., Willson,
J.K.V., Markowitz, S., Hamilton, S.R., Kern, S.E., Kinzler, K.W., and Vogelstein, B. Evaluation of
candidate tumor suppressor genes on chromosome 18 in colorectal cancers. Nature Genetics 13:343-
346, 1996.
Thibodeau. S.N., Bren, G., and Schaid. D. Microsatellite instability in cancer of the proximal colon.
Science 260:816-819, 1993.
Tlsty, T.D. Normal diploid human and rodent cells lack a detectable frequency of gene amplification.
Proceedings OfThe National Academy OfSciences OfThe United States OfAmerica 87:3132-3136,
1990.
Tlsty, T.D., White, A., and Sanchez, J. Suppression of gene amplification in human cell hybrids.
Science 255:1425-1427, 1992.
Toft, N., Arends, M.J., Wyllie, A.H., and Clarke, A.R. No female embryonic lethality in mice
nullizygous for Msh2 and p53. Nature Genetics 18:17. 1998.
Togo, G., Toda. N., Kanai. F., Kato, N., Shiratori, Y., Kishi, K., Imazeki, F„ Makuuchi, M., and
Omata, M. A transforming growth factor beta type-II receptor gene mutation common in sporadic
cecum cancer with microsatellite instability. Cancer Research 56:5620-5623, 1996.
Tomlinson, I.P.M., Ilyas, M., and Bodmer, W.F. Allele loss occurs frequently at hMLHl, but rarely
at hMSH2, in sporadic colorectal cancers with microsatellite instability. British Journal OfCancer
74:1514-1517, 1996.
Tomlinson, I.P.M.. Hampson, R., Karran, P., and Bodmer, W.F. DNA mismatch repair in
lymphoblastoid cells from Hereditary Non-Polyposis Colorectal Cancer (HNPCC) patients is normal
under conditions of rapid cell division and increased mutational load. Mutation Research-DNA
Repair 383:177-182. 1997.
Umar, A., Boyer, J.C., Thomas. D.C., Nguyen, D.C.. Risinger, J.I., Boyd, J., Ionov, Y., Perucho, M.,
and Kunkel, T.A. Defective mismatch repair in extracts of colorectal and endometrial cancer cell
lines exhibiting microsatellite instability. Journal OfBiological Chemistry 269:14367-14370, 1994.
214
van den Berg, F.M., Tigges, A.J., Schipper, Den Hartog-Jager, F.C.A., Kroes, W.G.M.. and
Walboomers. J.M.M. Expression of the nuclear oncogene p53 in colon tumors. Journal OfPathology
157:193-199,1989.
Vasen, H.F.A. What is Hereditary Non-Polyposis Colorectal Cancer (HNPCC)? Anticancer
Research 14:1613-1615, 1994.
Verma, R.S. andBabu, A. Fluorescence in situ hybridisation techniques. In: Human Chromosomes:
principles and techniques, New York:McGraw-Hill, Inc. 1995,p. 191-209.
Vindelov. L.L., Christensen, I.J., and Nissen, N.I. A detergent-trypsin method for the preparation of
nuclei for flow cytometric DNA analysis. Cytometry 3:323-327, 1983.
Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M., Nakamura,
Y., White, R., Smits, A.M.M., and Bos, J.L. Genetic alterations during colorectal tumor
development. New England Journal OfMedicine 319:525-532, 1988.
Vojtesek, B. and Lane, D.P. Regulation of p53 protein expression in human breast cancer cell lines.
Journal OfCell Science 105:607-612, 1993.
Wada, R., Matsukuma, S., Abe, H., Kuwabara, N., Suda, K., Arakawa, A., and Kitamura. S.
Histopathological studies of superficial type early colorectal carcinoma. Cancer 77:44-50, 1996.
Wahl, G.M., Windle, B., and Draper, B. Circular DNA, chromosomal deletions and gene
amplification. Cancer Genetics And Cytogenetics 41:220, 1989.
Wang. A.M., Doyle, M.V., and Mark, D.F. Quantitation of messenger RNA by the polymerase
chain-reaction. Proceedings OfThe National Academy OfSciences Of The United States OfAmerica
86:9717-9721, 1989.
Wang, L.M. Mutation in the nm23 gene is associated with metastasis in colorectal cancer. Cancer
Research 53:3652, 1993.
Wang, X.W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J.M., Wang, Z., Friedberg, E.C.,
Evans, M.K., Taffe, B.G., Bohr, V.A., Weeda, G., Hoeijmakers, J.H.J., Forrester, K., and Harris,
C.C. p53 modulation of TFIEH-associated nucleotide excision repair activity. Nature Genetics
10:188-195, 1995.
Weber, J.L. and Wong, C. Mutation of human short tandem repeats. Human Molecular Genetics
2:1123-1128, 1993.
Wei, Q.Y., Xu. X.D., Cheng, L., Legerski, R.J., and Aliosman, F. Simultaneous amplification of 4
DNA repair genes and beta actin in human lymphocytes by multiplex reverse transcriptase PCR.
Cancer Research 55:5025-5029, 1995.
Weisburger, J.H. Causes, relevant mechanisms, and prevention of large bowel cancer. Seminars In
Oncology 18:316-336, 1991.
Wieringa, B., Hofer, E., and Weissmann, C. A minimal intron length but no specific internal
sequence is required for splicing the large rabbit beta globin intron. Cell 37:915-925, 1984.
Wiggers, T., Arends, J.W., and Volovics, A. Regression analysis of prognostic factors in colorectal
cancer after curative resections. Diseases OfThe Colon & Rectum 31:33-41, 1988.
Wijnen, J., Fodde, R., and Khan, P.M. DGGE polymorphism in intron 10 of MSH2, the HNPCC
gene. Human Molecular Genetics 3:2268, 1994.
215
Wijnen, J., Vasen, H., Khan, P.M., Menko, F.H., van der Klift, H., van Leeuwen, C., van den Broek.
M., van Leeuwen-Comelisse, I., Nagengast, F., Meijersheijboer, A., Lindhout, D., GrifFioen, G.,
Cats, A., Kleibeuker, J., Varesco, L., Bertario, L., Bisgaard, M.L.. Mohr, J., andFodde, R. 7 new
mutations in hMSH2. an HNPCC gene, identified by denaturing gradient gel electrophoresis.
American Journal OfHuman Genetics 56:1060-1066, 1995.
Wijnen, J., Khan, P.M., Vasen, H., Menko, F., van der Klift, H., van den Broek, M., van Leeuwen-
Cornelisse, I., Nagengast, F., Meijersheijboer. E.J., Lindhout, D., Griflioen, G., Cats, A., Kleibeuker.
J., Varesco, L., Bertario, L., Bisgaard, M.L., Mohr, J., Kolodner. R., and Fodde, R. Majority of
hMLHl mutations responsible for Hereditary Non-Polyposis Colorectal Cancer cluster at the exonic
region 15-16. American Journal OfHuman Genetics 58:300-307. 1996.
Wijnen, J., Khan, P.M., Vasen, H., Vanderklift, H., Mulder, A.. Vanleeuwen-Cornelisse, I., Bakker,
B., Losekoot, M., Moller, P., and Fodde, R. Hereditary non-polyposis colorectal cancer families not
complying with the Amsterdam criteria show extremely low frequency of mismatch repair gene
mutations. American Journal OfHuman Genetics 61:329-335, 1997.
Wilson, T.M., Ewel, A.. Duguid, J.R., Eble, J.N., Lescoe, M.K., Fishel, R.. and Kelley, M.R.
Differential cellular expression of the human MSH2 repair enzyme in small and large intestine.
Cancer Research 55:5146-5150, 1995.
Wilson, C.L., Heppner, K.J., Labosky. P.A.. Hogan, B.L.M., and Matrisian, L.M. Intestinal
tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proceedings OfThe
National Academy OfSciences OfThe United States OfAmerica 94:1402-1407, 1997.
Windle, B., Draper, B. W., Yin, Y.X., Ogorman, S., and Wahl, G.M. A central role for chromosome
breakage in gene amplification, deletion formation, and amplicon integration. Genes & Development
5:160-174.1991.
Windle, B.E. and Wahl, G.M. Molecular dissection of mammalian gene amplification - new
mechanistic insights revealed by analyses of very early events. Mutation Research 276:199-224,
1992.
Wolley, R.C., Schreiber. K., Koss, L.G., Karas, M., and Sherman, A. DNA distribution in human
colon carcinomas and its relationship to clinical behavior. Journal Of The National Cancer Institute
69:15-22, 1982.
Wu, X.W., Bayle, J.H., Olson. D., and Levine, A.J. The p53 Mdm-2 autoregulatoiy feedback loop.
Genes & Development 7:1126-1132. 1993.
Wu, C.. Akiyama. Y., Imai, K., Miyakc, S., Nagasaki, H., Oto, M., Okabe, S., Iwama, T., Mitamura,
K., Masumitsu, H., Nomizu, T., Baba, S., Maruyama, K., and Yuasa, Y. DNA alterations in cells
from Hereditary Non-Polyposis Colorectal Cancer patients. Oncogene 9:991-994, 1994.
Wu, G.S. andEl-Deiry, W.S. p53 and chemosensitivity. Nature Medicine 2:255-256, 1996.
Wu, G.S., Bums, T.F., McDonald, E.R., Jiang, W., Meng, R., Krantz, I.D., Kao, G., Gan, D.D.,
Zhou, J.Y., Muschel, R.. Hamilton, S.R., Spinner, N.B., Markowitz, S., Wu, G., andEl-Deiiy, W.S.
Killer/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genetics 17:141-
143, 1997.
Wynford-Thomas, D. p53 in tumor pathology - can we trust immunocvtochemistry? Journal Of
Pathology 166:329-330. 1992.
216
Yadollahi-Farsani. M.. Gooderham, N.J., Davies, D.S., and Boobis. A.R. Mutational spectra of the
dietary carcinogen 2-amino-l-methyl-6-phenylimidazo[4,5-b]pyridine (PhiP) at the chinese-hamster
HPRT locus. Carcinogenesis 17:617-624, 1996.
Yaremko, M.L., Wasylyshyn, M.L., Paulus, K.L., Michelassi, F., and Westbrook. C.A. Deletion
mapping reveals 2 regions of chromosome 8 allele loss in colorectal carcinomas. Genes
Chromosomes & Cancer 10:1-6, 1994.
Yaseen, N.Y., Watmore, A.E.. Potter, A.M., Potter, C.W., Jacob, G., andRees, R.C. Chromosome
studies in 11 colorectal tumors. Cancer Genetics And Cytogenetics 44:83-97, 1990.
Yin, Y.X., Tainsky, M.A.. Bischoff, F.Z., Strong, L.C., and Wahl, G.M. Wild-type p53 restores cell-
cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948, 1992.
Yonish-Rouach. E.. Resnitzky, D.. Lotem, J.. Sachs, L.. Kimchi, A., and Oren, M. Wild-type p53
induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 352:345-347,
1991.
Young, J., Leggett, B., Ward, M., Thomas, L., Buttenshaw, R., Searle, J., and Chenevix-Trench, G.
Frequent loss of heterozygosity on chromosome 14 occurs in advanced colorectal carcinomas.
Oncogene 8:671-675, 1993a.
Young, J., Leggett, B., Gustafson, C., Ward, M., Searle, J., Thomas, L., Buttenshaw, R., and
Chenevix-Trench, G. Genomic instability occurs in colorectal carcinomas but not in adenomas.
Human Mutation 2:351-354, 1993b.
Zhong, S., Wyllie, A.H.. Barnes, D.. Wolf, C.R., and Spurr, N.K. Relationship between the GSTM1





Reagents arc listed in alphabetical order against the name of their supplier(s).
96-well PCR plates; Hybaid Ltd
a SdATP; Amersham International pic
a "PdCTP; Amersham International pic
ABC kit; Dako Ltd
Agarose; Sigma Aldrich Chemical Company
Alkaline phosphatase substrate kit BCIP/NBT; Vector Laboratories
Ammonium acetate; Fisher Scientific
Ammonium persulphate; Severn Biotech Ltd
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'Decon' detergent; Fisher Scientific
Dcioniscd distilled water (DDW); Elga Ltd
DEPC; Sigma Aldrich Chemical Company
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DNA mass ladder; Life Technologies Ltd
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DNA molecular weight marker 1 kilobasc DNA ladder; Life Technologies Ltd
DNA molecular weight marker cpX174 RF DNA///aeIII; Life Technologies Ltd
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Proteinase K; ICN Biomedicals Ltd
Pstl + buffer; NBL Gene Science Ltd
Pvull + buffer; Life Technologies Ltd
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International pic
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Silver stain kit; Bio-Rad Ltd
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'Vcctashicld' mounting medium: Vector Laboratories
Water-saturated phenol; Rathburn Chemicals
Whatman paper; Whatman Ltd
Wizard miniprep kit; Promega Ltd
Xylene: Fisher Scientific
Xylene cyanol FF: Sigma Aldrich Chemical Company
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DNA MOLECULAR WEIGHT MARKER SIZES
Band sizes of markers in base pairs:
lkb ladder Marker V DNA mass cpX174 RF DNA/ X DNA/
ladder HaeIII Hindlll
12216 587 2000 1353 23130
11198 540 1200 1078 9416
10180 504 800 872 6557
9162 458 400 603 4361
8144 434 200 310 2322
7126 267 100 281 2027
6108 234 271 564




















ALF Automated Laser Fluorography
APS Ammonium persulphate
bp Base pairs
BSA Bovine serum albumin
CAD Trifunctional enzyme carbamoyl-P synthetase, aspartate transcarbamylase,
dihvdroorotase
CCD Charged coupled device














DDW Distilled deionised water
DTT Dithiothrcitol
EDTA Ethylencdiaminctetraacctic acid (disodium salt)
FAP Familial Adenomatous Polyposis
GTBP G-T binding protein
hMLHl Human MutH homologuc
hMSH2 Human MutS Homologue
hPMSl Human post-mciotic segregation homologue 1
hPMS2 Human post-meiotic segregation homologue 2
HNPCC Hereditary Non-Polyposis Colorectal Cancer
IPTG Isopropyl p-D-thiogalactopyranoside




mRNA Messenger ribonucleic acid
NRS Nonnal rabbit serum
OD Optical density
PALA N-(phosphonacetyl )-L-aspartate
PBS Phosphate buffered saline
PCR Polymerase chain reaction
Pu Purine
Py Pyrimidinc
RER+ Replication error positive
228
RER- Replication error negative
RFLP Restriction fragment length polymorphism
RNA Ribonucleic acid
SAP Shrimp alkaline phosphatase
SCID Severe combined immuno-deficient
SDS Sodium dodecvl sulphate
STR Short tandem repeat
SSC Salt/sodium citrate buffer




TGFp Transforming growth factor p
TGFp RII Transforming growth factor p receptor subunit II



































































Pathol- Age Sex Site Side Type Dukes p53 RER Ch;
ogy ref. IHC status ref.
90 09283 76 F S L AC A NA N
90 14053 61 F R L MUC C N N 38
90 18573 74 F A R AC B P N
90 22158 67 M R L MUC B N N
90 24901 80 F C R AC C N N
90 09966 86 F A R MUC C N N
90 14113 63 F S L AC C N N
90 20472 56 F S L MUC C N S1 55
90 22641 43 F c R AC c N RER+ 82
91 16209 37 F R L AC B P S1 56
90 12596 80 F D L AC C P N
90 15056 64 F S L AC A P N
90 22704 77 F S L MUC C P N
90 13702 73 F R L AC B P N
90 13557 47 M D L MUC C N N
90 16283 74 F R L MUC C N N
90 21676 78 F A R MUC B P N
90 26744 85 M S L AC C P N 57
90 14018 69 M S L MUC B P RER+ 83
90 17564 73 M S L AC C P N 39
90 21776 77 F R L AC B P N 58
91 13546 74 M S L AC B P N
NA 93 F A R AC B N N
90 24900 47 F D L AC B P N
91 00184 64 F S L AC B P N 59
91 06883 73 M T R MUC B P RER+ 30
90 23997 70 F R L AC C P N 60
90 25170 58 M R L AC B N N
91 00385 75 F A R MUC C N RER+ 61
90 23997 80 M R L AC C P N
90 25251 64 M R L AC B P N
91 00765 63 M R L MUC C N RER+ 84
90 24393 82 F T R AC B N N
90 27079 63 F T R AC C N N
91 01206 69 M D L AC B P N 31
90 24672 68 M C R AC B P N
90 28426 67 M R L AC A N N
91 03489 79 M S L AC B P N
91 07197 73 M A R AC B P N
91 13235 84 F S L AC C P S1 32
92 00888 37 M R L MUC C P N 40
91 07239 74 M C R MUC B N N 33
91 13273 80 F R L MUC C N N
91 07283 41 M S L AC C N* N
91 16090 76 M D L MUC B N RER+ 34
91 08679 57 M S L AC B P N
91 19323 71 F R L AC C P N
91 21073 42 F R L AC C P N
92 02461 68 M S L AC B P N
92 07513 65 M R L AC B P N
91 21510 67 F A R MUC C P Y 62
91 25643 53 F S L AC C N N 63
92 19204 74 F R L NA B P N
92 16518 49 F C R MUC B N Y4 35
92 23361 37 F S L AC C P N
92 18759 73 M C R AC B P N
92 21270 81 M T R AC C P N
92 16946 63 F R L AC B P N
92 23420 79 M C R AC B P N
92 17967 71 F S L AC B P N
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Patient Xeno. Pathol¬ Age Sex Site Side Type Dukes p53 RER Chs
name ogy ref. IHC status ref.
66 92 21280 79 M A R AC C N N
67 92 17035 68 M R L AC A P RER+ 86
68 92 23518 74 M C R AC B P N 36
69 92 18324 63 M S L AC B P N
70 92 19066 64 M A R AC C N N
71 92 21973 88 M D L AC B P N
72 92 17066 66 M T R AC B P N
73 92 24208 81 M C R AC A P N
75 92 19066 see#70 C R MUC C? P N
76 92 24208 see#73 c R AC B P N 41
77 92 1 8557 94 F A R AC A N N
78 92 18409 83 F R L AC C P N 87
80 91 23749 65 F S R AC C N N
81 91 16959 76 F C R AC C P N 42
82 91 22448 84 M A R AC A N N
83 92 08987 79 F R L AC A N N
84 92 10402 82 M R L AC A P N
85 92 16621 46 F R L AC B P N
89 92 11405 67 F T R AC C P N 65
90 92 17710 81 F C R AC B P N 44
91 91 18129 69 F S L AC C N N
92 92 07720 62 M T R AC B N N 45
93 92 09802 70 M A/T R AC B N N
94 92 11777 68 M S L AC C P N
95 91 21208 88 M R L MUC B N N 46
96 ELWI 92 07753 84 M C R AC C P N
97 92 09859 42 M R L AC C N RER+ 66
98 SAGR 92 15601 39 F C R MUC B N N
99 91 21352 71 F A R AC C N RER+ 88
100 92 08746 68 F R L AC A P N
101 92 1 0009 79 M C R AC B P N
102 92 26072 74 F A R AC B P N
103 92 24371 49 M R L AC B P N 47
104 ROPE 92 12230 83 M C R AC C P N 48
105 90 27894 63 F R L AC C N N
106 90 21258 78 F C R AC c N N 49
107 93 00741 56 F R L AC B N N 67
108 90 23602 61 M R L AC C N N
109 90 27183 84 F D L AC C P N
110 91 03510 73 M R L MUC c P N
111 90 10048 67 M R L MUC c N N
112 93 03406 37 F S L AC c P N
113 93 12255 80 M C R NA c P S1 50
114 90 19430 56 F A R MUC B N RER+ 51
115 90 10965 65 M C R MUC B P N
116 93 09806 73 M S L AC A N N 68
118 91 00982 88 F A R MUC B N RER+ 89
119 90 20135 90 F R L AC A P N 52
120 90 11629 78 M T R AC B P N
121 93 09932 63 M R L AC A N N 98
122 93 12563 71 M T R MUC B P S1 53
123 93 12923 82 F NK L MUC B N N
124 91 03489 see#39 R L AC B P N
128 90 18647 61 F R L AC C P N
130 EDLA 91 08727 49 M A R AC C P N 69
131 90 13666 55 M R L MUC C N N
cc1 89 19963 63 F T R MUC B N RER+ 1
cc7 901009 63 F R L MUC C N S1 2
cc11 90 13455 59 M S L AC B P N
cc13 90 14812 71 F R L AC B N N

















cc19 903349 78 F A R MUC B N
N
cc21 89 29891 40 F C R AC C NA
N
cc25 90 20547 69 M C R MUC B N
RER+ 3
cc27 90 20904 see#120 C R AC A N
N
cc29 90 21237 68 M R L MUC C N
N
cc31 90 21524 69 F A R AC B P
N
cc33 90 21677 74 F S L AC B N
N
cc37 90 26513 80 F A R AC B
P N 14
cc39 90 25215 80 F C R AC B
P N
cc41 90 26578 61 M T R AC B
P N
cc43 90 26644 70 F R L AC A N
N
cc49 90 14688 84 M R L AC B
P N
cc51 90 6294 57 M S L AC C P
N
cc53 90 13758 79 F S L AC CD
N N
cc55 9011167 75 F A R MUC CD
N N
cc57 907740 72 F A R AC C
P N
cc59 8818014 87 F C R AC C?D NA
N
cc61 8910961 59 F R L AC C
P N
cc61 893942 55 M S L AC A P
N
cc65 893740 44 F R L AC B
N N
cc67 893719 80 F R L AC B P
N
cc69 8815396 56 M S L AC C NA
N
cc71 893362 77 F R L AC c N
N
cc73 893157 49 M R L AC B
N S1 4
cc75 892292 57 F C AC CD P
N 5
cc77 891812 57 F S L AC B P
N
cc79 89769 81 F R L AC A
P N
cc81 8829525 75 F C MUC C N
N
cc83 8829379 49 M R L AC B
N N
cc85 8826932 68 F S L AC B P
RER+ 6
rrfl7 ■ 8826553 70 M D L AC CD N NwW f-
cc89 8826457 68 M R L AC C
N N
cc91 8823757 82 F S L AC C P
N
cc93 8824479 75 F AA AC BA P
N
cc101 9101896 68 M R L AC C
P N
cc103 9103220 74 M C MUC B
P S1 7
cc105 9103437 60 M R L AC B
N N
cc107 91+G482172 M R L AC C P
N
cc109 9103541 90 F R L AC C P
S1
CC111 915034 76 F S L AC C P
RER+
cc113 914328 77 M A MUC B N
N
cc115 914818 71 F R L AC B
N N
cc117 913751 84 M R L AC A P
N
cc119 9104009 69 M R L AC C N
N
cc123 9105398 75 F A AC B P
S1 9
cc129 9106001 82 F S L AC B
P N
cc131 9106266 68 M R L MUC C N
N
cc133 9106317 69 M R L MUC B P
S1 11
cc135 9106383 80 M S L AC CD P
N
cc137 9106865 77 M S L AC B P
N
cc139 9107205 70 F R L AC A
P N 12
cc141 9107952 63 M R L AC C P
N
cc143 9107972 68 M R L AC C P
N
cc145 919806 53 F S L AC C P
N
cc147 919761 65 F C AC C P
N
cc153 9118416 78 M S L MUC B P
N 15
cc155 CADU 9119828 95 F S L AC B P
N
cc157 9120214 74 M R L AC B P
N
cc161 9109364 72 F A AC B N
N
cc165 9110345 74 M S L AC C
P N
cc167 9110738 76 F R L AC B P
N
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name ogy ref. IHC status ref.no.
4
cc169 9111087 84 F R L MUC C
P N
cc171 9111612 79 M C R AC B
P S1 16
cc175 9112153 85 F c R MUC C
N N
cc177 GRZBO 9112386 87 F u L AC A
N N yes yes
cc179 MEMCG 9112695 64 F A R MUC B
N RER+ 17 yes yes
cc181 9111273 28 M R L AC D N
N
cc183 THLE 9117951 67 M R L AC C P
N yes yes
cc185 9118936 76 F C R MUC B
P RER+ 19
cc187 9107351 34 F R L AC C
P N
cc189 9120281 79 F R L AC B
N N
cc191 PAMCI 9121142 65 F R L AC C
P N yes yes
cc193 WHO 9119029 76 M R L AC A
N* S1 20 yes yes
cc195 9121014 72 F T R AC C
N N 21
cc197 9120182 73 M C R AC C N
N
cc199 9116028 83 F R L AC B
P N
cc201 923180 81 M A R AC B
P RER+ 22
cc203 922676 72 M R L AC C
N N 23
cc205 JEGA 923835 69 F A R AC B
P N yes
cc207 9121842 60 M T R AC C
N S1 24
cc2C9 9122887 70 M R L AC B
P N
cc213 9124370 62 M S L AC B
P N
cc215 9126854 62 F R L AC C
P N
cc217 921493 64 F C R AC C
P N
cc219 921551 80 M T R AC B
P N
cc221 HIDE 924014 72 F A R AC C
N* N yes yes
cc223 AGSC 924160 71 F C R MUC C
N RER+ 25 yes yes
cc225 924223 80 M C R AC B
N N
cc227 924317 82 F R L AC A
P N
cc231 ANWO 924465 77 F A R AC B
P N yes yes
cc235 ANKE 924634 83 F A R AC B
P RER+ 26 yes yes
cc237 GEHA 924692 86 M R L AC B
N N yes
cc239 925332 70 M R L AC B
P N
cc243 CODR StJohns 41 M R L AC C
P S1 27 yes yes
cc245 925773 74 F C MUC C
P RER+ 28
cc247 926192 86 F S L AC B
P N
cc249 926223 79 F c AC B
P N
ANBA 94 16667 61 M s L MUC C P
N yes yes
ANSA 92 22249 73 F LN L MUC LN P N yes yes
BEBR 9418950 92 M S L MUC B P
N yes
BUCH 94 18363 82 M A AC C P
N yes yes
DUMA 91 01206 68 M D L AC B P
N yes yes
EDDO 91 17684 78 M S L AC B P
N yes yes
FRGA 9107239 73 M C MUC B N
RER+ yes
JAMU2 94 17252 85 M A AC C P
N yes
JEDO 91 18129 68 F S L AC B N N yes yes
LADI 9110174 39 M S L AC A N
RER+ yes
MABO 9121073 42 F R L AC C P
N yes
MACA 94 18836 81 F C AC B P RER+ yes
SHCH 9425782 NA F NA L NA NA P
N yes
WIMCF 9111273 28 M R L AC D N
N yes
AGMCK* 9116209 36 F R L AC B P
S1 yes
THCU* 9216621 88 M R L MUC B N
N yes
VIWA* 9216621 46 F R L AC B
P N yes
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Key to Appendix 5
Column headings
Patient and tumour details are given in columns headed age, sex, tumour site and side,
histological tumour type and Dukes stage. Patients and tumours referred to in chapters 3, 4
and 5 are indicated in columns headed Chapter 3, Chapter 4 and CGH, respectively. p53
refers mainly to IHC data unless otherwise indicated, and shift to RER status.
Patient and Pathology reference no. refer to departmental and hospital reference numbers,


















N* IHC negative but with evidence of p53 mutation
NA information not available
Shift
N no shift (RER-)
S1 shift at one locus only
RER+ shift at more than one locus
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atellite instability (MSI) occurs in most tumours
atients with hereditary non-polyposis colorectal
(HNPCC) and in around 17% of sporadic
tal cancers. Germline defects in mismatch repair
) genes are responsible for the majority of large
C families, with hMSH2 accounting for at least
MMR gene defects also occur in a small
ion of sporadic colorectal tumours with MSI.
e report a systematic analysis of mismatch repair
cy in 215 Scottish patients with sporadic colo-
tumours. We found that 16.4% of tumours
;d MSI; survival analysis by Cox proportional
> method showed a substantial survival advantage
ients with tumours showing MSI, independent of
prognostic factors. Tumours with MSI were
d for hMSH2 mutations and although 61% were
o have alterations, of these only 1/24 was exonic.
ijority of these changes were reductions in length
jnic mononucleotide tracts and we postulate that
alterations are the result of a genetic defect
;re, although they may compromise hMSH2
n as a second step in tumourigenesis. Our findings
j that instability confers an improved prognosis in
tal cancer and, despite the fact that these two
of tumours share similar biological character-
the genetic basis of HNPCC and sporadic
tal cancer with MSI is different.
rds: replication errors; sporadic colorectal
hMSH2; prognosis
iction
irs from hereditary non-polyposis colorectal
(HNPCC) patients are characterised by the
:e of multiple replication errors (Ionov et al.,
Aaltonen et al., 1993). As a consequence of
in the mismatch repair pathway in such
rs, mutations are unrepaired. Within microsa-
.equences such replication slippage is manifest as
ration in length, termed microsatellite instability
MSI has also been demonstrated in sporadic
:tal cancers (Thibodeau et al., 1993) and
uently in many other cancers, including pan-
(Han et al., 1993). gastric (Han et al., 1993;
laki et al., 1993; Mironov et al., 1994; Rhyu et
jndence: VJ Bubb
i 22 January 1996; revised 14 March 1996; accepted 14
996
al., 1994; Chong et al., 1994), prostatic (Gao et al.,
1994), endometrial (Risinger et al., 1993; Peltomaki et
al.. 1993), breast (Patel et al., 1994), non-small cell
(Shridhar et al., 1994; Fong et al., 1995) and small cell
lung cancers (Merlo et al., 1994) and in Muir-Torre
syndrome (Honchel et al., 1994).
Up to 86% of tumours from HNPCC patients
exhibit instability at multiple microsatellite sites
(Aaltonen et al., 1993, 1994; Wu et al., 1994). A
significant, although much lower, proportion (in most
studies around 17%) of sporadic colorectal carcinomas
show shifts in allele size in at least one microsatellite
locus relative to their corresponding normal tissue
.(Aaltonen et al., 1993, 1994; Ionov et al., 1993; Lothe
et al., 1993; Young et al., 1993; Kim et al.. 1994),
although others have found the frequency to be as high
as 28% in the population studied (Thibodeau et al.,
1993). The prevalence of tumour MSI is greater when
cases with some family history of cancer are included
(Lothe et al., 1993). Sporadic tumours with micro-
satellite instability have characteristics in common with
HNPCC tumours. They are usually located in the
proximal colon (Ionov et al., 1993; Thibodeau et al.,
1993; Lothe et al., 1993; Aaltonen et al., 1993; Kim et
al., 1994), associated with extracellular mucin produc¬
tion (Kim et al., 1994), poor differentiation (Ionov et
al., 1993; Lothe et al., 1993; Kim et al., 1994) and
diploidy (Aaltonen et al., 1993; Lothe et al., 1993).
They also show a negative correlation with mutation
(Ionov et al., 1993) or immunocytochemical stabilisa¬
tion of p53 (Kim et al., 1994) and Ki-ras mutation
(Ionov et al., 1993). In addition, loss of heterozygosity
at known tumour suppressor gene loci on chromo¬
somes 5q, 17p and 18q is relatively less frequent in
tumours with MSI compared to those without
(Thibodeau et al., 1993). Finally, these tumours show
a tendency towards increased patient survival (Thibo¬
deau et al., 1993; Lothe et al., 1993).
Recently, a number of genes that participate in
human mismatch repair have been identified, namely
hMSH2 (Fishel et al., 1993; Leach et al., 1993),
hMLHl (Bronner et al., 1994; Papadopoulos et al.,
1994), hPMSI and hPMS2 (Nicolaides et al., 1994) and
pl60/GTBP (Palombo et al., 1995; Drummond et al.,
1995; Papadopoulos et al., 1995). The roles of these
genes were inferred from their homology with bacterial
and yeast mismatch repair genes (Prolla et al., 1994),
and germ-line mutations of all except pl60/GTBP have
been found in HNPCC families. Defects in the
mismatch repair pathway account for the vast
majority of HNPCC families; mutations in hMSH2
are thought to account for at least 50% of kindreds
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(Liu et al.. 1994) and mutations in hMLHl for up to
33% (Han et al.. 1995: Liu et al. 1996). Mutations in
these genes may also play a role in the development of
sporadic colorectal cancer. However, mutations in
mismatch repair genes have so far been demonstrated
in only a small percentage of sporadic cancers or cell
lines derived from colorectal carcinomas (Liu et al..
1995: Borresen et al.. 1995).
We sought to clarify further the prevalence of
mismatch repair deficiency in a large unselected series
of 215 Scottish sporadic colorectal cancer cases. We
confirm the previously reported characteristics of such
tumours: their predilection for origin in the proximal
colon, tendency for mucinous histology, negative
correlation with abnormalities in p53 expression and
substantially better prognosis than tumours in patients
without MSI. To delineate the role of a specific
mismatch repair gene known to be important in
hereditary cancers sharing these characteristics, we
carried out an extensive mutation analysis of hMSH2
on selected cases. Our results revealed a substantial
difference in the nature and incidence of mutations in
this gene between sporadic and hereditary (HNPCC)
colorectal cancers, emphasising that the mechanism




We analysed 215 patients diagnosed as having primary
sporadic colorectal cancer. This group included
patients with more than one tumour and those with
cancer at other sites (either synchronous or asynchro¬
nous) who did not fit the criteria for HNPCC
(Percesepe et al.. 1994). When patients had more than
one carcinoma, each lesion was analysed separately if
DNA was available. Thus, a total of 219 carcinomas
were analysed, four patients each having two
synchronous cancers.
These 219 cancers were staged as follows: 25 Duke's
Stage A, 100 Duke's Stage B and 94 Duke's Stage CD
(for these purposes stages C and D were amalgamated
as information regarding distant metastasis was not
always available). The average age was 70 years, range
28-95 years, with one patient of unknown age. The
group comprised 46.5% (100/215) males and 53.5%
(115/215) females.
All samples were analysed for genetic instability at a
minimum of four microsatellite loci. 16.4% (36/219)
exhibited instability at one or more loci. The average
age of this group was 68.75 years, range 37-93 years.
This is not significantly different from the age of the
group without evidence of MSI (70.02 years, range
28-95). During the course of this study we identified a
polyadenine tract located in the 5' region of hMSH2
intron 5 which exhibited replication errors in 58% (19/
33) of samples showing microsatellite instability at
other loci. When instability at this locus was included,
we identified three additional patients with evidence of
MSI. one of which appeared to show instability at
another locus but despite repetition had not given an
unequivocal result. Thus, in total, 17.8% (39/219) of
sporadic colorectal cancers in this series exhibited MSI.
When we applied the more stringent requirement of
instability at two or more loci (including intron 5 of
hMSH2). a criterion often used to define a replication
error positive (RER-) phenotype (Aaltonen et al..
1993: Parsons et al.. 1993). the incidence of MSI was
10.5% (23 219).
The relationship between microsatellite instability
and site of tumour. p53 stabilisation and Duke's stage
was examined (Table 3). We found 59% (23 39) of
lesions with instability at one or more loci were in the
proximal or right side of the bowel (ie proximal to
and including the splenic flexure). This was signifi¬
cantly different (/: = 7.73, R<0.01) from the distribur
tion of those without MSI (non-shifters), where 35%
(63/180) were right-sided, similar to the general
distribution of all colorectal cancers in the UK oi"
which 28% are right-sided (Cancer Research Cam¬
paign. 1993). Of lesions with at least two unstable
sites, 74% were proximal (x2== 12.93. RcO.OOl). When
proximal tumours alone were considered, 27% (23/86)
demonstrated microsatellite instability at one or more
loci, as compared with only 12% (16/133) of distal
cancers.
When we looked for evidence of p53 stabilisation
in our series [scored positive if any tumour nucleus in
the section stained (Purdie et al., 1991)] 56.4% (22/
39) of tumours with MSI at one or more loci stained
positively for p53 protein, which was not significantly
different from those without MSI, in which 60%
(108/180) had evidence of stabilised p53 (x2 = 0.43,
Z'> 0.5). However, a significant inverse relationship
was seen between MSI status and p53 staining in
tumours with instability at more than one loci
(X2==4.43, Re 0.05). Fifty-nine percent of our total
population had positively stained nuclei. When the
site of lesion was considered 54% of proximal
tumours and 64.5% of distal tumours had evidence
of stabilised p53. We compared these results to data
generated from the analysis of a subset of these cases
for loss of heterozygosity (LOH) at 17p using three
restriction fragment length polymorphic (RFLP)
markers intragenic to p53 (Purdie et al., in
preparation). 125 lesions were analysed for intragenic
loss of p53, of which 49 were informative at one or
more loci. Of these informative cases, 19 had allele
loss involving p53 and in three (16%) of these we
demonstrated MSI, all located on the left side of the
bowel. Of the 30 lesions where heterozygosity in p53
appeared to be retained, nine (30%) exhibited MSI;
of these, six were located on the right side of the
colon. Thus there is an apparent trend for tumours
that exhibit MSI to retain heterozygosity in p53, but
this difference was not statistically significant. There
was no significant difference between Duke's Stage
and MSI status in tumours with MSI at one or more
locus (x2 = 2.37, P>0.3) or at more than one loci
(X: = 2.028, P>0.3) (Table 3), although lesions with
MSI appeared to be less common within the Duke.'s
A group.
Histological examination of the 39 tumours with
MSI revealed that 41% (16/39) of these tumours were
mucin-secreting. This is a much higher proportion than
in the unselected Scottish population of sporadic
colorectal cancers; in such a series overlapping with
the present study we observed only 17% (59/346)
mucinous carcinomas.
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11 analysis
al analysis was carried out on 169 patients for
information was available on all factors (46
ed) using the Cox proportional hazards method,
.ost significant predictor of survival was Duke's
X" = 38.4. P<0.0001) followed bv age (x; = 9.11.
1025), MSI (r = 7.83, P = 0.0051) and side
,35, /> = 0.012). The hazard ratio of patients
umours showing MSI to those without was
ted to be 0.39 (95% C.I. 0.19-0.82). Thus, at
oint in time after diagnosis, a patient whose
r showed MSI had a risk of dying which was
ted to be about 39% of that of a patient with a
r without MSI, even after allowing for the
ice of other predictive factors. The results are
ted as an estimated survival curve (Figure 3).
fects of p53 immunohistochemical status and sex
mrelated to prognosis.
>rder to eliminate any possibility that tumour side
tnsequence of MSI status the test was repeated
ing 'side'. The result showed negligible influence
predicted survival of patients whose tumours had
o those without [hazard ratio of 0.37 (95% C.I.
3.77)]. No evidence was found of interactions
:n Duke's stage, age, MSI status, side and sex.
ion analysis of hMSH2
ialysed 36 tumours with microsatellite instability
: or more loci (including hMSH2 intron 5) for
ons in the hMSH2 gene (Table 4). In addition,
tours without MSI were analysed as controls. We
two tumours which each had a single exonic
ine mutation. Both of these were mis-sense
ons and both occurred in the control group,
ane tumour with MSI was found to carry any
mutation, a frameshift creating a new stop
. This tumour also showed a reduction in length
polyadenine tract located three nucleotides
tream of the 3' end of exon 5, a change which
>und in an additional 21 tumours. Of these 21
rs the length change was somatic in 20 cases,
alterations were initially detected by abnormal
lg on SSCP gels, but were later found to be
detectable on denaturing polyacrylamide gels,
mal allele lengths ranged from 10 to 23 bases
.red with matching normal tissue which had 25
ie nucleotides in this tract, which differs from the
usly published sequence of 26 residues (Liu et al.,
further tumour with MSI had an intronic
ion, an alteration of unknown function, as well
: length reduction in intron 5 and a second
ion in the length of intron 1. Seven other
rs had this somatic reduction in the length of
ilythymine tract located 3' in intron 1, predicted
part of the splice site. Whereas in normal tissue
act extends for 12 or 13 nucleotides, this was
d to as few as nine base pairs in some tumours,
sis of cancer-free control samples demonstrated
12 or 13 bases was a normal polymorphic
on. Removal of this polynucleotide tract by
igestion and repetition of SSCP on the residual
icleotide fragment (containing 90% of the exonic
ice) revealed no further mutations.
2643
a b c
Tu N Tu N
GATCGATC
Tu N
Figure 1 Intron 5 polyadenine tract length change in one patient
(patient 19 in Table 4) shown by (a) SSCP, (b) heteroduplex and
(c) sequencing analysis (nucleotide lanes labelled). In each
analyses, tumour DNA (Tu) and normal DNA (N) are shown
for comparison
When these results are combined, 15 tumours had a
single change in the hMSH2 gene, eight tumours had
two alterations and one had three. Thus, a total of
61% (22/36) of tumours with MSI had an alteration in
hMSH2 compared to 6% (2/32) of non-shifters
analysed. Forty-six percent (11/24) of tumours with
hMSI-12 mutations showed mucinous histology.
Polymorphisms within the hMSH2 gene
Two alleles were detected by heteroduplex analysis in
intron 1, which sequencing revealed to be a C—>G
substitution at the +9 position. This destroyed a Bcnl
cleavage site, permitting use of a PCR-RFLP assay to
calculate allele frequency in 106 unselected healthy
blood donors. The allele frequencies were Al=0.38
and A2 = 0.62 in this local population. The same
frequency for each allele was found for the cases
analysed for hMSH2 mutation in our study popula¬
tion. Thus this polymorphism does not appear to
influence susceptibility to sporadic colorectal cancer.
Twenty-seven percent of patients with MSI were
heterozygous for a previously described polymorphism
in intron 12 (Fishel et al1993; Hall et al., 1994). Two
patients carried both the polymorphism described at
+ 12 position of intron 10 (Wijnen et al., 1994) and the
polymorphism described at —9 position of intron 9,
GTCGTT-GTCATT (Borresen et al., 1995).
Discussion
This study has identified a group comprising a sixth of
a population of Scottish sporadic colorectal cancer
patients that exhibit microsatellite instability. This
proportion is in agreement with the incidence of MSI
identified by others in sporadic CRC from other
geographic locations, including Lothe et al. (1993)
(16.5%); Aaltonen et al. (1993) (13%) and Kim et al.
(1994) (13%). Our data include a number of cases
where only one locus is altered, a phenomenon which
has been previously noted in colorectal cancer
(Peltomaki et al., 1993; Lothe et al., 1993).
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We examined other clinico-pathological factors that
may distinguish this group from the general population
of colorectal cancer patients. Although we found no
significant difference between microsatellite unstable and
stable tumours for age of onset. Duke's Stage, or gender
distribution, the data did confirm the proximal location
of colonic lesions with MSI which has been noted by
others (Lothe et al., 1993; Kim et al., 1994; Thibodeau et
al., 1993). Additionally, we found that there was a
significant inverse relationship between p53 stabilisation
and MSI status in tumours with instability at more than
one loci. This relationship has also been reported by
others (Ionov el al., 1993), although without indication
whether the tumours analysed were sporadic or
hereditary in nature. Moreover, we find that MSI
tumours are about twice as common within the group
of tumours which have retained both alleles of p53.
The results of the Cox analysis indicate a highly
significant favourable effect of MSI status on post¬
operative survival, even after allowing for the effects of
age. Duke's stage, sex and tumour side. Paradoxically,
histological features generally associated with aggres¬
sive tumour behaviour are common in MSI tumours.
In our series 41% are mucin-secreting. The frequency is
46% in tumours with a hMSH2 mutation. In addition,
a higher proportion of poorly differentiated tumours
associated with MSI has been reported by others
(Ionov et al., 1993; Lothe et al., 1993; Kim et al.,
1994). It has been suggested that this survival
advantage stems from an enhanced host immune
response to cancer cells arising as a result of a high
mutation rate of tumour-associated antigens (Kim et
al., 1994). Alternatively perhaps the situation is
reached where the tumour can no longer survive with
such a mutation burden if, for example, it compromises
the function of essential housekeeping genes. Recent
insights into the mechanism of development of
tumours with MSI suggest that many of these
carcinomas have inactivation of the TGF/I receptor,
rendering cells insensitive to TGF/3-mediated growth
inhibition (Markowitz et al., 1995). Thus, determina¬
tion of the MSI status of a colorectal lesion could be
important not only as a predictor of prognosis but also
in terms of potential cancer therapy.
Although sporadic colorectal cancers with MSI
demonstrate replication slippage in a similar manner
to HNPCC lesions and share similar biological
characteristics, there are clear differences. Unlike the
situation seen in sporadic colorectal cancer, micro-
satellite instability occurs as an early event in HNPCC
adenomas (Young et al., 1993; Aaltonen et al., 1993),
as it does in Barrett's oesophagus, oesophageal
adenocarcinoma (Meltzer et al., 1994) and ulcerative
colitis (Suzuki et al., 1994). The role of hMSH2 is
clearly different in HNPCC and sporadic colorectal
cancer. Only 3% (1/36) of unstable tumours and 6%
(2/32) of stable tumours had one or more mutation in
the exonic portions, splice acceptor or donor regions of
hMSH2. This concurs with the results of the analysis
of a similar series of sporadic tumours (Borresen et al.,
1995) and is akin to the incidence of hMSH2 mutation
in 20 cell lines derived from sporadic colorectal cancers
with MSI (Liu et al., 1995). However, it is in direct
contrast to the situation found in HNPCC where
analysis of these regions identifies a mutation incidence
of up to 40% (Liu et al., 1994; Wijnen et al., 1995).
We have, however, shown many intronic defects
within the hMSH2 gene, regions which to our
knowledge have not been examined extensively for
mutations in HNPCC tumours. Introns are likely-
potential targets for mutation because they contain
repetitive sequences and the observed alterations in
length of polynucleotide tracts would be consistent
with a primary defect in another mismatch repair gene.
Instability of polyadenine tracts in colorectal cancer,
this time in random stretches of DNA. has been
demonstrated by others (Chen et al., 1995) and it is
interesting to note that the mutation spectrum
associated with a recently discovered hMSH2 binding
protein. GTBP or pi60, tends towards reductions in
length of mononucleotide repeated units such as this
(Papadopoulos et al., 1995). The effect on gen^
function of these intronic alterations within the
hMSH2 gene is as yet unknown. We postulate that
they may compromise transcriptional efficiency of
hMSH2, but at this time we cannot predict whether
this would act globally or have a local effect by a
mechanism such as exon skipping. Unfortunately RNA
is not available from these lesions to fully address this
point. There is evidence that mutations of this type
within or outwith splice sites can cause inefficient or
aberrant splicing (Wieringa et al., 1984; Chu et al.,
1993). Thus, these hMSH2 defects might contribute to
the development of a proportion of sporadic colorectal
cancers through further crippling mismatch repair.
The possible impact of double and triple mutations
in hMSH2 is unclear. It is thought that both alleles of
hMSH2 are inactivated, like a classical tumour
suppressor gene, during the development of colorectal
cancer. However others have shown a dose-response
effect of this gene during in vitro studies (Parsons et al.,
1993). It is also not yet known if all missense mutations
described inactivate the gene to the same degree, which
could account for phenotypic variation. Unlike the
situation seen with other tumour suppressor genes, loss
of heterozygosity is not commonly observed at the
hMSH2 locus (Aaltonen et al., 1993).
The overall incidence of hMSH2 mutation in our
population of sporadic colorectal cancers is at least
11%, with only 1% having exonic mutations. Amongst
our population of patients with apparently sporadic
colorectal cancer we found three who carried germ-line
mutations in hMSH2. This small subset of patients
may be thought to represent hereditary, rather than
sporadic, colorectal cancers which do not fit the criteria
for HNPCC. Only one of these three patients had any
family history of cancer. Interestingly, this patient was
identified from the group of cancers without MSI. He
was younger (49 years) than our average age-group,
had a Duke's C carcinoma in the ascending colon, and
had a family history of pancreatic cancer. This
individual may belong to the class of familial RER +
tumours including lung, breast and pancreas, with less
prevalent microsatellite alterations (Liu et al., 1995)
although we are unaware that this has previously been
associated with hMSH2 mutation. A second patient
with no family history or evidence of microsatellite
instability, aged 74 and with a cancer of the caecum,
was also found to have a germ-line hMSH2 mutation.
Both of these mutations were missense and therefore
predicted to compromise protein function. The third
germline mutation was the shortened polyadenine tract
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•on 5 of unknown function: this was found in a
tr demonstrating MSI. These observations sup-
die view that a wide range of phenotvpes are
ated with germ-line hMSH2 mutation (Kolodner
1994; Mary et al.. 1994).
o major conclusions can be drawn from this
Firstly, although MSI is clearly a significant
in the clonal expansion of around one in six of
aradic colorectal cancers, exonic hMSH2 defects
ssociated with this instability in a considerably
proportion of tumours than in HNPCC. Indeed,
mutations in the intronic sequences of hMSH2
;cluded from consideration, hMSH2 mutation in
die tumours with MSI is no more frequent than
er tumours. Our study therefore suggests that the
c basis of microsatellite instability in sporadic
nherited colorectal cancer is different. This is
rted by evidence of a dramatic difference between
cidence of MSI in adenomas from HNPCC and
lie colorectal cancer patients (Young et al., 1993;
nen et al., 1994). Secondly, our data (from a large
of patients with extensive follow-up) clearly
istrate a survival advantage for patients who
a tumour exhibiting MSI. It will be of great
st to determine the mechanism by which such
c instability imparts improved prognosis since




s were harvested fresh from consecutive colorectal
omas removed at operation between 1988- 1993, and
at — 70°C. DNA was extracted from paired normal
olved mucosa or blood) and tumour tissue by the
d of Goelz et al. (1985). Representative portions of
r were paraffin-processed following standard metho-
trase chain reaction (PCR) of microsatellite sequences
amours were analysed for evidence of genetic
lity at four microsatellite loci, D2S119. D3S1293,
2 and D13S160 (Gyapay et al., 1994). In addition,
were examined at loci D15S132 and D17S849 by
tated Laser Flourography (ALF, Pharmacia Biosys-
,td.). Amplification conditions were 20 mM Tris-HCl
4), 50 mM KC1. 200 pM each dNTP, 0.5 /(M each
primer (Table 1). 2.5 units Taq DNA polymerase (Life
Technologies) in 100 /<1 reaction and 100 ng genomic DNA
template. Magnesium ion concentrations for each primer
set are indicated in Table 1. The upstream primer of each
primer pair was synthesised with a fluorescein molecule at
the 5' position to allow analysis by ALF.
Analysis of microsatellite marker sequences
For silver staining, products were heat denatured in 0.5
volume STR loading buffer (10 mM NaOH. 95% forma-
mide. 0.05% bromophenol blue. 0.05% xylene cyanol FF)
and electrophoresed on 6% 19:1 acrylamide: bis acryla-
rnide denaturing gels containing 7 M urea. Electrophoresis
buffer was 44.5 mM Tris. 44.5 m\i Boric acid. 1 mM
EDTA. pH 8.3 and gels were electrophoresed at constant
power (70 W). To facilitate silver staining the gel was
bound to the glass plate with y-methacryloxypropvl-
trimethoxysilane (Kobayashi, 1988; Storts et al., 1993)
and stained in situ according to the method of Bassam et
al. (1991).
PCR samples analysed by ALF were prepared by adding
an equal volume of denaturing solution [95% formamide.
0.8% dextran blue and 25 mM EDTA (pH 9)] and heat
denatured at 95 C for 5 min, then rapidly cooled on ice.
Internal standards between 65 and 313 nucleotides long, were
prepared by amplification from single stranded M13mpl8
vector using a variety of 20-24mer primers. Five microlitres
of PCR product in denaturing solution were loaded onto a
6% MDE gel (AT Biochem, PA, USA) containing 7 M urea
and electrophoresed at constant power (55 W) and tempera¬
ture (50°C). Evidence of microsatellite instability was
determined by a shift of allele peak to a new position.
Polymerase chain reaction of exons from hMSH2
Each of the 16 exons of hMSH2 was amplified using the
primers described in Table 2. PCR was carried out for 30
cycles at annealing temperatures calculated according to
primer composition, Reactions consisted of 50 p\ volume
containing 100 ng genomic DNA, 12.5-25 pmoles of each
primer, 200 ^M of each dNTP (Pharmacia Biosystems Ltd),
2.5 mM MgCL (except exons 15 and 1, which contained
1.5 mM), 1.25 U of thermostable DNA polymerase and
buffer consistiilg of 10 mM Tris-HCl (pH 8.8 at 25°C),
50 mM KC1 and 0.1% non-ionic detergent.
Mutation analysis of hMSH2 gene
Single stranded conformational polymorphism (SSCP)
analysis was carried out as previously described (Curtis et
al., 1994). Heteroduplex analysis was also performed on
those samples in which the banding patterns proved
difficult to resolve by SSCP. PCR products for hetero-
2645
Table 1 Microsatellite loci primers
Marker
name Locus [Mg:~] Primer
AFM077yb7 D2S119 2.0 mM CTTGGGGAACAGAGGTCATT
GAGAATCCCTCAATTTCTTTGGA
AFM200zal D3S1293 2.0 mM ACTCACAGAGCCTTCACA
CATGGAAATAGAACAGGGT
AFM234vf4 D8S282 1.5 mM GGGCACAGGCATGTGT
GGCTGCATTCTGAAAGGTTA
AFM157xal 1 DI3S160 1.5 mM CGGGTGATCTAAGGCTTCTA
GGCAGAGATATGAGGCAAAA
AFM265xf9 D15S132 1 mM C TGATAATAAAAC CAGGAAGACAC
TATTGGCCTGAAGTGGTG
AFM234wg3 D17S849 1 mM CAATTCTGTTCTAAGATTATTTTGG
CTCTGGCTGAGGAGGC
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duplex analysis were heated to 95°C and cooled slowly to
37°C over 30 min. 5 /ul of sample in 1 /d loading buffer
(30% glycerol, 0.25% bromophenol blue, 0.25% xylene
cyanol FF) was electrophoresed on a MDE gel containing
3.12 M urea according to the manufacturer's protocols (AT
Biochem, PA, USA) and run at 0.71-0.8 kV for 16 h. Both
glass plates were pre-treated, one with Gel Slick (AT
Biochem, PA, USA) and the other with 20 /d y-
methacryloxypropltrimethoxysilane in 5 ml distilled water
(pH 3.5 with acetic acid). Silver staining was performed
according to the following protocol: The gel was soaked
for 10 min in 10% ethanol then 10 min in 1% nitric acid,
rinsed quickly with water and washed for 5 mm in water. It
was then soaked for 20 min in 12 mM silver nitrate, rinsed
twice for 20 s, first with water then with cold developer
(0.28 M sodium carbonate. 0.0185% formaldehyde) until a
precipitate formed. The developer was replaced and the gel
soaked until an image appeared. The reaction was stopped
with 0.1 M citric acid and the gel rinsed in water. The
whole procedure was carried out on a rocking platform.
Twenty-one products generated from exon 5 were
abnormal by SSCP and sequencing revealed changes in the
length of a polyadenine tract within the intron. In order to
eliminate the possibility of other mutations in this exon, this
portion was cleaved away with Trail (MBI Fermentas,
Lithuania) and the remaining exonic fragment reanalysed by
SSCP. Similarly, eight products generated from exon 2 which
were abnormal by SSCP but revealed only a length change in
an intronic polynucleotide tract by sequencing, were cleaved
with PstI to allow reanalysis of the exonic portion by SSCP.
Samples which demonstrated an abnormal banding
pattern by heteroduplex or SSCP analysis were reamplified
with Taq polymerase and directly sequenced (Sequenase PCR
Products Sequencing Kit, United States Biochemicals) or
cloned into pGEM7ZF+ (Promega Ltd., UK) and sequenced






M A1/A1 A1/A2 A2/A2
Figure 2 Exon l polymorphism, C to G change at the + 9
position of intron 1, in normal DNA from three patients of
different genotype by (a) heteroduplex, where H indicates
heteroduplex formation (b) SSCP and (c) Ben I restriction digest
analysis. Allele sizes for Bcnl digestion products are 81 bp (A 1)
and 57 bp (A2). C indicates the constant bands of 152 bp and
48 bp (21 bp band not shown): M. DNA molecular weight marker
1 kb ladder (Life Technologies, UK)







Left 16 (41%) 6 (26%) 117 (65%)
Right 23 (59%) 17 (74%) 63 (35%)
Dukes stage
A 2 (5%) 1 (4.5%) 23 (13%)
B 21 (54%) 13 (56.5%) 79 (44%)
CD 16 (41%) 9 (39%) 78 (43%)
p53 Status
ICC Positiveb 22 (56%) 9 (39%) 108 (60%)'
ICC Negative 17 (44%) 14 (61%) 66 (37%)
Unknownc 6
Total 39 23 180
ano alteration in length seen at loci tested, immunocytochemistry.
CPLPD fixed tissue unavailable. d Three samples included with
strong cytoplasmic staining, nuclei were not stained
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Mutation Mutation MSI
Ill) Exon in iron Codon type genotype status
1 codon 21 CAC->CAG His-Gln mis-sense germ-line stable
-> T—>C. -19 position of intron 1 3' end intronic somatic shift
3 codon 131 AAT—>AGT Asn-Ser mis-sense germ-line stable
15 codon 847 deleted T. creates stop nonsense somatic shift
codon downstream
28.53. ") reductions in poiythymine tract intronic somatic shift
.89 length. 3' end intron 1
9.26.28.34. 5 reductions in polyadenine tract intronic somatic shift
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Time post operation (days)
; 3 Estimated survival probabilities for patients with MSI
and those without ( ) by days post-operation using the
iroportional hazards method. Probabilities are plotted for a
hetical set of patients with the same mean effects of Duke's
tumour side and age as observed in our sample. The
er of patients with and without MSI surviving at 1100 days
six and 29 respectively
termination method (Sequenase version 2.0. United
Biochemicals) with the appropriate PCR primer.
PCR fragments did not produce high quality
ce by this method, single colonies were sequenced
:he T7 promoter primer (Promega Ltd., UK). Due to
or fidelity of Taq enzyme, sequence data from single
:s generated by Taq polymerase were confirmed using
ernative polymerase, rTth DNA polymerase (Perkin
UK), which has proofreading activity and a
:antly lower error rate. These samples were cloned
asmid pCRII using the TA cloning kit (Invitrogen BV,
:ek. Holland) and single colonies sequenced,
requent abnormality in the exon 1 PCR fragment was
:d by the presence of an extra band by heteroduplex
s and a consistent SSCP banding pattern (Figure 2).
ditional allele was identified by sequence analysis and
status confirmed by restriction digestion (Bcnl)
;d by electrophoresis on a 20% polyacrylamide gel.
In addition, the incidence of a previously reported
polymorphism in intron 12 (Fishel et al., 1993; Hall et al..
1994) was investigated. A restriction digestion assay was
developed which included digestion by Sfc\ followed by
electrophoresis on a 3% agarose gel.
Immunocytochemical staining of p53 protein
Representative portions of tumour were fixed in periodate-
lysine-paraformaldehyde-dichromate (PLPD) and em¬
bedded in paraffin wax. Staining was performed with the
monoclonal anti-p53 antibody, Pabl801 (Oncogene
Science, UK) as previously described (Purdie et al.,
1991). Samples were scored as positive if any positive
nuclei were found in the section and were analysed by at
least two observers.
Statistical analysis
The effect on post-operative survival of all relevant
factors was investigated by analysis with the Cox
proportional hazards method, using the Cox Regression
routines of SPSS for Windows 6.0. Post-operative
survival was established by perusal of death certificates
held by the Registrar General for Scotland. Those
patients who did not appear in the registry on the
census date were traced through hospital records to
confirm survival by continuing out-patient attendance or
by letter to their family practitioner. The censoring date
for survival was taken as 31.12.93; thus, all who
survived later than this date were treated as 'last
known alive' at this time. Factors investigated as
possible predictors of survival were age, tumour side,
ploidy, p53 status, gender, shift status and Duke's stage.
Deaths from all causes were considered.
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